<SEC-DOCUMENT>0001014739-24-000022.txt : 20240423
<SEC-HEADER>0001014739-24-000022.hdr.sgml : 20240423
<ACCEPTANCE-DATETIME>20240423160134
ACCESSION NUMBER:		0001014739-24-000022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240423
DATE AS OF CHANGE:		20240423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Option Care Health, Inc.
		CENTRAL INDEX KEY:			0001014739
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				050489664
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11993
		FILM NUMBER:		24864757

	BUSINESS ADDRESS:	
		STREET 1:		3000 LAKESIDE DR
		STREET 2:		SUITE 300N
		CITY:			BANNOCKBURN
		STATE:			IL
		ZIP:			60015
		BUSINESS PHONE:		312 940 2443

	MAIL ADDRESS:	
		STREET 1:		3000 LAKESIDE DR
		STREET 2:		SUITE 300N
		CITY:			BANNOCKBURN
		STATE:			IL
		ZIP:			60015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioScrip, Inc.
		DATE OF NAME CHANGE:	20050314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIM CORP
		DATE OF NAME CHANGE:	19960516
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bios-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3aa0ccbf-2345-461d-8bfe-5351acc3ea16,g:764d9622-b6cc-4198-a6bd-78d38846c16c,d:3c48d3288baf4494ba04043c71d8bd64-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:bios="http://www.bioscrip.com/20240331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bios-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001014739</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-27">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bios-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="pharmacy"><xbrli:measure>bios:pharmacy</xbrli:measure></xbrli:unit><xbrli:unit id="suite"><xbrli:measure>bios:suite</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>bios:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bios:LegacyHealthSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:LargestPayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:LargestPayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bios:AccountsReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bios:AccountsReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">bios:FourVendorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">bios:FourVendorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienCreditAgreementSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienCreditAgreementSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014739</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3c48d3288baf4494ba04043c71d8bd64_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.311%"><tr><td style="width:1.0%"/><td style="width:23.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.766%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:4pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.081%"><tr><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2024</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the transition period from &#160;&#160;&#160;                  to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-11993</ix:nonNumeric></span></div><div style="text-align:center"><img src="bios-20240331_g1.jpg" alt="OPCH_Logo.jpg" style="height:81px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">OPTION CARE HEALTH, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.688%"><tr><td style="width:1.0%"/><td style="width:16.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.978%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">05-0489664</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3000 Lakeside Dr.</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 300N,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Bannockburn,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">IL</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">60015</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">312</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">940-2443</ix:nonNumeric></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.863%"><tr><td style="width:1.0%"/><td style="width:55.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">OPCH</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Large accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9745;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April&#160;19, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">173,816,267</ix:nonFraction> shares of the registrant&#8217;s Common Stock outstanding.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.686%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page<br/>Number</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_22">Unaudited Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_25">Unaudited Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_28">Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_31">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_91">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_91">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_91">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_121">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_124">28</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_130">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_130">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_130">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_133">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_133">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_133">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_136">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_136">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_136">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_139">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_139">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_142">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_142">30</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_145">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_145">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q (this &#8220;Form 10-Q&#8221;) to "Option Care Health," the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Option Care Health, Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning our expectations regarding industry and macroeconomic trends and our operating performance. Forward-looking statements can be identified by words such as: &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar references to future periods.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. If any of these risks materialize, or if any of our assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those set forth in Item 1A, &#8220;Risk Factors,&#8221; of Part I of our Annual Report on Form 10-K for the year ended December&#160;31, 2023 (our &#8220;Form 10-K&#8221;) filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this Form 10-Q. Any forward-looking statement made by us in this Form 10-Q speaks only as of the date hereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL INFORMATION</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_16"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">219,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">343,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">573,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">377,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-35">241,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-36">274,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">94,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">98,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">1,129,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">1,094,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NONCURRENT ASSETS: </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">120,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-42">120,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">87,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-44">84,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bios:FiniteLivedIntangibleAssetsNetExcludingCustomerLists" format="ixt:num-dot-decimal" scale="3" id="f-45">19,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bios:FiniteLivedIntangibleAssetsNetExcludingCustomerLists" format="ixt:num-dot-decimal" scale="3" id="f-46">20,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bios:FiniteLivedCustomerListsNet" format="ixt:num-dot-decimal" scale="3" id="f-47">307,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bios:FiniteLivedCustomerListsNet" format="ixt:num-dot-decimal" scale="3" id="f-48">315,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-49">1,540,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">1,540,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">44,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">42,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">2,119,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">2,122,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL ASSETS </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">3,249,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">3,217,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">485,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">426,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">42,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">92,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bios:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-61">83,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bios:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-62">75,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">19,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">18,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">636,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">618,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NONCURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of discount, deferred financing costs and current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">1,056,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">1,056,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">89,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">85,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-73">37,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-74">34,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-75">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">1,183,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">1,177,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-79">1,820,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-80">1,795,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">STOCKHOLDERS&#8217; EQUITY: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-81"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-82">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-84">12,500,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-86">no</ix:nonFraction></ix:nonFraction> shares outstanding as of March&#160;31, 2024 and December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-89"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-90">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-93">183,397,817</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-94">173,816,056</ix:nonFraction> shares outstanding as of March&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95">182,905,559</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96">174,575,537</ix:nonFraction> shares outstanding as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-97">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-98">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-99">9,581,761</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-100">8,330,022</ix:nonFraction> shares outstanding, at cost, as of March&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-101">295,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-102">255,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-103">1,205,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-104">1,204,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-105">502,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-106">457,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-107">16,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-108">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-109">1,429,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">1,421,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">3,249,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">3,217,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to unaudited condensed consolidated financial statements are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET REVENUE</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-113">1,146,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-114">1,015,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COST OF REVENUE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-115">907,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-116">786,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GROSS PROFIT</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-117">238,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-118">229,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING COSTS AND EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">154,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">147,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-121">14,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-122">14,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-123">169,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-124">162,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING INCOME</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">69,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">66,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">13,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">13,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-129">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-130">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-131">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-132">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-133">12,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-134">12,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME BEFORE INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-135">56,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">54,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME TAX EXPENSE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-137">12,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-138">15,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">44,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">39,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain (loss) on cash flow hedges, net of income tax (expense) benefit of $(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="3" id="f-141">454</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" format="ixt:num-dot-decimal" scale="3" id="f-142">1,152</ix:nonFraction>, respectively</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-143">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-144">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE INCOME (LOSS)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-145">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-146">3,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET COMPREHENSIVE INCOME </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-147">46,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-148">35,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EARNINGS PER COMMON SHARE:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-149">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-151">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-152">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-153">173,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-154">181,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-155">175,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-156">182,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to unaudited condensed consolidated financial statements are an integral part of these statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_25"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">44,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-158">39,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash (used in) provided by operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-159">15,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-160">15,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-161">7,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-162">5,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes - net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-163">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-164">8,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-165">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-166">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-167">1,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-168">1,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-169">9,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-170">5,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital distribution from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="f-171">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="f-172">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-173">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-174">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="f-175">195,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="f-176">17,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-177">32,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-178">25,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-179">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-180">9,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-181">59,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-182">70,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-183">49,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-184">28,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-185">6,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-186">14,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-187">6,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-188">5,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" scale="3" id="f-189">418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-190">5,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-191">68,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-192">89,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-193">5,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-194">5,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-195">5,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-196">5,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options, vesting of restricted stock, and related tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="bios:ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" format="ixt:num-dot-decimal" scale="3" id="f-197">8,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="bios:ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" format="ixt:num-dot-decimal" scale="3" id="f-198">1,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of debt principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-199">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-200">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-201">40,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-202">75,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-204">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-205">49,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-206">80,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-207">124,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-208">3,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents - beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-209">343,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-210">294,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS - END OF PERIOD</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-211">219,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-212">297,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-213">12,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-214">11,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-215">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:num-dot-decimal" scale="3" id="f-217">7,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:num-dot-decimal" scale="3" id="f-218">6,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to unaudited condensed consolidated financial statements are an integral part of these statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-220">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">2,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">1,176,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">190,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">21,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">1,386,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options, vesting of restricted stock, and related tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="f-226">1,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="f-227">1,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-228">5,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-229">5,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-230">75,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-231">75,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-232">39,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-233">39,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-234">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-235">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-237">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-238">78,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">1,180,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">229,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">17,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">1,350,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-244">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">255,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">1,204,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-247">457,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">1,421,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options, vesting of restricted stock, and related tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="f-250">8,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="f-251">8,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based incentive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">9,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-253">9,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of company stock, and related tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="bios:StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" format="ixt:num-dot-decimal" scale="3" id="f-254">40,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bios:StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" format="ixt:num-dot-decimal" scale="3" id="f-255">40,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-256">44,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">44,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-258">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-259">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance - March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-261">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">295,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">1,205,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">502,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">16,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-266">1,429,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes to unaudited condensed consolidated financial statements are an integral part of these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_34"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-267" continuedAt="f-267-1" escape="true">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-267-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of <ix:nonFraction unitRef="pharmacy" contextRef="c-3" decimals="INF" name="bios:NumberOfServiceLocations" scale="0" id="f-268">93</ix:nonFraction> full service pharmacies and <ix:nonFraction unitRef="suite" contextRef="c-3" decimals="INF" name="bios:NumberOfInfusionSites" scale="0" id="f-269">84</ix:nonFraction> stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-270">one</ix:nonFraction> segment, infusion services. The Company&#8217;s stock is listed on the Nasdaq Global Select Market as of March&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-271" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company&#8217;s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-272" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are <ix:nonFraction unitRef="number" contextRef="c-40" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-273">50</ix:nonFraction>% owned and are accounted for as equity-method investments. The Company&#8217;s share of earnings from equity-method investments is included in the line entitled &#8220;Equity in earnings of joint ventures&#8221; in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s equity-method investments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-274" continuedAt="f-274-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-274-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-275" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March&#160;31, 2024, cash equivalents consisted of money market funds.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-276">49.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-277">52.0</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-278" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March&#160;31, 2024 and December&#160;31, 2023, the balance of the investments was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-279">21.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-280">20.9</ix:nonFraction> million, respectively. The balance of these investments is increased to reflect the Company&#8217;s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company&#8217;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#8217;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company&#8217;s proportionate share of earnings was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-281">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-282">1.4</ix:nonFraction> million for the three months ended March&#160;31, 2024 and 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-283">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-284">2.5</ix:nonFraction> million, respectively. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bios:ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" id="f-285" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#8217;s largest payer was approximately <ix:nonFraction unitRef="number" contextRef="c-43" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-286"><ix:nonFraction unitRef="number" contextRef="c-44" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-287">14</ix:nonFraction></ix:nonFraction>% for the three months ended March&#160;31, 2024 and 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, approximately <ix:nonFraction unitRef="number" contextRef="c-45" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-288"><ix:nonFraction unitRef="number" contextRef="c-46" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-289">12</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="number" contextRef="c-47" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-290">14</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-48" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-291">12</ix:nonFraction>%, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company&#8217;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company&#8217;s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, approximately <ix:nonFraction unitRef="number" contextRef="c-49" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-292">66</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-50" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-293">72</ix:nonFraction>%, respectively, of the Company&#8217;s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-294" continuedAt="f-294-1" escape="true">REVENUE</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-295" escape="true"><ix:continuation id="f-294-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the&#160;three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-296">988,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-297">873,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-298">138,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-299">122,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-300">19,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-301">19,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-302">1,146,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-303">1,015,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i3c48d3288baf4494ba04043c71d8bd64_46"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-304" continuedAt="f-304-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-304-1" continuedAt="f-304-2"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company recorded tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-305">12.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-306">15.0</ix:nonFraction>&#160;million, respectively, which represents an effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-307">21.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-308">27.7</ix:nonFraction>%, respectively. The variance in the Company&#8217;s effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-309">21.4</ix:nonFraction>% for the three months ended March&#160;31, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the three months ended March&#160;31, 2024, the Company released $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-310">2.2</ix:nonFraction>&#160;million of state valuation allowance. The variance in the Company&#8217;s effective tax rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-311">27.7</ix:nonFraction>% for the three months ended March&#160;31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to difference between federal and state tax rates, as well as various non-deductible expenses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-312">4.2</ix:nonFraction>&#160;million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-313">12.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-314">15.0</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2024 and March&#160;31, 2023, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-304-2">The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (&#8220;Code&#8221;) Section 382 limitations. This may limit the Company&#8217;s ability to utilize its federal net operating losses</ix:continuation>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-315" continuedAt="f-315-1" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-315-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March&#160;31, 2024 and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-316" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-317">880,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-318">871,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-319">279,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-320">342,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-321">149,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-322">90,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-323" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-324">44,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-325">39,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-326">173,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-327">181,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-328">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-329">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-330">44,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-331">39,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-332">173,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-333">181,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-334">1,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-335">1,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-336">175,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-337">182,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-338">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-339">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-341" continuedAt="f-341-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-340" continuedAt="f-340-1" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-341-1"><ix:continuation id="f-340-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company incurred operating lease expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-342">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-343">7.0</ix:nonFraction> million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March&#160;31, 2024, the weighted-average remaining lease term was <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-344">7.0</ix:nonNumeric> years and the weighted-average discount rate was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-345">6.36</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-346" escape="true"><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-347">19,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-348">25,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-349">22,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-350">18,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-351">12,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bios:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-352">42,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-353">140,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-354">31,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-355">108,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-356">11.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March&#160;31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div></ix:continuation></ix:continuation><div id="i3c48d3288baf4494ba04043c71d8bd64_58"></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-357" continuedAt="f-357-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-357-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-358" continuedAt="f-358-1" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-359">36,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-360">36,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-361">24,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-362">23,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-363">100,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-364">99,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-365">50,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-366">50,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-367">33,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-368">33,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-369">245,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-370">244,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-371">124,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-372">123,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-373">120,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-374">120,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. <ix:continuation id="f-358-1" continuedAt="f-358-2">The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands):</ix:continuation></span></div><ix:continuation id="f-358-2"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-375">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-376">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-377">6,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-378">6,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-379">6,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-380">6,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-381" continuedAt="f-381-1" escape="true">GOODWILL AND OTHER INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-381-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the carrying amount of goodwill for the three months ended March&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="f-382" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-383">514,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-384">514,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-385">39,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-386">39,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-387">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-388">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-389">554,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-390">554,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-391">206,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-392">199,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-393">20,423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-394">19,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-395">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-396">341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-397">227,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-398">219,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-399">326,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-400">335,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-401">8.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-402">8.5</ix:nonFraction> million for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-403" continuedAt="f-403-1" escape="true">INDEBTEDNESS</ix:nonNumeric></span></div><ix:continuation id="f-403-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-404" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March&#160;31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-409">586,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-410">6,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-411">9,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-412">570,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-413">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-415">8,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-416">491,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-417">1,086,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-418">6,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-419">17,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-420">1,062,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-421">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-422">1,056,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-427">588,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-428">6,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-429">9,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-430">571,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-431">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-433">8,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-434">491,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-435">1,088,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-436">6,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-437">18,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-438">1,062,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-439">6,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-440">1,056,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the First Lien Term Loan was <ix:nonFraction unitRef="number" contextRef="c-91" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-441">8.19</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-92" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-442">8.21</ix:nonFraction>% as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was <ix:nonFraction unitRef="number" contextRef="c-93" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="f-443">8.20</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-94" decimals="4" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="f-444">7.28</ix:nonFraction>% for the three months ended March&#160;31, 2024 and 2023, respectively. The interest rate on the Senior Notes was <ix:nonFraction unitRef="number" contextRef="c-95" decimals="5" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-445"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="5" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-446">4.375</ix:nonFraction></ix:nonFraction>% as of March&#160;31, 2024 and December&#160;31, 2023. The weighted average interest rate incurred on the Senior Notes was <ix:nonFraction unitRef="number" contextRef="c-97" decimals="5" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="f-447"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="5" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="f-448">4.375</ix:nonFraction></ix:nonFraction>% for the three months ended March&#160;31, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-449" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-450">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-451">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-452">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-453">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-454">564,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="bios:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-455">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-456">1,086,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-457" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company&#8217;s debt obligations as of March&#160;31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of March&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-458">570,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-460">588,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-462">491,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-464">456,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-466">1,062,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-468">1,044,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (&#8220;First Lien Credit Agreement Amendment&#8221;). The First Lien Credit Agreement Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-470">400.0</ix:nonFraction>&#160;million (the &#8220;Revolver Facility&#8221;), pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. As of March&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-471">5.3</ix:nonFraction> million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="f-472">394.7</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-473" continuedAt="f-473-1" escape="true">DERIVATIVE INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="f-473-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company&#8217;s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company&#8217;s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company&#8217;s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-474">300</ix:nonFraction>&#160;million for a <ix:nonNumeric contextRef="c-113" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear" id="f-475">5</ix:nonNumeric>-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan&#8217;s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-476" escape="true"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company&#8217;s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-477">10,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-478">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-479">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-480">10,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-481">21,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-482">19,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive income (loss). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-483" continuedAt="f-483-1" escape="true">The following table presents the pre-tax gain (loss) from derivative instruments recognized in other comprehensive income (loss) in the Company&#8217;s unaudited condensed consolidated statements of comprehensive income (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-483-1"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-484">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-485">4,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company&#8217;s unaudited condensed consolidated statements of comprehensive income related to the Company&#8217;s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-486">2,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-487">2,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="i3c48d3288baf4494ba04043c71d8bd64_70"></div><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-489" continuedAt="f-489-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-488" continuedAt="f-488-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-489-1"><ix:continuation id="f-488-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at March&#160;31, 2024 and December&#160;31, 2023.</span></div></ix:continuation></ix:continuation><div id="i3c48d3288baf4494ba04043c71d8bd64_73"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-490" continuedAt="f-490-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-490-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company&#8217;s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</span></div></ix:continuation><div id="i3c48d3288baf4494ba04043c71d8bd64_76"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-491" continuedAt="f-491-1" escape="true">STOCK-BASED INCENTIVE COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-491-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), approved at the annual meeting by the BioScrip, Inc. (&#8220;BioScrip&#8221;) stockholders on May 3, 2018 and amended and restated on May 19, 2021, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors, resulting in a total of <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-492">9,101,734</ix:nonFraction> shares of common stock authorized for issuance. The 2018 Plan is administered by the Company&#8217;s Compensation Committee, a standing committee of the Company&#8217;s Board of Directors. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March&#160;31, 2024 and 2023. During the three months ended March&#160;31, 2024 and 2023, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-493">9.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-494">6.0</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i3c48d3288baf4494ba04043c71d8bd64_79"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-495" continuedAt="f-495-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-495-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the three months ended March&#160;31, 2024 and 2023, warrant holders did <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:fixed-zero" scale="0" id="f-496"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:fixed-zero" scale="0" id="f-497">not</ix:nonFraction></ix:nonFraction> elect to exercise any warrants to purchase shares of common stock. As of March 31, 2024 and December&#160;31, 2023, the remaining warrant holders are entitled to purchase <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-498"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-499">51,838</ix:nonFraction></ix:nonFraction> shares of common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the three months ended March&#160;31, 2024 and 2023, warrant holders exercised an <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="bios:ClassOfWarrantOrRightNumberOfSecuritiesExercised" format="ixt:fixed-zero" scale="0" id="f-500"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="0" name="bios:ClassOfWarrantOrRightNumberOfSecuritiesExercised" format="ixt:fixed-zero" scale="0" id="f-501">immaterial</ix:nonFraction></ix:nonFraction> number of warrants to purchase shares of common stock. As of March 31, 2024 and December&#160;31, 2023, the remaining warrant holders are entitled to purchase <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-502">13,365</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-503">13,888</ix:nonFraction> shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s Board of Directors approved a share repurchase program of up to an aggregate $<ix:nonFraction unitRef="shares" contextRef="c-132" decimals="-5" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="6" id="f-504">500.0</ix:nonFraction> million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-505">1,251,739</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-506">2,475,166</ix:nonFraction> shares of common stock for an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-507">31.96</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-508">30.30</ix:nonFraction>, totaling $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-509">40.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-510">75.0</ix:nonFraction> million, respectively. All repurchased shares became treasury stock. As of March&#160;31, 2024, the Company is authorized to repurchase up to a remaining $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-511">210.0</ix:nonFraction> million of common stock of the Company.</span></div></ix:continuation><div id="i3c48d3288baf4494ba04043c71d8bd64_85"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-512" continuedAt="f-512-1" escape="true">RELATED-PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="f-512-1"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-513">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-514">1.3</ix:nonFraction> million for the three months ended March&#160;31, 2024 and 2023, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-515">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-516">2.5</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due from its joint ventures of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-517">1.0</ix:nonFraction> million as of March&#160;31, 2024. The Company had amounts due to its joint ventures of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-518">0.5</ix:nonFraction> million and due from its joint ventures of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-519">0.1</ix:nonFraction> million as of December&#160;31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_94"></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this report to "Option Care Health," the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Option Care Health, Inc. and its consolidated subsidiaries. Management&#8217;s discussion and analysis of financial condition and results of operations (&#8220;MD&amp;A&#8221;) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial condition. The following discussion and analysis should be read in conjunction with the Company&#8217;s unaudited condensed consolidated financial statements and the related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q (this &#8220;Form 10-Q&#8221;). Certain statements in this Item 2 of Part I of this Form 10-Q, and in Item 1A, &#8220;Risk Factors&#8221; of Part I of our Annual Report on Form 10-K for the year ended December&#160;31, 2023 (our &#8220;Form 10-K&#8221;), may cause our actual results, financial position, and cash and cash equivalents generated from operations to differ materially from these forward-looking statements.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_97"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 177 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient&#8217;s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, and dietitians work with the physician to develop a plan of care suited to each patient&#8217;s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Update on the Impact of the Change Healthcare Cybersecurity Incident</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Change Healthcare, a subsidiary of UnitedHealth Group, experienced an incident on February 21, 2024, in which a cybersecurity threat actor gained access to some of its information technology systems (&#8220;Change Healthcare Cybersecurity Incident&#8221;). Since the time of the system disruption, Option Care Health has worked continuously to find alternative processes to help maintain patient care and overall operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company has not identified any compromise or unauthorized access of its systems or networks due to this third party incident. As of the end of the first quarter of 2024, the Company reconnected to certain applications maintained by Change Healthcare and resumed claims submission to several payers and utilized alternative platforms for the majority of its claims. The Company continues to work through accumulated unprocessed claims and to establish full recovery with Change Healthcare&#8217;s applications.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, the Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on the financial results as reported. The impact to the first quarter financial results was primarily related to cash flows from operations, which are expected to be recognized later in 2024, additional labor costs to support continued operations, and higher net interest expense due to lower-than-expected interest-bearing cash balances. The Company continues to maintain strong liquidity and, having resumed submission of claims to payers, has determined that the Change Healthcare Cybersecurity Incident is not reasonably likely to materially impact the Company, including its business operations, financial condition or results of operations.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_100"></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Composition of Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following results of operations include the accounts of Option Care Health and our subsidiaries for the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit represents our net revenue less cost of revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infusion and related health care services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Costs and Expenses</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation within this caption relates to fixed assets and amortization relates to intangibles. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest expense consists principally of interest payments on the Company&#8217;s outstanding borrowings under the First Lien Term Loan, Revolver Facility, Senior Notes, amortization of discount and deferred financing fees, payments associated with the interest rate cap, and interest income earned on cash and cash equivalents. Refer to the &#8220;Liquidity and Capital Resources&#8221; section below for further discussion of these outstanding borrowings.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in Earnings of Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with health systems.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other income (expense) primarily includes activity related to non-operating income and expenses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is subject to taxation in the United States and various states. The Company&#8217;s income tax expense is reflective of the current federal and state tax rates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Unrealized Gain (Loss) on Cash Flow Hedge, Net of Income Tax (Expense) Benefit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Change in unrealized gain (loss) on cash flow hedge, net of income tax (expense) benefit, consists of the gain (loss) associated with the changes in the fair value of derivatives designated as hedging instruments related to the interest rate cap hedge, net of income taxes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents Option Care Health&#8217;s consolidated results of operations for the three months ended March&#160;31, 2024 and 2023 (in thousands, except for percentages):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET REVENUE</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COST OF REVENUE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GROSS PROFIT</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING COSTS AND EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,470&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING INCOME</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,075)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME BEFORE INCOME TAXES</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME TAX EXPENSE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET INCOME</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain (loss) on cash flow hedges, net of income tax (expense) benefit of ($454) and $1,152, respectively</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER COMPREHENSIVE INCOME (LOSS)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,443)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET COMPREHENSIVE INCOME </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i3c48d3288baf4494ba04043c71d8bd64_103"></div><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023</span></div><div style="margin-bottom:20pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present selected consolidated comparative results of operations from Option Care Health&#8217;s unaudited condensed consolidated financial statements for the three months ended March 31, 2024 and 2023.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:20pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net revenue was primarily driven by organic growth in the Company&#8217;s portfolio of therapies, consisting of acute revenue that had single-digit growth relative to the prior year while chronic revenue grew in the mid-teens. The increase in cost of revenue was primarily driven by the growth in revenue, therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy pricing dynamics in the prior year. The decrease in gross profit margin was primarily due to the same comparable impact of certain temporary favorable pricing dynamics in the prior year that did not continue into 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:20pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses during the three months ended March 31, 2024 is primarily due to an increase in salaries, benefits, and equity compensation; however, these expenses have declined as a percentage of revenue to 13.5% for the three months ended March 31, 2024 compared to 14.6% for the three months ended March 31, 2023, due to the Company&#8217;s focus on leveraging existing infrastructure to control spending.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,834)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,075)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,396)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:20pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense, net during the three months ended March 31, 2024 was primarily attributable to additional interest income generated from our cash and cash equivalents, partially offset by an increase in the Company&#8217;s First Lien Term Loan variable interest rate, compared to three months ended March 31, 2023. See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the condensed consolidated financial statements for further information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:20pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $12.2&#160;million and $15.0&#160;million for the three months ended March 31, 2024 and 2023, respectively, which represents an effective tax rate of 21.4% and 27.7%, respectively. The variance in the Company&#8217;s effective tax rate of 21.4% for the three months ended March 31, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company&#8217;s effective tax rate of 27.7% for the three months ended March 31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, as well as various non-deductible expenses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income and Other Comprehensive Income (Loss)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands, except for percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in unrealized gain (loss) on cash flow hedges, net of income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in net income was attributable to organic growth from additional revenue related to the factors described in the above sections.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, the change in unrealized gain on cash flow hedges, net of income taxes was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net comprehensive income increased to $46.3 million for the three months ended March 31, 2024, compared to net comprehensive income of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2023, primarily as a result of the changes in net income discussed above.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_109"></div><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and the twelve months ended December&#160;31, 2023, the Company&#8217;s primary sources of liquidity were cash and cash equivalents of $219.5 million and $343.8 million, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, the Company had $394.7 million of borrowings available under its credit facilities (net of $5.3&#160;million undrawn letters of credit issued and outstanding). During the three months ended March&#160;31, 2024, the Company&#8217;s cash flows from operations were impacted by the Change Healthcare Cybersecurity Incident. See the caption &#8220;Update on the Impact of the Change Healthcare Cybersecurity Incident&#8221; included in this Form 10-Q for further discussion. During the twelve months ended December&#160;31, 2023, the Company&#8217;s cash flows from operations enabled investments in pharmacy, infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and share repurchases.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary uses of cash and cash equivalents include supporting our ongoing business activities, investment in capital expenditures in both facilities and technology, the pursuit of acquisitions, and share repurchases. Ongoing operating cash outflows are associated with procuring and dispensing drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on outstanding debt and cash taxes. Ongoing investing cash flows are primarily associated with capital projects related to business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on our outstanding debt, along with potential future share repurchases.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes the deployment of capital to pursue acquisitions that complement our existing operations. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company historically has funded its acquisitions with cash and cash equivalents with the exception of the BioScrip merger. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Liquidity Requirements</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash and cash equivalents in the future, which to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash and cash equivalents balances and expected cash flows generated from operations will be sufficient to meet our operating requirements over the next 12 months and beyond. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Revolver Facility provides for borrowings up to $400.0&#160;million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility will bear interest at a rate equal to, at the option of the Company, either (i) the Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the First Lien Credit Agreement Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent compliance certificate received by the Administrative Agent pursuant to the terms of the credit agreement. As of March&#160;31, 2024, the Company had $5.3 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $394.7 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.5&#160;million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the First Lien Credit Agreement Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.75% for Term SOFR Loans (as such term is defined in the First Lien Credit Agreement Amendment); or (ii) a base rate determined in accordance with the First Lien Credit Agreement Amendment, plus 1.75% for Base Rate Loans (as such term is defined in the First Lien Credit Agreement Amendment).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes bear interest at a rate of 4.375% per annum and are payable semi-annually in arrears on October 31 and April 30 of each year, which began on April 30, 2022. The Senior Notes mature on October 31, 2029.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest payments over the course of long-term debt obligations total an estimated $341.8 million based on final maturity dates of the Company&#8217;s credit facilities. Interest payments are calculated based on current rates as of March&#160;31, 2024. Actual payments are based on changes in SOFR and exclude the interest rate cap derivative instrument.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023 </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected data from Option Care Health&#8217;s unaudited condensed consolidated statements of cash flows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variance</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,336)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,926)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents - end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of cash in operating activities during the three months ended March&#160;31, 2024, as compared to the cash provided by operating activities in the three months ended March 31, 2023, is primarily due to changes in accounts receivable as a result of the Change Healthcare Cybersecurity Incident, with lesser impacts from accrued compensation and employee benefits, accrued expenses and other current liabilities, which were partially offset by higher net income and higher inventory turnover.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash used in investing activities during the three months ended March&#160;31, 2024 is primarily related to an increase in capital expenditures as compared to the three months ended March 31, 2023.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash used in financing activities is primarily related to the Company&#8217;s $40.0&#160;million repurchase of common stock during the three months ended March&#160;31, 2024, whereas the three months ended March 31, 2023 activity primarily related to the Company&#8217;s $75.0&#160;million repurchase of common stock.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_118"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its unaudited condensed consolidated financial statements in accordance with GAAP, which requires the Company to make estimates and assumptions. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates and assumptions are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making assumptions about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company&#8217;s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s critical accounting policies and estimates as presented in our Form 10-K, which are hereby incorporated by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our exposure to market risk from those included in our Form 10-K, which is hereby incorporated by reference.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_124"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, management evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures as of March&#160;31, 2024. Based on that evaluation, the Company&#8217;s Chief Executive Officer and its Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2024.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended March 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_130"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of legal proceedings, refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the unaudited condensed consolidated financial statements included in Item 1 of this Form 10-Q.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_133"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors affecting our business, financial condition or results of operations from those set forth in Part I, Item 1A. &#8220;Risk Factors&#8221; in our Form 10-K. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition and/or operating results, except for the updated risk factor below:</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in reimbursement may adversely affect our liquidity, cash flows and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reimbursement process for the services we provide is complex, resulting in delays between the time we bill for a service and receipt of payment that can be significant. Reimbursement and procedural issues often require us to resubmit claims multiple times and respond to multiple administrative requests before payment is remitted. The collection of accounts receivable is challenging and requires constant focus and involvement by management and ongoing enhancements to information systems and billing center operating procedures. While management believes that our controls and processes are satisfactory, there can be no assurance that collections of accounts receivable will continue at historical rates. The risks associated with third-party payers and the inability to collect outstanding accounts receivable could have a material adverse effect on our liquidity, cash flows, and results of operations. For example, in the first quarter of 2024, Change Healthcare, a subsidiary of UnitedHealth Group, experienced a cybersecurity incident that disrupted its operations, causing us to disconnect from certain Change Healthcare applications until the end of the quarter, preventing us from processing claims for services and reducing our cash flows from operations in the first quarter of 2024, which are now expected to be recognized later in 2024.</span></div><div id="i3c48d3288baf4494ba04043c71d8bd64_136"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Board of Directors approved a share repurchase program of up to an aggregate $500&#160;million of common stock of the Company. This program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to the Company&#8217;s repurchases of common stock from January 1, 2024 through March&#160;31, 2024:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2024 - January 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,913,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2024 - February 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,000,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2024 - March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,000,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,251,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.96&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,251,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,000,136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i3c48d3288baf4494ba04043c71d8bd64_139"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No director or officer of the Company has <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-520"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-521">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-522"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-523">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 plan or non-Rule 10b5-1 trading arrangement during the three months ended March 31, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i3c48d3288baf4494ba04043c71d8bd64_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3c48d3288baf4494ba04043c71d8bd64_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Exhibits.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101-optioncarexexecutive.htm">Form of Option Care Health, Inc. Non-Qualified Stock Option Certificate (Executive) (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102-optioncarexexecutive.htm">Form of Option Care Health, Inc. Restricted Stock Unit Certificate (Executive) (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex103-optioncarexexecutive.htm">Form of Option Care Health, Inc. Performance Stock Unit Certificate (Executive) (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex104-optioncarexdirectorx.htm">Form of Option Care Health, Inc. Restricted Stock Unit Certificate (Directors) (filed herewith).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="opch-ex311x2024033110xq.htm">Certification of Chief Executive Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex312x2024033110xq.htm">Certification of Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex321x2024033110xq.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="opch-ex322x2024033110xq.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Formatted Cover Page</span></td></tr></table></div><div id="i3c48d3288baf4494ba04043c71d8bd64_145"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.579%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;OPTION CARE HEALTH, INC.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April&#160;23, 2024</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Shapiro                          </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Shapiro</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8.4pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Executive Vice President (Principal Financial Officer and Duly Authorized Officer)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-optioncarexexecutive.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i741b375b00ed41b09f3584f492bd04bc_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. <br>NON-QUALIFIED STOCK OPTION CERTIFICATE</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">THIS NON-QUALIFIED STOCK OPTION CERTIFICATE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Option Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) is made as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) between Option Care Health, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Awardee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Company has established the Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan (as amended and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), a copy of which has been provided to Awardee&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Plan provides for the making of stock and other equity based Awards, including grants of Options to purchase shares of Company common stock, $0.0001 par value per share, of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS the Company desires to afford the Awardee an opportunity to purchase Stock as provided in accordance with this Certificate and the provisions of the Plan&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">NOW THEREFORE, the following terms and conditions apply to this grant of Options in accordance with the terms and conditions of the Plan and subject to the provisions of this Certificate&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The Company hereby grants to the Awardee the right and option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) to purchase all or any part of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> shares of Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;). The Option is in all respects limited and conditioned as provided in this Certificate, and is subject to the terms and conditions of the Plan now in effect and as they may be amended from time to time, in accordance with the Plan (which terms and conditions are and automatically shall be incorporated by reference and shall control in the event of any conflict with any other terms of this Option Certificate). It is intended that this Option be a non-qualified stock option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">NQSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">an incentive stock option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">ISO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) as such term is defined in Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. The exercise price per share of the Shares under the Option shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Unless earlier terminated pursuant to any provision of the Plan or of this Option Certificate, the Option shall expire on the ten (10) year anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;). The Option shall not be exercisable on or after the Expiration Date. Notwithstanding anything in this Option Certificate to the contrary, in the event the Awardee will not be permitted to exercise the Option on the date immediately prior to the Expiration Date because exercising the Option and selling the Stock acquired upon exercise of the Option would contravene applicable federal or state insider trading laws or regulations or other applicable federal or state securities laws or regulations (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) or would contravene the Company&#8217;s blackout or insider trading policies, then the term of the Option shall be extended for a period of thirty (30) days beginning on the first date that the Awardee is again permitted to exercise the Option under the Securities Laws and the Company&#8217;s blackout and insider trading policies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Vesting and Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">The Option will vest and may be exercised as to &#91;INSERT VESTING SCHEDULE&#93;, in each case rounded to the nearest whole share. The portion of the Option that vests and becomes exercisable in accordance with the foregoing shall remain exercisable, subject to the provisions contained in the Plan and in this Option Certificate until the expiration of the term of the Option as set forth in Section 3.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.11pt">Notwithstanding any provision of the Plan to the contrary, in the event the Option is assumed or substituted by a successor in connection with a Change in Control, upon a Qualifying Termination the unvested portion of the Option will fully vest. For this purpose, a &#8220;Qualifying Termination&#8221; will mean an involuntary termination of Awardee&#8217;s employment without Cause during the 12-month period following a Change in Control. For this purpose, &#8220;Cause&#8221; will have the meaning given to such term in an employment or other similar agreement entered into by Awardee with the Company, or, in the absence of such an agreement, with respect to Awardee, will mean the occurrence of any one or more of the following reasons&#58; (i) the commission of a felony or other crime involving moral turpitude&#59; (ii) the commission of any act or omission involving dishonesty, disloyalty or fraud with respect to the Company&#59; (iii) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other repeated conduct causing the Company substantial public disgrace or substantial economic harm&#59; (iv) unsatisfactory performance of Awardee&#8217;s duties for the Company, as determined by the Board in its good-faith discretion&#59; (v) any intentional act or omission aiding or abetting a competitor, supplier or customer of the Company to the material disadvantage of the Company&#59; (vi) breach of fiduciary duty or willful misconduct with respect to the Company&#59; (vii) any other material breach of this Certificate or (viii) Awardee engaging in illegal business practices or other practices contrary to the written policies of the Company, including, without limitation, sexual misconduct, harassment or discrimination.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">All vesting of Awardee&#8217;s Option under this Section 4 is further conditioned upon Awardee having remained in the continuous employment of the Company through the applicable vesting date. If Awardee does not remain in the continuous employment of the Company, with the exception of Sections 4(b) and 4(d), then Awardee will immediately forfeit any unvested portion of the Option in their entirety for no consideration, without any further action of the Company.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.11pt">Notwithstanding any provisions of this Certificate to the contrary, if Participant&#8217;s employment with the Company terminates due to Awardee&#8217;s Retirement, then the unvested portion of the Option shall continue to vest in accordance with the vesting schedule set forth in this Section 4. For purpose of this Award, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Retire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221; means that the Awardee voluntarily resigns employment and (i) has reached fifty-eight (58) years of age&#59; (ii) has provided ten (10) years of continuous employment with the Company&#59; (iii) has provided to the Company at least six (6) months advance written notice of intent to Retire, (iv) been continuously employed by the Company for at least twelve (12) months following the Date of Grant and is in good standing with the Company on the date of termination of employment, (v) complies with all applicable post-employment covenants, and (vi) if requested by the Company, provides the Company with a release of claims in such form as required by the Company in its discretion.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Method of Exercising Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Option Certificate and the Plan, the Option may be exercised upon written notice to the Company or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">securities broker then designated by the Company, and the form of such notice shall be provided by the Company upon request. Such notice shall state the election to exercise the Option and the number of shares of Stock with respect to which it is being exercised&#59; shall be signed by the person or persons so exercising the Option&#59; shall, if the Company so requests, be accompanied by the investment certificate referred to in Section 6 of this Certificate and shall be accompanied by payment of the full Option price of such Shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Option price shall be paid to the Company&#58;</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">In cash, or in its equivalent&#59;</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.11pt">In Stock previously acquired by the Awardee, provided that if such shares of Stock were acquired through exercise of a stock option, such shares have been held by the Awardee for a period of more than 12 months on the date of exercise&#59;</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">In Stock newly acquired by the Awardee upon exercise of the Option&#59; or</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.11pt">In any combination of (a), (b) and (c) above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">In addition, the Option price may also be paid (i) through any cashless exercise procedure then available to any other Director or Key Employee (as defined in the Plan)&#59; or (ii) by withholding Stock otherwise issuable in connection with the exercise of the Option.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">In the event such Option price is paid, in whole or in part, in Stock, the portion of the Option price so paid with Stock shall be equal to the &#8220;fair market value&#8221; of such shares of Stock on the date of exercise of the Option, as such &#8220;fair market value&#8221; is determined as set forth in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Upon receipt of such notice and payment, the Company, as promptly as practicable, shall deliver or cause to be delivered a certificate or certificates representing the shares with respect to which the Option is so exercised. The certificate or certificates for the shares as to which the Option shall have been so exercised shall be registered in the name of the person or persons so exercising the Option (or, if the Option shall be exercised by the Awardee and if the Awardee shall so request in the notice exercising the Option, shall be registered in the name of the Awardee and the Awardee&#8217;s spouse, jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person or persons exercising the Option. All</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">shares that shall be purchased upon the exercise of this Option shall be fully paid and non-assessable by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Shares to be Purchased for Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Unless the Company has notified the Awardee that a registration statement covering the shares to be acquired upon the exercise of the Option has become effective under the Securities Act of 1933 and the Company has not thereafter notified the Awardee that such registration is no longer effective, or unless counsel to the Company shall be otherwise satisfied that the Awardee would be permitted under applicable law to immediately resell shares acquired upon the exercise of the Option, it shall be a condition to any exercise of the Option that the shares acquired upon such exercise be acquired for investment and not with a view to distribution, and the person effecting such exercise shall submit to the Company a certificate of such investment intent, together with such other evidence supporting the same as the Company may request. The Company shall be entitled to restrict the transferability of the shares issued upon any such exercise to the extent necessary to avoid a risk of violation of the Securities Act </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> 3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">of 1933 (or of any rules or regulations promulgated thereunder) or of any state laws or regulations. Such restrictions may, at the option of the Company, be noted or set forth in full on the share certificates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Non-Transferability of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The Option is not assignable or transferable, in whole or in part, by the Awardee otherwise than by the laws of descent and distribution or in accordance with the procedures set forth in Section 13 of the Plan. During the lifetime of the Awardee the Option shall be exercisable only by the Awardee or by Awardee&#8217;s guardian or legal representative or Awardee&#8217;s permitted assignee or transferee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">If the Awardee&#8217;s employment with the Company and all Affiliates (as defined in the Plan) is terminated for any reason other than death, disability or Retirement, the Option may be exercised, to the extent of the number of shares which were vested on the date of such termination of employment, by the Awardee at any time on or prior to ninety (90) days following the termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Post-Termination Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;). The Post-Termination Period shall be twelve (12) months if the Awardee&#8217;s employment with the Company and all Affiliates is terminated due to disability or death. In the event of Awardee&#8217;s Retirement, the Post-Termination Period shall be &#91;__&#93; years. Notwithstanding this Section 8, the Post-Termination Period may be extended if such an extension it set forth in any severance agreement or other agreement then in effect between the Company and the Awardee. However, no Post-Termination Period may extend the Expiration Date of the Option set forth in Section 3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.38pt;text-decoration:underline">Withholding of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The obligation of the Company to deliver shares of Stock upon the exercise of the Option shall be subject to applicable federal, state and local tax withholding requirements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">No Stock will be delivered to an Awardee upon exercise of the Option unless Awardee has made arrangements acceptable to the Company for payment of any federal, state, local or foreign withholding taxes that may be due as a result of the delivery of the Stock. Awardee hereby authorizes the Company to withhold from payroll or other amounts payable to Awardee any sums required to satisfy such withholding tax obligations, and otherwise agrees to satisfy such obligations in accordance with the provisions of Section 19.3 of the Plan. If the exercise of the Option is subject to the withholding requirements of applicable federal tax laws, the Committee may permit the Awardee, subject to the provisions of the Plan and such additional withholding rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) as shall be adopted by the Committee, to satisfy the minimum federal, state and local withholding tax, in whole or in part, by electing to have the Company withhold (or by returning to the Company) shares of Stock, which shares shall be valued, for this purpose, at their fair market value on the date of exercise of the Option (or, if later, the date on which the Awardee recognizes ordinary income with respect to such exercise) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Determination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;). An election to use shares of Stock to satisfy tax withholding requirements must be made in compliance with and subject to the Withholding Rules, and the Committee may not withhold shares in excess of the number necessary to satisfy the maximum federal, state and local income tax withholding requirements. In the event shares of Stock previously acquired under the exercise of an ISO are used to satisfy such withholding requirement, such shares of Stock must have been held by the Awardee for a period of not less than the holding period described in Section 422(a)(1) of the Code on the Determination Date, or if such shares of Stock were previously acquired through exercise of a stock option, such option was granted to the Awardee at least six months prior to the Determination Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.63pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">The Company and Awardee shall execute such further instruments and take such action as may reasonably be necessary to carry out the intent of this Option Certificate, as may be determined by the Committee.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.11pt">Neither the Plan nor this Option Certificate nor any provisions under either shall be construed so as to grant Awardee any right to remain in the employ of the Company.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">This Option Certificate shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.11pt">The headings contained in this Option Certificate are for reference purposes only and shall not affect in any way the meaning or interpretation of this Option Certificate.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.76pt">Notwithstanding anything in this Certificate or in the Plan to the contrary, the Option granted to Awardee pursuant to this Certificate and Stock obtained upon exercise of the Option shall be subject to mandatory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forfeiture, recovery by the Company or other action pursuant to any  compensation recovery </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">policy adopted by the Company or any Affiliate at any time, including, but not limited to, any policy adopted to comply with the requirements of Section 10D of the Exchange Act, the SEC&#8217;s final rules thereunder (Listing Standards for Recovery of Erroneously Awarded Compensation, 87 Fed. Reg. 73076-73142) and any applicable listing rules or other rules and regulations implementing the foregoing, or any other applicable laws which impose mandatory recoupment or forfeiture of incentive compensation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Certificate will be automatically amended by the Committee to comply with any such compensation recovery policy.</font></div><div style="margin-bottom:12pt;text-indent:58.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:2.04pt">The Company may deliver any documents related to this Option Award by electronic means and request your acceptance of this Certificate by electronic means.  You hereby consent to receive all applicable documentation by electronic delivery and to participate in the Plan through an on-line (and&#47;or voice activated) system established and maintained by the Company or the Company&#8217;s third-party stock plan administrator.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Non-Qualified Stock Option Certificate to be duly executed by its officers on the day and year first above written.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">OPTION CARE HEALTH, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">By&#58; </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Its&#58;&#160;&#160;&#160;&#160; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">By signing this Certificate or otherwise accepting this Certificate in a manner approved by the Company, you agree to all the terms and conditions described above and in the Plan document.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> 5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:98px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Accepted and agreed&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-optioncarexexecutive.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7db825f604894f639381772894ee158e_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. <br>RESTRICTED STOCK UNIT CERTIFICATE</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">THIS RESTRICTED STOCK UNIT CERTIFICATE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) evidences the grant by Option Care Health, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) of Restricted Stock Units of the Company to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Awardee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Company has established the Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan (as amended and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), a copy of which has been provided to Awardee&#59;</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Plan provides for the making of stock and other equity based Awards&#59; WHEREAS, the Plan and the Award contemplated hereby has been approved by the Company&#8217;s Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to grant to Awardee Restricted Stock Units in accordance with the terms and conditions of the Plan and subject to the provisions of this Certificate.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">NOW, THEREFORE, the following terms and conditions apply to this grant of Restricted Stock Units&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:23.31pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Certificate and of the Plan, Awardee is hereby granted an Award of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), which include the right to be issued the number of shares of Stock equal to the Restricted Stock Units, subject to the restrictions and vesting conditions set forth in this Certificate.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:22.76pt;text-decoration:underline">Delivery and Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. As soon as reasonably practicable following the vesting of the Restricted Stock Units as set forth in Section 3 of this Certificate but in any event by no later than sixty days following the date on which such vesting occurs, the Company will issue in the name of Awardee shares of Stock in settlement of such vested Restricted Stock Units. Upon settlement of a vested Restricted Stock Unit in Stock, such vested Restricted Stock Unit will be deemed cancelled and Awardee shall have no further rights to payment of any kind in respect of such Restricted Stock Unit.</font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font><br></font></div><div style="margin-top:5.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.76pt;text-decoration:underline">Issuance and Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:5.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.15pt">As of the Grant Date, all of the Restricted Stock Units are considered unvested Restricted Stock Units and are subject to forfeiture in their entirety for no consideration. Unvested Restricted Stock Units will vest and be settled &#91;INSERT VESTING SCHEDULE&#93;, in each case rounded to the nearest whole share.</font></div><div style="padding-right:5.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">Notwithstanding any provision of the Plan to the contrary, in the event the Restricted Stock Units are assumed or substituted by a successor in connection with a Change in Control, upon a Qualifying Termination all unvested Restricted Stock Units will vest and be settled in accordance with Section 2. For this purpose, a &#8220;Qualifying Termination&#8221; will mean an </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">involuntary termination of Awardee&#8217;s service without Cause during the 12-month period following a Change in Control. For this purpose, &#8220;Cause&#8221; will have the meaning given to such term in an employment or other similar agreement entered into by Awardee with the Company, or, in the absence of such an agreement, with respect to Awardee, will mean the occurrence of any one or more of the following reasons&#58; (i) the commission of a felony or other crime involving moral turpitude&#59; (ii) the commission of any act or omission involving dishonesty, disloyalty or fraud with respect to the Company&#59; (iii) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other repeated conduct causing the Company substantial public disgrace or substantial economic harm&#59; (iv) unsatisfactory performance of Awardee&#8217;s duties for the Company, as determined by the Board in its good-faith discretion&#59; (v) any intentional act or omission aiding or abetting a competitor, supplier or customer of the Company to the material disadvantage of the Company&#59; (vi) breach of fiduciary duty or willful misconduct with respect to the Company&#59; (vii) any other material breach of this Certificate or (viii) Awardee engaging in illegal business practices or other practices contrary to the written policies of the Company, including, without limitation, sexual misconduct, harassment or discrimination.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.03pt">All vesting of Awardee&#8217;s Restricted Stock Units under Section 3(a) and Section 3(c) is further conditioned upon Awardee having remained in the continuous employment of the Company through the Vesting Date or the consummation of a Change in Control, as applicable. If Awardee does not remain in the continuous employment of the Company, with the exception of 3(d), through such applicable date, then Awardee will immediately forfeit any unvested Restricted Stock Units in their entirety for no consideration, without any further action of the Company.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Notwithstanding any provisions of this Certificate to the contrary, if Participant&#8217;s service with the Company terminates due to Participant&#8217;s Retirement, then the Participant&#8217;s unvested portion of the Award shall continue to vest in accordance with the vesting schedule defined herein, and the Restricted Stock Units shall settle after each vesting date in accordance with Section 2. For purpose of this Award, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Retire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221; means that the Awardee voluntarily resigns employment and (i) has reached fifty-eight (58) years of age&#59; (ii) has provided ten (10) years of continuous employment with the Company&#59; (iii) has provided to the Company at least six (6) months advance written notice of intent to Retire and continues to provide services to the Company through such notice period, (iv) continuously provided services to the Company for at least twelve (12) months following the Date of Grant and is in good standing with the Company on the date of termination of service, (v) complies with all applicable post-employment covenants, and (vi) if requested by the Company, provides the Company with a release of claims in such form as required by the Company in its discretion.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:5.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.76pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:5.05pt;padding-left:78pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:34.5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.65pt">The Restricted Stock Units and any rights granted with respect to them may not be sold, pledged or otherwise transferred.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">Except as may be otherwise provided for in Section 3 above or in any agreement between the Company and Awardee, if Awardee&#8217;s service as an employee of the Company terminates, any unvested Restricted Stock Units will be forfeited in their entirety for no consideration by Awardee.</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Rights as Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Certificate, Awardee will be issued the number of shares of Stock equal to the number of Restricted Stock Units that are deemed to have vested as provided in Section 2. Awardee will have all of the rights of a holder of Stock with respect to such shares of Stock from and after, but not before, the date that Awardee delivers any other documents required by the Company and such shares of Stock are issued to Awardee as set forth in this Certificate. No cash dividends or dividend equivalents will accrue on the Restricted Stock Units.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. Awardee acknowledges and agrees that he or she is solely responsible for any and all taxes that may be assessed by any taxing authority arising in any way from the award, the grant of the Restricted Stock Units and the issuance of shares of Stock and that the Company shall not be liable for any such assessments. The grant of the award, the vesting of the Restricted Stock Units, and the settlement of the Restricted Stock Units in Stock may give rise to taxable income subject to withholding. No Stock will be delivered to an Awardee in settlement of vested Restricted Stock Units unless Awardee has made arrangements acceptable to the Company for payment of any federal, state, local or foreign withholding taxes that may be due as a result of the delivery of the Stock. Awardee hereby authorizes the Company to withhold from payroll or other amounts payable to Awardee any sums required to satisfy such withholding tax obligations, and otherwise agrees to satisfy such obligations in accordance with the provisions of Section 19.3 of the Plan. Awardee may elect to satisfy such withholding tax obligation by having the Company retain shares of Stock having a fair market value equal to the Company&#8217;s minimum withholding obligation. Awardee represents that he or she has consulted any tax adviser(s) that he or she deems advisable in connection with his or her grant of the Restricted Stock Units and acquisition of the Stock.</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:5.7pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:5.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The provisions of this Certificate and the Plan are intended to be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), and accordingly, to the maximum extent permitted, this Certificate and the Plan shall be interpreted and administered to be in compliance therewith. Notwithstanding anything contained in this Certificate to the contrary, Awardee shall not be considered to have terminated service with the Company for purposes of any payments under this Certificate which are subject to Section 409A until Awardee would be considered to have incurred a Separation from Service from the Company within the meaning of Section 409A. Each amount to be paid or benefit to be provided under this Certificate shall be construed as a separate and distinct payment for purposes of Section 409A. If payment under this Award is to be made within a designated period which does not begin and end within one calendar year, the Awardee does not have a right to designate the taxable year of the payment.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.76pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.05pt;padding-left:78pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.15pt">The Company and Awardee shall execute such further instruments and take such action as may reasonably be necessary to carry out the intent of this Certificate, as may be determined by the Committee.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">Any notice required or permitted under this Certificate by the Company shall be given in writing and shall be deemed effectively given upon delivery to Awardee at his or her address then on file with the Company.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.03pt">Neither the Plan nor this Certificate nor any provisions under either shall be construed so as to grant Awardee any right to remain in the employ of the Company.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:17.02pt">This Certificate and the terms and conditions of the Plan (as amended from time to time in accordance with the terms of the Plan), which are hereby incorporated by reference, constitute the terms and conditions with respect to the Restricted Stock Units and are binding upon the Company, its subsidiaries, affiliates and successors, and Awardee and Awardee&#8217;s heirs, executors, administrators and successors.</font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.03pt">Notwithstanding anything in this Certificate or in the Plan to the contrary, the award granted to Awardee pursuant to this Certificate and stock obtained upon settlement shall be subject to mandatory forfeiture, recovery by the Company or other action pursuant to any  compensation recovery policy adopted by the Company or any Affiliate at any time, including, but not limited to, any policy adopted to comply with the requirements of Section 10D of the Exchange Act, the SEC&#8217;s final rules thereunder (Listing Standards for Recovery of Erroneously Awarded Compensation, 87 Fed. Reg. 73076-73142) and any applicable listing rules or other rules and regulations implementing the foregoing, or any other applicable laws which impose mandatory recoupment or forfeiture of incentive compensation.  This Certificate will be automatically amended by the Committee to comply with any such compensation recovery policy.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.7pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.15pt">This Certificate shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:5.05pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:17.65pt">The headings contained in this Certificate are for reference purposes only and shall not affect in any way the meaning or interpretation of this Certificate. Any references to sections in this Certificate shall be to sections of this Certificate unless otherwise expressly stated as part of such reference. </font></div><div style="margin-top:5.05pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">The Company may deliver any documents related to this Restricted Stock Unit Award by electronic means and request your acceptance of this Certificate by electronic means.  You hereby consent to receive all applicable documentation by electronic delivery and to participate in the Plan through an on-line (and&#47;or voice activated) system established and maintained by the Company or the Company&#8217;s third-party stock plan administrator.</font></div><div style="margin-top:5.05pt;padding-left:42pt;padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. Each capitalized term used but not defined in this Certificate has the meaning assigned to such term in the Plan.</font></div><div style="padding-right:5.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. I understand and agree that this Certificate will not take effect unless and until I sign an Option Care Non-Competition and&#47;or Non-Solicitation and&#47;or Confidentiality Agreement with the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;).  If I do not sign the Restrictive Covenant Agreement, this Certificate shall not be effective and I shall not be entitled to the benefits provided for in this Certificate.  I further understand and agree that, to the extent required by applicable law, a certain amount of the equity award is provided as </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">consideration in exchange for signing the Restrictive Covenant Agreement.  If I do not sign the Restrictive Covenant Agreement I will not be entitled to this equity payment. </font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Restricted Stock Certificate to be duly executed by its officers thereunto on the day and year first above written.</font></div><div style="padding-left:216pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">OPTION CARE HEALTH, INC.</font></div><div style="padding-left:211.5pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Its&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:120%">By signing this Certificate or otherwise accepting this Certificate in a manner approved by the Company, you agree to all the terms and conditions described above and in the Plan document.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Accepted and agreed&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex103-optioncarexexecutive.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic58cf53f7a7f482dbdd475d93f436bda_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. <br>PERFORMANCE STOCK UNIT CERTIFICATE</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">THIS PERFORMANCE STOCK UNIT CERTIFICATE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) evidences the grant by Option Care Health, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) of Performance Stock Units of the Company to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Awardee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Company has established the Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan (as amended and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), a copy of which has been provided to Awardee&#59;</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Plan provides for the making of stock and other equity based Awards&#59; WHEREAS, the Plan and the Award contemplated hereby has been approved by the Company&#8217;s Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to grant to Awardee Performance Stock Units in accordance with the terms and conditions of the Plan and subject to the provisions of this Certificate.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">NOW, THEREFORE, the following terms and conditions apply to this grant of Performance Stock Units&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:23.31pt;text-decoration:underline">Grant of Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Certificate and of the Plan, Awardee is hereby granted an Award with a number of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Target Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), which include the right to be issued the number of shares of Stock equal to the Earned Performance Stock Units, subject to the restrictions and vesting conditions set forth in this Certificate. The number of Performance Stock Units that become Earned Performance Stock Units (as defined below) (up to a maximum of two times the Target Number of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Performance Stock Units) will be determined by the level of achievement of the Performance Goals in accordance with Annex I attached hereto.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:22.76pt;text-decoration:underline">Delivery and Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. As soon as reasonably practicable following the vesting of the Performance Stock Units as set forth in Section 3 of this Certificate but in any event by no later than sixty days following the date on which such vesting occurs, the Company will issue in the name of Awardee shares of Stock in settlement of the Earned Performance Stock Units. Upon settlement of an Earned Performance Stock Unit in Stock, such Performance Stock Unit will be deemed cancelled and Awardee shall have no further rights to payment of any kind in respect of such Performance Stock Unit.</font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font><br></font></div><div style="margin-top:5.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.76pt;text-decoration:underline">Issuance and Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:5.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.15pt">As of the Grant Date, all of the Performance Stock Units are considered unvested and unearned Performance Stock Units and are subject to forfeiture in their entirety for no consideration. Unless otherwise set forth in Section 3(c), (i) Performance Stock Units that are earned in accordance with Annex I (such earned Performance Stock Units, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Earned Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) will vest on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), and (ii) any Performance Stock Units that do not become Earned Performance Stock Units </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">in accordance with Annex I will be forfeited in their entirety for no consideration on the date the Committee certifies the achievement of the Performance Goals. The Committee will certify the achievement of the Performance Goals no later than &#91;DATE&#93;.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">All vesting of Awardee&#8217;s Performance Stock Units under this Section 3 is further conditioned upon Awardee having remained in the continuous employment of the Company through the Vesting Date. Unless otherwise set forth in Section 3(c) or 3(d), if Awardee does not remain in the continuous employment of the Company through the Vesting Date, then Awardee will immediately forfeit any Performance Stock Units (whether or not such Performance Stock Units are Earned Performance Stock Units) in their entirety for no consideration, without any further action of the Company.</font></div><div style="padding-right:5.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.03pt">Notwithstanding any provision of the Plan to the contrary, (i) in the event of a Change in Control that occurs during the Performance Period, then the Target Number of the Performance Stock Units will be deemed Earned Performance Stock Units and vest as of such Change in Control and be settled in accordance with Section 2&#59; and (ii) in the event of a Change in Control that occurs after the Performance Period, but before the Vesting Date, then the Earned Performance Stock Units will vest as of such Change in Control and be settled in accordance with Section 2. The balance of the Performance Stock Units that are not earned or do not vest upon a Change in Control shall be immediately forfeited and cancelled for no consideration.</font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:39pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:14.02pt">Notwithstanding any provisions of this Certificate to the contrary, if Participant&#8217;s service with the Company terminates due to Participant&#8217;s Retirement, then Participant shall receive a pro-rated portion of Earned Performance Units, with such amount determined by dividing the number of actively employed days after the Grant Date by one thousand and ninety-five (1,095), and multiplying the quotient by the number of any Earned Performance Stock Units following the end of the Performance Period, which shall vest on the Vesting Date unless earlier vested in accordance with Section 3(c) and be settled pursuant to Section 2.  For purpose of this Award, &#8220;Retirement&#8221; or &#8220;Retire&#8221; means that the Awardee voluntarily resigns employment and (i) has reached fifty-eight (58) years of age&#59; (ii) has provided ten (10) years of continuous employment with the Company&#59; (iii) has provided to the Company at least six (6) months advance written notice of intent to Retire and continues to provide services to the Company through such notice period, (iv) continuously provided services to the Company for at least twelve (12) months following the Grant Date and is in good standing with the Company on the date of termination of service, (v) complies with all applicable post-employment covenants, and (vi) if requested by the Company, provides the Company with a release of claims in such form as required by the Company in its discretion.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:5.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.76pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:5.05pt;padding-left:78pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:34.5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.65pt">The Performance Stock Units and any rights granted with respect to them may not be sold, pledged or otherwise transferred.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">Except as may be otherwise provided for in Section 3 above or in any agreement between the Company and Awardee, if Awardee&#8217;s service as an employee of the Company </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">terminates, any unvested Performance Stock Units will be forfeited in their entirety for no consideration by Awardee.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Rights as Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Certificate, Awardee will be issued the number of shares of Stock equal to the Earned Performance Stock Units as provided in Section 2. Awardee will have all of the rights of a holder of Stock with respect to such shares of Stock from and after, but not before, the date that Awardee delivers any other documents required by the Company and such shares of Stock are issued to Awardee as set forth in this Certificate. No cash dividends or dividend equivalents will accrue on the Performance Stock Units.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.7pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Awardee acknowledges and agrees that he or she is solely responsible for any and all taxes that may be assessed by any taxing authority arising in any way from the award, the grant of the Performance Stock Units and the issuance of shares of Stock and that the Company shall not be liable for any such assessments. The grant of the award, the vesting of the Performance Stock Units, and the settlement of the Earned Performance Stock Units in Stock may give rise to taxable income subject to withholding. No Stock will be delivered to an Awardee in settlement of vested Restricted Stock Units unless Awardee has made arrangements acceptable to the Company for payment of any federal, state, local or foreign withholding taxes that may be due as a result of the delivery of the Stock. Awardee hereby authorizes the Company to withhold from payroll or other amounts payable to Awardee any sums required to satisfy such withholding tax obligations, and otherwise agrees to satisfy such obligations in accordance with the provisions of Section 19.3 of the Plan. Awardee may elect to satisfy such withholding tax obligation by having the Company retain shares of Stock having a fair market value equal to the Company&#8217;s minimum withholding obligation. Awardee represents that he or she has consulted any tax adviser(s) that he or she deems advisable in connection with his or her grant of the Performance Stock Units and acquisition of the shares.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.7pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The provisions of this Award and the Plan are intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;), and accordingly, to the maximum extent permitted, this Certificate and the Plan shall be interpreted and administered to be in compliance therewith. Notwithstanding anything contained in this Certificate to the contrary, Awardee shall not be considered to have terminated service with the Company for purposes of any payments under this Certificate which are subject to Section 409A until Awardee would be considered to have incurred a Separation from Service from the Company within the meaning of Section 409A. Each amount to be paid or benefit to be provided under this Certificate shall be construed as a separate and distinct payment for purposes of Section 409A. If payment under this Award is to be made within a designated period which does not begin and end within one calendar year, the Awardee does not have a right to designate the taxable year of the payment.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:27.76pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.05pt;padding-left:78pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.15pt">The Company and Awardee shall execute such further instruments and take such action as may reasonably be necessary to carry out the intent of this Certificate, as may be determined by the Committee.</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">Any notice required or permitted under this Certificate by the Company shall be given in writing and shall be deemed effectively given upon delivery to Awardee at his or her address then on file with the Company.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.03pt">Neither the Plan nor this Certificate nor any provisions under either shall be construed so as to grant Awardee any right to remain in the employ of the Company.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:17.02pt">This Certificate and the terms and conditions of the Plan (as amended from time to time in accordance with the terms of the Plan), which are hereby incorporated by reference, constitute the terms and conditions with respect to the Performance Stock Units and are binding upon the Company, its subsidiaries, affiliates and successors, and Awardee and Awardee&#8217;s heirs, executors, administrators and successors.</font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:18.03pt">Notwithstanding anything in this Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">or in the Plan to the contrary, the award granted to Awardee pursuant to this Certificate and stock obtained upon settlement shall be subject to mandatory forfeiture, recovery by the Company or other action pursuant to any  compensation recovery policy adopted by the Company or any Affiliate at any time, including, but not limited to, any policy adopted to comply with the requirements of Section 10D of the Exchange Act, the SEC&#8217;s final rules thereunder (Listing Standards for Recovery of Erroneously Awarded Compensation, 87 Fed. Reg. 73076-73142) and any applicable listing rules or other rules and regulations implementing the foregoing, or any other applicable laws which impose mandatory recoupment or forfeiture of incentive compensation.  This Certificate will be automatically amended by the Committee to comply with any such compensation recovery policy.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.7pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.15pt">This Certificate shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:5.05pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:17.65pt">The headings contained in this Certificate are for reference purposes only and shall not affect in any way the meaning or interpretation of this Certificate. Any references to sections in this Certificate shall be to sections of this Certificate unless otherwise expressly stated as part of such reference. </font></div><div style="margin-top:5.05pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:16.9pt">The Company may deliver any documents related to this Restricted Stock Unit Award by electronic means and request your acceptance of this Certificate by electronic means.  You hereby consent to receive all applicable documentation by electronic delivery and to participate in the Plan through an on-line (and&#47;or voice activated) system established and maintained by the Company or the Company&#8217;s third-party stock plan administrator.</font></div><div style="margin-top:5.05pt;padding-left:42pt;padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. Each capitalized term used but not defined in this Certificate has the meaning assigned to such term in the Plan.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.76pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. I understand and agree that this Certificate will not take effect unless and until I sign an Option Care Non-Competition and&#47;or Non-Solicitation and&#47;or Confidentiality Agreement with the Company (&#8220;Restrictive Covenant Agreement&#8221;).  If I do not sign the Restrictive Covenant Agreement, this Certificate shall not be effective and I shall not be entitled to the benefits provided for in this Certificate.  I further understand and agree that, to the </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">extent required by applicable law, a certain amount of the equity award is provided as consideration in exchange for signing the Restrictive Covenant Agreement.  If I do not sign the Restrictive Covenant Agreement I will not be entitled to this equity payment. </font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Performance Stock Unit Certificate to be duly executed by its officers thereunto on the day and year first above written.</font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">OPTION CARE HEALTH, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Its&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Accepted and agreed&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNEX&#160;I<br>PERFORMANCE METRICS</font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex104-optioncarexdirectorx.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i43ff7d480849468f8449ffa1d56e5d48_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OPTION CARE HEALTH, INC. <br>RESTRICTED STOCK UNIT CERTIFICATE</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THIS RESTRICTED STOCK UNIT CERTIFICATE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) evidences the grant by Option Care Health, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Restricted Stock Units of the Company to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Company has established the Option Care Health, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Amended and Restated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> 2018 Equity Incentive Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Plan provides for the grant of stock and other equity based Awards&#59; and</font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to grant Restricted Stock Units to the Participant in accordance with the terms and conditions of the Plan and subject to the provisions of this Certificate, as approved by the Management Development &#38; Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Company&#8217;s Board of Directors.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, the following terms and conditions apply to the grant of Restricted Stock Units&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.3pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Certificate and of the Plan, the Participant is hereby granted an Award of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which include the right to be issued the number of shares of Stock equal to the Restricted Stock Units, subject to the restrictions and vesting conditions set forth in this Certificate.</font></div><div style="padding-left:40.45pt;padding-right:5.7pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:5pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.75pt;text-decoration:underline">Issuance of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As soon as reasonably practicable following the vesting of the Restricted Stock Units as set forth in Section 3 of this Certificate but in any event by no later than ninety days following the date on which such vesting occurs, the Company will issue in the name of the Participant shares of Stock in settlement of such vested Restricted Stock Units. Upon settlement of a vested Restricted Stock Unit in a share of Stock, such vested Restricted Stock Unit will be deemed cancelled and the Participant shall have no further rights to payment of any kind in respect of such Restricted Stock Unit. The Participant will have all of the rights of a holder of Stock with respect to such shares of Stock from and after the issuance of the shares of Stock to the Participant and the Participant becomes a stockholder of record with respect to such shares.</font></div><div style="margin-top:5.05pt;padding-left:4.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.25pt;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  As of the Grant Date, all of the Restricted Stock Units are considered unvested Restricted Stock Units, unless one of the vesting conditions set forth in this Section 3 is satisfied.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Unvested Restricted Stock Units will vest and become non-forfeitable to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the shares of Stock (rounded to the nearest whole share) on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> so that the Restricted Stock Units shall vest and become non-forfeitable as to all shares of Stock on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;__&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> such anniversary of the date  hereof, subject to the Participant&#8217;s continued service on the Board through such date. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">In the event of a Change in Control, the Restricted Stock Units will vest and become non-forfeitable as to 100% of the shares of Stock immediately prior to such Change in Control, subject to the Participant&#8217;s continued service on the Board through such date&#59; provided, that if the Change in Control is not a &#8220;change in the ownership of the Company,&#8221; a &#8220;change in the effective control of the Company,&#8221; or a &#8220;change in the ownership of a substantial portion of the assets of the Company&#8221; as such terms are defined in Section 1.409A-3(i)(5) of the U.S. Treasury Regulations, then the Restricted Stock Units shall vest upon such Change in Control and shall be settled at the times specified in Section 3(a) or 3(c) of this Certificate, as applicable</font><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">In the event the Participant&#8217;s service on the Board terminates for any reason other than the removal of the Participant for Cause (as defined below), the Restricted Stock Units will vest and become non-forfeitable as to 100% of the shares of Stock on the termination date. In the event the Participant&#8217;s service on the Board is terminated due to a removal of the Participant for Cause (as defined below), any unvested Restricted Stock Units will be forfeited in their entirety for no consideration to the Participant.  For this purpose, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; (A) shall have the meaning set forth in an applicable director agreement or similar agreement between the Participant and the Company or (B) if no such agreement exists or &#8220;Cause&#8221; is not defined in such agreement, shall mean (i) the Participant&#8217;s continued failure substantially to perform the Participant&#8217;s duties (other than as a result of total or partial incapacity due to physical or mental illness) for a period of ten (10) days following written notice by the Company to Participant of such failure, (ii) dishonesty in the performance of the Participant&#8217;s duties, (iii) an act or acts on the Participant&#8217;s part constituting (x) a felony under the laws of the United States or any state thereof or (y) a misdemeanor involving moral turpitude, (iv) the Participant&#8217;s willful malfeasance or willful misconduct in connection with the Participant&#8217;s duties or any act or omission which is injurious to the financial condition or business reputation of the Company or any of subsidiaries, or (v) a breach of any covenant regarding confidential information, solicitation, or competitive activity, or any fiduciary duty of the Participant. </font></div><div style="margin-top:5.05pt;padding-left:4.5pt;text-indent:37.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.75pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Restricted Stock Units and any rights granted with respect thereto hereunder may not be sold, pledged or otherwise transferred other than in accordance with Section 13 of the Plan.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.05pt;padding-left:78pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.8pt">The Company and the Participant shall execute such further instruments and take such action as may reasonably be necessary to carry out the intent of this Certificate, as may be determined by the Committee.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.8pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.18pt">Any notice required or permitted under this Certificate by the Company shall be given in writing and shall be deemed effectively given upon delivery to Participant at his or her address then on file with the Company.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.8pt">This Certificate and the terms and conditions of the Plan (as amended from time to time in accordance with the terms of the Plan), which are hereby incorporated by reference, constitute the terms and conditions with respect to the Restricted Stock Units and are binding upon the Company, its subsidiaries, affiliates and successors, and the Participant and the Participant&#8217;s heirs, executors, administrators and successors.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.9pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.18pt">This Certificate shall be construed in accordance with, and its interpretation shall be governed by applicable federal law, and otherwise by the laws of the State of Delaware.</font></div><div style="margin-top:0.05pt;padding-left:42pt;padding-right:5.7pt"><font><br></font></div><div style="margin-top:0.15pt;padding-left:6pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.8pt">The headings contained in this Certificate are for reference purposes only and shall not affect in any way the meaning or interpretation of this Certificate. Any references to sections in this Certificate shall be to sections of this Certificate unless otherwise expressly stated as part of such reference.</font></div><div style="margin-top:0.15pt;padding-left:42pt;padding-right:5.85pt"><font><br></font></div><div style="margin-top:0.15pt;padding-left:6pt;padding-right:5.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.02pt">The Company may deliver any documents related to this Restricted Stock Unit Award by electronic means and request your acceptance of this Certificate by electronic means.  You hereby consent to receive all applicable documentation by electronic delivery and to participate in the Plan </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div style="margin-top:0.15pt;padding-left:6pt;padding-right:5.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">through an on-line (and&#47;or voice activated) system established and maintained by the Company or the Company&#8217;s third-party stock plan administrator.</font></div><div style="margin-top:0.15pt;padding-right:5.85pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21.75pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each capitalized term used but not defined in this Certificate has the meaning assigned to such term in the Plan.</font></div><div style="padding-left:216pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OPTION CARE HEALTH, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Its&#58; </font></div><div style="padding-left:216pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">By signing this Certificate or otherwise accepting this Certificate in a manner approved by the Company, you agree to all the terms and conditions described above and in the Plan document.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accepted and agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>opch-ex311x2024033110xq.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ice4ee4c5961941479128991aa62dba39_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 31.1&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Rademacher, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.&#59; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;23, 2024 </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Principal Executive Officer</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>opch-ex312x2024033110xq.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iceffc7f254ad454380e808b1bf519a3e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Shapiro, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.&#59; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;23, 2024 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Principal Financial Officer </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>opch-ex321x2024033110xq.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i18da4429f4274481a8c89ee351302244_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the Quarterly Report of Option Care Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John Rademacher, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;23, 2024 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Rademacher</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Principal Executive Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>opch-ex322x2024033110xq.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i51669498a3d24dc8b65dc1b6102882b6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the Quarterly Report of Option Care Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael Shapiro, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  April&#160;23, 2024 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Shapiro</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Principal Financial Officer </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>bios-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3aa0ccbf-2345-461d-8bfe-5351acc3ea16,g:764d9622-b6cc-4198-a6bd-78d38846c16c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bios="http://www.bioscrip.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bioscrip.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bios-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.bioscrip.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical">
        <link:definition>0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>0000008 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://www.bioscrip.com/role/REVENUE">
        <link:definition>0000010 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bioscrip.com/role/INCOMETAXES">
        <link:definition>0000011 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARE" roleURI="http://www.bioscrip.com/role/EARNINGSPERSHARE">
        <link:definition>0000012 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.bioscrip.com/role/LEASES">
        <link:definition>0000013 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000014 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETS" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS">
        <link:definition>0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESS" roleURI="http://www.bioscrip.com/role/INDEBTEDNESS">
        <link:definition>0000016 - Disclosure - INDEBTEDNESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTS" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS">
        <link:definition>0000017 - Disclosure - DERIVATIVE INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASURMENTS" roleURI="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS">
        <link:definition>0000018 - Disclosure - FAIR VALUE MEASURMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATION" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION">
        <link:definition>0000020 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000021 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000022 - Disclosure - RELATED-PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://www.bioscrip.com/role/REVENUETables">
        <link:definition>9954472 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARETables" roleURI="http://www.bioscrip.com/role/EARNINGSPERSHARETables">
        <link:definition>9954473 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.bioscrip.com/role/LEASESTables">
        <link:definition>9954474 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSTables" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables">
        <link:definition>9954476 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSTables" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSTables">
        <link:definition>9954477 - Disclosure - INDEBTEDNESS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSTables" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables">
        <link:definition>9954478 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails">
        <link:definition>9954479 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUENetRevenueEarnedbyCategoryofPayerDetails" roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails">
        <link:definition>9954481 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.bioscrip.com/role/INCOMETAXESDetails">
        <link:definition>9954482 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9954483 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" roleURI="http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails">
        <link:definition>9954484 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails">
        <link:definition>9954485 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9954486 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9954486 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTDetails" roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails">
        <link:definition>9954487 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails">
        <link:definition>9954488 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSDebtDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails">
        <link:definition>9954489 - Disclosure - INDEBTEDNESS - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSDebtDetails_1" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1">
        <link:definition>9954489 - Disclosure - INDEBTEDNESS - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails">
        <link:definition>9954490 - Disclosure - INDEBTEDNESS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSLongTermDebtMaturitiesDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails">
        <link:definition>9954491 - Disclosure - INDEBTEDNESS - Long Term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails">
        <link:definition>9954492 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails">
        <link:definition>9954493 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails">
        <link:definition>9954494 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails">
        <link:definition>9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDINCENTIVECOMPENSATIONDetails" roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails">
        <link:definition>9954496 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>9954497 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>9954498 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bios_A2015WarrantsMember" abstract="true" name="A2015WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_AccountsReceivableBenchmarkMember" abstract="true" name="AccountsReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_EquipmentFurnitureAndOtherMember" abstract="true" name="EquipmentFurnitureAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_CommercialCustomerMember" abstract="true" name="CommercialCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_InfusionPumpsMember" abstract="true" name="InfusionPumpsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" abstract="false" name="StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" abstract="false" name="StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_GovernmentHealthcareProgramsMember" abstract="true" name="GovernmentHealthcareProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_A2018PlanMember" abstract="true" name="A2018PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_SecondLienTermLoanMember" abstract="true" name="SecondLienTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_FirstLienTermLoanMember" abstract="true" name="FirstLienTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" abstract="false" name="ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bios_GovernmentCustomerMember" abstract="true" name="GovernmentCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_FirstLienCreditAgreementSecondAmendmentMember" abstract="true" name="FirstLienCreditAgreementSecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bios_A2017WarrantsMember" abstract="true" name="A2017WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_HCIIncentiveUnitsMember" abstract="true" name="HCIIncentiveUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_FiniteLivedCustomerListsNet" abstract="false" name="FiniteLivedCustomerListsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_PerformanceStockUnitMember" abstract="true" name="PerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_LargestPayerMember" abstract="true" name="LargestPayerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bios_RestrictedStockAwardMember" abstract="true" name="RestrictedStockAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_LegacyHealthSystemsMember" abstract="true" name="LegacyHealthSystemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" abstract="false" name="FiniteLivedIntangibleAssetsNetExcludingCustomerLists" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bios_PatientCustomerMember" abstract="true" name="PatientCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_NumberOfServiceLocations" abstract="false" name="NumberOfServiceLocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bios_NumberOfInfusionSites" abstract="false" name="NumberOfInfusionSites" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bios_FourVendorsMember" abstract="true" name="FourVendorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bios_CreditAgreementsEnteredInto2019Member" abstract="true" name="CreditAgreementsEnteredInto2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>bios-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3aa0ccbf-2345-461d-8bfe-5351acc3ea16,g:764d9622-b6cc-4198-a6bd-78d38846c16c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bios-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9711fe91-38d0-4782-9fb0-e00b92cc7705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_15f83d76-08bc-4aa1-9fe4-f3529cab4761" xlink:href="bios-20240331.xsd#bios_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9711fe91-38d0-4782-9fb0-e00b92cc7705" xlink:to="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_15f83d76-08bc-4aa1-9fe4-f3529cab4761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96b25394-c2bd-4a5e-8567-fffaecf2e794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9711fe91-38d0-4782-9fb0-e00b92cc7705" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96b25394-c2bd-4a5e-8567-fffaecf2e794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ccb6aeb2-7637-40dd-8ad2-fbd470d442bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9711fe91-38d0-4782-9fb0-e00b92cc7705" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ccb6aeb2-7637-40dd-8ad2-fbd470d442bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_35f26884-3762-4e41-a441-c04d2cf8426a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9711fe91-38d0-4782-9fb0-e00b92cc7705" xlink:to="loc_us-gaap_LongTermDebtCurrent_35f26884-3762-4e41-a441-c04d2cf8426a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_778b07ac-23cd-4b63-aeb8-aadb8d31ac1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9711fe91-38d0-4782-9fb0-e00b92cc7705" xlink:to="loc_us-gaap_AccountsPayableCurrent_778b07ac-23cd-4b63-aeb8-aadb8d31ac1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dce68640-ff98-42b4-a8a4-ff4422c7655a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dce68640-ff98-42b4-a8a4-ff4422c7655a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_54fae1de-b628-403d-bc6a-d23500a070c2" xlink:href="bios-20240331.xsd#bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:to="loc_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_54fae1de-b628-403d-bc6a-d23500a070c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_22a8e8f9-75a8-4be4-bc45-b161ed3c8b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:to="loc_us-gaap_Goodwill_22a8e8f9-75a8-4be4-bc45-b161ed3c8b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f9522ca1-4a78-4bd0-9683-1041c1f1dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f9522ca1-4a78-4bd0-9683-1041c1f1dbc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_415f8fa4-beb1-4a35-a461-34fd5b1a32b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_415f8fa4-beb1-4a35-a461-34fd5b1a32b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FiniteLivedCustomerListsNet_58d0030e-2404-4cb3-8ae9-f92612e8a338" xlink:href="bios-20240331.xsd#bios_FiniteLivedCustomerListsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_dc4ee113-f994-4567-8aa5-c58effbeecc3" xlink:to="loc_bios_FiniteLivedCustomerListsNet_58d0030e-2404-4cb3-8ae9-f92612e8a338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f62cbf46-4960-4147-8851-99a984c2afe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_639ce84c-43cd-438c-9509-530593f0ce08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f62cbf46-4960-4147-8851-99a984c2afe9" xlink:to="loc_us-gaap_LiabilitiesCurrent_639ce84c-43cd-438c-9509-530593f0ce08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_ac561001-98c2-41e9-b874-a34328a09c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f62cbf46-4960-4147-8851-99a984c2afe9" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_ac561001-98c2-41e9-b874-a34328a09c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dedd267f-f4db-42f4-8f77-c25a02f7411d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c412458-0af2-4938-adce-c5f585674a91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dedd267f-f4db-42f4-8f77-c25a02f7411d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c412458-0af2-4938-adce-c5f585674a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6c8574f2-695a-44c9-85c1-6b0470f717a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dedd267f-f4db-42f4-8f77-c25a02f7411d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6c8574f2-695a-44c9-85c1-6b0470f717a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c1535db3-073b-4e08-8862-bfa83e7639f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dedd267f-f4db-42f4-8f77-c25a02f7411d" xlink:to="loc_us-gaap_InventoryNet_c1535db3-073b-4e08-8862-bfa83e7639f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb0ee511-39ee-47aa-8081-ef9647d15571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dedd267f-f4db-42f4-8f77-c25a02f7411d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb0ee511-39ee-47aa-8081-ef9647d15571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_370ea31b-0c87-4bf2-813a-d25e98dc01a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4a64deb0-3b24-4ed5-a50a-441a9182b934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_370ea31b-0c87-4bf2-813a-d25e98dc01a6" xlink:to="loc_us-gaap_AssetsCurrent_4a64deb0-3b24-4ed5-a50a-441a9182b934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_239af796-1057-4630-bebf-54efc552f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_370ea31b-0c87-4bf2-813a-d25e98dc01a6" xlink:to="loc_us-gaap_AssetsNoncurrent_239af796-1057-4630-bebf-54efc552f52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ef995baa-2f01-46f9-9947-188ee6a04e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ef995baa-2f01-46f9-9947-188ee6a04e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_45df6992-11b2-4a71-a357-a80da692f53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:to="loc_us-gaap_PreferredStockValue_45df6992-11b2-4a71-a357-a80da692f53d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_083eba1e-8efd-43a5-ad6e-84a5bea92a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:to="loc_us-gaap_TreasuryStockCommonValue_083eba1e-8efd-43a5-ad6e-84a5bea92a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_42add091-8ceb-4877-a7aa-bcc85817e0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_42add091-8ceb-4877-a7aa-bcc85817e0ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a56f4be2-7beb-41ed-b580-aa54eba71cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:to="loc_us-gaap_CommonStockValue_a56f4be2-7beb-41ed-b580-aa54eba71cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f402fa9c-ba4d-40e9-a561-c39cea6dff1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_565abc65-2817-4161-a9ea-d6bcf2887465" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f402fa9c-ba4d-40e9-a561-c39cea6dff1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef501018-86df-43ed-b6f9-c7e6e0925288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_705662ff-698f-49e2-b763-b21ad5f1b8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef501018-86df-43ed-b6f9-c7e6e0925288" xlink:to="loc_us-gaap_StockholdersEquity_705662ff-698f-49e2-b763-b21ad5f1b8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e95d02aa-18f8-40b3-8a32-6cf277d6295f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef501018-86df-43ed-b6f9-c7e6e0925288" xlink:to="loc_us-gaap_Liabilities_e95d02aa-18f8-40b3-8a32-6cf277d6295f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_01f4b927-ffc2-4ce7-831f-ec33ac1ca092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3553560-2881-4394-8612-39bc6966f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_01f4b927-ffc2-4ce7-831f-ec33ac1ca092" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3553560-2881-4394-8612-39bc6966f34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_250f51a7-da8c-4184-b2d1-a86cb7053e81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_01f4b927-ffc2-4ce7-831f-ec33ac1ca092" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_250f51a7-da8c-4184-b2d1-a86cb7053e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d7bb36d-e1eb-4e86-8f03-cbae71e4f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_01f4b927-ffc2-4ce7-831f-ec33ac1ca092" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d7bb36d-e1eb-4e86-8f03-cbae71e4f8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fdb2aae9-c9b9-4285-8ae3-d5d17bc5044d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_01f4b927-ffc2-4ce7-831f-ec33ac1ca092" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fdb2aae9-c9b9-4285-8ae3-d5d17bc5044d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_114cd9df-5bf8-4d76-9f67-e955a0aae416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_994e80a8-c28f-45a8-9cec-0cbe672d129c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_114cd9df-5bf8-4d76-9f67-e955a0aae416" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_994e80a8-c28f-45a8-9cec-0cbe672d129c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_890e1ce2-e9de-4792-8c7d-b9021dedd51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_114cd9df-5bf8-4d76-9f67-e955a0aae416" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_890e1ce2-e9de-4792-8c7d-b9021dedd51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0d6b199-12d6-4ae0-bf5b-64fc0eadbac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0149e79f-2f85-46e4-ad42-f28a8c284b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d0d6b199-12d6-4ae0-bf5b-64fc0eadbac5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0149e79f-2f85-46e4-ad42-f28a8c284b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c9b836ed-bf91-49dd-a1b9-c16fd357a5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d0d6b199-12d6-4ae0-bf5b-64fc0eadbac5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c9b836ed-bf91-49dd-a1b9-c16fd357a5cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ba60ac8e-44b2-4150-89d8-c79f1971bcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_44bdf312-2be3-4f52-a0d7-494b0c5bcac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ba60ac8e-44b2-4150-89d8-c79f1971bcf2" xlink:to="loc_us-gaap_GrossProfit_44bdf312-2be3-4f52-a0d7-494b0c5bcac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9638b4f9-7cfd-4639-93da-13bcf7a072b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ba60ac8e-44b2-4150-89d8-c79f1971bcf2" xlink:to="loc_us-gaap_OperatingExpenses_9638b4f9-7cfd-4639-93da-13bcf7a072b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5995679d-06e4-4fba-8f43-80a6bedc90d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f7afd518-bd1e-417a-aac7-24afd973221b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5995679d-06e4-4fba-8f43-80a6bedc90d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f7afd518-bd1e-417a-aac7-24afd973221b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d471422c-d69a-4dd2-aa52-3481b166649a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c0c5266-7f1c-4ea6-a809-c94f911248b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d471422c-d69a-4dd2-aa52-3481b166649a" xlink:to="loc_us-gaap_NetIncomeLoss_5c0c5266-7f1c-4ea6-a809-c94f911248b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_eb34b0b8-0589-48c9-b021-4c3d703395be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d471422c-d69a-4dd2-aa52-3481b166649a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_eb34b0b8-0589-48c9-b021-4c3d703395be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_531faf6a-e73b-4eb5-a3ee-ddb31a0cce41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6ba6b394-d462-4b9d-9f0d-8e1e66e442aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_531faf6a-e73b-4eb5-a3ee-ddb31a0cce41" xlink:to="loc_us-gaap_InterestExpense_6ba6b394-d462-4b9d-9f0d-8e1e66e442aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_60f93107-2026-4139-b0a6-1e7c65ac7be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_531faf6a-e73b-4eb5-a3ee-ddb31a0cce41" xlink:to="loc_us-gaap_InvestmentIncomeNet_60f93107-2026-4139-b0a6-1e7c65ac7be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8607a2cc-cfc8-4a4a-8dcd-38033ff6ff96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_531faf6a-e73b-4eb5-a3ee-ddb31a0cce41" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8607a2cc-cfc8-4a4a-8dcd-38033ff6ff96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14045618-3989-425f-9937-c7bb71560dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fe0d554c-6b53-4051-bd9d-400c82bd9346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14045618-3989-425f-9937-c7bb71560dd0" xlink:to="loc_us-gaap_OperatingIncomeLoss_fe0d554c-6b53-4051-bd9d-400c82bd9346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4490d8e4-ace9-4208-9b48-ec91afc91d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14045618-3989-425f-9937-c7bb71560dd0" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4490d8e4-ace9-4208-9b48-ec91afc91d42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5221f62d-3db3-447a-a634-f9341b51f0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a07edf1b-1cc6-40a1-b9c8-b3e0e32df83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_5221f62d-3db3-447a-a634-f9341b51f0e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a07edf1b-1cc6-40a1-b9c8-b3e0e32df83e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_db5d8502-6e80-4bf0-8aca-47cbd3808f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_5221f62d-3db3-447a-a634-f9341b51f0e6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_db5d8502-6e80-4bf0-8aca-47cbd3808f2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c13bf84-a647-4018-b1b1-d709951368b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78229575-09e9-44b4-a5d2-cb432d1fc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c13bf84-a647-4018-b1b1-d709951368b9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_78229575-09e9-44b4-a5d2-cb432d1fc3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_4f0c5d9c-ba80-4133-8707-aceda446c47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_4f0c5d9c-ba80-4133-8707-aceda446c47d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eb0a5148-d5b9-4691-8b0c-5d21274b0ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eb0a5148-d5b9-4691-8b0c-5d21274b0ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5d503dbe-2f2f-407b-9e8e-616a57129b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5d503dbe-2f2f-407b-9e8e-616a57129b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fdf37120-7801-49ce-afce-ecd414069f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fdf37120-7801-49ce-afce-ecd414069f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_55ada9ba-1966-4e37-bffa-cfd56b4a64e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_55ada9ba-1966-4e37-bffa-cfd56b4a64e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_59289b7b-60d7-4724-b82d-7b72a29f10dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_59289b7b-60d7-4724-b82d-7b72a29f10dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a0721302-d4fa-4cc2-909c-825d4d0e04ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_OperatingLeasePayments_a0721302-d4fa-4cc2-909c-825d4d0e04ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9bf1b6c0-9a80-4c8c-8768-788218df75e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_9bf1b6c0-9a80-4c8c-8768-788218df75e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_37c4460c-d99b-4637-8cc8-b9c3a124a86b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_37c4460c-d99b-4637-8cc8-b9c3a124a86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d69ff02f-75da-4f44-a7c5-51b0e7e7270d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d69ff02f-75da-4f44-a7c5-51b0e7e7270d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_d7c02db8-9721-4a33-aca5-e2b7f221fc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_d7c02db8-9721-4a33-aca5-e2b7f221fc61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d908d2b-e282-4e05-9d35-a83fb6ca3145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_NetIncomeLoss_0d908d2b-e282-4e05-9d35-a83fb6ca3145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_3a8da435-cbe6-4d6d-955a-4bdbe5a6bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_3a8da435-cbe6-4d6d-955a-4bdbe5a6bb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4b50bb11-2f45-40ed-b741-2258062f3246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4b50bb11-2f45-40ed-b741-2258062f3246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_56124b83-be9e-4e4b-878a-72e49511a79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_56124b83-be9e-4e4b-878a-72e49511a79c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_de746844-6953-4f8f-b4b5-779fc1f01245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_de746844-6953-4f8f-b4b5-779fc1f01245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_133d7b64-5b2f-4dc3-9b76-46dc0bb8c727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c25f41cf-2fec-4d21-a119-dc06cc6e8b20" xlink:to="loc_us-gaap_ShareBasedCompensation_133d7b64-5b2f-4dc3-9b76-46dc0bb8c727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c8a3c9d-ca94-489f-a0c8-b3f07f0e3d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8451b491-8184-472d-811e-50ca820bddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c8a3c9d-ca94-489f-a0c8-b3f07f0e3d9a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8451b491-8184-472d-811e-50ca820bddd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b91136b1-8d64-43ba-8727-a925ddfd845e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c8a3c9d-ca94-489f-a0c8-b3f07f0e3d9a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b91136b1-8d64-43ba-8727-a925ddfd845e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_5be71bb2-91fc-407a-8675-e4a5e3e0fab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c8a3c9d-ca94-489f-a0c8-b3f07f0e3d9a" xlink:to="loc_us-gaap_RepaymentsOfDebt_5be71bb2-91fc-407a-8675-e4a5e3e0fab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_9c6620a0-5c1a-4c84-8214-afd074f52b49" xlink:href="bios-20240331.xsd#bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c8a3c9d-ca94-489f-a0c8-b3f07f0e3d9a" xlink:to="loc_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_9c6620a0-5c1a-4c84-8214-afd074f52b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41768b66-78f5-4f76-b6cf-a67a2aa66d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7dad6d9b-1ab0-4357-8284-a75ddedbd37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41768b66-78f5-4f76-b6cf-a67a2aa66d5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7dad6d9b-1ab0-4357-8284-a75ddedbd37f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f4816b0-b8ff-44d5-b3a6-ebf9b6f2ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41768b66-78f5-4f76-b6cf-a67a2aa66d5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f4816b0-b8ff-44d5-b3a6-ebf9b6f2ce0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71fbfdf2-269e-4b11-af84-a8c833e5dce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41768b66-78f5-4f76-b6cf-a67a2aa66d5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71fbfdf2-269e-4b11-af84-a8c833e5dce9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc025593-20a6-4da2-8dfb-5357776b6822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_38148917-d097-4791-9c66-d7d76f8d3f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc025593-20a6-4da2-8dfb-5357776b6822" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_38148917-d097-4791-9c66-d7d76f8d3f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9cf0c188-20ff-472d-8b98-a9317648c315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc025593-20a6-4da2-8dfb-5357776b6822" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9cf0c188-20ff-472d-8b98-a9317648c315" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae9e4595-b7b6-4f00-b16a-e11a40cc7084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae9e4595-b7b6-4f00-b16a-e11a40cc7084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_413a6c05-4a65-4fe9-a164-1ffbfd71cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_413a6c05-4a65-4fe9-a164-1ffbfd71cbc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1298c565-fded-41f6-a4f1-ec817746e669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1298c565-fded-41f6-a4f1-ec817746e669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_94f3f98a-616c-478f-903c-f27d87e3a25f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_94f3f98a-616c-478f-903c-f27d87e3a25f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8882696-2dc4-4a16-ad19-6e82d8cb394b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8882696-2dc4-4a16-ad19-6e82d8cb394b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_376d06a6-4455-4d97-b040-d93f9f47a4a3" xlink:href="bios-20240331.xsd#bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69a67c1d-54ac-4f31-b204-93f0435b25f0" xlink:to="loc_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_376d06a6-4455-4d97-b040-d93f9f47a4a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bios-20240331.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_80321f1b-6185-4371-8f98-a0363ec68bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_69d8b5f3-a9bb-4f6a-9055-5eb6517e5b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_80321f1b-6185-4371-8f98-a0363ec68bf9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_69d8b5f3-a9bb-4f6a-9055-5eb6517e5b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_924c6630-e144-4b01-b5b4-56231584c26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_80321f1b-6185-4371-8f98-a0363ec68bf9" xlink:to="loc_us-gaap_OperatingLeaseLiability_924c6630-e144-4b01-b5b4-56231584c26c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_167cb377-53ce-497c-8989-817483fb4b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3ff70074-ec31-4e88-a717-bb1d583e8446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_167cb377-53ce-497c-8989-817483fb4b6f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3ff70074-ec31-4e88-a717-bb1d583e8446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2a6ed2e4-ca6a-4de8-8545-9e41ab618c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_167cb377-53ce-497c-8989-817483fb4b6f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2a6ed2e4-ca6a-4de8-8545-9e41ab618c58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4549fbb8-e2d4-4790-8611-86a982d1988b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_729af70a-7b0e-4ff5-95d2-bc6c77cc2127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4549fbb8-e2d4-4790-8611-86a982d1988b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_729af70a-7b0e-4ff5-95d2-bc6c77cc2127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_83a64db0-8729-4018-806f-c48fcfb56753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4549fbb8-e2d4-4790-8611-86a982d1988b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_83a64db0-8729-4018-806f-c48fcfb56753" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_87d5af7f-1947-4be9-b9f7-b9ce5596e271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a30e5393-ad9f-4d2b-a23b-349effc9f210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_87d5af7f-1947-4be9-b9f7-b9ce5596e271" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a30e5393-ad9f-4d2b-a23b-349effc9f210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f037825e-f567-4993-aae4-7aa0cfd6a42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_87d5af7f-1947-4be9-b9f7-b9ce5596e271" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f037825e-f567-4993-aae4-7aa0cfd6a42b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_2b50c7cc-6ba2-486b-89aa-b642bd311344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_87d5af7f-1947-4be9-b9f7-b9ce5596e271" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_2b50c7cc-6ba2-486b-89aa-b642bd311344" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ff19c7e8-df97-416b-8e2d-77ec9f3d0340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_40e10dd8-e9a1-4b07-af71-9ae56653f15e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ff19c7e8-df97-416b-8e2d-77ec9f3d0340" xlink:to="loc_us-gaap_LongTermDebtCurrent_40e10dd8-e9a1-4b07-af71-9ae56653f15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_626d4c94-2a69-4d43-9e18-137cf20f8cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ff19c7e8-df97-416b-8e2d-77ec9f3d0340" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_626d4c94-2a69-4d43-9e18-137cf20f8cb6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSLongTermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ee166d97-ed23-436e-b6e3-6219ec7b4bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ee166d97-ed23-436e-b6e3-6219ec7b4bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f1cb7283-7719-4a89-808d-24a0007aae7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f1cb7283-7719-4a89-808d-24a0007aae7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a0361138-8b4d-4c57-985a-4a039aaba78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a0361138-8b4d-4c57-985a-4a039aaba78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f1a2b818-de64-4b2b-a02f-fd17678fb063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f1a2b818-de64-4b2b-a02f-fd17678fb063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ac24da4-1c40-46f8-8279-e3336b0a14e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6ac24da4-1c40-46f8-8279-e3336b0a14e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LongTermDebtMaturityAfterYearFour_174cea18-4f28-4c89-833b-446a89eb0066" xlink:href="bios-20240331.xsd#bios_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_1bf717c3-a1a5-48d3-9dd9-0ed7d4bd4a62" xlink:to="loc_bios_LongTermDebtMaturityAfterYearFour_174cea18-4f28-4c89-833b-446a89eb0066" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>bios-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3aa0ccbf-2345-461d-8bfe-5351acc3ea16,g:764d9622-b6cc-4198-a6bd-78d38846c16c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e0a09f3-c97a-495b-9e38-fdd30e5f3445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7e0a09f3-c97a-495b-9e38-fdd30e5f3445" xlink:to="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c9861f06-1950-4c31-8a95-249c4e307b37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:to="loc_us-gaap_EquityComponentDomain_c9861f06-1950-4c31-8a95-249c4e307b37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:to="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_82021332-ea84-4afd-9752-f8bef009c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_PreferredStockMember_82021332-ea84-4afd-9752-f8bef009c0d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86ae0a32-dd21-40c4-939c-9fccd1cd3676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_CommonStockMember_86ae0a32-dd21-40c4-939c-9fccd1cd3676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_15a4d4e9-ab5f-491b-93bb-941c8ba3587d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_TreasuryStockCommonMember_15a4d4e9-ab5f-491b-93bb-941c8ba3587d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_21ec7ae5-f589-469c-a310-eb86210519e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_21ec7ae5-f589-469c-a310-eb86210519e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2c93d95e-ab07-4668-bd2b-7e75613e9517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_RetainedEarningsMember_2c93d95e-ab07-4668-bd2b-7e75613e9517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6bbbaf9-62c8-4c80-9103-ac9b9e45c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6bbbaf9-62c8-4c80-9103-ac9b9e45c39f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e0a09f3-c97a-495b-9e38-fdd30e5f3445" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8fadacfd-6289-46ad-85a6-e642cd9449d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_StockholdersEquity_8fadacfd-6289-46ad-85a6-e642cd9449d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_f14aa8e4-710e-4e40-aab9-85e191d5e4e9" xlink:href="bios-20240331.xsd#bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_f14aa8e4-710e-4e40-aab9-85e191d5e4e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7527239b-e780-46ac-bf46-9e0481b48e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7527239b-e780-46ac-bf46-9e0481b48e5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_914204a7-ec77-4060-8226-db3c14063262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_914204a7-ec77-4060-8226-db3c14063262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_67a8681e-3448-46ea-9763-110595618a48" xlink:href="bios-20240331.xsd#bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_67a8681e-3448-46ea-9763-110595618a48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc326e3e-1874-43a6-b606-a6d10817e717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_NetIncomeLoss_cc326e3e-1874-43a6-b606-a6d10817e717" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1834b963-f08c-46b0-89be-efbe4d7fb39d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1834b963-f08c-46b0-89be-efbe4d7fb39d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3ac03ac1-7176-4883-b59d-ed42291c4263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_06e821c2-ffae-4cd7-b253-edfab3bd0696_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_06e821c2-ffae-4cd7-b253-edfab3bd0696_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4590c3e2-e284-4d4d-a4f4-552aef4527b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4590c3e2-e284-4d4d-a4f4-552aef4527b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LegacyHealthSystemsMember_922ec269-ca99-4d2b-8b0f-e6940573a4a0" xlink:href="bios-20240331.xsd#bios_LegacyHealthSystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4590c3e2-e284-4d4d-a4f4-552aef4527b0" xlink:to="loc_bios_LegacyHealthSystemsMember_922ec269-ca99-4d2b-8b0f-e6940573a4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfServiceLocations_5f5a436b-46bf-4203-a436-9851bfe4f49d" xlink:href="bios-20240331.xsd#bios_NumberOfServiceLocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_bios_NumberOfServiceLocations_5f5a436b-46bf-4203-a436-9851bfe4f49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfInfusionSites_ac862e7c-33b6-4b75-883d-d531436b8dc8" xlink:href="bios-20240331.xsd#bios_NumberOfInfusionSites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_bios_NumberOfInfusionSites_ac862e7c-33b6-4b75-883d-d531436b8dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_93791ac6-0864-4f8a-b96c-a9f140c4cbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_us-gaap_NumberOfOperatingSegments_93791ac6-0864-4f8a-b96c-a9f140c4cbeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4061ac38-d94a-4c9d-93cc-6dab80cb909a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4061ac38-d94a-4c9d-93cc-6dab80cb909a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7c56c9e5-6bdf-4b9c-8410-5f679a3bfa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7c56c9e5-6bdf-4b9c-8410-5f679a3bfa4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccountsReceivableBenchmarkMember_49ab6a04-5645-4b1a-87f4-f6834d9f4e89" xlink:href="bios-20240331.xsd#bios_AccountsReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:to="loc_bios_AccountsReceivableBenchmarkMember_49ab6a04-5645-4b1a-87f4-f6834d9f4e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember_c663598f-6c50-4b12-b48d-5c41930f6c08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:to="loc_us-gaap_CostOfGoodsProductLineMember_c663598f-6c50-4b12-b48d-5c41930f6c08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0cd2c683-d107-486a-9f8a-dba18d593a90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0cd2c683-d107-486a-9f8a-dba18d593a90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5c50489f-b7b0-400b-b868-145a4b980b43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5c50489f-b7b0-400b-b868-145a4b980b43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_df21beec-177f-410e-a8ee-a2fbb2251c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_df21beec-177f-410e-a8ee-a2fbb2251c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_fd6964b1-1668-4758-a518-e3a26d862f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_fd6964b1-1668-4758-a518-e3a26d862f13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_00a40611-8cf2-4086-bb23-f90179d4649e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:to="loc_srt_NameOfMajorCustomerDomain_00a40611-8cf2-4086-bb23-f90179d4649e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_39d46b35-0ae0-45c2-8be6-c0da2140a5c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:to="loc_srt_NameOfMajorCustomerDomain_39d46b35-0ae0-45c2-8be6-c0da2140a5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LargestPayerMember_6a8fab9e-fed5-4c82-a6fc-c7b9e63a7c65" xlink:href="bios-20240331.xsd#bios_LargestPayerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_39d46b35-0ae0-45c2-8be6-c0da2140a5c8" xlink:to="loc_bios_LargestPayerMember_6a8fab9e-fed5-4c82-a6fc-c7b9e63a7c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:to="loc_srt_ProductsAndServicesDomain_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_95544509-c4b6-4546-98c7-c49d7e538dd8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:to="loc_srt_ProductsAndServicesDomain_95544509-c4b6-4546-98c7-c49d7e538dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentHealthcareProgramsMember_e70b221b-c748-4e19-909b-203534eaed0b" xlink:href="bios-20240331.xsd#bios_GovernmentHealthcareProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_95544509-c4b6-4546-98c7-c49d7e538dd8" xlink:to="loc_bios_GovernmentHealthcareProgramsMember_e70b221b-c748-4e19-909b-203534eaed0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_c990de95-dd73-47f1-a2cc-4f006c198bb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_c990de95-dd73-47f1-a2cc-4f006c198bb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_55ab9b08-5acc-454c-adca-1301659c12ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_55ab9b08-5acc-454c-adca-1301659c12ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FourVendorsMember_a5c0292a-771a-4bac-900d-cef4a9d25144" xlink:href="bios-20240331.xsd#bios_FourVendorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_55ab9b08-5acc-454c-adca-1301659c12ce" xlink:to="loc_bios_FourVendorsMember_a5c0292a-771a-4bac-900d-cef4a9d25144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bd6d54e5-7fb1-4aad-a614-71a7bc02b377_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:to="loc_us-gaap_RelatedPartyDomain_bd6d54e5-7fb1-4aad-a614-71a7bc02b377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5a61ec7d-24aa-482c-ab0d-81b46debcb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:to="loc_us-gaap_RelatedPartyDomain_5a61ec7d-24aa-482c-ab0d-81b46debcb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_0949057d-feff-4c82-9f65-14ccd39f7c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5a61ec7d-24aa-482c-ab0d-81b46debcb01" xlink:to="loc_us-gaap_CorporateJointVentureMember_0949057d-feff-4c82-9f65-14ccd39f7c26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_ad36f28b-3917-496a-9c36-b4e595b5f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_ad36f28b-3917-496a-9c36-b4e595b5f9f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2b61605b-87f3-4136-8e65-5a481529b627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_EquityMethodInvestments_2b61605b-87f3-4136-8e65-5a481529b627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81a22f8a-cd43-4215-8379-462141e12004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81a22f8a-cd43-4215-8379-462141e12004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bba2d813-1223-493e-8b60-a430623c47db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bba2d813-1223-493e-8b60-a430623c47db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bb04acb4-90e9-4488-b553-b14cacb59022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bb04acb4-90e9-4488-b553-b14cacb59022" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#REVENUENetRevenueEarnedbyCategoryofPayerDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4411f1e1-b745-4893-858b-e1c5ac72b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4411f1e1-b745-4893-858b-e1c5ac72b3c1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:to="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f2a3ca5b-25f9-4fa3-bb39-666901922f60_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:to="loc_srt_NameOfMajorCustomerDomain_f2a3ca5b-25f9-4fa3-bb39-666901922f60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:to="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommercialCustomerMember_5b449c61-df73-4a4d-8a07-73e6e4e862a1" xlink:href="bios-20240331.xsd#bios_CommercialCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:to="loc_bios_CommercialCustomerMember_5b449c61-df73-4a4d-8a07-73e6e4e862a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentCustomerMember_e42a3744-7de5-41ed-8a91-64fc2f472fb4" xlink:href="bios-20240331.xsd#bios_GovernmentCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:to="loc_bios_GovernmentCustomerMember_e42a3744-7de5-41ed-8a91-64fc2f472fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PatientCustomerMember_bd5bfee4-5834-4c4d-aa84-ff303e7c9c4b" xlink:href="bios-20240331.xsd#bios_PatientCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:to="loc_bios_PatientCustomerMember_bd5bfee4-5834-4c4d-aa84-ff303e7c9c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8db4d0a0-e7ce-4847-ae98-f769a6cd07e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4411f1e1-b745-4893-858b-e1c5ac72b3c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8db4d0a0-e7ce-4847-ae98-f769a6cd07e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INCOMETAXESDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1f43cf78-e22e-46c1-bf50-af931d0d50ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1f43cf78-e22e-46c1-bf50-af931d0d50ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e948b705-ba12-474e-951b-b5d94b7ea5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e948b705-ba12-474e-951b-b5d94b7ea5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_01725869-788d-4960-b5dd-5e8dc9bcca81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e948b705-ba12-474e-951b-b5d94b7ea5b6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_01725869-788d-4960-b5dd-5e8dc9bcca81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_99c4d4c9-f34c-49c0-a473-0a16bf080f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_99c4d4c9-f34c-49c0-a473-0a16bf080f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d1d4f78c-9071-48f7-920f-474342b08777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d1d4f78c-9071-48f7-920f-474342b08777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_893b9b0d-6c67-4264-bef4-0ab46ef59f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_893b9b0d-6c67-4264-bef4-0ab46ef59f78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_131297b8-8b4a-4b9f-97f4-2f9c13e65a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_131297b8-8b4a-4b9f-97f4-2f9c13e65a86" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4f690113-6438-4dd6-8e90-6c283d55ceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4f690113-6438-4dd6-8e90-6c283d55ceaf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a8d6e02-7419-4d2a-b189-4e88c5a804dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a8d6e02-7419-4d2a-b189-4e88c5a804dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_d072336d-01c0-41d9-8a8c-b019abe71f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:to="loc_us-gaap_StockOptionMember_d072336d-01c0-41d9-8a8c-b019abe71f59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAwardMember_10751515-b22f-451a-8455-c1101d950f57" xlink:href="bios-20240331.xsd#bios_RestrictedStockAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:to="loc_bios_RestrictedStockAwardMember_10751515-b22f-451a-8455-c1101d950f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PerformanceStockUnitMember_bf88633d-852d-499b-a806-33efe29e19db" xlink:href="bios-20240331.xsd#bios_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:to="loc_bios_PerformanceStockUnitMember_bf88633d-852d-499b-a806-33efe29e19db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_388f445b-7b9c-4ddc-94db-e4ab47efd32e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4f690113-6438-4dd6-8e90-6c283d55ceaf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_388f445b-7b9c-4ddc-94db-e4ab47efd32e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1084d1eb-5b97-4548-a025-0d160c6124fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1084d1eb-5b97-4548-a025-0d160c6124fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember_f4c28266-8986-4bb9-821f-8bc0ac78cac4" xlink:href="bios-20240331.xsd#bios_InfusionPumpsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_bios_InfusionPumpsMember_f4c28266-8986-4bb9-821f-8bc0ac78cac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EquipmentFurnitureAndOtherMember_9001c33f-db01-4fd9-8cd9-a670c2d1e5ea" xlink:href="bios-20240331.xsd#bios_EquipmentFurnitureAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_bios_EquipmentFurnitureAndOtherMember_9001c33f-db01-4fd9-8cd9-a670c2d1e5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3d75d6b8-5a61-436f-bea7-384c11c862ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3d75d6b8-5a61-436f-bea7-384c11c862ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_02b6cc70-0397-4f9a-a6e1-400fb7eb0eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_02b6cc70-0397-4f9a-a6e1-400fb7eb0eee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_3f8dd7b9-a5fa-41ae-8f26-486a6a28ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_us-gaap_AssetUnderConstructionMember_3f8dd7b9-a5fa-41ae-8f26-486a6a28ef54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0c028a97-678c-4848-ac82-8e954164113f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0c028a97-678c-4848-ac82-8e954164113f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_189e4355-55c4-40cc-9d43-248e0e042ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:to="loc_us-gaap_CostOfSalesMember_189e4355-55c4-40cc-9d43-248e0e042ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_d175529d-5594-4c04-8e1f-2bd22dcce99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:to="loc_us-gaap_OperatingExpenseMember_d175529d-5594-4c04-8e1f-2bd22dcce99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_eb934379-27ec-4ec1-bcc5-a3d08101a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_eb934379-27ec-4ec1-bcc5-a3d08101a05e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e4f11d04-344c-4bb5-a3af-c647600f7999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e4f11d04-344c-4bb5-a3af-c647600f7999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15ccbbee-c032-49a9-84ec-e8e4d146dd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15ccbbee-c032-49a9-84ec-e8e4d146dd0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a8b8ddd6-b854-4ade-b267-26519b74b002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_Depreciation_a8b8ddd6-b854-4ade-b267-26519b74b002" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3f5e5503-48dd-460d-a140-84b59a2efc86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3f5e5503-48dd-460d-a140-84b59a2efc86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_9c5998f0-cf94-4608-8581-afac8317137b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:to="loc_us-gaap_CustomerListsMember_9c5998f0-cf94-4608-8581-afac8317137b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_cfef7b17-693a-4728-8ab1-d2d7e731d918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_cfef7b17-693a-4728-8ab1-d2d7e731d918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_b6c81303-2e73-45d7-b696-93801999ef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_b6c81303-2e73-45d7-b696-93801999ef1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_deef06bb-08f2-47d5-adc7-cbe63e42ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_deef06bb-08f2-47d5-adc7-cbe63e42ee48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_95a95dde-86fa-48af-b6f2-cc73c26152ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_95a95dde-86fa-48af-b6f2-cc73c26152ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e191b3af-8c40-4990-92be-72bf385d2079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e191b3af-8c40-4990-92be-72bf385d2079" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_20ee73bb-b3ad-4668-818c-0376b4a6fd20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_20ee73bb-b3ad-4668-818c-0376b4a6fd20" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d20fa908-05c9-4b74-99a6-9aa57517da27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d20fa908-05c9-4b74-99a6-9aa57517da27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d90eec56-9b5d-453d-9094-656b72c4cced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d90eec56-9b5d-453d-9094-656b72c4cced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b682623f-2dbc-4bb8-b3e2-8a9594f90451" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d90eec56-9b5d-453d-9094-656b72c4cced" xlink:to="loc_us-gaap_SeniorNotesMember_b682623f-2dbc-4bb8-b3e2-8a9594f90451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79c9d5a7-ec2d-41f3-8ce7-4346ce680936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:to="loc_us-gaap_CreditFacilityDomain_79c9d5a7-ec2d-41f3-8ce7-4346ce680936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b394c007-5561-440c-a0cf-9c3e658ef509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:to="loc_us-gaap_CreditFacilityDomain_b394c007-5561-440c-a0cf-9c3e658ef509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bf046303-46c1-4b71-9dfa-fd87a3ff78c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b394c007-5561-440c-a0cf-9c3e658ef509" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bf046303-46c1-4b71-9dfa-fd87a3ff78c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_743e8002-dac5-41e4-8131-c36d23f1baa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_743e8002-dac5-41e4-8131-c36d23f1baa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_be55ef52-228e-4cad-b3f3-4475ccbd5530" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:to="loc_bios_FirstLienTermLoanMember_be55ef52-228e-4cad-b3f3-4475ccbd5530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember_7ff47649-6226-4b0f-b80f-959ed5942df3" xlink:href="bios-20240331.xsd#bios_SecondLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:to="loc_bios_SecondLienTermLoanMember_7ff47649-6226-4b0f-b80f-959ed5942df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_77c14663-30a9-4018-b811-bacb652abe47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_77c14663-30a9-4018-b811-bacb652abe47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_83b0f10e-429b-49c7-87ce-406f6a8b17e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_83b0f10e-429b-49c7-87ce-406f6a8b17e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5d02710-6b91-4526-a2ef-88b836ba4b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5d02710-6b91-4526-a2ef-88b836ba4b40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4921054c-fd3b-4763-b29f-31336da414e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_LongTermDebt_4921054c-fd3b-4763-b29f-31336da414e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_623b189b-b30d-4d31-a94e-edc69c12da98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_LongTermDebtCurrent_623b189b-b30d-4d31-a94e-edc69c12da98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0ebea405-b665-4e57-b608-2523c5313367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0ebea405-b665-4e57-b608-2523c5313367" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_9ebbff21-2d47-48f3-b630-926aaf241669_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:to="loc_us-gaap_LienCategoryDomain_9ebbff21-2d47-48f3-b630-926aaf241669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:to="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_b4180611-1e0b-49fe-bba4-fab77ccc219c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:to="loc_us-gaap_SeniorLienMember_b4180611-1e0b-49fe-bba4-fab77ccc219c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_1fa90f87-1b9d-4d09-9366-3c89f3eb4fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_JuniorLienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:to="loc_us-gaap_JuniorLienMember_1fa90f87-1b9d-4d09-9366-3c89f3eb4fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_47b4de86-9264-4d79-a923-90001eedda28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_47b4de86-9264-4d79-a923-90001eedda28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_cfca8537-0fe8-49fc-b9db-f5697e49c533" xlink:href="bios-20240331.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_cfca8537-0fe8-49fc-b9db-f5697e49c533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienCreditAgreementSecondAmendmentMember_9e9be59e-3b31-4593-adba-a41e0ec5515c" xlink:href="bios-20240331.xsd#bios_FirstLienCreditAgreementSecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:to="loc_bios_FirstLienCreditAgreementSecondAmendmentMember_9e9be59e-3b31-4593-adba-a41e0ec5515c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85c0a3af-d9eb-44ea-8d9f-2c249f116c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85c0a3af-d9eb-44ea-8d9f-2c249f116c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9e43864f-7f61-42eb-8137-f90780deb360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_85c0a3af-d9eb-44ea-8d9f-2c249f116c7b" xlink:to="loc_us-gaap_SeniorNotesMember_9e43864f-7f61-42eb-8137-f90780deb360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_07b02aaa-69d0-4875-8415-96620c00b940_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:to="loc_us-gaap_CreditFacilityDomain_07b02aaa-69d0-4875-8415-96620c00b940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0706a120-c771-43dc-aca7-723812926912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:to="loc_us-gaap_CreditFacilityDomain_0706a120-c771-43dc-aca7-723812926912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_79a68dc0-ae71-40f4-be14-469ebb81c1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0706a120-c771-43dc-aca7-723812926912" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_79a68dc0-ae71-40f4-be14-469ebb81c1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_06d44dac-a3ec-4ed5-a33f-82a52130977e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_06d44dac-a3ec-4ed5-a33f-82a52130977e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_d50b1237-289b-4cf9-abd7-575da82f061e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_d50b1237-289b-4cf9-abd7-575da82f061e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1f0ad3a7-323f-48ee-b283-530cf2936bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1f0ad3a7-323f-48ee-b283-530cf2936bb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_365bee0e-40a8-4534-b238-4d842ac1e834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_365bee0e-40a8-4534-b238-4d842ac1e834" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_583cfd24-2188-457b-93f1-72397842e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_583cfd24-2188-457b-93f1-72397842e66f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ccf67af2-2c4e-49dd-a210-5778e5f015e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccf67af2-2c4e-49dd-a210-5778e5f015e9" xlink:to="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f92c3ac4-23ff-4677-905b-7e5a51cc5581_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f92c3ac4-23ff-4677-905b-7e5a51cc5581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7e80d931-e7db-4f84-a8a5-9deebbbed924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7e80d931-e7db-4f84-a8a5-9deebbbed924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_275c0eb6-4e18-489a-8f22-7d74bdbd84ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7e80d931-e7db-4f84-a8a5-9deebbbed924" xlink:to="loc_us-gaap_SeniorNotesMember_275c0eb6-4e18-489a-8f22-7d74bdbd84ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_877a8bd2-6519-4bab-bc3f-ebfdfeccec94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_877a8bd2-6519-4bab-bc3f-ebfdfeccec94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cf645cd4-1808-46ba-a7e2-b82d04f16804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cf645cd4-1808-46ba-a7e2-b82d04f16804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9f7ffa2c-e2a3-41a2-9e24-4224d9f34744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9f7ffa2c-e2a3-41a2-9e24-4224d9f34744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_08c10d2d-24f1-42fb-93af-ee5d8d88eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_08c10d2d-24f1-42fb-93af-ee5d8d88eafc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ca771e72-55aa-410e-9745-f0515b6ece4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ca771e72-55aa-410e-9745-f0515b6ece4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc2f6bb6-0002-4172-8c5d-5613e3ceb0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc2f6bb6-0002-4172-8c5d-5613e3ceb0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_14d087ec-4467-43b3-a025-ec0b7d09cf1a" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc2f6bb6-0002-4172-8c5d-5613e3ceb0a7" xlink:to="loc_bios_FirstLienTermLoanMember_14d087ec-4467-43b3-a025-ec0b7d09cf1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_635613ef-c4c3-4335-be97-e6c3fd82fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccf67af2-2c4e-49dd-a210-5778e5f015e9" xlink:to="loc_us-gaap_LongTermDebtFairValue_635613ef-c4c3-4335-be97-e6c3fd82fa84" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:to="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ff7dda63-3482-44ac-85b1-52e54693f8cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ff7dda63-3482-44ac-85b1-52e54693f8cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_18ba26b7-92ce-4272-b984-69dbe27b357d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_18ba26b7-92ce-4272-b984-69dbe27b357d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_bb3b14b2-af45-438c-8500-33f7d343c040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_18ba26b7-92ce-4272-b984-69dbe27b357d" xlink:to="loc_us-gaap_InterestRateCapMember_bb3b14b2-af45-438c-8500-33f7d343c040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64f25822-a8ec-496d-adcc-9533d594196c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64f25822-a8ec-496d-adcc-9533d594196c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ad6f3b31-ce9c-46f1-a7ec-2e45e9d59e38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ad6f3b31-ce9c-46f1-a7ec-2e45e9d59e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_25487bad-0c80-4500-be09-6fcb1cf741fd" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ad6f3b31-ce9c-46f1-a7ec-2e45e9d59e38" xlink:to="loc_bios_FirstLienTermLoanMember_25487bad-0c80-4500-be09-6fcb1cf741fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b38c49f9-5bf8-48d8-bd64-25617d31db39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:to="loc_us-gaap_HedgingDesignationDomain_b38c49f9-5bf8-48d8-bd64-25617d31db39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3309aee1-42e5-48e5-b768-f371f6cae8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:to="loc_us-gaap_HedgingDesignationDomain_3309aee1-42e5-48e5-b768-f371f6cae8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_12433782-755e-4b7d-9a25-8e0592aa9aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_3309aee1-42e5-48e5-b768-f371f6cae8d2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_12433782-755e-4b7d-9a25-8e0592aa9aa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7d83e444-fc1a-42ee-82d1-1f3740522f4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7d83e444-fc1a-42ee-82d1-1f3740522f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fcddaf01-16de-4d87-98d2-68aa7bd632ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fcddaf01-16de-4d87-98d2-68aa7bd632ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6e7095b1-fd70-4491-b19d-de51d03a0648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fcddaf01-16de-4d87-98d2-68aa7bd632ca" xlink:to="loc_us-gaap_SeniorNotesMember_6e7095b1-fd70-4491-b19d-de51d03a0648" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1fdfa646-6e3d-4315-bd7f-dd4e19628610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1fdfa646-6e3d-4315-bd7f-dd4e19628610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_70d14d91-6f47-46c1-b7f9-63952e19ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:to="loc_us-gaap_DerivativeTermOfContract_70d14d91-6f47-46c1-b7f9-63952e19ddae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d22fbb41-e708-4d27-9bbc-c409857f4062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_d22fbb41-e708-4d27-9bbc-c409857f4062" xlink:to="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b09eee4f-4f9c-40c1-b744-0fdbb2345b15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:to="loc_us-gaap_HedgingDesignationDomain_b09eee4f-4f9c-40c1-b744-0fdbb2345b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8e61ffd3-b1d7-4957-adac-ce6c12eca5da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:to="loc_us-gaap_HedgingDesignationDomain_8e61ffd3-b1d7-4957-adac-ce6c12eca5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa5a4d7c-a499-4fde-bf9b-21a118752da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8e61ffd3-b1d7-4957-adac-ce6c12eca5da" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa5a4d7c-a499-4fde-bf9b-21a118752da8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e9b703d3-5cd6-4189-95de-1e49439cb70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e9b703d3-5cd6-4189-95de-1e49439cb70e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_792616e9-34df-437e-8540-e95320d189bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_792616e9-34df-437e-8540-e95320d189bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6918d39f-070d-4544-9504-7d1e91b8ed93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6918d39f-070d-4544-9504-7d1e91b8ed93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c4fadb5d-0254-4c7d-920c-0ab96fe5ca89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c4fadb5d-0254-4c7d-920c-0ab96fe5ca89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_b8699ca5-0f38-4c71-9da9-a378dc634d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c4fadb5d-0254-4c7d-920c-0ab96fe5ca89" xlink:to="loc_us-gaap_InterestRateCapMember_b8699ca5-0f38-4c71-9da9-a378dc634d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_50438ace-0065-4f91-b7aa-b0cec41505fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d22fbb41-e708-4d27-9bbc-c409857f4062" xlink:to="loc_us-gaap_DerivativeAssets_50438ace-0065-4f91-b7aa-b0cec41505fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:to="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_76fa4093-9ae1-4ce4-a618-17de00b0c039_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_76fa4093-9ae1-4ce4-a618-17de00b0c039_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0dcb75ac-b5fe-448d-b03c-7fc2760c55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0dcb75ac-b5fe-448d-b03c-7fc2760c55d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_29a25841-1a89-443f-89ed-0ca37430a42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0dcb75ac-b5fe-448d-b03c-7fc2760c55d5" xlink:to="loc_us-gaap_InterestRateCapMember_29a25841-1a89-443f-89ed-0ca37430a42d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_190e5c9f-527f-4b6b-afdc-9b19e32390e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_190e5c9f-527f-4b6b-afdc-9b19e32390e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20e6c7a6-af1a-47a0-a16b-28f39b6248e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20e6c7a6-af1a-47a0-a16b-28f39b6248e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_131f5337-2842-4e8c-805b-a8cc61bbad11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20e6c7a6-af1a-47a0-a16b-28f39b6248e9" xlink:to="loc_us-gaap_InterestExpenseMember_131f5337-2842-4e8c-805b-a8cc61bbad11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ea9bc410-a801-4887-842c-e696e3624063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ea9bc410-a801-4887-842c-e696e3624063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c9259072-0385-4b6a-a968-e4040446482f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c9259072-0385-4b6a-a968-e4040446482f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#STOCKBASEDINCENTIVECOMPENSATIONDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:to="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c2f1d2b-f068-45a3-baa1-f31a16a0f916_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c2f1d2b-f068-45a3-baa1-f31a16a0f916_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd3b3e34-fcab-438d-aa8f-54d5467e963a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd3b3e34-fcab-438d-aa8f-54d5467e963a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember_5a29bdbe-6efa-4647-874b-38c4e51f2bf3" xlink:href="bios-20240331.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd3b3e34-fcab-438d-aa8f-54d5467e963a" xlink:to="loc_bios_HCIIncentiveUnitsMember_5a29bdbe-6efa-4647-874b-38c4e51f2bf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:to="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e8b1257-c7fb-4712-beda-259ea0e7dbb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:to="loc_us-gaap_PlanNameDomain_6e8b1257-c7fb-4712-beda-259ea0e7dbb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ab876463-85b1-4f8a-81b9-e4412f710207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:to="loc_us-gaap_PlanNameDomain_ab876463-85b1-4f8a-81b9-e4412f710207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2018PlanMember_693bf2b6-71d6-4137-8026-65b37bb9d4f5" xlink:href="bios-20240331.xsd#bios_A2018PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ab876463-85b1-4f8a-81b9-e4412f710207" xlink:to="loc_bios_A2018PlanMember_693bf2b6-71d6-4137-8026-65b37bb9d4f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9166c822-addd-4890-95da-e47f6adeffed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9166c822-addd-4890-95da-e47f6adeffed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27b70cb5-7179-4d94-bd51-359e70d8897a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27b70cb5-7179-4d94-bd51-359e70d8897a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_37137514-e688-40a9-91b9-21183c5940fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:to="loc_us-gaap_EquityComponentDomain_37137514-e688-40a9-91b9-21183c5940fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ea57f76-4625-46cf-9264-e606ac1f044b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:to="loc_us-gaap_EquityComponentDomain_9ea57f76-4625-46cf-9264-e606ac1f044b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e4727a9f-5fc7-4f27-8334-d8bc639e4029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9ea57f76-4625-46cf-9264-e606ac1f044b" xlink:to="loc_us-gaap_CommonStockMember_e4727a9f-5fc7-4f27-8334-d8bc639e4029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2017WarrantsMember_197fc2ee-5dc8-4628-85b3-4513988b5acb" xlink:href="bios-20240331.xsd#bios_A2017WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:to="loc_bios_A2017WarrantsMember_197fc2ee-5dc8-4628-85b3-4513988b5acb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2015WarrantsMember_2568cd38-b2b0-4d71-ac1d-cc1c3ae0e154" xlink:href="bios-20240331.xsd#bios_A2015WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:to="loc_bios_A2015WarrantsMember_2568cd38-b2b0-4d71-ac1d-cc1c3ae0e154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1db99458-d9c4-4beb-85c9-ca03656a0258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1db99458-d9c4-4beb-85c9-ca03656a0258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5c875a41-0aa1-4cc4-a1c2-0c70895b9b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5c875a41-0aa1-4cc4-a1c2-0c70895b9b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_d912ec41-bcbf-4af9-bb89-394e26586275" xlink:href="bios-20240331.xsd#bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_d912ec41-bcbf-4af9-bb89-394e26586275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_9e85046f-9474-41e2-ad84-cbfa14934eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_9e85046f-9474-41e2-ad84-cbfa14934eaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_620b64c4-8a87-4073-b4c6-d367a2d69d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_620b64c4-8a87-4073-b4c6-d367a2d69d04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1828ece2-d341-469e-8208-06ce19c66860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1828ece2-d341-469e-8208-06ce19c66860" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e4fb3b5-6a8d-4a03-a1f7-05bbb505da97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e4fb3b5-6a8d-4a03-a1f7-05bbb505da97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_492910e0-e05b-4356-ad92-e3d350ad55a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_492910e0-e05b-4356-ad92-e3d350ad55a1" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_099e57c2-1921-441d-8422-274aac520393_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:to="loc_us-gaap_RelatedPartyDomain_099e57c2-1921-441d-8422-274aac520393_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_64082e7c-b517-4852-aa32-f65244564fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:to="loc_us-gaap_RelatedPartyDomain_64082e7c-b517-4852-aa32-f65244564fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_2d71083b-719d-4ebe-8194-a5731a4e2879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_64082e7c-b517-4852-aa32-f65244564fa2" xlink:to="loc_us-gaap_CorporateJointVentureMember_2d71083b-719d-4ebe-8194-a5731a4e2879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d190614-5857-4195-8673-c04f85390c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d190614-5857-4195-8673-c04f85390c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5b0675e6-9360-4d18-98eb-ad15442becbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5b0675e6-9360-4d18-98eb-ad15442becbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_bd3e95d4-9600-4c5e-9f41-8ec85ed4b37d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_OtherReceivables_bd3e95d4-9600-4c5e-9f41-8ec85ed4b37d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_c2588673-75a2-416c-8f28-5d4bd3f2e195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_c2588673-75a2-416c-8f28-5d4bd3f2e195" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember_eb76ff1f-97b4-424c-9f55-cab8e66058dd" xlink:href="bios-20240331.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_bios_HCIIncentiveUnitsMember_eb76ff1f-97b4-424c-9f55-cab8e66058dd" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>bios-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3aa0ccbf-2345-461d-8bfe-5351acc3ea16,g:764d9622-b6cc-4198-a6bd-78d38846c16c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_641d0b28-3727-41e3-b599-a84933bbf7dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8c17b800-1177-4e1f-8553-9d9757a35577_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_072ef1fb-9d15-48aa-af5e-9cda0283233c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_00a2bff6-7d09-4b06-9d73-725268229c32_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_A2017WarrantsMember_fa574738-eda9-4256-99f3-94296bfbff7d_terseLabel_en-US" xlink:label="lab_bios_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Warrants</link:label>
    <link:label id="lab_bios_A2017WarrantsMember_label_en-US" xlink:label="lab_bios_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Warrants [Member]</link:label>
    <link:label id="lab_bios_A2017WarrantsMember_documentation_en-US" xlink:label="lab_bios_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2017WarrantsMember" xlink:href="bios-20240331.xsd#bios_A2017WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_A2017WarrantsMember" xlink:to="lab_bios_A2017WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_80fbd827-d7e1-45bc-828f-b3568321255e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INDEBTEDNESS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b82081f2-20eb-4f09-b28f-261778a6f70e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_cc51bf5b-7b65-4dc6-8ddf-6239e361f575_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolver Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LegacyHealthSystemsMember_72f7f342-c913-4416-8b26-bd1cebf5e527_terseLabel_en-US" xlink:label="lab_bios_LegacyHealthSystemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy Health Systems</link:label>
    <link:label id="lab_bios_LegacyHealthSystemsMember_label_en-US" xlink:label="lab_bios_LegacyHealthSystemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legacy Health Systems [Member]</link:label>
    <link:label id="lab_bios_LegacyHealthSystemsMember_documentation_en-US" xlink:label="lab_bios_LegacyHealthSystemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legacy Health Systems [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LegacyHealthSystemsMember" xlink:href="bios-20240331.xsd#bios_LegacyHealthSystemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LegacyHealthSystemsMember" xlink:to="lab_bios_LegacyHealthSystemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_dc28bb6c-3ef2-456e-9b19-6ef9620c1897_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0162bf11-1333-445a-85f8-4dda63a56332_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d97f49e9-11b3-476d-ad60-f4260d3f8c17_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_59508d2b-4c33-4005-b5c3-176b7524ec9d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0c87b07e-1d34-48ee-bb96-25489063b91b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_14fe321c-caeb-47dd-87ec-abffedec7955_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_e6b19368-375e-4078-bf1e-c15853e6eacb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1c622dd8-30cd-45be-ab21-c4d608f3ec49_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AccruedExpensesAndOtherCurrentLiabilities_abef92ab-2d52-4f48-952e-01b29bab642e_terseLabel_en-US" xlink:label="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_bios_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_bios_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="bios-20240331.xsd#bios_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_bios_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c462bd6d-6329-4131-bda2-a4973be7c5d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e55f55e2-dcca-43c8-a9b6-b1637a1f4760_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_8d6cc889-c69f-4268-b818-72e261a0a996_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1a66b192-f2f8-4706-8eb8-c529c59cda7f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8efc05fc-dad2-4135-b51f-940f41197540_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8d61ada4-4a82-4bd3-b147-14aa54e1ec83_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0a2b9ae4-187d-4625-88a6-c4972169134b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March&#160;31, 2024 and December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_af7edb78-63cb-4e1d-b54d-ae8f7d181a12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7d389290-d9f2-44fc-9207-74ad7be7c8e8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f14efad2-517e-4dac-9002-f5defe300a48_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_c422bacb-9ed4-41d1-bf5a-74fa7f66b3f1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf88e314-9a80-408e-bf50-05f1dfa49fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_96f91a60-1f0f-44ac-bb9b-846bb210ce65_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_23067c40-4e4a-48df-952f-2b470d1210e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d097a2f1-770c-4445-a55c-9e6ec3014e50_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_69e32956-22ed-47e2-837c-0820a659fbf4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NONCURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a1b64846-717e-4436-a09d-3adda0da7de5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7fb4bbd4-059c-452e-8871-f4f608d118a4_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undrawn letters of credit issued and outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LongTermDebtMaturityAfterYearFour_e8927194-c64d-45aa-bef1-087131d84932_terseLabel_en-US" xlink:label="lab_bios_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bios_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_bios_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:label id="lab_bios_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_bios_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LongTermDebtMaturityAfterYearFour" xlink:href="bios-20240331.xsd#bios_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LongTermDebtMaturityAfterYearFour" xlink:to="lab_bios_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_727090c4-5f8e-4b17-af19-d61455dc81c8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total debt instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4dd05d12-4fdc-420a-a9e0-3e26b574bbb8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e7d7a7b9-b2e7-444a-9291-9c59928f81f2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c37cd6f6-fbfb-4ea8-bcdf-8fc91a784b20_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_462ec8c7-8121-4d62-bb6b-471c4fbe491a_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_32c12c2b-b7fe-425b-846c-c3f6ee36d4eb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7a2ec717-102d-4229-92d0-c410053a19db_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9792a241-1f83-4b23-bca8-eee0ba488278_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_0e9af3fb-ab34-47df-9856-445eeb7bf49d_terseLabel_en-US" xlink:label="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_label_en-US" xlink:label="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Exercised</link:label>
    <link:label id="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_documentation_en-US" xlink:label="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:href="bios-20240331.xsd#bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:to="lab_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d0361f58-aa1d-4879-9e98-f2ff6419a2f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4de817d-39f7-4d0f-b171-ee71070b1ce9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_896a7556-08e3-41ed-8aaf-b01e2e08dd09_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_379f9b78-1d8e-4470-976a-6bcb161f4332_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Governmental Healthcare Programs</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_6ad813d3-e11c-4daf-8dda-02ae408834bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_85ca6407-dd6f-4a28-adc4-8795cc493a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_31dd9523-1b34-4877-bc62-1ec78559ad01_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate cap designated as cash flow hedge</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_PerformanceStockUnitMember_a6881e73-d0e9-4eae-8835-c953404fc19d_terseLabel_en-US" xlink:label="lab_bios_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock unit awards</link:label>
    <link:label id="lab_bios_PerformanceStockUnitMember_label_en-US" xlink:label="lab_bios_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Unit [Member]</link:label>
    <link:label id="lab_bios_PerformanceStockUnitMember_documentation_en-US" xlink:label="lab_bios_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PerformanceStockUnitMember" xlink:href="bios-20240331.xsd#bios_PerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_PerformanceStockUnitMember" xlink:to="lab_bios_PerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_88f6db71-27a3-497e-8e03-894f3773b141_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_000fbea6-67ef-4375-9487-a816976eff49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_acb86085-627a-4d8c-a0f8-1637724fbd94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c2389ffd-3b4e-4544-b1cf-50050322f434_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COST OF REVENUE</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ac70c3fd-9118-42ce-9b92-9266da242dba_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d784606b-8a21-4e6e-bd04-f3ecaef81b5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Markets for Identical Item (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_2cd794bd-9ac0-43d3-898c-dd893e34e4dd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6eaeffec-2a42-4841-9041-2744a420d22e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3bed78d1-9709-4b87-b36f-8b7f743f55d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_50de606e-0bd1-4efe-8ed8-4db97aee566f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1a205e57-a3d3-41c4-8558-fe2fd88454c3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a84242f7-631a-4e8b-b991-fa2099a317d3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ee8dace6-615e-437c-a48c-2dff46fab471_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_0c22b8ff-decf-459f-868d-8f93e9ff9fe1_terseLabel_en-US" xlink:label="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_label_en-US" xlink:label="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Business Risk, Policy [Policy Text Block]</link:label>
    <link:label id="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Business Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:href="bios-20240331.xsd#bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:to="lab_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_HCIIncentiveUnitsMember_626f0fd9-d23a-44ab-ad49-b10a07150939_terseLabel_en-US" xlink:label="lab_bios_HCIIncentiveUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HC I Incentive Units</link:label>
    <link:label id="lab_bios_HCIIncentiveUnitsMember_label_en-US" xlink:label="lab_bios_HCIIncentiveUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HC I Incentive Units [Member]</link:label>
    <link:label id="lab_bios_HCIIncentiveUnitsMember_documentation_en-US" xlink:label="lab_bios_HCIIncentiveUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HC I Incentive Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember" xlink:href="bios-20240331.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_HCIIncentiveUnitsMember" xlink:to="lab_bios_HCIIncentiveUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_25a6a33a-3061-44bc-918a-7a306edecf7a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount of derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fa34fde1-6e71-4a7c-a7c1-3e21dd7406e4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b1e907e1-c2dd-4e96-b509-6b5de178f96f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_877f0de0-d8ba-4861-8f2a-1b0aeb6aacea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_82d3f7c3-6444-4558-a138-698b6693184f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5e54e23e-c904-47d7-b183-75175ce8365a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6a1e03b4-7194-46ba-934b-76e5601c1017_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f67dbe36-5313-4f6f-b77b-1f99eea321fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FirstLienTermLoanMember_4551a23a-ee69-4ba1-b78f-2de06209be62_terseLabel_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Lien Term Loan</link:label>
    <link:label id="lab_bios_FirstLienTermLoanMember_25a74169-2c4a-4658-868e-9b8d7055ff4b_verboseLabel_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">First Lien Term Loan</link:label>
    <link:label id="lab_bios_FirstLienTermLoanMember_label_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Lien Term Loan [Member]</link:label>
    <link:label id="lab_bios_FirstLienTermLoanMember_documentation_en-US" xlink:label="lab_bios_FirstLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Lien Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FirstLienTermLoanMember" xlink:to="lab_bios_FirstLienTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3afeaa88-1a86-45cb-9c2c-d14e81eea43e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Lease Liabilities, Operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fc395390-e68a-41c5-a3fb-2bd28479a1db_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_eeebffe6-1d19-4a7a-9967-28dbd8c47992_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_A2015WarrantsMember_a3dac407-13df-45db-8b48-83544f3ad5d0_terseLabel_en-US" xlink:label="lab_bios_A2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Warrants</link:label>
    <link:label id="lab_bios_A2015WarrantsMember_label_en-US" xlink:label="lab_bios_A2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Warrants [Member]</link:label>
    <link:label id="lab_bios_A2015WarrantsMember_documentation_en-US" xlink:label="lab_bios_A2015WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2015WarrantsMember" xlink:href="bios-20240331.xsd#bios_A2015WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_A2015WarrantsMember" xlink:to="lab_bios_A2015WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLienMember_ffe3d7ab-4914-48be-b888-ea4c4250baad_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLienMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Lien Term Loan</link:label>
    <link:label id="lab_us-gaap_SeniorLienMember_label_en-US" xlink:label="lab_us-gaap_SeniorLienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Lien [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorLienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLienMember" xlink:to="lab_us-gaap_SeniorLienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_2a495bf5-95c3-4f13-9eae-521c818e3e33_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d1b927e2-5b11-4817-be8b-f749ae1ad9a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9b8fd26b-d512-4274-80ea-da9825540de4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_f8bc5ff0-19b8-4d03-b0c3-5d925c88d2af_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_22804c08-9cce-4b49-8985-5b5c449f9d74_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_21174fc1-6354-489a-9e37-5c1445b8e853_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4761d953-3e2f-4fe3-8c55-b9bc681facdd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b9fe7354-e2e7-48f3-a60b-ee2624a6b59d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_65a2ab1f-328c-4898-820e-f900259d2f61_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4409499e-6ddb-40fc-a5d5-cd2fc2ee0258_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b66eeeb7-cbdf-437d-9f7a-d776833b9547_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b7056297-f02c-4006-843e-2d30cc862846_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6d791a2c-2628-4ccd-bccd-048c0c9058cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_4e0e56b5-224e-4861-98ce-7984dd6207e5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c7fef697-e025-48c5-bd43-a21c57da5437_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_366a494f-413d-4b22-8c10-f813dbc89dfa_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in operating lease right-of-use asset and lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_SecondLienTermLoanMember_b640fd4f-9b43-44a8-9232-b5577a09d384_terseLabel_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_bios_SecondLienTermLoanMember_label_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Lien Term Loan [Member]</link:label>
    <link:label id="lab_bios_SecondLienTermLoanMember_documentation_en-US" xlink:label="lab_bios_SecondLienTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Lien Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember" xlink:href="bios-20240331.xsd#bios_SecondLienTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_SecondLienTermLoanMember" xlink:to="lab_bios_SecondLienTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_06e239b0-de1a-4c77-bf3b-b0e79b19b86e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED-PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45592ade-ba97-4053-81f6-8e57c9b3bc32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_206c1a92-2cbc-4986-a909-0186c0716c2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LienCategoryAxis_94476d46-6d10-4ed0-a2dc-0b87ee124e5e_terseLabel_en-US" xlink:label="lab_us-gaap_LienCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lien Category [Axis]</link:label>
    <link:label id="lab_us-gaap_LienCategoryAxis_label_en-US" xlink:label="lab_us-gaap_LienCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lien Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LienCategoryAxis" xlink:to="lab_us-gaap_LienCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_56fb3e9b-ae66-4cb6-a289-a081d00e4d9a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cbc353f4-730a-4c21-9ab3-3000f809d5df_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e4dd28a6-ddce-4b9b-a457-db16145d7282_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_a04b9465-6dc4-4c6e-906c-98b559a22e19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a80e602a-1ddf-43a5-81e0-6e0bbb010be0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_0f486da4-663c-4e56-94f1-aca53913f2f6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4545fe65-2f11-4fff-be27-18306e3f468a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_222b2c63-df70-40a8-a6e4-9424f0b3264f_negatedLabel_en-US" xlink:label="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, vesting of restricted stock, and related tax withholdings</link:label>
    <link:label id="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_label_en-US" xlink:label="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings</link:label>
    <link:label id="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_documentation_en-US" xlink:label="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" xlink:href="bios-20240331.xsd#bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" xlink:to="lab_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LienCategoryDomain_abe06bb2-2192-4169-a2fa-1f5dfea0aed7_terseLabel_en-US" xlink:label="lab_us-gaap_LienCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lien Category [Domain]</link:label>
    <link:label id="lab_us-gaap_LienCategoryDomain_label_en-US" xlink:label="lab_us-gaap_LienCategoryDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lien Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LienCategoryDomain" xlink:to="lab_us-gaap_LienCategoryDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_923c1f43-3a09-497e-b3e4-a4f264e4d731_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d701f896-9722-46f3-9959-75c16cf0c30a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d0690c9-d74d-4a93-a152-c098833058f6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6dc099fa-a21e-4825-838f-6d6eb1d7e5e8_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0711f7cc-561a-4b4c-b350-057c0e80c7e8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4c15d9e5-2068-4fb8-b0e1-01f195e62c31_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock acquired, average cost per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50b51b44-c60b-4150-9f98-793d203e20d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents - beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_771e0891-d40b-4f84-9d3a-5a65777c3948_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS - END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7c368c75-ce97-41e6-9a79-706f162389ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1730d70f-349a-41f1-93eb-89c96e496b82_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1189c3be-29ee-4f5b-b56d-3c6c1465f0d7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5a45f01f-174a-473b-a2dd-77256d186942_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_448d46d5-6e23-4e12-802c-3b84c67e6db4_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_5a58f77e-5012-4b74-8f92-642939f2cb4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock; 9,581,761 and 8,330,022 shares outstanding, at cost, as of March&#160;31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_74fd3582-9635-4131-b9ec-fc5738bdd611_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_4d22e0a5-4745-4691-b72b-2643ada62248_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_63459ceb-a2e6-4f13-9740-e7f6e7fe38c2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a4b4a6a-37eb-4a7e-a2b3-83f13fb92778_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_24e73d8f-50c7-4acd-b8f5-99256e712e45_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3733af91-3252-4018-9305-fd98cb3649ea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DERIVATIVE INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_60fb48ad-103a-456b-9c35-af9502856c69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_01ede0c2-fe47-4595-8d16-88c48f8203e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3d6cb81a-0f5a-45d9-a3d0-c5e1a5de8c41_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_24dc372b-b4d7-4b0f-a6ba-258212c778f3_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_497915ba-40ae-4cb9-95cd-ac373a93fa2d_terseLabel_en-US" xlink:label="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_label_en-US" xlink:label="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Excluding Customer Lists</link:label>
    <link:label id="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_documentation_en-US" xlink:label="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Excluding Customer Lists</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" xlink:href="bios-20240331.xsd#bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" xlink:to="lab_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_067210fb-eeba-40c5-afa6-8d70ba31abe6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5986922d-adf5-4524-a0d8-4f10d19c37e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_810f484e-deb1-4f48-adeb-e71ea2043551_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_57dea4ff-654b-47a7-ad6b-35821bed5a92_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2fe58258-79a6-4371-ae1f-2b48e797d134_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ab019a48-42fb-4e9f-87dc-fad08051a415_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED INCENTIVE COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5fcb76d0-319e-4249-b95a-3c1abc0c1ef8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_6202f67d-df5d-4856-bce8-b7fcfd44b077_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to joint ventures</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_c816a35e-93bb-4ddc-b2fa-2e2330c45eea_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks/names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_005092f5-a635-48cf-8f1a-157a9a6abdf2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_69680664-a048-46e6-ae61-d66ba2e65c68_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's Largest Payer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_473fc9d6-1aed-45ff-8aa4-0122568ab9a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f7bac97c-5ed2-49e8-bb43-c4234f9a8882_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0155d295-59fd-4a41-a1bd-7ec36a596c6f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8763ad67-a294-443e-9138-30f301ab7b45_terseLabel_en-US" xlink:label="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="bios-20240331.xsd#bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_73b296bc-18de-4e7c-b2c9-69577431ac96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_455ec18e-acdc-4054-9eef-ca4963c08660_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share, diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_31a25c59-d4af-436d-aec0-4ab8a862b161_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b2c1083-7764-4620-8294-27ca8b310a65_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_80d0f9d5-646d-499a-8d90-e1fe7cfb6876_negatedTerseLabel_en-US" xlink:label="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of company stock, and related tax effects</link:label>
    <link:label id="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_label_en-US" xlink:label="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value, Including Related Tax Effects</link:label>
    <link:label id="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_documentation_en-US" xlink:label="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value, Including Related Tax Effects</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" xlink:href="bios-20240331.xsd#bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" xlink:to="lab_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bdc5bc4b-d12b-422a-8d99-2dd85476c994_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_c18b43a8-34fc-42c5-985e-6b330ad6ae7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in equity-method investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7e48524b-84eb-416b-aa1f-ea3657fb62c1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_5d0dcef9-f311-4771-bad1-a67e38b3c7a1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_97406b15-765f-414f-909e-61da4a748cb8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8704eeba-3db8-4902-8aa1-9b89c7a97fba_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e5326767-ed68-43f7-97b1-47dca31d2113_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1f788f20-8770-4a0d-af25-9047082a4b97_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7441c47e-0a46-4547-880a-974586c5e65a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_584d5fcc-27ca-4e65-9d05-a62bc27c9a9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3f33ef7b-a1af-4673-b24d-f1c825d92cfe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5aff7028-a158-47c9-b249-9c591478453a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_dcc47541-f214-4ed6-8da9-4bea5a4d95ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f2d444a3-d4be-45b2-b9ab-519b10fea6a0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aa1b3e42-eaac-4b77-86cc-56d1f49403fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_68228b33-d01b-47a2-b750-e9af709e509b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_37bf3669-202a-4df9-82d8-c4e28c4a092a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_98e5507f-9f41-4524-9bf6-3264fea552aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Fair Values of Debt Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf240d6a-dbc1-447e-a1ac-b57a85559a65_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_740248ac-c370-4fb1-baba-509fa4202bd3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_61ca5145-53ac-488d-a215-82332a96fafd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_3cb7c8fa-4902-42fd-b4d4-581abba45c90_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_76547b5b-fac6-4e28-b918-60fc6c84ab0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1129219b-cb55-40b3-ae92-5e18f217c959_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JuniorLienMember_a090baea-656b-4105-857d-303169e7b3e1_terseLabel_en-US" xlink:label="lab_us-gaap_JuniorLienMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Lien Term Loan</link:label>
    <link:label id="lab_us-gaap_JuniorLienMember_label_en-US" xlink:label="lab_us-gaap_JuniorLienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Junior Lien [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_JuniorLienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JuniorLienMember" xlink:to="lab_us-gaap_JuniorLienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_1ed2b73c-b6c0-4957-bbc9-ca900dc89b81_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share, basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_acf1295c-46d4-439f-a95a-e86f04110d4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from joint ventures</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_a83bd07f-1a9a-4e29-a7ca-19c2325f36b6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerListsMember_bf188ee0-0ba5-4c32-86c1-9c4a84e2a041_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerListsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Referral sources</link:label>
    <link:label id="lab_us-gaap_CustomerListsMember_label_en-US" xlink:label="lab_us-gaap_CustomerListsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Lists [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerListsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerListsMember" xlink:to="lab_us-gaap_CustomerListsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_a62baccb-7fb9-4c5e-bf31-2475706a360f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9a836119-94ae-4554-9024-de679466f592_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9ff1eb3-fcc2-471d-b239-e723999fee05_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_e81f3443-6cb6-4e7e-9af8-61562239c2bf_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c458f936-e973-4019-ad11-e0b3a61cdac5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate cap designated as cash flow hedge</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a620f79b-2f87-4926-82e0-95cd6a88eab5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5fda5146-f72f-4e66-ac7a-c99c868fb6bf_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1b26f53c-834d-485c-89cb-4a561841a365_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt principal</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9f0a689f-678e-4cd7-9c87-ef144ad52c89_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_NumberOfInfusionSites_386848cf-b1b4-40b4-9a9c-edc04d0c2a51_terseLabel_en-US" xlink:label="lab_bios_NumberOfInfusionSites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of infusion sites</link:label>
    <link:label id="lab_bios_NumberOfInfusionSites_label_en-US" xlink:label="lab_bios_NumberOfInfusionSites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Infusion Sites</link:label>
    <link:label id="lab_bios_NumberOfInfusionSites_documentation_en-US" xlink:label="lab_bios_NumberOfInfusionSites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Infusion Sites</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfInfusionSites" xlink:href="bios-20240331.xsd#bios_NumberOfInfusionSites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_NumberOfInfusionSites" xlink:to="lab_bios_NumberOfInfusionSites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_754b62ba-b6fc-4267-a3c5-196351bf14fa_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ac92d350-438d-4828-a521-2f2f2325efca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes on unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7a90e618-0b21-4d92-9d9d-b0157fdd3d20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d4190aae-457f-4d82-b11f-f0299d756de7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb5b7cf8-ff66-4bca-96e9-c471fa57e06d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_39ea9c09-d5d0-45e8-8dd3-d1bdce2937a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1c9133b7-0b03-4d1b-a228-274b2abf944f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_EquipmentFurnitureAndOtherMember_28877d82-57e0-421d-b8d5-1a51e891759d_terseLabel_en-US" xlink:label="lab_bios_EquipmentFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment, furniture and other</link:label>
    <link:label id="lab_bios_EquipmentFurnitureAndOtherMember_label_en-US" xlink:label="lab_bios_EquipmentFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Other [Member]</link:label>
    <link:label id="lab_bios_EquipmentFurnitureAndOtherMember_documentation_en-US" xlink:label="lab_bios_EquipmentFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EquipmentFurnitureAndOtherMember" xlink:href="bios-20240331.xsd#bios_EquipmentFurnitureAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_EquipmentFurnitureAndOtherMember" xlink:to="lab_bios_EquipmentFurnitureAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_c9db6b01-54ff-4899-a503-4b3758fa1db5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NONCURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_26863634-2974-4814-8dec-d90819bc5779_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5f11f738-cbea-4bad-8c37-14725e67f0c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_999bfb0d-1b22-42a1-b995-4c3ffcd3b01a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8e478457-e655-4d77-825e-62177a71362e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS PER COMMON SHARE:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ae08b02b-89f1-46e3-bbfe-be953504a4b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock; $0.0000 par value: 250,000,000 shares authorized, 183,397,817 shares issued and 173,816,056 shares outstanding as of March&#160;31, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66325b1d-0a0d-47df-a250-40e1d683cce5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2909e6bf-2c55-4ad3-ad1a-0911f3a97779_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_91200723-3737-40de-9eb1-372135e92b33_terseLabel_en-US" xlink:label="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, vesting of restricted stock, and related tax withholdings</link:label>
    <link:label id="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_label_en-US" xlink:label="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised, Restricted Stock Vested And Tax Withholding</link:label>
    <link:label id="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_documentation_en-US" xlink:label="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised, Restricted Stock Vested And Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" xlink:href="bios-20240331.xsd#bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" xlink:to="lab_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_InfusionPumpsMember_e38f313a-df64-41fa-8fa4-fe596a2ced2e_terseLabel_en-US" xlink:label="lab_bios_InfusionPumpsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Infusion pumps</link:label>
    <link:label id="lab_bios_InfusionPumpsMember_label_en-US" xlink:label="lab_bios_InfusionPumpsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Infusion Pumps [Member]</link:label>
    <link:label id="lab_bios_InfusionPumpsMember_documentation_en-US" xlink:label="lab_bios_InfusionPumpsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Infusion Pumps [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember" xlink:href="bios-20240331.xsd#bios_InfusionPumpsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_InfusionPumpsMember" xlink:to="lab_bios_InfusionPumpsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_5c6ba598-849e-4f6b-b6e6-d64d59356b53_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_81203c1e-c0cc-4f8f-8eb4-f882edfc1382_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebate receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e3597120-ec22-4af3-8f0c-b1c5588c95ac_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_bea23682-488d-4e7c-b20b-deae0a0dad76_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity in earnings of joint ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_9a6c5130-346b-4a5a-99b7-042db376527f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_126d0b96-a2c3-4683-bf11-014dfbc51719_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f9a5bdb3-69e4-4a61-993f-1467a8452265_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ab4405fd-d8cb-4627-9f71-3ba49aee1a29_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f19620e6-9610-4500-a1b6-e42e5a358c23_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_9f2b7abc-cbfb-4d2e-ba85-17c9c2776404_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate cap designated as cash flow hedge</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_071faa4a-d6c8-4da0-bec2-6769087aacc3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b5d13884-1350-490a-8390-b10c070ba525_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_dbc71754-7c12-42a6-b04a-61ca4a79dd01_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6a46e551-3729-4a5c-a2f9-a69251568ce6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOODWILL AND OTHER INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ddd7c666-606a-476b-95aa-e34a6e743c42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_82065277-42cf-40b8-a3af-74b7efeb9d89_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration &#8203;risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_bef95a88-bcbc-4923-bda3-40d4d9f308d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0f6ac2fb-ab82-4a8c-b98e-7aa37f75a0b5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e5795d0a-e90a-4475-9006-9af96d0745cb_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef236417-e485-400d-a98d-cd1b18fd2222_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_765a45cd-e39d-4058-9a1d-e63b6a13f59d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e1fd1aa5-6099-4bad-9194-411bc0975471_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_20bf8a7c-d5d5-47fa-97c0-a7e7919d545a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d9ada628-aa22-4b2e-ad76-70787e4b5166_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_411654a1-06b2-4ff6-a172-64021a89dace_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_32ca4314-2389-4e8a-9dcd-d4eeacce26be_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26ddd110-65aa-4bfa-a62c-cf5d17f8e2ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d6eef10b-0fdc-46d0-bc80-c295743117e0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9881640d-dff8-4a25-9890-46587ad19fff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_327110fe-4d0c-46bc-9aec-0ea4378d41f7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_3aad9a89-3c8f-4384-ac6b-99184ec91625_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSE):</link:label>
    <link:label id="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_label_en-US" xlink:label="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expense, Nonoperating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190ce03f-1390-4b7a-b33d-4b86ae0e910c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">INCOME BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e8373c52-01df-48d4-bf9b-445c7407e203_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_988767f2-8896-4dfc-b506-988f662caf01_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_0dd02f6a-5c48-42d1-9a5e-dc1617a53196_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9957a5de-2be4-4752-ad12-a0b9c00e85e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_9426efc9-f55a-4a15-ba99-5722f180f11e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense in operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_RestrictedStockAwardMember_640f002b-0d64-45d9-988b-cc0458a73420_terseLabel_en-US" xlink:label="lab_bios_RestrictedStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_bios_RestrictedStockAwardMember_label_en-US" xlink:label="lab_bios_RestrictedStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Award [Member]</link:label>
    <link:label id="lab_bios_RestrictedStockAwardMember_documentation_en-US" xlink:label="lab_bios_RestrictedStockAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Award [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAwardMember" xlink:href="bios-20240331.xsd#bios_RestrictedStockAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_RestrictedStockAwardMember" xlink:to="lab_bios_RestrictedStockAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_76e479e9-799c-4eb2-a16b-672c140ffe59_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_66999fc6-e56c-4d2c-a31c-1c66f04a57fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FourVendorsMember_4a3a1921-726b-47d6-8cd6-d4674fd139ec_terseLabel_en-US" xlink:label="lab_bios_FourVendorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four Vendors</link:label>
    <link:label id="lab_bios_FourVendorsMember_label_en-US" xlink:label="lab_bios_FourVendorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Vendors [Member]</link:label>
    <link:label id="lab_bios_FourVendorsMember_documentation_en-US" xlink:label="lab_bios_FourVendorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Vendors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FourVendorsMember" xlink:href="bios-20240331.xsd#bios_FourVendorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FourVendorsMember" xlink:to="lab_bios_FourVendorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_AccountsReceivableBenchmarkMember_3fc1cf2f-6937-408b-9a03-48aceabc2dae_terseLabel_en-US" xlink:label="lab_bios_AccountsReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Benchmark</link:label>
    <link:label id="lab_bios_AccountsReceivableBenchmarkMember_label_en-US" xlink:label="lab_bios_AccountsReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Benchmark [Member]</link:label>
    <link:label id="lab_bios_AccountsReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_bios_AccountsReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccountsReceivableBenchmarkMember" xlink:href="bios-20240331.xsd#bios_AccountsReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_AccountsReceivableBenchmarkMember" xlink:to="lab_bios_AccountsReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_c499c825-b4af-4cd1-9369-8188ef89e6fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a3f66d93-6ae6-45cd-ac76-09e45e603b7c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective rate on term loans at end of period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6a80611f-16ee-4844-8350-54896e98bf1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_NumberOfServiceLocations_b8f32ecb-7bfb-404b-8be7-8b0054e1d126_terseLabel_en-US" xlink:label="lab_bios_NumberOfServiceLocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of service locations</link:label>
    <link:label id="lab_bios_NumberOfServiceLocations_label_en-US" xlink:label="lab_bios_NumberOfServiceLocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Service Locations</link:label>
    <link:label id="lab_bios_NumberOfServiceLocations_documentation_en-US" xlink:label="lab_bios_NumberOfServiceLocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Service Locations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfServiceLocations" xlink:href="bios-20240331.xsd#bios_NumberOfServiceLocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_NumberOfServiceLocations" xlink:to="lab_bios_NumberOfServiceLocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c80c0c2-08f9-4a23-ae1f-f522c7e41063_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1a3f42f4-0662-4818-b164-cadbfe5e9535_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_75b07bbe-fefc-4874-b024-efe63cf326ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19e45ba2-5787-4081-87d9-f90f56664b27_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_97fba0ec-8868-4baf-a153-3ff60b475feb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_03d74e19-0cad-4180-9610-3bdf5d8f9b4d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e623314c-d0cc-4a77-beec-b52531cbc9b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based incentive compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_83a7b3ed-5787-48be-a9b5-212344f9c598_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2c6d859d-6115-4df2-b751-64c7010cfffe_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_70b360b6-c19e-46e6-a8dd-890bc38b8f59_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1140bcd5-05dd-4a73-9b59-31b62ce6be90_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2ca58c07-d65d-48ee-bad6-65daa634ba1f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5e70c95e-c300-4b2f-94cb-60bf2c0551c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_6d9b7d36-bb41-4b81-8ab9-938aa0f431ae_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_913478bf-58c7-46b2-b260-9602572e17c6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3b9a989c-9b3f-4a48-818b-f6791b1fe457_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_2b6691c6-04a5-4518-93e3-38313717585c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_24105225-00e0-4009-b38f-dc3b74dee7ae_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software, purchased and internally developed</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9ea6cd31-fb39-4bdb-9f6d-fc47e2911ced_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2a2489ad-cfff-4519-8272-6283dcc80f6f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_897e95d6-288e-4208-91f0-f1e38f6f7d8f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital distribution from equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_32a4e523-f946-498b-9c16-b84ccd0ee8d2_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributions received from the investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_6f743d62-e1d6-4531-baa8-67ac448e20d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a441d3fd-a57e-45af-b870-ba7f80986624_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_PatientCustomerMember_7859e74f-fcd9-42c9-9e41-1c073fcf74c9_terseLabel_en-US" xlink:label="lab_bios_PatientCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_bios_PatientCustomerMember_label_en-US" xlink:label="lab_bios_PatientCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Customer [Member]</link:label>
    <link:label id="lab_bios_PatientCustomerMember_documentation_en-US" xlink:label="lab_bios_PatientCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PatientCustomerMember" xlink:href="bios-20240331.xsd#bios_PatientCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_PatientCustomerMember" xlink:to="lab_bios_PatientCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CreditAgreementsEnteredInto2019Member_5b8eb7f1-749f-4196-969f-828784ceda32_verboseLabel_en-US" xlink:label="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreements Amendment</link:label>
    <link:label id="lab_bios_CreditAgreementsEnteredInto2019Member_label_en-US" xlink:label="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreements, Entered Into 2019 [Member]</link:label>
    <link:label id="lab_bios_CreditAgreementsEnteredInto2019Member_documentation_en-US" xlink:label="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreements, Entered Into 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member" xlink:href="bios-20240331.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CreditAgreementsEnteredInto2019Member" xlink:to="lab_bios_CreditAgreementsEnteredInto2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5226c530-2995-4457-93c8-637f109541db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_36669436-d1ec-4bd8-a9ef-0f045adadc0e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6bb1323c-0588-48d7-9d87-7cf65aa80bb6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_A2018PlanMember_73d4c7c3-d277-4459-9ef3-457d1961e16d_terseLabel_en-US" xlink:label="lab_bios_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_bios_A2018PlanMember_label_en-US" xlink:label="lab_bios_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Plan [Member]</link:label>
    <link:label id="lab_bios_A2018PlanMember_documentation_en-US" xlink:label="lab_bios_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2018PlanMember" xlink:href="bios-20240331.xsd#bios_A2018PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_A2018PlanMember" xlink:to="lab_bios_A2018PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b716f1a3-734b-4f4b-b452-10ec1e2be19a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amount and Location of Derivatives in the Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_19cc26cc-a914-4194-9332-03e49a50c0a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8804e507-1e41-4e7c-8d6f-b2d8d636c82d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0140bc9-9f67-4ed7-bbb4-553c7b8b5f3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fb966a67-2adb-48be-b273-1e7f9b572809_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6212b92f-c6ab-4703-8c5a-f9e07df57bb7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9eadd911-b156-4122-9dd5-be050d3d0cc4_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bc25ab38-cc2f-4023-a96f-fa76287a3052_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c115b060-a0f0-497a-8997-b9b3ab5a52b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_98b40608-338f-4b34-b9f3-4ea198746495_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ca1ea058-e5ec-4b89-9ca5-8e36020760fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b0a78508-41ad-4712-b1ab-10aba5789135_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized gain (loss) on cash flow hedges, net of income tax (expense) benefit of $(454) and $1,152, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_030aca32-898c-40fd-86e0-d9b372276724_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_cf64f912-4371-4de3-ba01-1b8c3ee645be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_51e916c7-f236-4f59-97c3-17c95b073518_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option awards</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1f8c1703-311e-44c5-826c-3604fe954cdc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_GovernmentHealthcareProgramsMember_e4a55bed-f5b9-4d9f-9ff3-0a70d7929c81_terseLabel_en-US" xlink:label="lab_bios_GovernmentHealthcareProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Healthcare Programs</link:label>
    <link:label id="lab_bios_GovernmentHealthcareProgramsMember_label_en-US" xlink:label="lab_bios_GovernmentHealthcareProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Healthcare Programs [Member]</link:label>
    <link:label id="lab_bios_GovernmentHealthcareProgramsMember_documentation_en-US" xlink:label="lab_bios_GovernmentHealthcareProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Healthcare Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentHealthcareProgramsMember" xlink:href="bios-20240331.xsd#bios_GovernmentHealthcareProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_GovernmentHealthcareProgramsMember" xlink:to="lab_bios_GovernmentHealthcareProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FirstLienCreditAgreementSecondAmendmentMember_e614eafc-93a0-4e83-a4cc-1f3442cd21c9_terseLabel_en-US" xlink:label="lab_bios_FirstLienCreditAgreementSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Lien Credit Agreement</link:label>
    <link:label id="lab_bios_FirstLienCreditAgreementSecondAmendmentMember_label_en-US" xlink:label="lab_bios_FirstLienCreditAgreementSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Lien Credit Agreement, Second Amendment [Member]</link:label>
    <link:label id="lab_bios_FirstLienCreditAgreementSecondAmendmentMember_documentation_en-US" xlink:label="lab_bios_FirstLienCreditAgreementSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Lien Credit Agreement, Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienCreditAgreementSecondAmendmentMember" xlink:href="bios-20240331.xsd#bios_FirstLienCreditAgreementSecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FirstLienCreditAgreementSecondAmendmentMember" xlink:to="lab_bios_FirstLienCreditAgreementSecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_73f5d0bc-ba5d-4647-aa09-13cfa8fe9ad0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_656c22ac-f5d3-4029-bc30-b11ab3c00c86_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5aa5ed21-fb15-48ea-993f-ea2ff4d9fdd0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_78777519-926c-460f-908e-9f6f90fc3f6e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_03697419-bae4-4362-99a6-8fb1d6804ccb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7e715c2e-0a4c-48c5-936d-8eb5d546bdb3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_78fd84a0-fd8f-432d-8eac-4ef7fb7d9d06_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f22037a4-5b0f-4173-a5c3-0f0e3785f1dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2033de46-8e15-4df7-b380-43a4c7b4c9a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_0e2011c7-adc2-4d3e-bef4-05e345a13b1f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets under development</link:label>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_label_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8600af30-b817-41be-b5e7-89f4a8e42b28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1f71f491-7b1a-473a-b342-1adee9c43aea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6aa3a397-c1fa-4072-ae9c-10254a2e21cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7e065d1d-0452-4d43-bb66-57a37538d580_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c4b76446-63b7-428b-a732-fec9cd4eca13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Release of valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171c0725-077c-4084-8e1a-3a9803ac7454_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash (used in) provided by operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_d28615ff-cb9a-4d61-8f6d-8c9fc205fbb0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_8cb198ad-7afb-4fd1-a875-6c36c5e2ed49_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Supply Vendors</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_0b0645d6-e405-49a9-a02e-44a74b8c1ab8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a9464655-77b0-4ecf-909d-e11a30102e6b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e5af7be2-1da7-4fd8-9d1d-9c62a83d0309_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes - net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_LargestPayerMember_77ea53ff-2dd8-4c31-9dce-88c6e54ab2e6_terseLabel_en-US" xlink:label="lab_bios_LargestPayerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Largest Payer</link:label>
    <link:label id="lab_bios_LargestPayerMember_label_en-US" xlink:label="lab_bios_LargestPayerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest Payer [Member]</link:label>
    <link:label id="lab_bios_LargestPayerMember_documentation_en-US" xlink:label="lab_bios_LargestPayerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Largest Payer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LargestPayerMember" xlink:href="bios-20240331.xsd#bios_LargestPayerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_LargestPayerMember" xlink:to="lab_bios_LargestPayerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_19a36104-6697-4bf7-bdb2-2995c53a7081_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e8fd2f25-549f-436d-9b8a-44f3fe0e152d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_2705ca8d-53be-42d3-80bd-74680487efec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a493313c-4fbd-499b-89dc-1e4f55f81d9e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b995b6e4-a21f-4444-bbac-2fd3bf6d1ad5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0d71cba0-0104-4cc4-badd-dadfd81330cf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_ca2c425e-f450-4cae-820a-b5ef4faba957_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense in cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f540095a-55a4-4ba8-b563-5ff61d7e95fa_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ffbef81-3027-4cec-bafa-e326a6d1040d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_243503fb-8447-4097-ae0a-e681e9d9d87e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_f88d40b6-a505-4587-9df0-122de9a5f32d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_d45e0c3c-2248-4533-9acc-30ce646e302e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_25080419-e047-463e-855e-b31cbd6634e7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4633441c-a7b6-432b-a552-fe23af43ad0a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_131ab7f6-6687-437f-95fd-b30b5641f1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_08049b79-94ed-475b-a5f7-f7a595ce8315_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c07170fa-d29a-4895-8613-aa58b6ed4f98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total gross intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_56f94058-b091-475e-b00f-5c0ed94ce49a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAX EXPENSE</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f74e7850-cf33-4523-84f3-9b37d099bdce_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_873c3a34-8ebd-44fe-8093-c88db99ab4ac_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_97ecd20f-106c-435a-9cee-d34c7a77128d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_757f379a-dbfa-491a-a755-4c56e32d6528_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f1b2e520-3c05-4cbf-9f5c-0fe4ececf409_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c7f3da17-c859-4805-ac93-c1451a087922_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9dc7dfec-7b39-451c-af83-e30d22fabc20_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_edd10d42-3047-4f78-ab40-d7339f6ff4c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ad097fc8-163a-48bc-8b76-12def77031ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Revenue Earned by Category of Payer</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_853e088b-2fde-4a64-ac41-a78add1ef08c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePaymentsUse_9537ba40-f91d-4f9c-b292-e0887da6f57d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePaymentsUse_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments, Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePaymentsUse" xlink:to="lab_us-gaap_OperatingLeasePaymentsUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ef3bf22b-efa4-4606-aac0-ee0c54746e18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_53af48c2-b080-4d4f-9d38-8921f182b775_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87c2c751-d782-418d-b9c7-118080e2ae7a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_201a6378-9e6d-47f8-a481-65176b499fee_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_01eb4600-9c8a-43f8-b795-d67517c42526_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4f6aa9d1-d939-4c9f-94d0-732d10b0f96d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_GovernmentCustomerMember_a4b984ea-4ef9-45cf-90ab-ae1fa6262387_terseLabel_en-US" xlink:label="lab_bios_GovernmentCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government payers</link:label>
    <link:label id="lab_bios_GovernmentCustomerMember_label_en-US" xlink:label="lab_bios_GovernmentCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Customer [Member]</link:label>
    <link:label id="lab_bios_GovernmentCustomerMember_documentation_en-US" xlink:label="lab_bios_GovernmentCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentCustomerMember" xlink:href="bios-20240331.xsd#bios_GovernmentCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_GovernmentCustomerMember" xlink:to="lab_bios_GovernmentCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsProductLineMember_b950b4da-8986-4969-9d40-19b28ec8300b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsProductLineMember_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsProductLineMember" xlink:to="lab_us-gaap_CostOfGoodsProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_307d759d-5ddd-4dda-8310-de2a03a8f1e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8c9a16c0-20f9-462a-85a6-eb041e66b06b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a5dd4524-abca-4c85-976d-8d457d49108f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_68f3a836-240f-4e4e-bba8-6cdcb83169f3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_dcd97426-b4f4-4c0e-895a-9afacc0565a5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares, acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_912534ac-ea72-4545-a463-69244d712a7f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_7b954976-a9ad-43f8-b8af-90d638bf3c65_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of discount, deferred financing costs and current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_86ed9e01-6bfa-42b5-889f-796729640582_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5486f5bb-dc66-48a0-818e-bc2552bdbfa1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_da23f5ab-485b-43d6-b006-b6b9281aefe6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7cf5190a-0434-4b63-a221-9056a99af3ca_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_95b59d04-707e-4897-a05c-4130323d491e_totalLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b1fa4806-8ccd-4194-825c-d631819ea30d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING COSTS AND EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5a251e79-45b6-40e4-a469-4cf2b1adac94_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_241494b0-0f72-49cf-8682-f35107866520_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_300c1b08-51b0-47e1-9a7c-75495ad9e846_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7c2199a7-ffda-4a6c-90b6-ea8673f3b0ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b69c680f-f344-4c4d-af89-6b303997673c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f6310ab4-a253-44fa-bd45-b2c1f9dcd913_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5072c813-35aa-4fe1-8ed1-3a7ff2924f29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity in earnings of joint ventures</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_60da57d3-e56c-4fe6-9195-8ae7c84e4ac5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportionate share of earnings in equity-method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ea35d271-6637-4c8a-a71b-157b3cbd72ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based incentive compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_CommercialCustomerMember_4d5aef6c-6131-4568-b2b8-29f7924c8133_terseLabel_en-US" xlink:label="lab_bios_CommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial payers</link:label>
    <link:label id="lab_bios_CommercialCustomerMember_label_en-US" xlink:label="lab_bios_CommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Customer [Member]</link:label>
    <link:label id="lab_bios_CommercialCustomerMember_documentation_en-US" xlink:label="lab_bios_CommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommercialCustomerMember" xlink:href="bios-20240331.xsd#bios_CommercialCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_CommercialCustomerMember" xlink:to="lab_bios_CommercialCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d22cb636-dd48-466a-b085-16879c8494bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7f73a8f1-54df-43f2-bd7e-23fd6343551f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_a67cfa32-08d1-4c2f-80d9-e1692313ca64_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate paid on term loans during period</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_59089379-69c4-4200-b43a-78c258ea092d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b4dc4a8-daae-4d66-a44c-606e394a5111_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9f0dd014-8ac4-4d98-945a-cd681b243497_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8fbab7cd-0ba4-4aa4-96aa-3f9f45d67241_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_cb2381a8-4518-4e3c-ad8b-6ae7ae19fc79_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b698db89-b33d-42cf-8a45-5d2d24f9c989_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00705648-e1d0-4486-9b36-21b2ca0bf2d1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6aa7b45a-d5b5-4a80-8a72-7654981ff4a7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_66374beb-4498-4acb-8490-74e796104930_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0beca78c-47ed-4058-beaa-fec10d250f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b68c87bf-35d5-4b76-a4ed-d8e5b9691528_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">OPERATING INCOME</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4785bc5c-fa83-4b10-b88b-cffdff86cff5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bios_FiniteLivedCustomerListsNet_4358e4e8-ddcb-4bac-a22f-6bd1b2e21e13_terseLabel_en-US" xlink:label="lab_bios_FiniteLivedCustomerListsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Referral sources, net</link:label>
    <link:label id="lab_bios_FiniteLivedCustomerListsNet_label_en-US" xlink:label="lab_bios_FiniteLivedCustomerListsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite Lived Customer Lists, Net</link:label>
    <link:label id="lab_bios_FiniteLivedCustomerListsNet_documentation_en-US" xlink:label="lab_bios_FiniteLivedCustomerListsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite Lived Customer Lists, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FiniteLivedCustomerListsNet" xlink:href="bios-20240331.xsd#bios_FiniteLivedCustomerListsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bios_FiniteLivedCustomerListsNet" xlink:to="lab_bios_FiniteLivedCustomerListsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_53f10508-5fc2-4459-be7c-27408cee94a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_f3fe39eb-947b-4d19-95c4-57a6f85050d3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cb192043-e55c-4d5e-a0f2-a4dee0c95ae0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_4ffa50bc-c340-4e52-b0f6-1963d8959c7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_44ace3d7-eda4-4591-bf09-d1376e53a96c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_ecd15505-b5f0-4ac5-b44f-ee9ee6b2a4bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized to be repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>bios-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3aa0ccbf-2345-461d-8bfe-5351acc3ea16,g:764d9622-b6cc-4198-a6bd-78d38846c16c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bioscrip.com/role/CoverPage" xlink:type="simple" xlink:href="bios-20240331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a93ef106-40c7-4021-848d-1467bef100fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_DocumentType_a93ef106-40c7-4021-848d-1467bef100fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fd45e95a-7b63-44ae-83a8-3a1af00730f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_DocumentQuarterlyReport_fd45e95a-7b63-44ae-83a8-3a1af00730f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_60410f90-463a-4632-975f-74b5905bf4c7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_DocumentPeriodEndDate_60410f90-463a-4632-975f-74b5905bf4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_72b891af-b341-496c-9ab5-ae7057f7a9bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_DocumentTransitionReport_72b891af-b341-496c-9ab5-ae7057f7a9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b511d7ff-b4a7-49bd-ad4f-fa1d30243776" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityFileNumber_b511d7ff-b4a7-49bd-ad4f-fa1d30243776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ff287189-0b10-4852-ad20-f18b041f2b59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityRegistrantName_ff287189-0b10-4852-ad20-f18b041f2b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9f958778-9ca1-4d24-8f67-5cae66212c4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9f958778-9ca1-4d24-8f67-5cae66212c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d8ab3fb0-0849-4dfa-9371-bbad66ebd542" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityTaxIdentificationNumber_d8ab3fb0-0849-4dfa-9371-bbad66ebd542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c9c23903-e01e-4e62-9d43-64c551a02b3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityAddressAddressLine1_c9c23903-e01e-4e62-9d43-64c551a02b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_86122614-f89a-4af9-8da6-d7544c315ed0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityAddressAddressLine2_86122614-f89a-4af9-8da6-d7544c315ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_18c58c35-1d1f-4ef4-9cfc-07f5c63697f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityAddressCityOrTown_18c58c35-1d1f-4ef4-9cfc-07f5c63697f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f70f9274-92ee-48e3-984e-51e0711a8dd8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityAddressStateOrProvince_f70f9274-92ee-48e3-984e-51e0711a8dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4089f655-e207-47d9-bb05-8988fb77852e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityAddressPostalZipCode_4089f655-e207-47d9-bb05-8988fb77852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eb928407-adef-420a-bdd3-b23911807c00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_CityAreaCode_eb928407-adef-420a-bdd3-b23911807c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d07ebac1-476c-47d4-8d06-3e052c5e789e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_LocalPhoneNumber_d07ebac1-476c-47d4-8d06-3e052c5e789e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e9e2c501-4f79-4330-9448-7df289b24f7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_Security12bTitle_e9e2c501-4f79-4330-9448-7df289b24f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_707bc9af-a9e7-4ff2-8270-c1b18a1dc11a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_TradingSymbol_707bc9af-a9e7-4ff2-8270-c1b18a1dc11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_02857d58-f70a-4762-afd0-f85337de6a56" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_SecurityExchangeName_02857d58-f70a-4762-afd0-f85337de6a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_605cb692-467f-4c89-a91c-c31d682883cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityCurrentReportingStatus_605cb692-467f-4c89-a91c-c31d682883cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_eab79502-f097-47f2-b121-b00f47ef8c80" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityInteractiveDataCurrent_eab79502-f097-47f2-b121-b00f47ef8c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5db2bbfd-a8d7-430c-8230-210418694060" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityFilerCategory_5db2bbfd-a8d7-430c-8230-210418694060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d4bcb1da-8199-477f-a84e-30e940da6e65" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntitySmallBusiness_d4bcb1da-8199-477f-a84e-30e940da6e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1ec7c8b1-7bbc-4e6e-af7f-32a68a6511b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityEmergingGrowthCompany_1ec7c8b1-7bbc-4e6e-af7f-32a68a6511b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4c89f716-bc11-48c1-a590-1425ed118ed3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityShellCompany_4c89f716-bc11-48c1-a590-1425ed118ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c179aa6d-916b-4f0d-979e-a505fa7dc0b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c179aa6d-916b-4f0d-979e-a505fa7dc0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7694cb0c-354b-4b0c-8663-35ed904b4c72" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_EntityCentralIndexKey_7694cb0c-354b-4b0c-8663-35ed904b4c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_630d211f-592b-4f83-8612-c5a17677919a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_CurrentFiscalYearEndDate_630d211f-592b-4f83-8612-c5a17677919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_00bb9ce8-735d-4afd-b967-e4e088689949" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_DocumentFiscalYearFocus_00bb9ce8-735d-4afd-b967-e4e088689949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e7856e3b-1ed5-4fbd-a6e2-f49569d37d9d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e7856e3b-1ed5-4fbd-a6e2-f49569d37d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_85e6f80b-6ae9-4b67-b278-e061ec931fcb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f3836e07-d19c-4d0f-91c0-8d2f56412084" xlink:to="loc_dei_AmendmentFlag_85e6f80b-6ae9-4b67-b278-e061ec931fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bios-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b47c6e67-293d-4d8c-90b8-bea28fe13bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e066e89c-82c2-467d-bd07-ec6637ec5d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b47c6e67-293d-4d8c-90b8-bea28fe13bab" xlink:to="loc_us-gaap_AssetsAbstract_e066e89c-82c2-467d-bd07-ec6637ec5d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e066e89c-82c2-467d-bd07-ec6637ec5d81" xlink:to="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa6c29c1-9f03-4e6b-b6e8-8625b730ad83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aa6c29c1-9f03-4e6b-b6e8-8625b730ad83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d72ad7ce-e0d2-4ee1-8931-326e9c2829b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d72ad7ce-e0d2-4ee1-8931-326e9c2829b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f38a7769-af6e-4fee-96ea-5a98ef41a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:to="loc_us-gaap_InventoryNet_f38a7769-af6e-4fee-96ea-5a98ef41a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d45001ba-c23c-421b-ad4a-c8b29d03133f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d45001ba-c23c-421b-ad4a-c8b29d03133f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_95a9f4ce-9809-47ef-9766-8cd774cb4fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_77f52c81-d985-4027-9c6b-300d5e896f48" xlink:to="loc_us-gaap_AssetsCurrent_95a9f4ce-9809-47ef-9766-8cd774cb4fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e066e89c-82c2-467d-bd07-ec6637ec5d81" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9d1dd8a8-3c63-4004-ae5a-4ca16231aae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9d1dd8a8-3c63-4004-ae5a-4ca16231aae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0b28d550-971b-42f3-864c-80de4a0abb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0b28d550-971b-42f3-864c-80de4a0abb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_5278a472-94e7-4ce8-902e-19bd3124736f" xlink:href="bios-20240331.xsd#bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists_5278a472-94e7-4ce8-902e-19bd3124736f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FiniteLivedCustomerListsNet_14579d4e-992c-4e26-8842-859477ad4628" xlink:href="bios-20240331.xsd#bios_FiniteLivedCustomerListsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_bios_FiniteLivedCustomerListsNet_14579d4e-992c-4e26-8842-859477ad4628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc94ef79-8462-4eda-a507-cba3c593a898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_us-gaap_Goodwill_dc94ef79-8462-4eda-a507-cba3c593a898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5bc1f740-45d7-4269-9453-9dced5b498c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5bc1f740-45d7-4269-9453-9dced5b498c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_d924ec27-2cbd-4ac4-93a3-81dbd8a64120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_37ade17d-272e-4142-99f9-65acfd216b50" xlink:to="loc_us-gaap_AssetsNoncurrent_d924ec27-2cbd-4ac4-93a3-81dbd8a64120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_021816a8-5198-4897-b0f6-492a84ce025d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e066e89c-82c2-467d-bd07-ec6637ec5d81" xlink:to="loc_us-gaap_Assets_021816a8-5198-4897-b0f6-492a84ce025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b47c6e67-293d-4d8c-90b8-bea28fe13bab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_10122f7d-b284-452d-90a0-e5fa82741512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:to="loc_us-gaap_AccountsPayableCurrent_10122f7d-b284-452d-90a0-e5fa82741512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0bfc0fa0-36fd-4db0-839e-db4a5c553404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0bfc0fa0-36fd-4db0-839e-db4a5c553404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_487ed63a-1309-4157-bd48-c5d964330dae" xlink:href="bios-20240331.xsd#bios_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:to="loc_bios_AccruedExpensesAndOtherCurrentLiabilities_487ed63a-1309-4157-bd48-c5d964330dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8c48a47-b6e7-47de-b769-09cc4bc2bc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8c48a47-b6e7-47de-b769-09cc4bc2bc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_88277c69-1b50-45d9-900e-e2d5f7b1fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:to="loc_us-gaap_LongTermDebtCurrent_88277c69-1b50-45d9-900e-e2d5f7b1fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f2363e9-757e-4330-8218-c9ce5b76bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d32c9f68-44f3-4325-ac68-c96910d3101f" xlink:to="loc_us-gaap_LiabilitiesCurrent_6f2363e9-757e-4330-8218-c9ce5b76bdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d09e3990-280c-47f6-a094-e0e1db53ffba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d09e3990-280c-47f6-a094-e0e1db53ffba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9aef0b76-db68-4caf-8127-68002979e499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9aef0b76-db68-4caf-8127-68002979e499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2cdde803-4738-4484-9452-534dcb496927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2cdde803-4738-4484-9452-534dcb496927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f1d4dac2-03d7-4382-98c8-c6e41c87a3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f1d4dac2-03d7-4382-98c8-c6e41c87a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_dde68214-b3d9-4fa4-8c0d-263e11611543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_53dd963c-270b-4983-9dcf-810431bd2aff" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_dde68214-b3d9-4fa4-8c0d-263e11611543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6f6fa4aa-3bb4-4981-a503-c1f1c67cbd23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:to="loc_us-gaap_Liabilities_6f6fa4aa-3bb4-4981-a503-c1f1c67cbd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4a665f76-5bef-41d8-bce0-2453c299e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_PreferredStockValue_4a665f76-5bef-41d8-bce0-2453c299e4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_69a8cc7a-9783-4f54-bbb2-a76e78d37cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_CommonStockValue_69a8cc7a-9783-4f54-bbb2-a76e78d37cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_2a5d404b-08fe-4520-8015-51998e76cce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_TreasuryStockCommonValue_2a5d404b-08fe-4520-8015-51998e76cce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27fd5f15-6e27-4db1-8842-814070e6047e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27fd5f15-6e27-4db1-8842-814070e6047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_338b8483-bad1-4bda-aa67-c3d39ada4ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_338b8483-bad1-4bda-aa67-c3d39ada4ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_854d5d7f-3912-47ea-9709-adac59dca8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_854d5d7f-3912-47ea-9709-adac59dca8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71cce273-f06b-4cc8-8dad-be860b302e67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_90e233d9-2c28-48d5-ba69-6ed4f27a1a53" xlink:to="loc_us-gaap_StockholdersEquity_71cce273-f06b-4cc8-8dad-be860b302e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1dcb023d-e2b9-4c26-a1ca-ddbfec76eddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0908c52f-f47a-4f1c-9d05-3441d961a1c4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1dcb023d-e2b9-4c26-a1ca-ddbfec76eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bios-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a3486a89-ffef-48d6-8de7-067a94efb434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a3486a89-ffef-48d6-8de7-067a94efb434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b1f7f52b-cf2d-4129-9eb9-2128f6a717e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b1f7f52b-cf2d-4129-9eb9-2128f6a717e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6ba61b57-9960-4fe5-8be0-aa07d9b2da63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6ba61b57-9960-4fe5-8be0-aa07d9b2da63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9adfbe3b-ddf6-4f50-9447-4046631435d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9adfbe3b-ddf6-4f50-9447-4046631435d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_16869b00-0af6-4d86-bc14-c9abcc01e796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_16869b00-0af6-4d86-bc14-c9abcc01e796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_374fd238-b67b-4b14-841f-c6ac6cca7187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_CommonStockSharesIssued_374fd238-b67b-4b14-841f-c6ac6cca7187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_78c55f8e-99ad-4f8c-a563-fd54b14ee5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_78c55f8e-99ad-4f8c-a563-fd54b14ee5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_efc4de62-f2c0-461e-9d12-7e33e77ff8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bbae2cb-a5ba-4c4c-a4c4-161ef832b4dc" xlink:to="loc_us-gaap_TreasuryStockCommonShares_efc4de62-f2c0-461e-9d12-7e33e77ff8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_930b9bad-6ede-4d17-8c15-05352ff30776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_930b9bad-6ede-4d17-8c15-05352ff30776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8987a4d8-249f-45a6-ab48-69571379bd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8987a4d8-249f-45a6-ab48-69571379bd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0cd5c513-57db-4b1d-98ee-75f8c4f5680f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_GrossProfit_0cd5c513-57db-4b1d-98ee-75f8c4f5680f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d5fc3be6-fb67-4439-aa3e-39d9489d3d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d5fc3be6-fb67-4439-aa3e-39d9489d3d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b014ef99-04b0-4afa-8705-239053897ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d5fc3be6-fb67-4439-aa3e-39d9489d3d85" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b014ef99-04b0-4afa-8705-239053897ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c2b49877-a202-4e2b-946b-99503bca6de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d5fc3be6-fb67-4439-aa3e-39d9489d3d85" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c2b49877-a202-4e2b-946b-99503bca6de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8f919228-cef5-4fcf-ae1a-e1e3c31dcaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d5fc3be6-fb67-4439-aa3e-39d9489d3d85" xlink:to="loc_us-gaap_OperatingExpenses_8f919228-cef5-4fcf-ae1a-e1e3c31dcaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8f71c167-5528-4805-a21f-7c2211dbc14a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_OperatingIncomeLoss_8f71c167-5528-4805-a21f-7c2211dbc14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_56108bd7-7bd5-418d-bc88-b02ca2958a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_56108bd7-7bd5-418d-bc88-b02ca2958a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c5ae4620-6b3d-4098-b53a-1fb47b6641f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_56108bd7-7bd5-418d-bc88-b02ca2958a86" xlink:to="loc_us-gaap_InterestExpense_c5ae4620-6b3d-4098-b53a-1fb47b6641f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_ec247106-72ff-422f-bd71-062b8f0c898d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_56108bd7-7bd5-418d-bc88-b02ca2958a86" xlink:to="loc_us-gaap_InvestmentIncomeNet_ec247106-72ff-422f-bd71-062b8f0c898d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_624a4a05-a726-43f4-9c4b-328c37595e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_56108bd7-7bd5-418d-bc88-b02ca2958a86" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_624a4a05-a726-43f4-9c4b-328c37595e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4f0272f6-5d09-4dff-b8b4-9f8cf2e153bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_56108bd7-7bd5-418d-bc88-b02ca2958a86" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4f0272f6-5d09-4dff-b8b4-9f8cf2e153bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b541d418-94ca-48a5-a5d8-eea356251ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b541d418-94ca-48a5-a5d8-eea356251ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c9f9a16-4754-493b-ba7b-f339956f7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c9f9a16-4754-493b-ba7b-f339956f7da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7a80127-5014-4630-b546-3f431cb594b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_NetIncomeLoss_a7a80127-5014-4630-b546-3f431cb594b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_838132b7-11fa-4c08-b1c8-395f078e2110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_838132b7-11fa-4c08-b1c8-395f078e2110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_34f9afd7-dc9e-4fa0-b05e-55659a2cf64c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_838132b7-11fa-4c08-b1c8-395f078e2110" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_34f9afd7-dc9e-4fa0-b05e-55659a2cf64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fdd1206e-f4ed-41fb-923f-be6d64a7b87a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_838132b7-11fa-4c08-b1c8-395f078e2110" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fdd1206e-f4ed-41fb-923f-be6d64a7b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8e4b6ff2-7a25-408d-8c41-84016d7083a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8e4b6ff2-7a25-408d-8c41-84016d7083a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_086b668f-94ef-4f06-aa03-618475dd4739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_EarningsPerShareAbstract_086b668f-94ef-4f06-aa03-618475dd4739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9ebe064a-618a-40bb-a008-a1ef737ca33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_086b668f-94ef-4f06-aa03-618475dd4739" xlink:to="loc_us-gaap_EarningsPerShareBasic_9ebe064a-618a-40bb-a008-a1ef737ca33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2831ad8e-9aa2-4c84-afeb-77803013f610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_086b668f-94ef-4f06-aa03-618475dd4739" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2831ad8e-9aa2-4c84-afeb-77803013f610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_986ff006-30ce-4113-852a-184e890e887f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_986ff006-30ce-4113-852a-184e890e887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f281769-e888-4bb6-bd16-84cfa03f6eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_44936951-0d9e-4e23-a614-8673b8912ba9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f281769-e888-4bb6-bd16-84cfa03f6eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_bcbb8117-f2e4-49e8-99d0-02626b990d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2a4c5ccc-da4a-4329-98e7-42d62b87a2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bcbb8117-f2e4-49e8-99d0-02626b990d16" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2a4c5ccc-da4a-4329-98e7-42d62b87a2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f061d6f-07d2-42e4-a2d1-1edab24deefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f061d6f-07d2-42e4-a2d1-1edab24deefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23ab6596-c42c-4717-8258-ddb500675925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f061d6f-07d2-42e4-a2d1-1edab24deefc" xlink:to="loc_us-gaap_NetIncomeLoss_23ab6596-c42c-4717-8258-ddb500675925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f061d6f-07d2-42e4-a2d1-1edab24deefc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_743b93da-1f9e-43f3-824e-a0b19ff379cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_743b93da-1f9e-43f3-824e-a0b19ff379cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26c7018e-778d-4a75-8e04-22582e41b83c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26c7018e-778d-4a75-8e04-22582e41b83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b73de2d0-4bcb-4d18-9365-4f9f9353de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b73de2d0-4bcb-4d18-9365-4f9f9353de9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b23bd793-5724-4dc8-9b08-3326dbfa94a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b23bd793-5724-4dc8-9b08-3326dbfa94a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7568eea2-d39a-47e8-8d03-9472752507e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7568eea2-d39a-47e8-8d03-9472752507e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_242d1da5-5e7d-483c-a506-37ac4527b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_ShareBasedCompensation_242d1da5-5e7d-483c-a506-37ac4527b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_04c9a0d8-fb90-4ade-9caf-6aeb2532bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_04c9a0d8-fb90-4ade-9caf-6aeb2532bdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3182a615-a488-4a5e-bc03-1bc1e29c376a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3182a615-a488-4a5e-bc03-1bc1e29c376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd12b443-1470-44d6-9449-bf3e3f76c8d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_de8528c9-33f8-4478-82fd-218f603cbd41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_de8528c9-33f8-4478-82fd-218f603cbd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d9ed6a66-08da-4761-b127-b45f56128631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d9ed6a66-08da-4761-b127-b45f56128631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21c7b69a-c922-4225-bf5c-ac7e5cf231de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21c7b69a-c922-4225-bf5c-ac7e5cf231de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_62aff5b0-7988-4f6f-b4cd-deb51c59f17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_62aff5b0-7988-4f6f-b4cd-deb51c59f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a81232f2-9590-4516-8545-46f4e2eed20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a81232f2-9590-4516-8545-46f4e2eed20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_3bc06914-cd04-4d6f-8560-e41eb73de75f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_3bc06914-cd04-4d6f-8560-e41eb73de75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_6e0e24e8-05ff-45e9-b057-47787c3b0587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_OperatingLeasePayments_6e0e24e8-05ff-45e9-b057-47787c3b0587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_fed813c0-d7c5-495e-8420-42f5ff321918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ce2d8bc-d392-4f9e-9246-bf663fca1edf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_fed813c0-d7c5-495e-8420-42f5ff321918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_68025346-dec1-40d1-b620-e580bd79b438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8f061d6f-07d2-42e4-a2d1-1edab24deefc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_68025346-dec1-40d1-b620-e580bd79b438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0187ca0b-0ffe-4018-a70e-f85081ffe8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0187ca0b-0ffe-4018-a70e-f85081ffe8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_776ef46e-a1e1-42b9-9677-3f136d9a39da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0187ca0b-0ffe-4018-a70e-f85081ffe8e6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_776ef46e-a1e1-42b9-9677-3f136d9a39da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f149135a-3c39-4b44-a8da-e33e70333932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0187ca0b-0ffe-4018-a70e-f85081ffe8e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f149135a-3c39-4b44-a8da-e33e70333932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_1b7e0ae7-853e-4e12-8b95-0d2f84ee024a" xlink:href="bios-20240331.xsd#bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:to="loc_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding_1b7e0ae7-853e-4e12-8b95-0d2f84ee024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_fe5f1eef-6b31-4592-bb1c-03bd2c6c6ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:to="loc_us-gaap_RepaymentsOfDebt_fe5f1eef-6b31-4592-bb1c-03bd2c6c6ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ff0ddd49-7058-4559-9d72-390fc3ea8f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ff0ddd49-7058-4559-9d72-390fc3ea8f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_01b82b6a-770d-4ae8-a132-8300848bbc79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_01b82b6a-770d-4ae8-a132-8300848bbc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54b31084-938c-45b6-a75b-14c248d66143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a4eb484f-e884-4ff6-b5cc-161ada311233" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54b31084-938c-45b6-a75b-14c248d66143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2ba2d0ad-6e0d-4be1-8d17-99b0f25e39ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2ba2d0ad-6e0d-4be1-8d17-99b0f25e39ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95641a3f-ca2c-44af-b326-e0145c0aecac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95641a3f-ca2c-44af-b326-e0145c0aecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_885cabb0-35fd-41f6-a455-c03534053b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_885cabb0-35fd-41f6-a455-c03534053b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_dfb57985-aa64-44b3-ac94-7115ba9b817a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fe975b09-d61d-41f4-ac5b-b0c5261a018b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_dfb57985-aa64-44b3-ac94-7115ba9b817a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f4a22198-de9e-4e2a-8806-3e062486d1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dfb57985-aa64-44b3-ac94-7115ba9b817a" xlink:to="loc_us-gaap_InterestPaidNet_f4a22198-de9e-4e2a-8806-3e062486d1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3a598a34-d420-4589-acbd-141c2000cae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dfb57985-aa64-44b3-ac94-7115ba9b817a" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3a598a34-d420-4589-acbd-141c2000cae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePaymentsUse_0f908493-49bf-46d4-9c33-23dce979ec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dfb57985-aa64-44b3-ac94-7115ba9b817a" xlink:to="loc_us-gaap_OperatingLeasePaymentsUse_0f908493-49bf-46d4-9c33-23dce979ec1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20240331.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ea8c171a-cd6e-4374-b2d2-7dd31c129265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ea8c171a-cd6e-4374-b2d2-7dd31c129265" xlink:to="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c9861f06-1950-4c31-8a95-249c4e307b37" xlink:to="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_82021332-ea84-4afd-9752-f8bef009c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_PreferredStockMember_82021332-ea84-4afd-9752-f8bef009c0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86ae0a32-dd21-40c4-939c-9fccd1cd3676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_CommonStockMember_86ae0a32-dd21-40c4-939c-9fccd1cd3676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_15a4d4e9-ab5f-491b-93bb-941c8ba3587d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_TreasuryStockCommonMember_15a4d4e9-ab5f-491b-93bb-941c8ba3587d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_21ec7ae5-f589-469c-a310-eb86210519e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_21ec7ae5-f589-469c-a310-eb86210519e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2c93d95e-ab07-4668-bd2b-7e75613e9517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_RetainedEarningsMember_2c93d95e-ab07-4668-bd2b-7e75613e9517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6bbbaf9-62c8-4c80-9103-ac9b9e45c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfca9d11-6a4a-413e-a51c-be66f002b708" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6bbbaf9-62c8-4c80-9103-ac9b9e45c39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e0a09f3-c97a-495b-9e38-fdd30e5f3445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29486cf7-c421-4355-b7ef-2a18022a7742" xlink:to="loc_us-gaap_StatementLineItems_7e0a09f3-c97a-495b-9e38-fdd30e5f3445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e0a09f3-c97a-495b-9e38-fdd30e5f3445" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8fadacfd-6289-46ad-85a6-e642cd9449d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_StockholdersEquity_8fadacfd-6289-46ad-85a6-e642cd9449d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_f14aa8e4-710e-4e40-aab9-85e191d5e4e9" xlink:href="bios-20240331.xsd#bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings_f14aa8e4-710e-4e40-aab9-85e191d5e4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7527239b-e780-46ac-bf46-9e0481b48e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7527239b-e780-46ac-bf46-9e0481b48e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_914204a7-ec77-4060-8226-db3c14063262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_914204a7-ec77-4060-8226-db3c14063262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_67a8681e-3448-46ea-9763-110595618a48" xlink:href="bios-20240331.xsd#bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects_67a8681e-3448-46ea-9763-110595618a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc326e3e-1874-43a6-b606-a6d10817e717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_NetIncomeLoss_cc326e3e-1874-43a6-b606-a6d10817e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1834b963-f08c-46b0-89be-efbe4d7fb39d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1834b963-f08c-46b0-89be-efbe4d7fb39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3ac03ac1-7176-4883-b59d-ed42291c4263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c14ca94f-549f-43a4-92b3-30867b359ca7" xlink:to="loc_us-gaap_StockholdersEquity_3ac03ac1-7176-4883-b59d-ed42291c4263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="bios-20240331.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_55769465-17b5-45e8-9093-d6100f8a75c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2f81f5f6-408f-4d0d-aadb-6d437a1a9738" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_55769465-17b5-45e8-9093-d6100f8a75c3" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2f81f5f6-408f-4d0d-aadb-6d437a1a9738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bios-20240331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b3507a51-71ba-4308-b547-6ccd9208f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_eae98b74-3385-4022-8d38-413233762a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b3507a51-71ba-4308-b547-6ccd9208f1f2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_eae98b74-3385-4022-8d38-413233762a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUE" xlink:type="simple" xlink:href="bios-20240331.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8517080e-e4e2-4647-9ff3-f5faf2861be2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7980ee5b-00ce-4187-9723-5d1fa9d3d05a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8517080e-e4e2-4647-9ff3-f5faf2861be2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7980ee5b-00ce-4187-9723-5d1fa9d3d05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bios-20240331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8c85cb41-f688-4196-bceb-000d4ed326ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f499a937-efea-4cfb-a861-3106c2941fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c85cb41-f688-4196-bceb-000d4ed326ed" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f499a937-efea-4cfb-a861-3106c2941fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EARNINGSPERSHARE" xlink:type="simple" xlink:href="bios-20240331.xsd#EARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/EARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1ee9c974-e720-4b31-858e-749838bc9926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_af46d6b2-3477-4096-9f06-45adc6bd96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ee9c974-e720-4b31-858e-749838bc9926" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_af46d6b2-3477-4096-9f06-45adc6bd96cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASES" xlink:type="simple" xlink:href="bios-20240331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4d867762-c859-43d6-9978-d724d0518bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_227be1ea-b3ce-479d-b967-7f0cd1f38d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d867762-c859-43d6-9978-d724d0518bdf" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_227be1ea-b3ce-479d-b967-7f0cd1f38d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ffc794c4-b7e3-45c7-8b02-7cf444b9340e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d867762-c859-43d6-9978-d724d0518bdf" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ffc794c4-b7e3-45c7-8b02-7cf444b9340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bios-20240331.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_81151d84-13c7-48de-9999-6cb78e69abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a219a0cd-566a-446b-b41b-fa7b60a95fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_81151d84-13c7-48de-9999-6cb78e69abdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a219a0cd-566a-446b-b41b-fa7b60a95fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="bios-20240331.xsd#GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d7805fb-8e0e-433b-9e26-4c33de749b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_91b7bf77-79a2-4329-8ff2-227d6b13cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5d7805fb-8e0e-433b-9e26-4c33de749b7c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_91b7bf77-79a2-4329-8ff2-227d6b13cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_72afdcb2-6d38-4483-9a87-512db0fb9bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8f740aca-8c00-4eeb-a1d6-4578176dfca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_72afdcb2-6d38-4483-9a87-512db0fb9bbd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_8f740aca-8c00-4eeb-a1d6-4578176dfca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cc783a1d-8c69-431a-8ee8-3c575f86725a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_bb727dc8-edab-4c80-8384-e687bb14518a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cc783a1d-8c69-431a-8ee8-3c575f86725a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_bb727dc8-edab-4c80-8384-e687bb14518a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="simple" xlink:href="bios-20240331.xsd#FAIRVALUEMEASURMENTS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9cff7000-4670-43c3-91be-801a02338ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d8cf64c4-d59c-413c-9440-3262469fa0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cff7000-4670-43c3-91be-801a02338ed3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d8cf64c4-d59c-413c-9440-3262469fa0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bios-20240331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_464158aa-34d3-44c0-990d-45bb32a60c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0060a2a6-a702-4366-b619-82fa7f3ad3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_464158aa-34d3-44c0-990d-45bb32a60c6b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0060a2a6-a702-4366-b619-82fa7f3ad3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="simple" xlink:href="bios-20240331.xsd#STOCKBASEDINCENTIVECOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a7f4f67-85e9-40ce-90f8-f7fe8943a981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d9bad696-525d-4206-89ba-39af1166b4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a7f4f67-85e9-40ce-90f8-f7fe8943a981" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d9bad696-525d-4206-89ba-39af1166b4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="bios-20240331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d4e6fdec-3559-427b-a2ca-252763a595fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_96804f20-370d-41af-9cf3-2073f9da4272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d4e6fdec-3559-427b-a2ca-252763a595fd" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_96804f20-370d-41af-9cf3-2073f9da4272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="bios-20240331.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c8b5376b-141a-4f28-8139-377ebb9d539e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c767668d-23e2-4a15-8cdf-e85dcab582c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c8b5376b-141a-4f28-8139-377ebb9d539e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c767668d-23e2-4a15-8cdf-e85dcab582c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bios-20240331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_72ea06b6-c0b5-4b15-892f-7c04addbce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_72ea06b6-c0b5-4b15-892f-7c04addbce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2716c92b-a10f-4606-a999-e890a47fb372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2716c92b-a10f-4606-a999-e890a47fb372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9e972c28-7847-4878-9d84-83f23dd34b00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9e972c28-7847-4878-9d84-83f23dd34b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_262595c9-0b4b-420f-89e5-49396e396798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_262595c9-0b4b-420f-89e5-49396e396798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_b37de795-6da7-48fa-9e05-8d489f63abe6" xlink:href="bios-20240331.xsd#bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:to="loc_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock_b37de795-6da7-48fa-9e05-8d489f63abe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c952af29-f860-48d6-8f50-c39d294e5ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18c0ef1d-8140-49fd-a6c2-29a2089073aa" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c952af29-f860-48d6-8f50-c39d294e5ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUETables" xlink:type="simple" xlink:href="bios-20240331.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_981afa99-9b48-44e3-a06f-a9d9fa4e06b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b84d148d-a914-4837-b835-a0d6d12f21dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_981afa99-9b48-44e3-a06f-a9d9fa4e06b1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b84d148d-a914-4837-b835-a0d6d12f21dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EARNINGSPERSHARETables" xlink:type="simple" xlink:href="bios-20240331.xsd#EARNINGSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/EARNINGSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6375aa23-fa9c-43b5-8256-a587ffd9e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_79d64180-c668-4fa2-a3b8-2c2f342253f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6375aa23-fa9c-43b5-8256-a587ffd9e4de" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_79d64180-c668-4fa2-a3b8-2c2f342253f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4a9160da-96cd-450d-ba22-ba29a78711cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6375aa23-fa9c-43b5-8256-a587ffd9e4de" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4a9160da-96cd-450d-ba22-ba29a78711cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESTables" xlink:type="simple" xlink:href="bios-20240331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_396772ed-d4bf-48e2-b7bd-ec8e182c832c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_787a9aad-c7cb-407d-b091-201a53a2707b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_396772ed-d4bf-48e2-b7bd-ec8e182c832c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_787a9aad-c7cb-407d-b091-201a53a2707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bios-20240331.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5f9f2693-05af-4ae2-a897-10a301131223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_21044e97-2e81-4031-8562-c52006296a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5f9f2693-05af-4ae2-a897-10a301131223" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_21044e97-2e81-4031-8562-c52006296a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="bios-20240331.xsd#GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9de9e619-bd52-4e63-964f-0d1fe02fefa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_25ae8988-8ebe-489d-a9e4-69e90991fd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9de9e619-bd52-4e63-964f-0d1fe02fefa7" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_25ae8988-8ebe-489d-a9e4-69e90991fd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b6ce0198-f307-44e9-b5b7-239102ce2ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1edca1fb-9a55-492a-adb3-d8f8f12b2068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b6ce0198-f307-44e9-b5b7-239102ce2ed4" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1edca1fb-9a55-492a-adb3-d8f8f12b2068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_130caf97-6463-4713-8d33-b81766c09bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b6ce0198-f307-44e9-b5b7-239102ce2ed4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_130caf97-6463-4713-8d33-b81766c09bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_540d0cfb-ec00-4f47-ba97-7c14f848ac41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b6ce0198-f307-44e9-b5b7-239102ce2ed4" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_540d0cfb-ec00-4f47-ba97-7c14f848ac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1e597c23-704f-4ec5-b9ec-c0134977b368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_566c134a-d778-47bc-abed-eae7610697fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1e597c23-704f-4ec5-b9ec-c0134977b368" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_566c134a-d778-47bc-abed-eae7610697fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_668d38e9-0695-4655-8e47-05b55c06a43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1e597c23-704f-4ec5-b9ec-c0134977b368" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_668d38e9-0695-4655-8e47-05b55c06a43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1e3a78d-207a-48bb-b029-6028e0eb2d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1e3a78d-207a-48bb-b029-6028e0eb2d96" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4590c3e2-e284-4d4d-a4f4-552aef4527b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06e821c2-ffae-4cd7-b253-edfab3bd0696" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4590c3e2-e284-4d4d-a4f4-552aef4527b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LegacyHealthSystemsMember_922ec269-ca99-4d2b-8b0f-e6940573a4a0" xlink:href="bios-20240331.xsd#bios_LegacyHealthSystemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4590c3e2-e284-4d4d-a4f4-552aef4527b0" xlink:to="loc_bios_LegacyHealthSystemsMember_922ec269-ca99-4d2b-8b0f-e6940573a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b5983b1a-71c6-4c79-8563-288767ed6036" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfServiceLocations_5f5a436b-46bf-4203-a436-9851bfe4f49d" xlink:href="bios-20240331.xsd#bios_NumberOfServiceLocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_bios_NumberOfServiceLocations_5f5a436b-46bf-4203-a436-9851bfe4f49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_NumberOfInfusionSites_ac862e7c-33b6-4b75-883d-d531436b8dc8" xlink:href="bios-20240331.xsd#bios_NumberOfInfusionSites"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_bios_NumberOfInfusionSites_ac862e7c-33b6-4b75-883d-d531436b8dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_93791ac6-0864-4f8a-b96c-a9f140c4cbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_us-gaap_NumberOfOperatingSegments_93791ac6-0864-4f8a-b96c-a9f140c4cbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4061ac38-d94a-4c9d-93cc-6dab80cb909a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_516716e0-4c03-41d5-be1b-598ba894a824" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4061ac38-d94a-4c9d-93cc-6dab80cb909a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fad85ffe-2d77-4ec3-8a20-fea8ec475910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fad85ffe-2d77-4ec3-8a20-fea8ec475910" xlink:to="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1c46a11a-bed9-45d2-8b9f-c0a24f4ac429" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7c56c9e5-6bdf-4b9c-8410-5f679a3bfa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7c56c9e5-6bdf-4b9c-8410-5f679a3bfa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_AccountsReceivableBenchmarkMember_49ab6a04-5645-4b1a-87f4-f6834d9f4e89" xlink:href="bios-20240331.xsd#bios_AccountsReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:to="loc_bios_AccountsReceivableBenchmarkMember_49ab6a04-5645-4b1a-87f4-f6834d9f4e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsProductLineMember_c663598f-6c50-4b12-b48d-5c41930f6c08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsProductLineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b10cd213-9fe3-45b4-ac49-3ed881c5e912" xlink:to="loc_us-gaap_CostOfGoodsProductLineMember_c663598f-6c50-4b12-b48d-5c41930f6c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0cd2c683-d107-486a-9f8a-dba18d593a90" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5c50489f-b7b0-400b-b868-145a4b980b43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5c50489f-b7b0-400b-b868-145a4b980b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_df21beec-177f-410e-a8ee-a2fbb2251c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_df21beec-177f-410e-a8ee-a2fbb2251c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_fd6964b1-1668-4758-a518-e3a26d862f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f4f085fc-17c6-4800-8dad-521277e5d56a" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_fd6964b1-1668-4758-a518-e3a26d862f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_39d46b35-0ae0-45c2-8be6-c0da2140a5c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_00a40611-8cf2-4086-bb23-f90179d4649e" xlink:to="loc_srt_NameOfMajorCustomerDomain_39d46b35-0ae0-45c2-8be6-c0da2140a5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LargestPayerMember_6a8fab9e-fed5-4c82-a6fc-c7b9e63a7c65" xlink:href="bios-20240331.xsd#bios_LargestPayerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_39d46b35-0ae0-45c2-8be6-c0da2140a5c8" xlink:to="loc_bios_LargestPayerMember_6a8fab9e-fed5-4c82-a6fc-c7b9e63a7c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_95544509-c4b6-4546-98c7-c49d7e538dd8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4f1d3ffb-9dd3-4420-b3b3-8ee371c4736a" xlink:to="loc_srt_ProductsAndServicesDomain_95544509-c4b6-4546-98c7-c49d7e538dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentHealthcareProgramsMember_e70b221b-c748-4e19-909b-203534eaed0b" xlink:href="bios-20240331.xsd#bios_GovernmentHealthcareProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_95544509-c4b6-4546-98c7-c49d7e538dd8" xlink:to="loc_bios_GovernmentHealthcareProgramsMember_e70b221b-c748-4e19-909b-203534eaed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_55ab9b08-5acc-454c-adca-1301659c12ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_c990de95-dd73-47f1-a2cc-4f006c198bb2" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_55ab9b08-5acc-454c-adca-1301659c12ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FourVendorsMember_a5c0292a-771a-4bac-900d-cef4a9d25144" xlink:href="bios-20240331.xsd#bios_FourVendorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_55ab9b08-5acc-454c-adca-1301659c12ce" xlink:to="loc_bios_FourVendorsMember_a5c0292a-771a-4bac-900d-cef4a9d25144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5a61ec7d-24aa-482c-ab0d-81b46debcb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bd6d54e5-7fb1-4aad-a614-71a7bc02b377" xlink:to="loc_us-gaap_RelatedPartyDomain_5a61ec7d-24aa-482c-ab0d-81b46debcb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_0949057d-feff-4c82-9f65-14ccd39f7c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5a61ec7d-24aa-482c-ab0d-81b46debcb01" xlink:to="loc_us-gaap_CorporateJointVentureMember_0949057d-feff-4c82-9f65-14ccd39f7c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_f53a4e73-e99a-4e2d-a4fb-6230e4a136a6" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_ad36f28b-3917-496a-9c36-b4e595b5f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_ad36f28b-3917-496a-9c36-b4e595b5f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2b61605b-87f3-4136-8e65-5a481529b627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_EquityMethodInvestments_2b61605b-87f3-4136-8e65-5a481529b627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81a22f8a-cd43-4215-8379-462141e12004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81a22f8a-cd43-4215-8379-462141e12004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bba2d813-1223-493e-8b60-a430623c47db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bba2d813-1223-493e-8b60-a430623c47db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bb04acb4-90e9-4488-b553-b14cacb59022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9979c863-b2bb-4a79-87d1-38338115bfb6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bb04acb4-90e9-4488-b553-b14cacb59022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#REVENUENetRevenueEarnedbyCategoryofPayerDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a05ff2c0-e45c-432d-ab50-18e2f213d5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a05ff2c0-e45c-432d-ab50-18e2f213d5df" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:to="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f2a3ca5b-25f9-4fa3-bb39-666901922f60" xlink:to="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CommercialCustomerMember_5b449c61-df73-4a4d-8a07-73e6e4e862a1" xlink:href="bios-20240331.xsd#bios_CommercialCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:to="loc_bios_CommercialCustomerMember_5b449c61-df73-4a4d-8a07-73e6e4e862a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_GovernmentCustomerMember_e42a3744-7de5-41ed-8a91-64fc2f472fb4" xlink:href="bios-20240331.xsd#bios_GovernmentCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:to="loc_bios_GovernmentCustomerMember_e42a3744-7de5-41ed-8a91-64fc2f472fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PatientCustomerMember_bd5bfee4-5834-4c4d-aa84-ff303e7c9c4b" xlink:href="bios-20240331.xsd#bios_PatientCustomerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_08e96ae0-5341-4819-b238-6efa14d15bef" xlink:to="loc_bios_PatientCustomerMember_bd5bfee4-5834-4c4d-aa84-ff303e7c9c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4411f1e1-b745-4893-858b-e1c5ac72b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_58c74b95-0932-48ef-b7ff-c81967d23390" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4411f1e1-b745-4893-858b-e1c5ac72b3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8db4d0a0-e7ce-4847-ae98-f769a6cd07e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4411f1e1-b745-4893-858b-e1c5ac72b3c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8db4d0a0-e7ce-4847-ae98-f769a6cd07e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e87bd8d0-4536-44fe-8d68-47dea7f27fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e87bd8d0-4536-44fe-8d68-47dea7f27fa1" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e948b705-ba12-474e-951b-b5d94b7ea5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1f43cf78-e22e-46c1-bf50-af931d0d50ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e948b705-ba12-474e-951b-b5d94b7ea5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_01725869-788d-4960-b5dd-5e8dc9bcca81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e948b705-ba12-474e-951b-b5d94b7ea5b6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_01725869-788d-4960-b5dd-5e8dc9bcca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b2a3d19-d06a-4288-b551-5622ba76da7a" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_99c4d4c9-f34c-49c0-a473-0a16bf080f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_99c4d4c9-f34c-49c0-a473-0a16bf080f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d1d4f78c-9071-48f7-920f-474342b08777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d1d4f78c-9071-48f7-920f-474342b08777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_893b9b0d-6c67-4264-bef4-0ab46ef59f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_893b9b0d-6c67-4264-bef4-0ab46ef59f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_131297b8-8b4a-4b9f-97f4-2f9c13e65a86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_97eef2bb-8695-4ecb-a4f9-1f0862130703" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_131297b8-8b4a-4b9f-97f4-2f9c13e65a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eca98d70-92ee-4e42-805a-3942fd805e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eca98d70-92ee-4e42-805a-3942fd805e80" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a8d6e02-7419-4d2a-b189-4e88c5a804dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_d072336d-01c0-41d9-8a8c-b019abe71f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:to="loc_us-gaap_StockOptionMember_d072336d-01c0-41d9-8a8c-b019abe71f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_RestrictedStockAwardMember_10751515-b22f-451a-8455-c1101d950f57" xlink:href="bios-20240331.xsd#bios_RestrictedStockAwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:to="loc_bios_RestrictedStockAwardMember_10751515-b22f-451a-8455-c1101d950f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_PerformanceStockUnitMember_bf88633d-852d-499b-a806-33efe29e19db" xlink:href="bios-20240331.xsd#bios_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0540f72c-15cd-4b10-b21b-3ed988fd1906" xlink:to="loc_bios_PerformanceStockUnitMember_bf88633d-852d-499b-a806-33efe29e19db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4f690113-6438-4dd6-8e90-6c283d55ceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_431719e7-0e76-4591-820b-bbd10d4df5db" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4f690113-6438-4dd6-8e90-6c283d55ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_388f445b-7b9c-4ddc-94db-e4ab47efd32e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4f690113-6438-4dd6-8e90-6c283d55ceaf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_388f445b-7b9c-4ddc-94db-e4ab47efd32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b6f0421-1b1d-42e4-b246-4ae0a986dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_c3ebb744-4adb-42af-ad5a-371b6c6867b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b6f0421-1b1d-42e4-b246-4ae0a986dc67" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_c3ebb744-4adb-42af-ad5a-371b6c6867b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f42a72c6-6c21-4f68-aa03-5f292a710eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_c3ebb744-4adb-42af-ad5a-371b6c6867b9" xlink:to="loc_us-gaap_NetIncomeLoss_f42a72c6-6c21-4f68-aa03-5f292a710eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6ccda234-5d7e-4c89-b083-12dae0543512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b6f0421-1b1d-42e4-b246-4ae0a986dc67" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6ccda234-5d7e-4c89-b083-12dae0543512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45f7b5ad-d7f5-4968-b12f-498e10df2c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6ccda234-5d7e-4c89-b083-12dae0543512" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_45f7b5ad-d7f5-4968-b12f-498e10df2c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_41a2638e-77d2-4d2d-92a3-45cba0fe04b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6ccda234-5d7e-4c89-b083-12dae0543512" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_41a2638e-77d2-4d2d-92a3-45cba0fe04b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8c977f1-b747-4d26-93b1-fc9f1f319e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6ccda234-5d7e-4c89-b083-12dae0543512" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c8c977f1-b747-4d26-93b1-fc9f1f319e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4ccc909e-4416-494a-a685-7e8ec00105d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b6f0421-1b1d-42e4-b246-4ae0a986dc67" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4ccc909e-4416-494a-a685-7e8ec00105d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_580090a2-d9da-45e7-be8a-38b3223e4e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4ccc909e-4416-494a-a685-7e8ec00105d7" xlink:to="loc_us-gaap_EarningsPerShareBasic_580090a2-d9da-45e7-be8a-38b3223e4e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_9c797fa4-14e9-4f2c-820f-563f4d7eaebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b6f0421-1b1d-42e4-b246-4ae0a986dc67" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_9c797fa4-14e9-4f2c-820f-563f4d7eaebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fd300a89-2632-4705-8002-767baf6eb1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_9c797fa4-14e9-4f2c-820f-563f4d7eaebc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fd300a89-2632-4705-8002-767baf6eb1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#LEASESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_43c1be36-89ba-45ce-9000-a00acaf46feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e57757fd-77d4-43bd-a6c3-eed3a54ee9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_43c1be36-89ba-45ce-9000-a00acaf46feb" xlink:to="loc_us-gaap_OperatingLeaseExpense_e57757fd-77d4-43bd-a6c3-eed3a54ee9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3921845f-5655-4628-a4eb-a04841e49372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_43c1be36-89ba-45ce-9000-a00acaf46feb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3921845f-5655-4628-a4eb-a04841e49372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87eacb47-c2f7-4025-8f63-4528307b0868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_43c1be36-89ba-45ce-9000-a00acaf46feb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87eacb47-c2f7-4025-8f63-4528307b0868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_64aa16e6-bcd8-4695-b2ce-4fe040d2f6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_43c1be36-89ba-45ce-9000-a00acaf46feb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_64aa16e6-bcd8-4695-b2ce-4fe040d2f6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef36fff3-6169-48bb-af73-816da2dd790d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef36fff3-6169-48bb-af73-816da2dd790d" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a4838fe1-4876-43b7-ba01-8950959c4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a4838fe1-4876-43b7-ba01-8950959c4f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_492eb262-6a4b-48b9-b881-e2f61b847c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_492eb262-6a4b-48b9-b881-e2f61b847c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd883299-59d6-4ce7-9eba-63728bda03cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd883299-59d6-4ce7-9eba-63728bda03cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66f47111-d6b7-4dac-a062-26eba939f914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_66f47111-d6b7-4dac-a062-26eba939f914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4367896-02a5-4ded-8bf8-e5be9a2b2872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b4367896-02a5-4ded-8bf8-e5be9a2b2872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b854d5a8-2f01-45a3-9326-345878f8a91c" xlink:href="bios-20240331.xsd#bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b854d5a8-2f01-45a3-9326-345878f8a91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fff056f4-686e-4cbd-b2ea-86f2a11dd82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fff056f4-686e-4cbd-b2ea-86f2a11dd82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_966b5b9d-353c-47e2-9710-32ed988b9cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_966b5b9d-353c-47e2-9710-32ed988b9cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_17522500-fc9a-4a56-bd0d-8346c8749c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_76391868-5c33-491a-bb30-b9f9932acbbe" xlink:to="loc_us-gaap_OperatingLeaseLiability_17522500-fc9a-4a56-bd0d-8346c8749c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dd0ab6c7-7316-4b9c-9b1b-8f5fa45a5d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dd0ab6c7-7316-4b9c-9b1b-8f5fa45a5d93" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1084d1eb-5b97-4548-a025-0d160c6124fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_InfusionPumpsMember_f4c28266-8986-4bb9-821f-8bc0ac78cac4" xlink:href="bios-20240331.xsd#bios_InfusionPumpsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_bios_InfusionPumpsMember_f4c28266-8986-4bb9-821f-8bc0ac78cac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_EquipmentFurnitureAndOtherMember_9001c33f-db01-4fd9-8cd9-a670c2d1e5ea" xlink:href="bios-20240331.xsd#bios_EquipmentFurnitureAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_bios_EquipmentFurnitureAndOtherMember_9001c33f-db01-4fd9-8cd9-a670c2d1e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3d75d6b8-5a61-436f-bea7-384c11c862ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3d75d6b8-5a61-436f-bea7-384c11c862ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_02b6cc70-0397-4f9a-a6e1-400fb7eb0eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_02b6cc70-0397-4f9a-a6e1-400fb7eb0eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_3f8dd7b9-a5fa-41ae-8f26-486a6a28ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_798f74d4-fed4-48a7-a832-af11c4bca014" xlink:to="loc_us-gaap_AssetUnderConstructionMember_3f8dd7b9-a5fa-41ae-8f26-486a6a28ef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0c028a97-678c-4848-ac82-8e954164113f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_189e4355-55c4-40cc-9d43-248e0e042ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:to="loc_us-gaap_CostOfSalesMember_189e4355-55c4-40cc-9d43-248e0e042ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_d175529d-5594-4c04-8e1f-2bd22dcce99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a70f575f-a859-4750-bdac-0c01437fa313" xlink:to="loc_us-gaap_OperatingExpenseMember_d175529d-5594-4c04-8e1f-2bd22dcce99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14325771-79bb-43d1-82bc-97ddc2fdf297" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_eb934379-27ec-4ec1-bcc5-a3d08101a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_eb934379-27ec-4ec1-bcc5-a3d08101a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e4f11d04-344c-4bb5-a3af-c647600f7999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e4f11d04-344c-4bb5-a3af-c647600f7999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15ccbbee-c032-49a9-84ec-e8e4d146dd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15ccbbee-c032-49a9-84ec-e8e4d146dd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a8b8ddd6-b854-4ade-b267-26519b74b002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7bf4729a-0647-4413-8414-ee2d2897587f" xlink:to="loc_us-gaap_Depreciation_a8b8ddd6-b854-4ade-b267-26519b74b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c763c3d-1cab-4062-8c09-8794396c7ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c763c3d-1cab-4062-8c09-8794396c7ff8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f5e5503-48dd-460d-a140-84b59a2efc86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerListsMember_9c5998f0-cf94-4608-8581-afac8317137b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerListsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:to="loc_us-gaap_CustomerListsMember_9c5998f0-cf94-4608-8581-afac8317137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_cfef7b17-693a-4728-8ab1-d2d7e731d918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_cfef7b17-693a-4728-8ab1-d2d7e731d918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_b6c81303-2e73-45d7-b696-93801999ef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_082201fe-484c-49b9-8a1b-e0341013b5d6" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_b6c81303-2e73-45d7-b696-93801999ef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8c3f86c6-c156-472b-80c9-00bc076d3f80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_deef06bb-08f2-47d5-adc7-cbe63e42ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_deef06bb-08f2-47d5-adc7-cbe63e42ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_95a95dde-86fa-48af-b6f2-cc73c26152ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_95a95dde-86fa-48af-b6f2-cc73c26152ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e191b3af-8c40-4990-92be-72bf385d2079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e191b3af-8c40-4990-92be-72bf385d2079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_20ee73bb-b3ad-4668-818c-0376b4a6fd20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a664f584-ff85-4742-b776-ab691c099fca" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_20ee73bb-b3ad-4668-818c-0376b4a6fd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e162e7ef-4228-4143-b633-e8b100389937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e162e7ef-4228-4143-b633-e8b100389937" xlink:to="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d90eec56-9b5d-453d-9094-656b72c4cced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d20fa908-05c9-4b74-99a6-9aa57517da27" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d90eec56-9b5d-453d-9094-656b72c4cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b682623f-2dbc-4bb8-b3e2-8a9594f90451" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d90eec56-9b5d-453d-9094-656b72c4cced" xlink:to="loc_us-gaap_SeniorNotesMember_b682623f-2dbc-4bb8-b3e2-8a9594f90451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b394c007-5561-440c-a0cf-9c3e658ef509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_79c9d5a7-ec2d-41f3-8ce7-4346ce680936" xlink:to="loc_us-gaap_CreditFacilityDomain_b394c007-5561-440c-a0cf-9c3e658ef509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bf046303-46c1-4b71-9dfa-fd87a3ff78c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b394c007-5561-440c-a0cf-9c3e658ef509" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bf046303-46c1-4b71-9dfa-fd87a3ff78c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_743e8002-dac5-41e4-8131-c36d23f1baa5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_be55ef52-228e-4cad-b3f3-4475ccbd5530" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:to="loc_bios_FirstLienTermLoanMember_be55ef52-228e-4cad-b3f3-4475ccbd5530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_SecondLienTermLoanMember_7ff47649-6226-4b0f-b80f-959ed5942df3" xlink:href="bios-20240331.xsd#bios_SecondLienTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22faa903-3442-48eb-af7b-5b62f0ba6467" xlink:to="loc_bios_SecondLienTermLoanMember_7ff47649-6226-4b0f-b80f-959ed5942df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9efd90c6-113b-4923-83c9-f53af1fb7fdb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_77c14663-30a9-4018-b811-bacb652abe47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_77c14663-30a9-4018-b811-bacb652abe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_83b0f10e-429b-49c7-87ce-406f6a8b17e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_83b0f10e-429b-49c7-87ce-406f6a8b17e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5d02710-6b91-4526-a2ef-88b836ba4b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5d02710-6b91-4526-a2ef-88b836ba4b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4921054c-fd3b-4763-b29f-31336da414e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_LongTermDebt_4921054c-fd3b-4763-b29f-31336da414e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_623b189b-b30d-4d31-a94e-edc69c12da98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_LongTermDebtCurrent_623b189b-b30d-4d31-a94e-edc69c12da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0ebea405-b665-4e57-b608-2523c5313367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d017a0f-1ba1-450f-8dc6-9543381f8bb5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0ebea405-b665-4e57-b608-2523c5313367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8e4e85fc-ae4a-429f-a618-ffadf29b34f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8e4e85fc-ae4a-429f-a618-ffadf29b34f3" xlink:to="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LienCategoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryAxis_9ebbff21-2d47-48f3-b630-926aaf241669" xlink:to="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLienMember_b4180611-1e0b-49fe-bba4-fab77ccc219c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorLienMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:to="loc_us-gaap_SeniorLienMember_b4180611-1e0b-49fe-bba4-fab77ccc219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JuniorLienMember_1fa90f87-1b9d-4d09-9366-3c89f3eb4fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_JuniorLienMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LienCategoryDomain_c4d79bbc-c2b3-4f2b-a39a-f82dbee0bae2" xlink:to="loc_us-gaap_JuniorLienMember_1fa90f87-1b9d-4d09-9366-3c89f3eb4fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_47b4de86-9264-4d79-a923-90001eedda28" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_CreditAgreementsEnteredInto2019Member_cfca8537-0fe8-49fc-b9db-f5697e49c533" xlink:href="bios-20240331.xsd#bios_CreditAgreementsEnteredInto2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:to="loc_bios_CreditAgreementsEnteredInto2019Member_cfca8537-0fe8-49fc-b9db-f5697e49c533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienCreditAgreementSecondAmendmentMember_9e9be59e-3b31-4593-adba-a41e0ec5515c" xlink:href="bios-20240331.xsd#bios_FirstLienCreditAgreementSecondAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fab49a69-d40b-4bc9-96c2-2acbe77400ef" xlink:to="loc_bios_FirstLienCreditAgreementSecondAmendmentMember_9e9be59e-3b31-4593-adba-a41e0ec5515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85c0a3af-d9eb-44ea-8d9f-2c249f116c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_16ccab46-bb1a-4ca5-a44f-88b930f4a3fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85c0a3af-d9eb-44ea-8d9f-2c249f116c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9e43864f-7f61-42eb-8137-f90780deb360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_85c0a3af-d9eb-44ea-8d9f-2c249f116c7b" xlink:to="loc_us-gaap_SeniorNotesMember_9e43864f-7f61-42eb-8137-f90780deb360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0706a120-c771-43dc-aca7-723812926912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_07b02aaa-69d0-4875-8415-96620c00b940" xlink:to="loc_us-gaap_CreditFacilityDomain_0706a120-c771-43dc-aca7-723812926912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_79a68dc0-ae71-40f4-be14-469ebb81c1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0706a120-c771-43dc-aca7-723812926912" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_79a68dc0-ae71-40f4-be14-469ebb81c1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_696877e2-92a8-483f-9ebd-c7afd63c4bd9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_06d44dac-a3ec-4ed5-a33f-82a52130977e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_06d44dac-a3ec-4ed5-a33f-82a52130977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_d50b1237-289b-4cf9-abd7-575da82f061e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_d50b1237-289b-4cf9-abd7-575da82f061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1f0ad3a7-323f-48ee-b283-530cf2936bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1f0ad3a7-323f-48ee-b283-530cf2936bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_365bee0e-40a8-4534-b238-4d842ac1e834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_365bee0e-40a8-4534-b238-4d842ac1e834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_583cfd24-2188-457b-93f1-72397842e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d406274-48f8-4f8c-861f-886efb49a576" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_583cfd24-2188-457b-93f1-72397842e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSLongTermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3ab79650-45c8-4660-a631-1fb5860d4471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3ab79650-45c8-4660-a631-1fb5860d4471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9b9a625f-abd8-49ba-a128-90c5e2fe60cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9b9a625f-abd8-49ba-a128-90c5e2fe60cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a2198bcc-dfce-4965-91d9-909c74dc95c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a2198bcc-dfce-4965-91d9-909c74dc95c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_007b1fbf-4557-43ea-8a24-e6f6b6b5bcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_007b1fbf-4557-43ea-8a24-e6f6b6b5bcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f153d397-a381-43cb-be43-eeff1534b894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f153d397-a381-43cb-be43-eeff1534b894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_LongTermDebtMaturityAfterYearFour_2e7d6cde-f3c5-43d4-9156-02524575ef03" xlink:href="bios-20240331.xsd#bios_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_bios_LongTermDebtMaturityAfterYearFour_2e7d6cde-f3c5-43d4-9156-02524575ef03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec2e3909-058b-4b5b-a1f5-c7cfbbcea670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fcded719-d73d-41e4-b0e1-dab325df5911" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ec2e3909-058b-4b5b-a1f5-c7cfbbcea670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4ab55ba6-7622-4bd1-bcab-6429cd9727ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4ab55ba6-7622-4bd1-bcab-6429cd9727ea" xlink:to="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7e80d931-e7db-4f84-a8a5-9deebbbed924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f92c3ac4-23ff-4677-905b-7e5a51cc5581" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7e80d931-e7db-4f84-a8a5-9deebbbed924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_275c0eb6-4e18-489a-8f22-7d74bdbd84ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7e80d931-e7db-4f84-a8a5-9deebbbed924" xlink:to="loc_us-gaap_SeniorNotesMember_275c0eb6-4e18-489a-8f22-7d74bdbd84ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_877a8bd2-6519-4bab-bc3f-ebfdfeccec94" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cf645cd4-1808-46ba-a7e2-b82d04f16804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cf645cd4-1808-46ba-a7e2-b82d04f16804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9f7ffa2c-e2a3-41a2-9e24-4224d9f34744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9f7ffa2c-e2a3-41a2-9e24-4224d9f34744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_08c10d2d-24f1-42fb-93af-ee5d8d88eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84601926-e6ef-4cae-b307-58869cc326a8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_08c10d2d-24f1-42fb-93af-ee5d8d88eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc2f6bb6-0002-4172-8c5d-5613e3ceb0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca771e72-55aa-410e-9745-f0515b6ece4d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc2f6bb6-0002-4172-8c5d-5613e3ceb0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_14d087ec-4467-43b3-a025-ec0b7d09cf1a" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc2f6bb6-0002-4172-8c5d-5613e3ceb0a7" xlink:to="loc_bios_FirstLienTermLoanMember_14d087ec-4467-43b3-a025-ec0b7d09cf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ccf67af2-2c4e-49dd-a210-5778e5f015e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_79beb1cf-c2b3-40cd-a727-aa4b787c4504" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ccf67af2-2c4e-49dd-a210-5778e5f015e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_635613ef-c4c3-4335-be97-e6c3fd82fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ccf67af2-2c4e-49dd-a210-5778e5f015e9" xlink:to="loc_us-gaap_LongTermDebtFairValue_635613ef-c4c3-4335-be97-e6c3fd82fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ef1ffc52-e85d-4816-9cbb-deaf654f3dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ef1ffc52-e85d-4816-9cbb-deaf654f3dee" xlink:to="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_18ba26b7-92ce-4272-b984-69dbe27b357d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ff7dda63-3482-44ac-85b1-52e54693f8cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_18ba26b7-92ce-4272-b984-69dbe27b357d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_bb3b14b2-af45-438c-8500-33f7d343c040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_18ba26b7-92ce-4272-b984-69dbe27b357d" xlink:to="loc_us-gaap_InterestRateCapMember_bb3b14b2-af45-438c-8500-33f7d343c040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ad6f3b31-ce9c-46f1-a7ec-2e45e9d59e38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_64f25822-a8ec-496d-adcc-9533d594196c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ad6f3b31-ce9c-46f1-a7ec-2e45e9d59e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_FirstLienTermLoanMember_25487bad-0c80-4500-be09-6fcb1cf741fd" xlink:href="bios-20240331.xsd#bios_FirstLienTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ad6f3b31-ce9c-46f1-a7ec-2e45e9d59e38" xlink:to="loc_bios_FirstLienTermLoanMember_25487bad-0c80-4500-be09-6fcb1cf741fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3309aee1-42e5-48e5-b768-f371f6cae8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b38c49f9-5bf8-48d8-bd64-25617d31db39" xlink:to="loc_us-gaap_HedgingDesignationDomain_3309aee1-42e5-48e5-b768-f371f6cae8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_12433782-755e-4b7d-9a25-8e0592aa9aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_3309aee1-42e5-48e5-b768-f371f6cae8d2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_12433782-755e-4b7d-9a25-8e0592aa9aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fcddaf01-16de-4d87-98d2-68aa7bd632ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7d83e444-fc1a-42ee-82d1-1f3740522f4d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fcddaf01-16de-4d87-98d2-68aa7bd632ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6e7095b1-fd70-4491-b19d-de51d03a0648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fcddaf01-16de-4d87-98d2-68aa7bd632ca" xlink:to="loc_us-gaap_SeniorNotesMember_6e7095b1-fd70-4491-b19d-de51d03a0648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9b788d6c-5a1b-4827-ac8d-6506a7019187" xlink:to="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1fdfa646-6e3d-4315-bd7f-dd4e19628610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1fdfa646-6e3d-4315-bd7f-dd4e19628610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_70d14d91-6f47-46c1-b7f9-63952e19ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b4032638-9378-4ae1-99e9-62c53663dd75" xlink:to="loc_us-gaap_DerivativeTermOfContract_70d14d91-6f47-46c1-b7f9-63952e19ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5fea65d4-9d33-460b-ab7e-4fd5b7e2cd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5fea65d4-9d33-460b-ab7e-4fd5b7e2cd3e" xlink:to="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8e61ffd3-b1d7-4957-adac-ce6c12eca5da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b09eee4f-4f9c-40c1-b744-0fdbb2345b15" xlink:to="loc_us-gaap_HedgingDesignationDomain_8e61ffd3-b1d7-4957-adac-ce6c12eca5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa5a4d7c-a499-4fde-bf9b-21a118752da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8e61ffd3-b1d7-4957-adac-ce6c12eca5da" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_aa5a4d7c-a499-4fde-bf9b-21a118752da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5b92b301-3fa2-4426-9fd9-bdcb0f1f4c86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e9b703d3-5cd6-4189-95de-1e49439cb70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e9b703d3-5cd6-4189-95de-1e49439cb70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_792616e9-34df-437e-8540-e95320d189bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6084de38-bf41-41a1-9788-64cb2d51e9d3" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_792616e9-34df-437e-8540-e95320d189bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c4fadb5d-0254-4c7d-920c-0ab96fe5ca89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6918d39f-070d-4544-9504-7d1e91b8ed93" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c4fadb5d-0254-4c7d-920c-0ab96fe5ca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_b8699ca5-0f38-4c71-9da9-a378dc634d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c4fadb5d-0254-4c7d-920c-0ab96fe5ca89" xlink:to="loc_us-gaap_InterestRateCapMember_b8699ca5-0f38-4c71-9da9-a378dc634d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d22fbb41-e708-4d27-9bbc-c409857f4062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a89cddda-f334-4aa7-a154-26ede9717d7b" xlink:to="loc_us-gaap_DerivativeLineItems_d22fbb41-e708-4d27-9bbc-c409857f4062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_50438ace-0065-4f91-b7aa-b0cec41505fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d22fbb41-e708-4d27-9bbc-c409857f4062" xlink:to="loc_us-gaap_DerivativeAssets_50438ace-0065-4f91-b7aa-b0cec41505fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_219cddee-3d42-4e79-8370-6ed7de92a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_219cddee-3d42-4e79-8370-6ed7de92a21a" xlink:to="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0dcb75ac-b5fe-448d-b03c-7fc2760c55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76fa4093-9ae1-4ce4-a618-17de00b0c039" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0dcb75ac-b5fe-448d-b03c-7fc2760c55d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_29a25841-1a89-443f-89ed-0ca37430a42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0dcb75ac-b5fe-448d-b03c-7fc2760c55d5" xlink:to="loc_us-gaap_InterestRateCapMember_29a25841-1a89-443f-89ed-0ca37430a42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20e6c7a6-af1a-47a0-a16b-28f39b6248e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_190e5c9f-527f-4b6b-afdc-9b19e32390e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20e6c7a6-af1a-47a0-a16b-28f39b6248e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_131f5337-2842-4e8c-805b-a8cc61bbad11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20e6c7a6-af1a-47a0-a16b-28f39b6248e9" xlink:to="loc_us-gaap_InterestExpenseMember_131f5337-2842-4e8c-805b-a8cc61bbad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e31d4924-3faa-48ff-94a4-349972afe4b4" xlink:to="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ea9bc410-a801-4887-842c-e696e3624063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ea9bc410-a801-4887-842c-e696e3624063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c9259072-0385-4b6a-a968-e4040446482f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f0ceb2bf-50a1-48ce-baa5-aa00c11a302b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c9259072-0385-4b6a-a968-e4040446482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#STOCKBASEDINCENTIVECOMPENSATIONDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16ffd2be-a1f3-48e8-8fa9-17b5e04ada92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16ffd2be-a1f3-48e8-8fa9-17b5e04ada92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:to="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd3b3e34-fcab-438d-aa8f-54d5467e963a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c2f1d2b-f068-45a3-baa1-f31a16a0f916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd3b3e34-fcab-438d-aa8f-54d5467e963a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember_5a29bdbe-6efa-4647-874b-38c4e51f2bf3" xlink:href="bios-20240331.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd3b3e34-fcab-438d-aa8f-54d5467e963a" xlink:to="loc_bios_HCIIncentiveUnitsMember_5a29bdbe-6efa-4647-874b-38c4e51f2bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:to="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ab876463-85b1-4f8a-81b9-e4412f710207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6e8b1257-c7fb-4712-beda-259ea0e7dbb1" xlink:to="loc_us-gaap_PlanNameDomain_ab876463-85b1-4f8a-81b9-e4412f710207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2018PlanMember_693bf2b6-71d6-4137-8026-65b37bb9d4f5" xlink:href="bios-20240331.xsd#bios_A2018PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ab876463-85b1-4f8a-81b9-e4412f710207" xlink:to="loc_bios_A2018PlanMember_693bf2b6-71d6-4137-8026-65b37bb9d4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_e74483ac-5776-463e-8ed8-c62d95f3cddf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9166c822-addd-4890-95da-e47f6adeffed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9166c822-addd-4890-95da-e47f6adeffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27b70cb5-7179-4d94-bd51-359e70d8897a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6e9ba695-2340-4a9f-b27c-328dbb2860ef" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27b70cb5-7179-4d94-bd51-359e70d8897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_02c6c8e1-7f80-4440-ba0c-bf0a3249f0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02c6c8e1-7f80-4440-ba0c-bf0a3249f0af" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ea57f76-4625-46cf-9264-e606ac1f044b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37137514-e688-40a9-91b9-21183c5940fd" xlink:to="loc_us-gaap_EquityComponentDomain_9ea57f76-4625-46cf-9264-e606ac1f044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e4727a9f-5fc7-4f27-8334-d8bc639e4029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9ea57f76-4625-46cf-9264-e606ac1f044b" xlink:to="loc_us-gaap_CommonStockMember_e4727a9f-5fc7-4f27-8334-d8bc639e4029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5eb91fbe-f9d3-4544-89b3-b0c672d86ab9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2017WarrantsMember_197fc2ee-5dc8-4628-85b3-4513988b5acb" xlink:href="bios-20240331.xsd#bios_A2017WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:to="loc_bios_A2017WarrantsMember_197fc2ee-5dc8-4628-85b3-4513988b5acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_A2015WarrantsMember_2568cd38-b2b0-4d71-ac1d-cc1c3ae0e154" xlink:href="bios-20240331.xsd#bios_A2015WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1114d91e-acf2-4a06-b650-ab1e6dec4eed" xlink:to="loc_bios_A2015WarrantsMember_2568cd38-b2b0-4d71-ac1d-cc1c3ae0e154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f519a2f-c1a9-4cfa-a63c-1eb2a6568e05" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1db99458-d9c4-4beb-85c9-ca03656a0258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1db99458-d9c4-4beb-85c9-ca03656a0258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5c875a41-0aa1-4cc4-a1c2-0c70895b9b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5c875a41-0aa1-4cc4-a1c2-0c70895b9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_d912ec41-bcbf-4af9-bb89-394e26586275" xlink:href="bios-20240331.xsd#bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised_d912ec41-bcbf-4af9-bb89-394e26586275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_9e85046f-9474-41e2-ad84-cbfa14934eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_9e85046f-9474-41e2-ad84-cbfa14934eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_620b64c4-8a87-4073-b4c6-d367a2d69d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_620b64c4-8a87-4073-b4c6-d367a2d69d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1828ece2-d341-469e-8208-06ce19c66860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1828ece2-d341-469e-8208-06ce19c66860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e4fb3b5-6a8d-4a03-a1f7-05bbb505da97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e4fb3b5-6a8d-4a03-a1f7-05bbb505da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_492910e0-e05b-4356-ad92-e3d350ad55a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dc973759-0f55-4a53-b408-d13313c1f66e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_492910e0-e05b-4356-ad92-e3d350ad55a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="bios-20240331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7b157533-89e7-47eb-b238-582192931e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7b157533-89e7-47eb-b238-582192931e4c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_64082e7c-b517-4852-aa32-f65244564fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_099e57c2-1921-441d-8422-274aac520393" xlink:to="loc_us-gaap_RelatedPartyDomain_64082e7c-b517-4852-aa32-f65244564fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_2d71083b-719d-4ebe-8194-a5731a4e2879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_64082e7c-b517-4852-aa32-f65244564fa2" xlink:to="loc_us-gaap_CorporateJointVentureMember_2d71083b-719d-4ebe-8194-a5731a4e2879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76cabace-3c1c-4755-a78f-a220491415ec" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d190614-5857-4195-8673-c04f85390c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d190614-5857-4195-8673-c04f85390c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5b0675e6-9360-4d18-98eb-ad15442becbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5b0675e6-9360-4d18-98eb-ad15442becbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_bd3e95d4-9600-4c5e-9f41-8ec85ed4b37d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_OtherReceivables_bd3e95d4-9600-4c5e-9f41-8ec85ed4b37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_c2588673-75a2-416c-8f28-5d4bd3f2e195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_bfbd8d26-927d-44bf-95f8-40756a9403c7" xlink:to="loc_us-gaap_AccountsPayableOtherCurrentAndNoncurrent_c2588673-75a2-416c-8f28-5d4bd3f2e195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_bios_HCIIncentiveUnitsMember" xlink:href="bios-20240331.xsd#bios_HCIIncentiveUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_bios_HCIIncentiveUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>bios-20240331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bios-20240331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QY;VYS+"!!
M;F1R97<   60 P "    %   $*:0!  "    %   $+J2D0 "     S4R  "2
MD@ "     S4R  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D&W8^7&?>EHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=:45L?M.62PN:8.G5G%-I6?R+/B#Q9J?B2V%M?NBV^[<8HA@,??UK#50BX4
M = *UOLD4O+)^(XJ1-*@8\[_ /OJM'FE-KWDSVJ4:&'CRTXV1DU=LM.GO6'E
MKM3N[=*V+;3;:-@1$"?5CFM6)0  !@5Y>)S32U-&5;%V5HH=I6GQ6$>V,98_
M><]374^'<_VIQ_<-8<(KI/#5N3)).>F-HKR\OYZV.@WJ[W/F,?4O3DY=3HZ*
M**_1#Y<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=&5:C"M'ED?/EQ!/:3-#<QM%(IPR.N"*B+>M>]W^CV.J)MO[6.88X++R/QK
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M+IFFD;'+$G _04 6_#EWXD\.Z%J5_P#$?4+1XX<2))!C"KCD< <YKD(/&?Q
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M7 %$OC;Q[\/[J ^/+.'4=*D<(;NU W)[Y&,_0BMV/XW^"XHU2-[U%48519L
M!69XF^+/@CQ#X:O]+G>]87,+(N;-N&Q\I_ XH ]2T_4+;5-.@OK&59K>= \;
MKT8&O-O$_P 0]>U#Q?+X4^'UI#->6_%U=S<I$>X';CN3WJO^S]JL]WX.NM/N
M"W^A3_N\CHK#./SS73^'_!NC> ]3U35SJ+_\3!M\K7;J OS%C@\>M '+/HGQ
MBM$-U%K^GW,@&3;E1@^PRN*W/AM\1+GQ7->Z1KMFMEK.GG]\B9"N,X) /0@]
M13]6^,_@S3)&B34'OI1QLLXC)S]>GZUPOPUUF'7_ ([:SJ=M;RVT5S:NXBF&
M&'*=0* -S]H3_D5-)_["*_\ H#5T_B'_ (3/^QM(_P"$(^Q;O)'VC[5CIM7;
MC]:YC]H3_D5-)_["*_\ H#5ZCIG_ "";3_K@G_H(H ^=M,_X3W_A<.H?9/[/
M_P"$A\@^?NQY6SCI[]*]:M?^$K_X0#7_ /A-?LGVK[--Y7V7&-GEGK[YKEM"
M_P"3E]9_Z]#_ .RUZ9XI_P"10U?_ *\9O_0#0!X5\-?&6KV/@V'P[X/T];[6
M9YWD9I/]7;IQAFKJ+I/C-I,+ZBUUI]\L8WO;1JK<=P!@?H:D_9XTV&+P?=Z@
M$'G7%QL+8YVJ!Q^M>O'I0!R'PZ\>0^.M#>X:#[+?6S>7=09R%;U'L:S->\0:
MB-01HIY8XY)I88HH6*[?+=5R2 ?F8MGYOE Q]:YOX4 6WQ:\:6<0VQ+,Y"CH
M,2G_ !KTZ]\-6MW=2SK)- TPQ*(FP'Z<X]>!R/04 2^'[Z>^T]_M>#-!,\#N
MHX<J<;OQK4J"RLX;"T2VM4V1H, ?UJ>@14U6U-]I%W:CK-"Z#\017DW[/UR+
M:UU_19CLN;6[#E#UP1M)_-:]DKRGQA\/]:T[Q9_PE_P_D1+YL_:;1SA9O7';
MGN*!GJU>,?'VZ%\^@:!:_/=W%SO"#K@_*/U/Z5:_X6)\1&A^S+X$E%WC'FDG
M9GU]/UJYX*^'VKS>*3XO\>3+-JG_ "[VZ'*P<8S^ / H#8R/CU']B\&^'X^O
MD7 7Z[4'^%>N:1=Q7VC6=U;N'CFA1U([@@5Y5^T.H;P]HRGH;P@_]\TR"#Q[
M\.XQ:Z!8#7M#;Y[="<R0@\[?I0!ZGX@U.#1_#]]J%TX2.W@9R3WXX'YUYE^S
MW92IX9U/495(6[N\(?7:.?U-9.HZ?\1?BA-'8:O8#0M'#AI0W!;'MU/\J]DT
M+1K3P]H=KI>GILM[:,(H[GU)]R>: /+M4_Y.<T__ *\E_P#06KV"O(?B-H7B
M73_B3IWB_P ,:<=2$4(BDA3J"">H]"#77^!=4\5ZP]]=^*M,73(#L6TM\_,.
MNXG]* .+^%?_ "5SQI_O?^U#5?5Y!H'[36GWEW\D%_#Y:NW RR%>OU 'XUO_
M  ^\+ZOH_P 1_%&I:C:&&TO6S!(6!W_.3_*MOXC> 8?'&CQK%+]FU&U;?:W'
MH?[I]C0'4[+-<YX_U6'1_ 6L74[!?]%>-0?XF8;0/S-<!9^+OB9X;A%AJ_A5
MM7:(;4NH#G>!W)%5Y_#GC;XHZA;_ /"66XT31(9-YME/SR?AZ^YH W_@3ILE
MC\-HY95*_:IWE4$=5X /Z5B_!7_D<?%__7T?_1C5Z]9V<&GV,-I9QK%! @2-
M%'"J. *\X^%OA;6- \3>);G5K,P0WEP7@8L#O&]CGCV- 'IU>-:K_P G0V'_
M %Z)_P"@M7LM>8:CX6UB;X^6FOQV9;3([94:?<, A6&,=>] 'I]<_P".M/DU
M7P'K-E ,R2VCA!ZG&1_*N@I",C!Y!H$>6_ /58[OP(^GY FL9V5T/4!N0:]3
MS7CVN> ?$GA'Q9-XD^'926.X):XT]S@-GD@#N._J*?)\0/B1<P?9K3P.\-TW
MR^=)G:#Z\\4#/5Q>VK736RW,)G49,0<;A^'6O%KR+4OBM\3-4T6XOY;/0](<
MH\4+8,A!QS]3FNC^'?PYU#3-:N/%'B^=;G6KG. #D19Z\^O;VK+\1>$?%/A/
MQY=>*O \*WT5]EKJS8\DGK@=^>: .ST3X8>$M!53:Z3#)(O_ "UG'F-^M<#X
MWO+23X^^%;*S,8-F%614  0LQ('Y?SJ])XK^*6O+]DTWPNFDLXVM<W#<)[C-
M9>K?!_7M+72];T&Z6_UZ"9I[QYGQYSDY&,]ATH ] ^*__),-9_ZX_P!13?A'
M_P DNT;_ *XG^9K/U2W\5>*/A1JMIK&E1VVKRYCCMXI 0ZC&#G/UK<^'.DWF
MB> =,T_4HO)N8(RLB9!P<GTH X/]H2PD_LS1=75-T=I=%).. &P1^JXKTO1[
M?2-3T6TO;>SM'CGA5U81*<Y'TJQK^AV?B/0KG2M13?;W";6]0>Q'N#S7DFGZ
M=\1?ABSV6DV:^(-&#EHE!^=!].HH ]@_LG3?^?"V_P"_*_X5F:/KGAF^UF[T
M_19K1KZT)6>.&,!E]><<UYU>^)_BCXGB:PTKPV=%$HVO<S'!0'N">GY5V?PZ
M\ V_@?1WC:3[1J%R=]S<8ZGT'M0!V-4=;_Y -_\ ]>TG_H)J]53587N-'O(8
M5W220.JCU)4@4"/-/V>_^1#O?^PC)_Z"M>K&O/?@UX;U3PQX1NK/6[;[-/)>
MO*J;@<J54 \?0UZ$: /&O O_ "<1XL_Z]W_]#2J7Q*BCT7XX>'-:OD4V4Y1'
M+C*\$J<_]] UTOA/PKK&G?&CQ#K=Y:&/3[R%EAFW [B70].O0&NH\=^"[/QO
MX=;3[IO*F0^9;S@<QO\ X'H:!FPNE::R@K8VI&."(5_PI)=-TJ&)I);*T1$!
M9F:)0 !WZ5Y+IVJ_$_P/ FF76AC7[6$;89XFRVWMD]?S%,U)_B9\1(CICZ6O
MA[393B=Y#AF7N/4_2@#TG1_$OAW4-%O-2\.36\]O;*S2^0FW!4$X(P/2O*?"
M7ANZ^,%[>>(/%M]-]@CG,=O90OM48YQ[ #'UKUKPQX1T_P ,>%X]$M%WQ;")
M78<RL?O$UY=9Z)XY^%NK7L?AK3AK>BW,OF)&#\R?AV../?% 'INC^ _#.@(/
M[.TBVC91_K'3<WYFO-/!-[!?_M%>(9K5U>(PR(K+T.TH./RJY/>?$_QNIL%T
MR/PW8R_+-.[?O-O?'>J,OPV\2^ _%L&L> X8M0A^SB*6*=\,3CYLY]2,T :?
M[0G_ "*FD_\ 817_ - :O4M+_P"03:?]<$_]!%>:_$S0/$?C#P+HB1::/[22
MY6:Y@5QB/Y2#R>O)KTRPC:'3;:.08=(E5AZ$ 4 >2Z#_ ,G+ZS_UZ'^2UZ9X
MI_Y%#5_^O&;_ - ->7^*M&\6>&?BP_BOPWI)U2"ZBV/&AZ<8(/IT!S76Z,_B
MS7/!>MGQ+8QVEW=12):6J$952A !]\T 8_[/_P#R3<_]?;_R%>HUP/P=\.ZG
MX9\$?8=:MS;W'VAWV%@>"!Z5WU 'C'PP_P"2U>-O^NK_ /HVO9Z\Q\!>%-8T
M?XH>*=5U"T\JSOI'-O)N!W@R9''TKTZ@ HHHH$%%%% !BBBB@#R']H-6?0=&
MV*6_TT]!G^&O6+,?Z%#G_GFO\JD>*.0 2(K@=-PS3L4 &**** "BBB@ HHHH
M ,4444 %%%% !1110 4444 %&*** "BBB@ Q1110 4444 %%%% !1110 444
M4 %%%% !1110 8HHHH *,444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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M4B(:^]N]8MB6&\VD-4!*W#U("924J*BHJ/Q+45*BHJ*B<ILEL)K1?:26=(_
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M0.6Q(C25-\@%(L7L9)K0B1X2C_QOEV[V'J8$5B:BHJ*B\L]'28F*BHK*[9:
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M=ED8Y=_[G5=145'Y-:*D1$5%1>57C"$EV@5G=RGQ!DP3[,?_8%YC.MWH;.U
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M&PM#UP3,\$[&E.UI, C.Q-A]V1@6F@N=\#RH1^5C8$PA!B248$!*!09D5&-
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ML[X2 DD"@22!0))(($DZ"*64*BBE54,IO9I@PC919)LJLEW?"]$_N0C/I99
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M,=X-(P,/S!Y+,!GM#:-QA)*) 9@SC4 R;Q=F&(=B\M8#&.N4A,%N D9>\$[
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M4')/[.+I0TDG'S'IZ$-)SZ,HZ9)0(I544OW#):%$*JFD>G*JY\'(&Z?_+91
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M)THEE53_0$DHD4HJJ9Z<^A.4*&[GURE&$26*,.GJ[.9])=]_=0F%6<?@(TO
MHCF>F#'%'08&7I@X;Q<,UD1@C$4<ACHF0EV6A!?<$]'//1YJG@E0]4J$FC?K
M(V$@$5'B):!$S2\=*OX94-Z6":5 0HD<)CL)'KL('<'BKN[[""0A>0),]N?R
MJ(026$(+H!I63"&0A!%&""4J$022R%(H19403(J@&E. %Y**H9M5@:GE1V%\
M_&TX?O@Y@K[^'@?.7$#RN4O(O' 9&><O42X@_=QYI/UP%JFGSR#[S%D4G[N
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M-@99"[<A8;0C$K2MD33($FGJ5H01 2?I&@X$$1>*&T^JAA.2"2()&N:(4[=
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MPZ+P9'04H60FI./""2/!D(T-H/A"-LZ'H$(8(9!("21<""0R@@B7R9Z0<_&
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M0=(W$O*^,Z#H%PY%_W H^\_@;A7]0PDFOT2)'P<3^3!?;AF7? 0]'D7/CPZ
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M9&@0-TA1.HQ>$V)&B6ID(%2CS%T2'P*))V03W"&=Z K))!=43B* L%@XHYQ
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MQY$\1N'&2\S*2%Q_F==6AA,EX3"\% ;#RSQ?'4Z0\/HZ F9=-+3K8IA8GD^
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M5T3 ^F(D$PT+46)ZB;!8.0DZHJ1S52QNK(G!];4.E*P/AV9=*+3KB0E&OX%
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MI&+<O!2XS-L&9^)DK"-C")31,DZ8AQ+DD9/1,DP2,7*)H[^):+RX. 5.#^_
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MF-/"8-E.9.P@-M*#(.TD/'8QNP-AS6#V!$+:2Y#L%R@)@.4@<XCX.!P \Y$
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MIBW"-UNG0[-Q$DP;8IE(&#<0)J^&$"+$QL9(8B0&QLWC&1X)$N,67ML:#H,
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M*(.H5UDE^A:5XMZ"(HS-S4=8SEG,/W<4+V;O0G)6 HZ=6HN"XR^@X<AC>/O
M0OQQ[PQ\F3$1UW;'H#,C&MK=401()/2[PAA"Q!%M!K,W6 ')P6!H#O'+_J$@
M=!X.E*,]3&B(!HF,28R.'!8@\8<IT__F"(D B4Z )$M!B>F,/RP_Z$=BD4=(
M%)#(*,D7*%$B]R8I\(1TD2GR)$I$?Y)Q1(DSC!5C8*@:!7W=:.B:G*%M\T'G
ME4ATOC47FO>>A/[#]3!]LA/2%Z=A^ZX2=LU;L!L^AMURG2 Q.!:DV[^'$LG>
M-:JAEEIJJ?4_NU24J*666FK]A"46P]M$DSJ;2>EQ HMC(3SD9HMFBPT=G29\
M]OEUO//^)ZAJ> <GS]4C>6<>7EA]! _^(@T3YFZ2.\'[CU\MX\1OTD8$3-F*
M@*F$R+1$!$U-0##/0R=O9;8@=.I6!,TF5A9OA\?SAS!V2S:<#I3@WO/U&%#2
MBKX58E>L9@*!F"@3D*B5,=*CO(KG(M4,85+>-6K2-7+20(PT*BEIE$=$>HJ(
MS^!K[^![Y/>5$AHEA$FQ R9%A$F1@(D8+1&+WEL)$Z*DO(FIEW]>SY)R]!,P
M*;R(L?EY",S+QI0+Q[#T_#Z\>#8-"5E;</CD*R@\^C1:#B_#?QQ<@(\.SL:G
M!V?BBX/3\<V!*;B^+Q:=>R*@R0B].65+MX_9'ZR@Y#!!<B00'4<"T$%X:!AM
MIA_TC-$1DS@>$VM(_&'H&B')XCEC/.,'<[8/+&>]Y7XD8@V).=>=$'&',9\I
M4&(B1,QR/&$I]%0ZN N0E! JI>X$R3@8RUV@KW2!MF8<- T^T+2%0?/Z ]"^
M^RAT'ZZ#_B^[8?HB&Y9O*V'KN R[[K>PF?X.F_4&[R>SO!!=!HF,$9L<JV,]
MB(H2M=12ZW]#J2A12RVUU/H)2]FA2S1=-,JQV168V!UK3<0_8BMAO<&"?WS;
MB3]\_ 6NO/41"LI?P][,,JS9>A(//YN.!Q;%(?J!#0B9O Z!$]83*!N9S0B8
M0(!,C$,($S9A"\(G;.9Q$Y&R%?YBK<EC>^"\ZB2&[RS"_5GU&%C4CKYE[81$
M"WJ4$@4E]0HB2@4FJGB]DDBH5'!27NW 2HV,#H$4>?2DM%X>"5%2)[^_1VDU
M42+"]Y4(9-00(;4*3(H:F68'3,2("4%2*L*?3]3<P???45J)WB5EZ%=<C$%%
MA7 JS(-K_CD$YY[&E)RC6'YN#UX^DX(=)S?@]+$749;Y%%J./(*W,I?B@R,/
MXB]'YN(?!Z>B8W\L='LC8"1(C'N#8=H7!-.!(!@.!D)W. ":(_[H)#PZC_HR
MQ "C8_3'?&%@C,?\E(7M)_V5=22G Q209/G"?(8@R?:"]2QQ<=X-IEQ78L0%
MA@("HY#GC*G E1AQ<X1 *60N,L7$2"FOE?(U97Q/I2MT-1[0- 9"TSX!FC<6
M0O?^"S#\,0G&OY^$^=LJ6#JOPFKX@!CY%#;+-[Q/='+O&WD+!;NRHY8"$HFQ
MRMOXRCMOJ2A12RVU_A>4BA*UU%)+K9^PE"V$S4H/"9N8<F-08")ZG<B]3"2E
M2:/XB[=5@D9GPI??:O#^AY^AKO4]G#K?@*2=.7ANU2$L?#05$V=O1NC$]?"-
M6 .?\'7,!OA';D1PU":$16]"1,Q&A,>\BF#"Q'_R%G@N2H?+\YD8L:T @X_7
MX:X"HJ3T,B'12CPTH4=Q WH6UQ$$1$0)45(J0%(AYX[R2J8*=U00)R)$2J\R
M 1@Q$N((X=&3".E14BG#X@X!&I[W%)]57"T_W[M(@4F?B\WH=;$%/8F3'L7-
M!)% 42/?5R=CIE=9.?J4E:!O21'Z%UW$P,("#"G(AW->+D(O9&/6^6-X.FL7
M-IV(1T;F6F0=>1'%F<^B-?,Q_"9S"?Y^>#8T!R?#O#\2MKTAL.T)Y%%L]ZML
M\VLZY ?]$5]H,[V)$2_&$YW'O* ]Y@W=<1\8CA,EQ_FZ$V+[7W]YMRWC:9YG
M^<&2Y0-K%D&2[0[K.<(CQQG&O#'0%8Z&[J(28^$86/+',LXP$RL"* (JQHM,
MD0N,)6-A+!T-0_EHZ&N(DB8_:*],A/:=)=!_L K&CS-@_J( UFN7(.D_@F3Y
M@O?+#49'<)B5AH9B=(3WE=FNQ&(G2NP")!89+**?C@)>M=122ZW_V:6B1"VU
MU%+K)RW)T6S1=!,F-KOQ5F=X>=3DUBY=8@J.WBSAJV\[\=''7^+RFQ_B8L55
M[,VLP-HM9[#LR=V8-C<1H>,W(#!R'?S"UB$P8@-"").(Z(V((DHB8S8@-/95
M!(S?",^Y*7!^?!]&;#J'^_958,#9)O0I;",*%!CT*&XD'(B2HAKT+B8,"(H>
MI0Z4R#!A*GA-I%R,I%3+HRJ]2APIKI8!TJ.$KRL5*9>/,DS$YQ7S<XOJ")(&
MI@F]"W\$)J7URM0O(JAG>1EA5,+/+N;KBM&OL!3W%)1A='XQ_'/S,>7,"2P]
ML0>_.IR$K0=?1<:A5<@Y_ *:,Y_$!T>6X&O"1'=P$JR$B;2/,-D7I/0@$5O]
MBKXC1WQ@S/2"X:@']$?=H6/TQSP)$B^8"!/S"5]83HH0(J?XGM-^L)[VA420
MV++<(66[$B5C8<H9"7W><&@+G:"]Z$24#(>Q8"2L^:-A)58L><Y$B0L,1(F^
M:!ST)4RI"_3EKC!4N<'0' C#U8DPO+],WN;7]-E^6+XJ@G3M#4C:/\-FO@:;
MI)>A894[J]MA(DA,N!6SO)Y$<J#$K*)$+;74^E]5*DK44DLMM7[2$E\01<\(
M,\.OD@2)W>Z8QN6(7>X>886]6T<(L4N7SF#&U]]I\=$G7Z.Q_?<XD=V*]5O.
MX^$G]F+R W&(FK"1&%F'T,@-"(]^%=&Q&Q%#B,3$\C%A$A"] 9XS$N"\.!U.
M*X]C4$H!^ATC*G(:T>-BLXR"GF(A>E$]P2#P(%!20124$R;E"C <,.GA2$\Q
MHE%:)8^JR"$\>I8(A(C7ESG2'2;5_-S:FRCI0Y3T+FQQP$3\#HXI7&5UCE$9
M\3/Y&26EN*.(0+E8A=X7ZW!782V&YE?!/3L/8<=.8/J!/5BV;QM6[-N*[0?6
MXOSA%;A$F'R<N13?'9D-PZ'),!V(@F5_&($23)0$PG;8'[9, N.H%ZR9[K!D
MNL%\=!S,Q]Q@.>X!ZPDO2">]&1_81$[Y,CZPG_*&_;0'D#4.]NRQD,Z-($J&
M09<W&-J"^^7H"X; E.\$*6\$I%P!$\*EP!F&B^.@*_& MLP3V@I/Z*I]H*\/
MA/&UR3"_OQ363]9!^NH ;#?*8-.^#;O^[["9.F&S2/*TOEO]1;J:']IAZ&J
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MTFD72%DBA,II#]@($ML)$9Z?<H.-*+&>'07+>8&2(=#GW _]>8+D_!"8SX^
M)=>5(/&&J3@0AO)PZ&O&0]OT #3M#T%S]0EHWUX)P_OQ,'^X%]*G9V'_N@I\
M C#]GO^1_\[_[-<8@[);FV2342IVUS++*)$<##$P.IYI864DNUZ>#FB7P2LI
M71)5DZBEEEK_"TI%B5IJJ:763UER;SJEI;:=L?&+IDT24W.LC-@J6(DR4M*%
M$F6-25<7;?%VL75PI\:$+[Z\@3]\]#G>?.LCU-6_@]S\5F0>K\+VC$)L23Z/
M59M.XOE5A_&+Y_=@\1-IF/O8-DQ[-!GCG]F.L%?VPF?;28PYG(?[\BK0O[A&
MWA:X1W$]>A DO0KJT3N?*;B%DYY%5?(TK![=1T[DB(7M B35CO-N,.E"B5@P
M7^K8C4N&B9C&54>4-*!_7B/3A'ZY3>A+H/0J;.1KZA68B*E<9?7*6I-BGO/W
MN*.0/[^@C+]?"6%2A/X7+N*N\Q=Q[[E".#'.9PO@>SX/43GG,>O":3QZX0A6
M7MB%Q)QX'#R[&KG9+Z A^TF\G?T(/LI>A+]DS<%G65.9&'QV)AR?9@?CL[/!
M^-NY8'QQ-@Q?G8G$MZ>C<.V42"2^RPK#-WSNN]P@7"\,0&=1(/3%03 5!<-2
M% ZIF- IGP9S]5P8&Q=!W_XH=%>?@>[MEZ%];PNTO]\%W9]/P?AI*2Q?MD.Z
M]A[LFC_#;OP<=LNWO#<Z^9]:QQCD]4=B]$/<%U:[,CE+K"RQR(O=]8R&USOY
M&L:FE=<IV7DOV7E?R?.]5)2HI99:_PM*18E::JFEUD]9CH;9=IL2FZ3 1))A
M(LD-\&SV6Y&GW]Q$R:V>$^)_Y1VZ+!*T.B.^^ZX#GWSR!?[CW3^BJ>U=%%6\
MAJR\9APZ78V=ATN0G)&'S:G96)=X$B]O/8;G$T[@\;0L+#R8AXEG2N!-)#CQ
MRW]?T8&]N!9W%-2B)T'2*Z^!7_P;"1-EY*2GF#Y57,T0%\65MW;9N@F2&N4H
M1DQN3N,JOXD29;2D^B9,>E^L)4KJ,""O'@-S&S#@0B-ATDB8-/#GU<M 4K8)
M%FDD2NH=*"%P"DK1BRCIG5^*/@7E/%;P]ZU$[]PJ]+E0A?ZYE1A$;(WB:WP*
M\A%;> ;S"P[CZ=QT;+B0B)TY&W$R9PT*<U:@XMPSJ#G["&K/+D+MN?FH/3\;
M#3FST7QA#B[ES,?KYQ;BG>P'\>Z9A7COS *\=VXNWKTP&Q\6S\5?*Q?@N_K%
MT#<MA[7I,=B:GH2]^9>0VE^&^>H&&-^)A^$WJ=#_/@/Z/V5"]]?ST']>!</7
M5V&Z_B$LVJ\@&3M@^S_LG0>875=U[S4JMBDA>2$OO'Q\(7D\0C$8'$R'T'M"
M"0F]A1 2(#$02BBAF!I*(-0$;,MJ4S4JHYF19-ERM]R-+5MRD6W)EN4FV5:7
M9N:6]?9OG_._L^?HG%M&,]*,O-=\^[MW[CWWG%U6^Z^]]MXC!ZU2<D"T7$I2
MKX*5(W[%B,!)"DO\>P=:RE4'1!PPJ3@@4RGO=6!DORM#CFU*''X3T[<B18IT
M3% $)9$B18HTD50=S>!*)TS\>I&D5&JE:J/%@C-,])?>*EUK4K;AX1';O6>O
M/;#]0;M]RSUV_4U;[++K-MGY5VRTU9>LMX'SK[7E9U]A2P?76<^*BVU1WT7V
MZQ47V?=67FRGGGVQO>V<B^S/5Y]GC^]?;2<XL#"CRX$/!Q3:.L]UX&2MS>H^
MQZ=TS>Q=Y<&$+RFX *3,H"Q=F:18 6JXAP,N,QQP\>!DJ693!&"2&1-VZSK.
M@8Q'=:VR1W>LML>T TS.=L#D;)O3M=IF+5Z= ).E:Y+B0<DJ!T@&' !987,Z
M^^RXCCX[WKT_SI79'0Z8N-+F  FO?'^" RR_V[/4_FAQM_W9X@7VY]VGV\N[
M?FE_U?43>W?7#^PCG=^Q?W(@Y9/M7[)_;O^<G=KQ&?M,YZ?MBUV?L:]W_:M]
MK^-S]N/V+]C/%WW!?KGH<_;?#LB<T?5I6[CX4[9ZY;_9-1=^W;9=]0/;?\//
MK;SQUU:]Z4RSF^=;95.GE38OM>&M S9TSQH;NO]\.[ACG1U\^%H[N/L6&]J_
MS8:'=MI(:<B-8<GAATI2JGYC:'^H9L5*Z<8'2:FH^&VED[2_B@,@U?)!!T .
MN+(_*157JNZSZDB"?B-%BA1IFE,$)9$B18HT@:3L+<XBJ=; R-B2_=/TRJ&?
MU>[H"RE@0\-#MGOO/MO^\&[;MOUAVW*? RG;MMMM6^^W6[?<:[?<OLUNWK35
M;KCE+KORYBVV>N/M=N;U-]N_7WV]O>.BR^P9J\ZUQW/N2-> !R4S'"AI<Z"D
MC74>B]?X1?"<8S)S20).VBB]#H#XLBI)_>I=[=>GM"UF43J+T_M3<#)Z=HDO
MRY*%\;-[!^WX;@=,.E?98SI<:7< Q97CW?^SNU?YA>TS>DG=6I.\,F/C/I_5
MN=(!$O?;]@$'8OI=6>$!RNR.Y3:S8YFK_S('KESI=O_W++?C%R^UW^GIM3_H
M[K8G=G?XPQB?UCW73NHZW4[N_)4]M^/G=DKG3^WY73^U%W;_U%[1_7-[8_<O
M[.T.P+R[\Q?VOHZ?V8<Z_\O^H?L_[;-+?V+?&?B9=5PTSRZ];HEMO?T<.W#O
MI5;9?I79CFNM^N#U5GEX@Y5WW6*E/;=;:=\6*^W?:B,'[G% 9+L-C^QR8.2
M/^200P])TO,E?9_,CR7[KU7\NY&QA6VEW6]]\6E:S(HX ,(,2>5 +?7+[_+F
M[Q8I4J1(TYLB*(D4*5*D":116!'.AH30X]"2O</84JF]%] AVNYG3TII&7%@
MA3(\DI2A$3O@RJX#0W;W[KUVU0,[K.>..^W+UZZW-ZR]R/[?BK,=2.AWP&25
M<^H=$.A9:S,6N[(D.5P1X"%@DNR&Y4J/>]_C/N]QP(54KV[6I#C@TCWH/G/
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MOAWQYXF4S8$2.Y 6!TS<:\4!$ITUDHQ!4I+9DN&@)+,GH^ D+&':UEA0HF3
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M;;8#+G,6.E RO\].F#=@CSIKI3UJWBKW?K4=Y\KL^9P]LMK:%G)((B>W#R:
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MBA1INE&XIJ0.*"F^K)H!)G7^JLG!@]HF>$1%*5%LN5NMU$HUG1FIAD4[?^6
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M4_;^][_?WOG.=_KW/_G)3^SLL\_V/@3@H15;+1X&C#";<=UUU]EEEUWFP31
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M!GB4^DK^K[GFFIH.X+,L+[?2GE9T;'BB>SU00AW"#7&RCGPV",LK;44O<R0
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MW ]\X .^\#\[-("PB13!8# 'QH:!8\ 0>!A. ]1*U%>*'.'&\"$0*&_J![B
M41E@!$_H%&%4:A3/1XEC>&%<' N,QS_]TS]Y ?GH1S_J7VD?;3CUU%/MLY_]
MK'<\<)11 @@M#([B1#D0P<U3FD+"."'4AWK!P-P#@93#C8&1X<$Q^]2G/N7[
M$46#(L"P\9[^ID^Y!@$4>.(59Y[[4>@'E 6*$*4.XZMN&F?Z ^%"^ %>W =E
MB@"C2*DK_:43W?.F'ALI?5VGZ!_W0T!Q]!@SE D\A?*#I^AW<E;%4[Q^^,,?
M]F."XN4:Q@*>HLWP%'5E3!%Z'*(P,A/R45X=BYQ4ZHLRA?\!B1A5GL>XHS@T
M+:X9,!0(!@=^P%#@5/$;E"/R @]1?_$7!?Y"N3.>\"#.&?W/V/%[ "+CAR*#
MCT.PU8PS,1Y0TL@9K@=*>,7( @PUUC@G& _Z#9Y'?G#,X&_D#3W!&*,WWO>^
M]_DH'.";_^%UK@&<8_"1#YP6#!_C@N*&MYN-I.?I1!D<G==#?V-$D DY(L@3
MC@=U9LRH+_7$>!+5(P?Z7>]ZE_^,[QAC\2DZ SF5SH#OZ1-TJ^0J3U[J;1=)
MT90_=4:>,(S4%3E&5\,[Z%B>H9E9="6\BWZ$-]')Z!'& _V'KH-'Z7/J3KOA
M??H:N<INK*'Q1K^A_Q2YE$.*CL5A0*?1?SR#_D.^&5_&66,M&4<>&&_ZC>=3
M3P -]Y.N19?FS?Q.A47?>: $_2U0 H#%!B+3<M1H#^V"]Q@?Z0[T 6-#^@SC
M@JS03Q1D@\_X#OW".#*>_([G8A-Q.@&' L!Y\A'R6K9D^3#O]WQ'.^ /^ N'
M#%[$AF!/J!>ZG7J&_D(X_OS/V",S7(L]P"Y@'V@'02': 8_EM4-U:01(ZJ4>
MTP[D"2 '#Z,#: ?\"Q\R;O F8T"=W_.>]WB91P?P^NYWO]OK+]H%?]-6M0?@
MA?PC2^)CV@,X4(I.MAWU]/CA@!(=SHR,XH=@:Q2(E?\ WR%_V"QX#1""__&:
MU[RFEL*%KJ,_Z!=L',^CH-\5G$8789OA:WP-95S0S^CN>J $?2]0PKC37NPK
MNHA[4F_JBUZ1;86WJ"]^ X7WH1\*D(0G 5+<&\ ).%'@KTAO: 80_8<N#0/U
MZ%G #CH5N<4GQ&_BWH +?##Z6=_!R_Q>P32!'62'=L$CW(OKD*DP )/E\V;I
MJ(,2J,BY"+^OYU @F# 23 -C(50H%10' HD 8HQA5@K"D"U\SC5<RV\05#$Q
M"H>!9."(A""<1>LTBNJ*<D(H41[4$:<.IH1!$0KN#],PL%JS0 0))D&(4?8P
MJQP,% O.A=JDQ>44VH&@H(A0//0##@K.!I$0HB P-^V@7F%?"^0AE!@J& _!
M8*T(?4+?4&\4"45.&OU&VI:4 5$*WC.-RG<(';_G>CFYH2-/^S!0U(U^0A&$
MH(2QQNG&B# >](4<0MJ&LL"I(*J@T^/SHF=Y!_R$)&'F'O 4#B6*'I["8--V
MGBD%'XZ!^$AC$8Z#^HU^1#&A6*DO2DL&+ 2)S8(H78NBP*E#H7!_%"=UQ $
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M/,:XTE?P+,$EGD>_<U_T*,_"7BI"VZSSGM7OX<P_M@XP"A]K_2.\I8@Z;5'
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M/*4<8D";=K' "=>.55J AZ%'F=)6>$H; :!D!' P'CA4/#MOD6Z1\Q)^CY'
MR:5>U!-#_]2G/M7+ TJ4,4-64#B,(9\)>/,*T* >C ?U!10# +7C$#R @J*>
M7 ,/TQ<\B_Y!<3(F&#$, \J5YP&4PO$L<L+&"TJ:*>'URHFGGS&"&&GJJK%6
M= T#H-1 '%*NHSW(&_T!H.?WC#UC#>\BC\@?UVMV#0,I0$L_T=?TO6;)T$$R
M\N&N;*%319V13ZZ#MW@&_8_>8'SI=_J?L:3.\!FRRE@SAM1/.Z<I?YCW\"PZ
M3(M[D4L,(X8>)U/!'1E>'%9X SZG+DHYS!N/+&5!"?HG#%SP3($,] 5]1%O@
M)708>I?O9"QQ'M"7]#DZ 3G$4))6@/R',U"\)Z4"V43/<!^<$ZU_4\03>43/
MHE]P/%GS@AP@Q]H=!Z>6L>:9?*?%\$HK09Z1;[4-YP4]KA1= !/&/3L#4!1P
MF&S*@A+& 'M!_>$GQ@&;H\6Y.(6TDW'1S!7C []+3A@7[!%]!&_1;OI*ZP&P
MUP!+^DJS,O OK_ =_:^@AG;]R@/L]6:1];W69F*G&4.>S_VIMQSY,'B)+D!7
MXVS1#NH.;VD',62>\>=SK1- WN1_R!FF;PC@84?@(QQ:HMLX==JEJ)X3&?(!
MKUHWB]Z"SQ6%5W"(9Z)K& L!?.P3N@J=@9Z1[/.JG>OXCK8Q3N@+] 9CB6Z!
M![1N@O_I&_J$>VS9LN60;(1Z]FF\H$2',S.[R?C)!L%G^$'PI(+*M%LS7^H3
MQI=Q82P HLAA"-#0>0HHTC;-!FMC&/E"]'L6E&C-"C80_84.P,ZBVY$C;*IF
M<N%W@*P"+\B:=D#4+H[P%.W3VDYL#_H(NZ$S47@N\D=]&3?JJD!FGN\L$JB%
M_]"1\  %72E0@G_%^% /ZHANA=?A%5+&M)TP.IRQ@%_H,_0C^H-Z9'<\/"9
M2;WO*,H+I9-P$& $F!##@G'&N/ _B@<&03FBW+0[$&A.BREUF S_P_B@1NZ+
M<.#THXQA+.4/*I*&XD1P$2X&44YPT;:??*:9$AB0.J,$J2\,!^.BO.2HR^%0
MNH]F$F!6+;Q'P6G_=YB)J"_3;S ,S@;78;AA;OH"9P@A5405PPG(X9X@9OHF
MG%Z6HQ[NE*-H&6W6K@L(!N. D"AJH[0YS02@.'!JN9;?4/B]=M% R:+H8&S
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M[W5.C@Y-0[YXCWSSG78;0RX5@) LPR/4%QEC3'$H,9RT4_GR>>.1):5O,5M
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MQP(E+$.OWVEJ5"5T,+(H?SR@I"A]2WU%.^A3G"2$'N7+/5'VS+Y@4!!\E">
M!86'H*)<BYR5(IX*@0G]P,P!!@9%@V*6XP(_,.8H,O@\;Z>>O-W#LJ $!UB@
M!&4IX(M#AD&#]YAM$M#2^3A:V%=DB,/=/&B/' P,)M$3^)H(CE(_<)AQ!E!B
MU$VY](WDOQEJ%90@"XPWLD3?4R\<;&0 )4]?$2@ +"*CS#2&SGW>-J-A/<*Q
MEH./T\DX,I[,.N"8(-_PEX")3LTFTHJ<9K<.54X\!@0]0QT!)!1T!R!%AHEQ
M1,;"+4B;T:U96=<Y%,@2#@3@#?ZAC] =@'3T$N..0] ** %<P0^ $G@4/:0
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M_1C>,YQQRX)"@1+XGKHC!P+IC .O_,\X8U_1]XPS]D8'$,H7#?5RGHZ6OZ
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M8-%)UHTHCP\D5!@9^H\H*P8>9P8!5;1(9[TT B4H">J#TJ4_$&R4&,:#/'/
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M7>@N74@]-8NH,TL48("7L1/*1*C'__7:1;N1#^Z%?B!@1DJ*TIKA!^7-:W.
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MA#Q=D==_6>)WR E&2CGY&%^<*^1-&S+0KF;Z(@^4T!: ,WR*<T)@1.N/"(S
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M06,<"0G8Z!/V*BF!>)CJ!'R8;VT*  (,0!M%)3-9.*"AW=0DA-I]B\U?0TH
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M CR84Q\IX2.^^9N_^5D'.^_",XR$2A#Q!_[RRRZO5]?XN=]<NK;NXS/MT\_
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M_!-],!I2-K01$02]]FZU3QU]7V99/[%KSWWOI$1[@0/$C*R_\1N_\1G< JD
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MRZ;)6, W4B$#!Y@!UGR-J9;(55,U3,&DTV1LF@?;!M(Z\V"O'5NDSO_ZC[T
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MIX7\@C4G0+%]?UQX^ZAV-/\6B+'0%\#7AK8T1K2 $ %"H/@(I*3^,VQ/?F0
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M[F04@9M&D610Z;S@3M; (8=^M+V7OC>3$?;O_H I>;*O\41OGS5ELZV ]9<
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M.J=D2\[J^-*DA$\<20F,**9*-.I'_?52I.0EUY3P(?3C)"6O5"Z!.$Z#H^G
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MO6STBJRT]H9<W(^/X*/X4\&/GQ#\])4$0".ZUI3H3SIU9"W$D<,3'T%*\K6
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MGT;6KW%F1GTVVD?3C5Z*E"2C:TG)D=VW5J1T;!?YLXW6[45V(M?^9^]LE!T
M==H),Z@/?<V69OE'0-D;NV.K?N\^[E?"23N:!>$U $LGQ"JQ@,V[]UPB5>*=
MNK,_]=8G9%/LID?\&?Q!9_F?T?Y=])3LZ"F=UH_T5'WA"IB$+Q$GV#5?(S;1
M4[:OG_AP=J\-8J2I7:8WDPM?5Y_E?SQS/!QTBY30M4>0$NV",<16,M5?K2-3
M9\_SW/1(7XQX#_XPFX0]:DOK.,>%[I&2""Y_WL@1>;\&*:%;;#120E8G*7F!
M<B03FW $/@HB8\X@Q_GX%(4Q<:3 G2 #I)H"!4PR6@I'@=V' 3,DCL%G0+^
MXC<<&:.C; RSG9$"!0(<H,5I".X"?=.>9H,J\]DY)9WH'C% 2"@:8&"TQVN.
MP"5@<A:F &@/D,+X."$@5U^H-\>@'A27LV/@@@EG(W/-V;0](M#MN9P.,* O
M.>^M@Y N@;T"2ME_!D,6B GY %4RL4"I/F"XG*(V<!(,2K]HFWJ0A[Z<1TI&
M4J(=AL/;$KAS2@2%U@7L37D;IZXP9@ZG>?2"B?XA:PZ8X<L,R;AI!_VP,%E;
M %#U=1\Z1;?2)_5M;WK.&+FD4S(Y,EUEG^F6?@KD^=V\%?&>;8RDA)ZLUI3(
M&#Z2E,Q].^Z^-2]T[YR2>4W).$S^$J1DO)HWK0_X@T8_]95@*[B0>=-ZR)J]
MZ3?]2H[D0K?(7%O)V>6>=)H]LC]Z[/[\ _+@GIXA4RJ0T5W/1>"!$\^8MR1N
M'G&!B,X$#)KBR4_(;+:]*+OGOX#JZDH/U<W_@1"Z*( B!\" >O!'^3CR0MC4
MG>^@/YY%9]ET"X;Y0$%:6[597?E9?</^QFFL\^&);<<];@G<CEC7K"F98\>H
M2\ ^.VI-3UO* T*(B:F?C7@#&L@CN=>?]#6YZT=@QD7^^3#^E]\U78?OX<OT
MJ_88E6X*7"!?+.$/V\2"SWB+\TDJ(RE9+72G _S6HTC)*J'A-;])-_G'U3DE
M_,HE4C+[RW;N'.V=+8[MH_?TG^]%SL5"SQIC+,":_-DZ^>L/<==W).3,1 "(
MW4<?>DZ'*R,2DH_>$T?$9,]HJO1J'5%K/-S;E%/W%+_;*9*_8J<2EP@UG66#
M?%7VW[;CB+FZTE,Z[7OP#3WEEV$.)$-?L&LZ*LG']K/_IG/JNVQ6OR&1<(:8
M6)^QB48<B^-L6O_Q/>*L>"=!X'XP3IO[W$)*$$7/XOOH:H=3(R5TB S&=63Z
ME%V3+7^D[NP1ME '_=0:GTB)_MLB)>3"=^C3%2FY)[YMD9+YG!*)YY.4/*BL
M',L*>/7=%FU3?DH  "$B EP9$$I"T1D;=FRT@[()VHP6H*1X%--?3HNB O*4
MFJ$1M #6O$KW]@S*P& %+YD]O^=01Q"]:N-(2AAY4VS:LDZ@XB3,(0=F(B8,
MUW<Q?8!?8*68VLX1:I=Z,QB**;!P>IRC]IM>EB/N?(;F5*N'OM$/E'[.;JZR
M4'/[.'[RT ^>SXEQ")QP  =X41^!0>"6C>0(.#-$PF^ HPZ>S+"W2 D'31YV
M S+/7ML\ R"/E%PZ;+"V=2;#.-TBD$;NVN O0$@&^BQ'S+ES\O2'/@KL_G)T
M")C[J:]@QQ'[K7O0J8:6Z10G-Y/#<9[NI6RCOYR1H*YN @N':0M)()(>O 0I
M&4<\(B7DRG8\U_QI(P-TF$YOD9)[B,D>$5E-JQ/PVGV-O9%U6UYVD"F=Y3\$
ML4 J.9*GC0\ 4 &"W%V",9UF@^Q/H!>D 'OW:JHDF0CH= O)H&ON*8BSH?$P
MM\XJH?/TC!\##/1KV3^OZ8Y["9; "__%QY"WNO)YZN9_;3!JJ4T"-]#,=Y*/
M^W6>@[:S2?5CLY$7-M;:##;1V4;\DGMFWR46VK6.+,8M@8T,>38?X7E\*O_'
MG]Y+2F9@ZKF /Z#&/P%P0!<Y\(5M]J$NXH;^!!SUIW8G=_I"[F1-C_4K7>>#
M 1H^F8Q,N14?]"O?W@X] *KGZE>^ X!2KY<^P.]268V4C"2=?;PD*>GS,MW\
MI/A!Q_B.UB\ \<C 45*B^+]$A'NW&U=9=/;>0<QD(]EE030?RD[(E7S)F?S=
M WX@?S8E]HK#])E]('!BN416B\/)ONGE?(+O=FQ 6X"O=+V#?F="W;0AHR_J
MSP>PUVP0Z&;_[)".NO@!==6>\(68P)[5BX^B_VW  #.P$[[,Q0[@+,\I*:%-
M? $RPY?0?3;@&?"(?M)&-M_&'>*#>I%Q]RK^>=XX6^.:6##O<D>&L)/^&4=$
M^2J?D2V[YF_X+$18&]2AS7(ZUF$^T9V<^?7\1YL3\<%;I&2%98^6F920GX1.
MQSFP%;B";^-WSX7N#RA; &)+B.W]+N@A%XPFD ]L=Q >IX/9M\.-(",K2:B<
M+V64"?67(0OHC)5R,DI"9Z28=D!^!!.,G,-HRM;>?."9E' (3>=H&AC# &HX
M7^"4@Z%\/N<$M*<,IDRNX*=-Z@P$>2VP-]+"T+6A &-$@7&VA5T+Z3L'HZV4
M]X#="CB2!:-M?0:C-;)0EJ+=R8 0P44[R2&0SJFU/2;'I^WZB7&-SXR4R$1J
MGW8 W:8HD8W?NW<GL>^=/S"W3QM:0X04<<)-N6ENL[:00XX8\-;W@HQ@1X]<
M=(O3HT\<-9G0&8"RX7SZU,YQG*?O<&B<BN \+\0; _O*1B(E@J9GZF_U_?*7
MO_P<Q 2L=DIZR>E;P#[PZWF"P)>^]*5GO5,'I'2>OI5<[R$F6Z-X<YV[?P&R
M1<B14+;5[CCMP$9>^0\!2]_279E^MD/N+OKB?;KON^P9P,T&!,82$#YCNWP.
M8"-;V@XVH\PCS(WD"?:M:V//_)RK) Q[1];II;KR'TBZ]JF;_Q%?H"Q=Y-]:
M0]6IUS[C2P0Y]4,BV 0_Z]Z"(+^ECSR?3= W =_G[($-\@<(:%,0Z0>RW68#
M?&PCS_Q1V[3>LOO65OSH??X9 9 PT(_Z@5R!1_[)B$D[[^5G]2>0Z;M\E81)
M!]]IHS[E;^BUNK-Q?D$<HN](J'[51V7)^;=V6Y+!GQ>VO\5H2:1$4JGU"^K+
MYXD=@+HX>0\IV4LZ]IDX*A;QJ255V")9T'M <45*]GQ2_J6#^_@?MLH&6N/#
M#Y,[/: /])MNDB>Y(@-("IV%'=@]'6!7ZBJFL3MDA/T@4]V3#D3<W:LLO1$V
M.MY(XLKO\5,==DPVXD/3.,6-[+_=,]D0VU7O?!6=54] 6UWY';Z.;K>^33W3
M?_W!OZ@KF7?Z/%)#Y\?ME3V[]3F2"I[-7OQ6?[$S"1LQIQW18#:DA"^"8]A)
M9+W-/FXA)8V"ZU=ZPB;=4_]+6KHZ@XS_%=O9M7[RFB^@<R4=88R. AA/=.>?
M2FKH<WW'QLE=WYA%L5KH_@A2TG$.]!>9Y/,;,6\]BSB!R)Y; C^@7$-**NV@
MQ)$!@4 V1]-\X<X/X6@8&L< &'.R%(CQ4DB7U]X75!@]1QB@R%@I[9CI:+<6
MQG"IOB,I ;H1!X:LK@$5SD/PIUB,V?> G,ZO:.>;IGMQ@G['H SA<@H,75OU
M U!8&SAW4YTX>@8DD\=1<3:<@+JM=MO:"B)CZ<"R%G!W BQGTUS:P+SZ,2B!
MK^'B,B]>ZU]@2#\QKAF\ G#C2(GI249+_+XM? &BK9&2N5TSJ.9,.+8OOKXK
M5SJEW^E3\X(%&F1"WZL+?4J7O.:<$2?!30  2+33;UNLZ)YE.00 0&7>X6LO
MH*](2=,?]#50\96O?.59OSBM>T=*+MFH_A/XD1_]0/^^Z9N^Z=E^V*#@?HF4
MW.*\MX)ZGXVDI/?:CU_@T2_ZC/ZHIT!#UA$3LF:#_ ?=[? SND'6+O_3:?9(
MINY3X&8#9.&]MKX$,,A*5JWA]EGF(Z"286R##\_G SK?2#T]2X G=_Y+%E)[
M^#O?S]YF7:2'ZE=RQ'<D. 1?!%G]/)L](G#UD]]ZKF#O'OG9P)>1  1 (.U,
M@(B_$0*@3MT$5;ZM*3JWDI)1UBM?%3$1+R2R^!C 17L!E3+/$=*F5 KX^I(=
MLW-R=GFM3[W?]L[\EWM%]/(7[J7/Q1@$MFV^R75./-PZ6GA/::'[N"5PYV<!
MG(V4W'MXXE%20O\ZEX=^Z]-&2E;3M_9(R=C&$A$=L*>=@)UVEDWGD[79^^0I
M7I$O725S?IW=ZQ._9POB,/WE[X#@_ >YL[-F"0"-;!YH;4?%O1D(/O,=,8D-
MZAL)+[Z</TK/6CS?6@\ZFZ]29Q<?H*[: SOP%4"ZW\(%^KFM?K4-GNKL%)>X
MBS#PX>PA/)+O:(1%GY7$:8I:YX)T@*SWD'PVTP)Z]4(2&BDYLDOGW%?\"_L6
M1R4,.H?-NE-^JBETL!T?K1WJH#^:MNHU^8[GDW4(9B,EIIF1.3UIE-4]&RE9
M;0E\CUUOC90@H>&FB)318/IRDI('E*VLYOCY"@S+),ZG8N<<&C'QNFE=[=35
MO$C?9:"4TE_O-57+;UT<%2=)6;%43DW@Y%A6IS]OM6\F)9T3TD)+A@0,<UK:
MA)Q0\K849/P-%S(@;5%7ES;YOQ&5MO K4U?F1AL1!N "&&M$836<OA=$YK:1
MA4RD.K>/MF?U_+'.];TZM_C3Q9DR+OU3)FFLDV=XGV,@"_?B;#@=]P(0FKZU
M6NB^ROC/[6[N:[N)M7UL6?3Z7[T#5.V8YB)+_VMC"X)]AUSH5!GFLL/-<94!
M:5O*,J=;(&MLQUCW<4W):DM@_=+I]-?:YHJ8S+H0*:%7VB5 FK[5 :>M*9E)
MR0PJCMC35OU6GVW)ND/VC+X9H90!ZZ"PYFWS'>PIO27?KE'F+I\G:[]O+KG7
M[3 C\"+51E@%Z)(!LPZ._5NF3I <#P-L&D>!D;P;><@W9&OI9/5K :C?J5]3
M-F17Z8EGT:<V<=!/ZHQLT"7?=X\(MK8V,@VT(QU\,GUH-*"%Q\A*.\BHDW8\
MXD3W/5*B-/)$_[3%LX"L=B,,Y&E+<F^:RBC[V;Y[W51/OVU:F'N6S!([^'>@
M!<A9)4QN'2V\I[1],D C.0)X:R>]$!?WP-:1,K=KM,GQ_W'Z5HNZ^0Z WY0;
M_EA<W",E>W[ YP ;G1RW:6Z*75BA*5UD7VQ=8871YENGV5H/_[,%-J4]P'9)
MS-'F5SH[U[OMI<4T4['8%OP@*=9(7[:<#YCC4MBF]6C%HE%/L]W.%6OZ4AMX
M(/.F>M-E,O'<M@AN PY]T@8]_!2_"LRS._>!$21"2UR.YY08G1T7NM^B9R6:
MC$:FQW2H9,.(!?.%8:4.ZA2[PB#J$2G)_W;N37JC[?J#3! #Q/G1YY1$2CH\
MD9S&A>[-,&F+^-<^Z^C1Y=V0DDL@; 8?(XADL((I8(_I"]K &*4,$&:X@B@%
M[6)8E)*"C0J;@6'QIB5$2&0-FK=W-'C,I(3B1TI:<,Y)<CJ (^.*&0.M@(#L
M""/F",<VJ7M&%6CV?CM(<3B<E^?)[@"'G*3 O%K8OD5(]K(Z_N>XR"'@I-\:
MK6DK05>&W&O]W=;*''@9L7%'DF3M_D!O!^ U#U80:Q>5+[Z^'?2X)F76L1D$
MC^W*"0&K1L3HE,!,1HU >:;^[YR+G#O=ZAK!3:"6'-RC86*RE9%"1.GQ#%#W
M,HLSR-;_ 3Y]25?4D1PX?+K5NJ%;;',F0RM2TJFZ 6?M%Q!EI! \62Q3E5:D
MY!$C):MK)B5CG[6>R'QZ 85M-!6#G.BE0,[>!'LZJTVSW27K_(??^*U[N)=[
MNK=GF(HA.-/O63]7!*HL(-FUCDZV#EF6)4,02J94SW2S2[WIX5@W^L&&Z&*9
M3;9%[_5)Z\L:"04(Z:I,G=$AOY,LD57F:]V/KK4M.]\UGKW1@E%^QS0'4TD
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3 ));-<?<UP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M4B(:^]N]8MB6&\VD-4!*W#U("924J*BHJ/Q+45*BHJ*B<ILEL)K1?:26=(_
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M0.6Q(C25-\@%(L7L9)K0B1X2C_QOEV[V'J8$5B:BHJ*B\L]'28F*BHK*[9:
M]4>T6;6T;4]2$K@BNT0,36KI0,OU>M0=N8*JOQU"^8:O46%[$Y4//XW*>Y:C
M8D ^*D3OB!BJ91+-[#94F^RHED+BD&N*&$)2+_M#LOU2$J55482(5$7[J8X.
MD!-=1#1IT=8EJ22:E&2CA!3':&)2).1$DN.C*(9R$A5(KH\B/F\1Q>.:B?(2
MQN<*)2$.8D=QL W7@JVX%NZ0YQ8.6X*+X]?C0MIKN+S^<Y1^LA^UAZZ@C9^-
ML[G#/]0- >A#W[R>'E!2HJ*BHO)/1TF)BHJ*RFT6KWY1[#$(6+G=N#CN:18N
MN6"BVXO6BB8TG"A!U6<'<>/)O^%ZXBNX<?\J5,92($*S4-4['=5]S:@.M:+6
MY)#5#ZT71%1 M&J(J(YH0B*&:F6C/L(O)371.5)"A(Q4QFCXY,17/<GA?<H(
MJ>!C!.7D!KE.\2F+<J TVD$YH4 0(2)78W0Q$5L^3E1%BN1PK5R-"!T3"=<H
M-FD4A?-<BLG5( NN],I$X>_2<2'8@C/\&:?O6X%S<U_"U;6?H_SC_6@\6H2.
M&_7:3&5B,@"@QS5@#(S?0Y?9S%145%14_J$H*5%145'Y7XGW%OS2D9X?Z_5Z
MY*KC;A]: [N\@!:S0\';O0]>]DATM#K16M6,QI^+4/?I(52M^5P.UZJZ=SFJ
M^^6ACA)2QPOU>@I)'>6D-MR&V@@A)=E22(1PU%$81&6D06]P;]2;W)M,V1)Q
MWY 5H[&]1J^4&&)2&:51(1$5&=&L3IGAXVO"!0Y4F<24PPXI**6D1#2LDVO1
M@@ AD5*20_'0H8B4"!D)SZ.4Y*&(0G*5%%)*+H<Y<#G4ADM]LW"ICP47N#T7
M9L6Y ?DX-V85+B9N1-&:3U'^T5[4'RI$1V437*V=LD*BK?ZNC93K1#?A,^1$
MQWNK7VB7GA/O+_R^>_KNW/H;I:*BHO);B)(2%145E?^)W'3%V/,5:D\7ISTK
MBW_]=K&$GQMB03^7;,1VRWV:J!C/Z)87TGK+":^4.UP>"DD3&L]<1]WG/Z-Z
M_9>HGO,R:NY:BCJ3%0U],M#4BP29T11B04.XE6)A1UV4G6+AD-1%"2%Q4$8<
ME \'FB@2S1':=,"M<GV2;#D#5Y-O+1)]UBU=3*201&LR(IO9Q9;'Q<Q98A:M
M>K$H8B@)<<A%&*LI)Q64DQNDC#^G1$ A*HX,&+HEA(3[B_FS2\)R2"Y*P_(H
M)GE23*20D$M\_HOD L^[P.>^$&*GE%AQ(2@+Y_E>S_7+P=G[EN-\PDNXLNXS
ME']V$$W\K-KYF;G<+CD3E]"3#GZN[?Q,.Q#0RN/M*B:^V;AZZ#G1JBF!0\+^
MNW:4F[7EEP56145%Y?:,DA(5%1657SF^]2I\ZU9X_5T)8C8G!.*YJ5_!C_$X
M0S'$97"[O"SV>-MY$2RV'3RC4_X=WTM)\>B"X@[\Z[Y8@Z.Q'<UG2E'W[5%4
M/_4EJA)?0>VHY6B@=#3W2D/+[U+1VCL#+<%F-(=G42@H)5$V"H6-0J)1%VFC
M9) (.X_S<123%@I!:[@.I:)%7\'=6"RQ28I)'FK%-+]BBE]2P=OE!A&\3VFH
MXKFU?)R@AF)2Q>>JX'/>,&6CS"2F^LV13>K%HE\DHNN0+:U"DJ-+28Y>*=&&
M;UWEL4)R*4)(22XND//<?SZ4MRD_%X*M.!]BQMD(,TX.<.#DN)4XD_HJKFSX
M!N7?G43#F1*TUS6@L[.5GW(G.J280(J)^&UHE1+M=Q<XG,OH]PE<-$:;'4U;
M.=XEU=+C6TW>F"'M9OWH:C3^;U+7_GH5%165VSU*2E145%1^Q?A$I,L,LL:0
M*PJ#$ >O<4GJEKB-6_ITO9Y ?'JA"0G0RMO$*Z"@>#OD,4-*O$;5!-IS.?D:
M.IH[T5I:C_KM9U'YV@\HM[V)\O%K4#L@'XVA%K3VR4!K4"9:0K,H$92.:#OJ
M8^RH)34Q-E23FFBK%!,A*@V1=KU2(J3$$2 DFI0T2_1U2DS:RNRU^MHC8LV1
MB@ AD5 4*GANI4X%!>,&N4Z9*#5UE9$BB='0;O20:%)2'*9OR3710\+7=85"
M<YD(*;G <\^;\G$NG(3EXSQ?[X50&\Z%9.),:!J.FS)P;' NCC^P#N>L;Z/H
MY:VH^N$XFB\7HZ.A!BYW*YS\C,6G+<1$")]/*[T>_^],+E))7/R].TFGAL>I
M3<7LI+6(=5 Z=#J]AICHJ\7[ZF==YQSV&O*C2TR@R*BHJ*C<[E%2HJ*BHO(K
M1@J(L5*ZT>?A\<BU+CP"MPMNCY/"(!!#L-Q^A* $](K(X5BRLB(N?XV_S[?I
M!/ZMOOL@(/V2EKN</*6ULA7U)Z^CXN.#*%[Q,8IGO8C2NY:B>L!\-,3DH3DV
M'TUQ!:CO7X :BDJEF'UK &6A?P[*^V6C(CX;E;$.RHD#M=$.BHF#8B+Z1[+E
M$*XF"H"@42R42!ITZL.U5=AK*28U$?FH(A61^122?-R(T+A.RGB.1AXE))<2
MDDL)T84C4A.0JX%$^"DRY6A-[+J(2"@A128A) X4$BDE8NB629.2L^1,N" '
M9\-MQ(S38>DX&9*&$Y%6'!^\ *<?VH +MO=1]OH6U.\\CH[B8GC:ZOF9=N@#
MZ R!Z+HJC%0&H^>'OP"WBW1JN&B(+M[O%%,RDW:)6$G>+?>YC-^YKQ82L/2E
MUR\^<IT9O3+C\2HI45%1^6U$28F*BHK*KQEOH(AXNDJ)6T/T*,@^!0^WGFY2
MHHN))T!*M'%  6W6WDY]'F"W[R_H/H0,N7A)VT&5:7*CN;(3U6>J4;SE/"Z]
M^B/.9+^'<]-?P,51JU$\8B5NW+$2E2-6HWSD:I2-7(EK(Y;CRIU+43A\,0J'
M+L#5P?-Q;6 !ROI3)N(I%A28:HI,352>?[T1L1*[7(T]G_ORY8KL5?JPK'*3
M6.0P5ZN(B.I(%$6$VS)22DHB-0&1F'09T47$D)$K 10:\+PK$3D4#XVKX3H4
MD*M=A,1!(7'@(O>=YWEG^3-.DY/D%/>=CJ"4F$3#>R;.]<W V6 +3H=GX^RP
M93@W^5D4+_H0-1_\A/:?S\!;?AW>EGI^_,WPN%KX.;?0%UK]>#2\WC;^[MKX
M.VV'TTU<'<1)^#LW*B6BST?*B2$EXKO@DM4T;Z",Z,+I%QVO#VW*8C7CEXJ*
MRF\C2DI45%14?LUT&;^E_=5<P@M0#R](Q9 >\==RIXL7HL0I)$47DX"!7/Z_
MEG?OFC86(O%58: -%9+#A?C\G:35 U>=!ZVE':@\58_";5=Q_+V#.+CV&^S)
M> L'9FS$T0G/XLP#S^'B R_@\L07<7'B\SC[P+,X.?8I'!N]#L?N68WC(U;@
MU!V\.!]*21F\!,4#%^-Z_T4HCUN(BICYJ(PN0&641E4T[\<L0$7L I3S6&ET
M/HIESX<V[$HL<%@:)59FIXQ0:(KENB*4B"@*1*1&D=$O(H9H18I%$"D<.H4Z
MEP.)T-&':/GQRX@F) Z<CW#@+#D5D8T3Y!AOGXBPXU0DI23"BHMA5A0&D5Y6
M7/HO*RZ$Y>+\P$6X-OME5*W_%*U?[X/GS$5X*TJ 1B$GI*T<WHY*4DU1J:$W
M<NNJIBS44"QKJ8_UZ$ #VKU-%(\VBH=3"HE+])6(*I9'#*_C]X""VNEV<I^3
MO]9.O3+FKX!YO5[?(#Y9(9'#P[C?K4NODA(5%97?0)24J*BHJ/R:Z2(D+FWX
ME2XE7KW/P.T3$X_L,7")83Y>=V#+>]<YN731<7>XT='D1'--&^HJFE!95H<;
MUZI1>J4"Q1>OH^A<":Z>*$;AX2)<V%6(D]^?Q_Z_'L6V5[;CZQ5?X(NL=_#9
M8R_AJX>>PZ9Q3^/'<1NP<]RSV$4YV3E^ WZZ_RELO6\=-M^]"C^,6(YMPY=B
MU["E.$A.4$S.#EZ*2X.6X&K_Q;@6OP@E<8M02J['+Y;<Z">V8M\"%,<4X"H%
MY(HN%V+Z7B$BVNKK8N:L; J) U=(H=A**<GV2PFYJG.EFY!<,H@0P[*Z<E&7
M$,$%G?,F.\7#CM/D9*0=Q\E1N;7QO@WG3#9<#K.CJ*\#1;^WX\K_I9CTMO-Q
ME*7Q:U&:]3IJ7_D2S=]N1^O!O6@]1<[O1NNE_6@M/(RVHF/H*#X)Y_73<%6>
MI1!>@*OY"ISM)>APE:-#"(JW!4ZO4P[1\JUQ(N7$HU?.G' 3C\>H@KE\DR#X
MA$0@JB2B&F9(B5N-WU)14?EM1$F)BHJ*RJ\8;T ?B(;>PNSU&JY",>$%*7&)
MK=LK>P\\>D6EZWHD_B%9HDFZK=Z)NI(6E)ZOQL6C)3BQ[Q(.;3^-/3\<Q8ZO
M#^+'3_=@RP<[L.E/V_#52]_CD_5?X=V%'^%URUMX><[+>&G*!KP\?AU>'[,.
M;]^[#N_?NQX?WO<$_DK^POM_OF<UWJ>,O#ML"=X?L@A_';007PY9C!^&+L'N
M8<MP<.@R'!NR#*<&+<7Y@124@<MP9< R% U<CF)2POO%_9>@F&)2%#L?5V+R
M*1VY1%1$C'5%*!^4D*)H!Z6% A!MXW%N(QVZE&2CF#)@](4(*2F4%9%LR27*
MRT6="Q%^\;C014+\G!-"0LY$V&15Y$24#<?(D6@KMU9*B56>4QC*G]N7TM2+
MK_'_VE#X_[)POI<9%X<M1.'4)U Z_W54O/P!JO[R :J_>@]5W[^-JBWOH_JG
MCU"WZV]H// =6H_^@/:S/Z&S<#><98?AK#V-SM8KZ'"7P^EII)!TZO+IGVW-
M3;%PBSXC%X6$4N(EH)AH,ZGY9U#SK8NB-]&+A1UEN45)B8J*RF\D2DI45%14
M?L7XI,3KU#&J)5[?2"Q/-PSY\$W[*BY4G2YTMG6BK:D=C57-J"JNQ]53-W!R
M=R%V?W,"F_ZR#Y_\:2O>??%KO/[DQ]BX\GV\L. -;+#_ 4^EOHBU<S=@Q8PG
ML?BA-5@X?@46W+L$BT<NQ+*A\[%Z\'P\,;  3P^8CPWDN8%D0 &>[9^'#7'9
M>";&AN<I#*_$./!V?![^RG/^1D'9-'@1MI*=9-_@Q?AY\%(<'[0,I\DY"LG%
M 4MQF5)RA5)R)7XAKL8M0%'<? I* 8IB\B@CHD^$LB$$)-*.:Y0$#=ZF8 @A
MN18H)*30E.T7$IYS4<<0DO,W24A7I)"8[+)W1$C)28K(\2@A)%DX'IF%DQ%6
MG VWXR*EY$HP7U^?'%SY'>_WLN)T'S-.#<C!Z3&+<6[.&ES*78\K:U:CZ#E*
MV,9%*'EM&4K_N!KE[SR-Z@]?0L/GKZ%YT]MHV_X7M!_Z$AUGMJ&]Z"#:J\Z@
MH^$:G*U5<'4T\G?;2K'HY.^>XF$,Z],K'[S!K38I@ABJ)1:]#%RPT>75IA7V
M=ED8Y=_[G5=145'Y-:*D1$5%1>57C"$EV@5G=RGQ!DP3[,?_8%YC.MWH;.U
M4VT3JLMJ4';Y!BX=*\*QG>>QXV]'\-7;._'><]]BXXJ/\$3N6UB6L1$%\YZ!
M8_H:9$U:BLS1!4B]TX&D(5E(&)")>?TRD1"7B918,S)B++!&69 =84&>R8("
MDQD+R$)))A:&9V!A6!H6AJ1B66@ZUH1GXMDH&UZAJ+Q)87EO0#[^,C ?GPV:
MCV\&+< /@Q9AQZ#%V#MP,0X-6(RC_1;A%#E'*;G4?S$*!RQ!$?=?Z[]0RHD8
MSG4U4E0_[)0.&XI)J<1.'%TK)"9M.M]"O4=$"LE-P[+\(G*V&V=\4$@,*8FP
MR<K(2<K(B4@+3D102DQ6G GC\X3DX!*EY')0+B[UYG,&67$BV(RCL5;\/-R!
MH^-S<&(FGR\] Q>S$U&X<!:N+IF+:\N24;;:@HHG<U'[PB(TO+X*S>\_A=;/
M7T'KYG?1LN\+M)S\$:V%A]!VG7)2<Q7.QG*XQ4Q>SC8Y&YLV$0+\O4)ZCY#H
M.>GT]KQ0HS&SFY(2%165WTJ4E*BHJ*C\BM&J'H:4&+BUOX@;0V\\1F4D\(':
M)%NM]6VH+*G!Q>-7<.BG$]CZV6Y\_N9FO//LY]BX_$,\E?,FEJ=N1/[C&V"=
ML@YI$Y8C8<Q"S+DK%[.&6/%X? 8>BTS!C/ DS A+Q,RP)#P>GH(YIC0D4CI2
M*1H989DPAV;"$II!TB59H6FPAJ;"%I(">W *<GE_07@ZED6:L2;&BB?B;'@F
MWH[GR2OQ#OPI/AOOQ>7@KW&Y^#PV%]^2K;%YV!U7@,/]%N+$H*4X-W0Y+@U;
M@<(ARR@HBU#(8X51.;A"P2@*MZ$DS(8R03BE)-R!$G(M/$!(>/\RN20J&12+
M"X)PC?/$/S3+SVD^M^"4R<".4SSW%.7G% 7DE"F+6(B9^[D-M^)T*$4F. ?G
M^^;J\#F";3@::L&AJ"SL[Y^%@R,L.#(^%6=FS,;EI$=18GD0UVV346%_!)79
MTU&=/PMUBQ+0L#(5C4]DH?'Y?#2\NAQU[SZ-FD__@-K-[Z-NSY=H/OD3VJ\<
M@:OJ,CQ-%? ZQ8Q=3F.53>U[($9EB49X-X6$VW8O?*O(R[51 H56+>FNHJ+R
M&XF2$A45%95?-=Z :HD?K=G=+R1>_2)4#-MQ=KKD,*V&JF9<NW =Q_:<PP^?
M[L&'KWR-EU>\AW7V5[ @051#UB%STDJDW+\$\^Y9@%DC\C%S6#:F#;)B6C\S
MID6G8[HI!=-#DC ]F%)"'@M)QJRP5,RA8,RCD"2%F9%"4BDFJ6&4E+!TG32D
M\;P,8A:"$IX&ARD=N9&9*(@R8V&T&8O),K*:/!%EP;.1%KP<D877R3ODHT@;
MOHK)P=9^!=@]>#$.#5^.XW>LP*GARW!F\"*<[3<?YV-R95_(5<I"L9"1,#O%
M1&PI).0J)<20$9^0A.M"(J7$1B&QX9Q<7\2&,Y2-TR:M"G)*S*8EFMDI)8(3
ME)(3X0+NX[DG*2"GPBDE81:<#A-KDW ;RGTAE!=*R6D*R1FQ#7;@./?_S.,'
M*#![HRW8/R@#1^Y.PKE),U$T\R%4)(]#3=I8U*>3C'&HSWP #5F3T&!_& VY
MTU"W8!9JEB2A:K4%Y<_DH>+5%:C\\P;4??L&FO9^CO8S.^ L.0E/72F\+;7P
M=K8!+J<<S^>5T_U"6_C2V[.4> *E1$5%1>4W$"4E*BHJ*O]D M<'Z7;$MXJ[
M]Z8&=M\I\N*SL]V)QKHFE%VMQ+DC5['SNY_QZ1L_8..J/V-YYDO(FKH*\\;,
MQ[3A-DP9E(5'^EGP2+P%4^(LF"HQX]'83$R/R<3,J$P\3HF8$Y&)N1%FS",)
M%(?$R"PD15HER1%6I'";RGVI/"9(B:2H1&:0=*1QFTG,41G(XO-9>5M@(_:(
M=&23/,K* DK+$LK+BI!4K",;>'MC> ;>BLK"7^.R\>6@ FP>MA@_#E^"W63_
MX 7XN7\!CL?EX:P0DRAM9JWB\&P4ZT)RA5PFER@IAHR("HFO2F+2*R1"1LAI
M(BH=8@C6"8K)B0B;G.97<)Q2<HQ2<HQ2<ES YSP11@$)I92$"AD1\'8(9842
M<H(RHL%S0T25) N'*"7[*3%[35DX$)^)H\-3<''<+%Q_= KJ$Q] <\H8M*;=
MBY;4>]"<>C>:N&U,'86&M-&HI;!4IS^ "O-#N&Z;AAL+YZ!\;0:J7EF VK\\
MA:;-;Z'UX-?HO+@?KK)SE)/K\+8V4DPZM;5GH*U2$KALIEPNTQO05Z(6*5%1
M4?D-14F)BHJ*RC^1+@L6]B@FW1K8#2'19<35Z49K8SO*2ZIQ]OAE[-Q\&)^]
MLT4VK:_/^2/RYVQ VL3E>&QD'AX9:,6DZ'1,I#1,,J5A,L7@$4K"%$K#HV1Z
M= 9F1F=B%ID3;<&\Z"PD4@Z2HBDA)"7:AE1!%*&0I/%8NL2B8^:^#)+.V^G(
MY&TSG],BX&T+?ZZ%/S.+,F(CCO!TY(2E(3\T%0LH)$N"4[ R) 7KPU+Q7$0&
M_L#7\&:\'>\/R,%' W/QQ< \?#L@%]OZY6)/?"Y^IIB<BLO'^9A\RDD>+D?D
MXK(IAQ*2C0L4B/-AFGR<#ZR0""$Q"2&QR\;T,X:0A LAL>*X <7D&*7DF,GN
MDY)C80**2BBE)92/\<'[(3PO)!M')0X<X;XC/'8X+ L'A93P]C[*S %^3D<'
MIN'BJ'DHFSP-];,FH2F14D(9:4F]DPRGF Q'4\H=:$P>@?JDNU&;. HUB?>A
M*GDL*LT349DW!94KYJ#J60MJ_K08]9\\AZ8M[Z'MX":XSA^"YWHAT%!-"VF%
MU^W2%DO49]\2/26B:B*E1%92M&FFE92HJ*C\5J*D1$5%1>4?3$]"<BLQZ2XD
M8CT\M\N#UJ8.5)34XL3!B_CVDQUX_9F/L,SZ(FR/K4/"N,68,2*?,N+ Y-@L
M3(HT8V)X!B:1R>21B$Q,C<S$-#*#/!:E"TF,&?-BLI 0:T5BC!5))"6&(D+2
M!104(2,9D19D\CG-4089%!'*2&0:MVD4DC0*"25$P/U9NI!831FPAV=22C(D
MV6'ILO<D/S0%"\B2L&2L"$_!6E,*GN1S;:#4O!23B==CS7B7[^.3.!N^ZY>#
M'?WS<6C  ASKOP"GXN?C3$P!SE!.SD3D:(WJ<FB6)A_G YK:S_F:V.VR2G*2
MLG"<\G LG)@$5F+#41Z74$B.ANF$4CY"A9CH"%$)%?NS*2'9^)FW#X?9<$B7
M$<$!WMX78B-V'*#\'(W+Q/D[DE \]C%43YV,^MECT$0!:4X=BN;T06A.&\S;
M0R@FE).D.]"4, *-\T:B8=Y=E)1[4)M.0;&-0T7^9-Q8.A/E3V6@\K5%:/CD
M);3_] G<)_< I1<I)E523. QQ 1PZD(BFM]=<K8NMY(2%165WU24E*BHJ*C\
M-^E)/(S;6@.[QBW%1&]>;F_I1'VU&*I5@;/'"K'[AR/XY.W->'[ENUB0]BR2
M)E%&[LG#0X/L>##>A@<I$I.C;'B(/$*F1EDQC<R(SL+,: L>(X]'FS&;""&9
M&VO!O%@A)5E())J46)%&&<F04$BB*"1"1"@S%I(EAV=1."@161%IW*9*;)03
M"8\)Q- M!Z4DVY2)' 'E))=BDA>>COSP-,P/3\5""LEBBLG2L"0L#T_"JO!D
MK#,EXYF(5+S$Q_^)\O1GOIXOXAS8W"\//_4OP)[^\W&PWWP<B2O \9A\G(S*
MU9K531IG=#DYZZN0""&Q^ZHDQ\,U*3FJ<X3[?N;Q(V$ZH8YNZ!(2ED,)R:&$
MY%! '!00&\4C"_O#+=@7;L9^HTH2;,?^O@X<I,@<B<S"Z0'IN'S7/)1.F(;*
M&1.D;#2F4T#,E)%,DC$43>G#9-6D)>4.M"3?B>:D.]&8<B?J4T>@)N,N5%I&
MX89U#,H+'D;%BCFH>R$7S>\^@?9OWH9SS[=PG=X/][5S<-=<A[NY'FYG!T5$
MFR)8+DT24"E18J*BHO);B9(2%145E5_(K:HAW87D5F(B;HH5W)WM;E3?:,#E
M,Z4XL/TDOO[K=KSQ_*=8F_\JLAY;@\?'%&#"@$R,C4[':%[DC^6%\023%0]%
M.C U.@<S8G/Q6&P.'H_+QJQ8.V;'VH@5<R@?<V,L%)(LC;@LS(O3Q"0I)@LI
M%)%TDBFAD$2+RH@0D@PI))IPI,%![*94;@4I<%!,-'@L4O229" G@B)B,DOR
M))G(-Z6CP$0IX6/G4TKF4TCFAR1@ 5D8,@]+R K>7AN:A T4EXU\GC?Y.C[D
M>_B\7RZ^'3 ?VP8NP)X!"W"XWP(<B\W'B>A<G(C,QDDQ>U:X0TK(:9^,^)O6
M3^@<"Z.,D)_)X3 Q],J.PY2(GP4A#LGAD&P<$H120D)S*2%Y%(\\[ O+Q5[^
MC+U\GKU\3WOXG@1[A9R$VK _F,(2Q,?U%4)CQ_&H+)P=G(K"^V:C;,K#J$D<
M@WJ*1J-U.!JRB'D8Q8120EHSAJ,UG:0*21F&QM2AJ$L9@JKD(:A(&H+RM)&H
ML-R/F@734+\V'4T;%Z'US\^B[=MWT;'W.W2>/PSG]2MP-]7!W=$F%]ETBP47
MO?J"FX:8*"E145'Y#41)B8J*BLHMTI-X=!6.[L?= 4WM_MZ1QKI67+]6@V/[
M+^+[S_?C[9>_Q!.+WD!>RM-(?F09IHW*Q>2A-HR/LV \+]C'1V9A8J2HD&A"
M,CTF!S,I)%)*8OU2,H=2,E>B"<F<..W^/'WX5K)1)>&%=&:4!>9H TH)Q20K
M2JN2&%*23;G(II0$HDD)]_.\')^89$HAR3-E(#\\G3(BI@].Q8*P%"P,3::,
M)&%12"(6A29B,;=+R0KN6T.>Y/'GPM*PD8]_(]J&#^)S\/F  FRFF.P>L%"O
MFN3C2$P>CD;FR+Z0X^&B25T@>D)L."Z';8DJB<91WCXBA40TIUN)C5)"0FP4
M$@H*Q>)0<#8.4DKVA^10-B@BH?G80RG932G9S>??%9Z%77Q-N_B>!+O#+-@K
MAFY11@[TR<&A/MDX'*0-\SK!W]/9$<DHFC03%7,GH39]#!JL=Z/>,A+UYCO1
M2!D1%9.6S"%HR1A"01F"IO0A:$@?C+JTP:A-'8R:9)(Z'#7I=Z'&.@ZUN0^C
M=O$LU*W+0,-+"]#T_K-H^?Y#M/^\'9W7SL-56PY/>PO<;J>4$I<N)YY;#AM4
M45%1N;VBI$1%147E%@F4#K?;+0D4DYN&<'F-8]I^,;-60VT+KERXCH,[S^"+
M#W;@Y2<^P2++1J0\NA*/WI>+B<.R,+9?)L;%4D9B;)@88\>#,=EXF"(R)287
MT\@,74@>HY \UD5*;)00#2$D4DKB_%*2(H7$2B&QPDPQ,>MB(JHEF4),HC4Q
ML<M*2!IR*"4Y8MM%2E)]4F*(22XOV@TA*2 +Q(*+8:E81"E9%$I"DBDC)#2)
M6XTEP4E8%IR(E7T3L(:WGPA)P;.4@(U\S^_TR\&GNICL'+  !R@F!RDFAR@F
MARDF1TRB+\2.HQ2-HR&4D%!-1(Y);!02JZR2:/T@5F+#09Y[B%)Q*%A@QT&*
MR7Z*R=[@'.P)H8Q02G:%YF%G6 ZQ8V>X!3OYG@0[A)A02O8$2DDOTCL'!_OD
MXK"8W6NP&1?'S479K*FH3)V NJPQJ#/?B_K,N]"0<0>:,H>B.7,0MX/0J-.0
M,0CU&8-1+P0E=0CJ4X>A/N4.2LI(5*>/0E7F:%39)J!Z_G34KC>C_H^KT/S5
M6V@[M!6=5T[!77<#[O9FN#PNN/@=<P%23)22J*BH_!:BI$1%147E%ODE*>D1
M^(5$-+/7U33CPNEB_/C=(;R]\2NL7_0V' G/8LZDY7AH9"[&#K!@=&PF1E,2
MQ@DAH7!,CLW%([%YF$JF\?;T.*-*H@G)X[$.2HF#4N*@E CLE!&-V?%V2HD=
M\T@2Y28MV@9SI V6""NR(H284%"$J,18D!XC5G@WRZJ)E6+BB,S0*R'IE [*
MATF;_E<,W3+(UN4EE_(B^D@*1(6$0K(H-)7B89 B9^,2V\6&G) E9*D0D[Y)
M6$Y6DC5\W),4@)>BL_ 6W\NG_7+Q7;]\;.]?@-W]"K OK@ '*":'*":'PQUZ
M]<-*LO"S@'(B9\H2T_>2@^2 Q(H#/.]@L,"& WWMA%+2EU+2-P>[@W.Q*S@/
MNT*X#<TF-BDAN\(S*2<4$VYWA5IXG@U[@_BX/MDX0"DY\/M<[.V5+X=\'>QO
MPZG[4E X[3&4)3R"JHP)J,D8ASJ*10/%I#%SN"XC ]%@'BBW4DPRAZ Q8R@:
MTX>A,6TX&DA=ZAVHH9Q4)=^!RI01J,RX%U4YDU&](@%U?UB,QL]?0^O^[]!Y
M]02<==?AZFR!2V^ ]]?E5%145&[O*"E145%1N45ZDI);BHG^3ZP?T=GA0D-M
M*RZ=+<76;P_B3R]\CH59+R%]QEI,'[,0#]Y!(>%%[7V4@_MX07X_Y>$!"L>#
M\7EX."X?4^+R\&B<$))<S!!2$N<7DINEQ'&3E"209$I)>I2=0F*#56*%)5*3
MDO28+*3%"C'1JB9B/1*[+B6YLA*B2XF8_C= 3(2DB$I*GLDO) N)D)$E@?BD
M)"5 2E*PE-MEP0)=3GA[%<]_,CP=+T68\19?V\=\/]_$YV(+Y61'O_G80S'9
M'Y./@Q23@Q03(1P'!9220P+>-H1DO\X^T:!.*=E/*=G?UZ9CEU6//123W123
M7123W<&\'>(@5D(I":6,A%%,0LT4EBQ=2NQ22O;WRL8^2LGN7@4\)E:NIR2-
M3,.I!V>C<.8TE"4]C*K4!U&7,9[B<1\%9 09S-N#="D9C*8,O1%>#.]*OT,V
MR#>0.HI);>IP5"</1572$%0F#4-E^EVHLH]'S<JYJ-LX'XU?O(J6@YO05G02
MG?7E<#G;X/:ZU8+N*BHJOYDH*5%145&Y17Y)2F[5U.YTNM%8WX:K%RNP8_-Q
M_/'YS[' \B*FC<O'I#OM&-/?@C'Q5HRA.(SEA>TX2L<$2LBD^ (\U*\ C\0;
M4I)#*<FFE#@H)0Y*B4.7$GL/4J(Q.]Y!*7%02AQ(B;8C(]*.+ J)S22P(BM2
M&\J5)AK@*26IHF)"*1']);;(3*U?1!^>E2-GVLK0I$3*2#J/I4LAD;-MZ4*R
MZ)928@SATE@:FH)EH:E8+J"@+!>"TC=95DU6<?LD][T8EHXW(LWXD$+U-XK)
MYOX%V-%_ ?;&+Y!BLI]BLB_<KDL'!80<"-&J(YJ,9&$OV2.@:.RAE.RED/BQ
M4TH$%)%@ 6]3//8$\_Q@41DQ4TZ$D%BZ28D#^WIG8V^O7.SL/1\_A>3CQ^AL
M[!R:COVCY^#D0S-1^/BCN)$T!;5ID]&8,8X2<@^%9!BW0R1"1IK%K%SIP\D=
ME)([*24C4)\Q@B)S)VHS[D -CU>G#4%URB!4I0PFO&\?B^JE,U'SR@+4??$:
MF@[_@+;BLW UU\+C$LLJ*B5145'Y;41)B8J*BLHOY!?%Q-NU\5WL:ZAOQ=5+
MY=BYY13>^</W6&)_#0F/K,2XH1:,[F_&O;%F"HE-"LGX> I)O"8DDRDD#_>;
M+Z5D:A<IR=:EQ*X+B4WO*;'+H5MS#828^*3$+M<FR8S2*B1VDX8U0NLM28_6
MA"15#.'R54J,!G8QS2^E)%R3DFR]:B*J)W*F+4-(0L6P+0H)6=)=2HPJ2:B8
M(EBL7R)(I9BDZF*B28D0DA5]$K&2K E*HI@DXP4^_VM\+1_P]7]!,?F!G\LN
MBLD^*28%V$LQV4,QV4-IV"NJ(62?+B1[='8+1/4CV"K%8D]?@56RVT >X_E]
M!1;L":*4<+N+^W:273PN$(_=1S'9VR<;NWOG8GM0/K:&Y.)[RMX/_5.Q;?@L
M'+Q_)LX^,AVELV>@-F4JA6,B)60TY<1H>M=$I"5M!%I31Z*%-*?=12FYBU(R
M$G69E)+,.U!K'L;M$$K*0-2E$<I)+:6EVCX.5:L24/F'I:C]YFTT'=V.CO)"
MN%OJY%HF2DQ45%1^"U%2HJ*BHO)WQ) 3GYAXW%VD1&Q=3C?*2JIQ</<YO/?:
M%BS+?@MS)J_&Q!&YN#LF%??$9%!*++@_WH[Q_2@D_7(QL5\>'NSGEY(I/BG1
M^DE\4D*1>3S.BEDDL,E]'DF(U?I(YE)*Q#8Q3BR8J/606".R*"19<(1;8>/6
M$FFAB&A2DA:C-;R+GA(QY6\^120_3"-7%Y/<\'2Y%DF!G&4K7:N.""$)$142
MC>Y2LCA4DQ!)N(Y^?ZDN)"N(Z"M9):2D=P+%) &K^L[#NI!$/$.)>35"B(D=
M7U/:?AJP 'L'+,+^^(78$YV/W2;1!V*5C>ABAJR]XK8N([O(3MZ7\-BN8 U-
M1GA<B(>4#S/O9U(Z,K$WR$SIH)0$441XW@Z>OX-"(N1D=U]-3/8$.; K* <_
M!>=A<V@VON9G^554$E_?8]@Y8B:./_ 8KLV8A9K$F12.A]"2/A9-%(_F-"$@
M(R@B=\G5W]N21Z$U912:4T>A,>T>U%%,:H64F(>C+FL8ZJU#T& 1#?(#^;@!
M:$@9+/M-RNT3<7UY(LK_M :UFS]$ZX5#<-64 JYV?OG<_^;_.U145%3^]2@I
M45%14?D[<],4P &S;;G<3C0W-^'TR4)\^<D>K%_\(5*G;\"#(Q9BS  [1L5F
MX+XX"DD_*\;WMV-"_VQ,[)^#2123R?WRM:%;9$I\ 84D'],H)OZ>$DI)/*4D
MGE(2GX79<=H4P'+E=HE-5D?FBIZ2>'';BI18;;%$GY006X2%4F*6BR=F&#-P
MB29WO8]$B$=!F$:>6*U=%Y)\GY"DR\J(E)%@C26WD)+%/4B)-H0K&<N#M4;W
MU4&)6$,I62W$)"B!^Q/DFB9K0A/Q',__HRD3'T7:\%TT92"6,A);@+TQ!=@3
ME8<]%),]878I)J)JLCO$$!)-2G;H4K)3EY)=NI#LI(3L[)M!Z4CG-IW[TBDC
MF=C=A\>#*"-][10/$F+%]A +S[-HCPVR\Y@#VT*RL2G,AB_YVKZ(2,3?HA_'
M]J&S<&S,;)1,G8OZN8^C+>41M*6-IXC<3?G0:$F]ES(RFE(R1FZ;4^^CE(Q"
M/:5$#-^J,U-(+!22+ I)UD"TF >B+9UB0BFI2QR.BO3[49H['65/YZ#\PQ=1
MO_=;M%XY"5=+'3S.CG_W_QHJ*BHJ_W*4E*BHJ*CT$*-QO<N^@,9VT="NW19B
MXD9;>PLJJRJP:\=1_/'EKV!->!D/W[,,]\0Z<#?EX%Z*A!22 38\0$F9,,"!
M2123!RDF#_7+P\,4$R$E4Z64%%!*-#&903'Q2TD6I<2".92;><18M3U)2HE-
M"LE<BLL\DARK+9J811&QFRS()O8(,[(BM<43#2&QB@9WDR8>"R@="T(I("0_
MS"\D!?JQ161)J"XBP1I+!121I3U(B2$F2RDE2\,T(5D6DH05?1.QBD*RMH_&
MFB Q57 B'YO YT_@>?/P1$@B7@Q.P=LAZ?@TU(+O379LC\K%GMCY4DSV1NMB
M(F;.$D)">=@9HDF)$)(=(0)-2B04BQU]S40(21JV\[EW!*=R?QIV4DIV4DIV
M4#Q^$N)!*=G&QV_CS_TIQ,QS25\KC]FPA3_ONW +OC"EX7-3(L5D-GX:.!?'
M[DE Z<.):)P]&QU)4]"1\H"LB+3(JLB]W(XAX]":3%+&<M_]E))[I9349]R!
M^LRALD+2*(2$M%%*.M('\7R*2L(P5"2-0DGF@RA>FH32C4M1^?5;:#BV QU5
MI7"W-?U[_B=145%1^16CI$1%146EAW1?P5W?"V/*7V._J):(!>UJ:JMQ_OQ%
M?/')CUB_[#W,>_@)C!LR'R,C[902&\;TLV-L?SO&44JDF/2W86)_!Z4D&P_U
MSZ64Y%%*\F6E9&K\?)^8W"PE9DJ)64I)$L4C.58(B$T.V1)KE&A2DB6E1 S3
MRHH44F*FE)BEE%@CM843S=$9<HT2L:)[CEXE$4*RD"R@",P/T\2D(#P#\\F"
ML Q=2M(I()J,+#.@B"S3Q43*B1B^I2-EA"P7%1*R0E^K9'6?! I)@B8E%)*5
MP4E8&IHH6296@.<Y&WHGX ^]$O!NKV1\2IG8%&[#]IA\[.9GLR^V 'LBLK$[
M5$B'14-("=&$1%0ZC*%8?%QP%GZB7/P4G$[12,6/(<F\G4K92*.,4#KZ4#J"
M*"24DBW!A&*S)<Q,.3'C1S[N1TK-5HK)#Y2>[\(R\65X&DG&5Z8$[!R0B!-W
M):'LP20T/#8'[0E3T)[\ %J2A8S<2P$9S>U8,I[['I#;YE0QO.L^-*3?C8:,
M.]%@'HI&\V T4T9:S0/0EC$0[:E"2H:A*7$$JE/NP_7,B2C)GX&2]19<?WL]
M:G[\&*U73L#94,%OI=NGT>*KZ47/=/TNJZBHJ/S_)TI*5%145'I(]RE__9=U
M'@2N#B'Z2]H[VE%45((]NW[&GS9^@;S,C9@Z>CGNC<_%B @A)0[<WS\'8P<X
M*"6ZF%!0A)1,&I"-R0-R*2;^:LD4HV(2KPWADE,"4TJTH5L6RH<%";J4),5J
ME1(QC&L>I40,W4J,RT)JC+:*NS52DQ''+:5$FVDK7Q>/A:$:"\C\,(T%O A?
M2!9SWQ*RE-(B9&2Y#S&CE@$E) !Q7_:/2)*P*EA42824S-.E)$%*R2H>6QY*
M1"6%YZSM/0]/_6XN7OA_L_'J?\W!N[V3\&EH)KZ/R<%/E+7=_'QV1V5C5YA-
MDQ%#3/1&]1UD>X@0$:MD6X@%V_CX;92JK7R=6_FZMO%U_R@D)<B"'_O8L(U2
MLI52\@.EY(<0(2 6;*&4;*64;.W+VQ23S7R>[_@\7X>ED11\2S'9U3\9)T8D
MHWA"$FJGS4'+W*EH39R YN31:)9#M<9P.XXR(D2%^[G5I&0T&M-'H3%C)(5D
M.)K,0]"2.1BM&8/0EC88;:F\G\+]R2-1FWHO*C+&H<PV":6+'\?UY^RH_NPE
M-)_8AHZ*2_!XVBC(+NW;Z16+*D*N8V+@_]8&?H][UA45%165?T>4E*BHJ/P'
MYE9_1^[Z)^:;>TC<W"?7T89V40=T=CK1V-""$T<OX?./MF/=TO>1//UI3!RQ
M"*-B<W!7I .C8H20Y)%<C!N8C?$#-":0B0-S,&E@+A[D\<GD(?(P!>41,K5?
M+J;%YV!F?#8>%^N0B&H(160>I2.!)$H!\2-Z3,1P+M'DGA$EFMJU/A*['+IE
MH8"(F;;$@HEFN3Z)6:[HG@F'/O-607@F)2132L@"7G@OE)BQB"SFQ?D222:E
M)(/"D4X929=2LH(7]ROZ"E*P4A"<K),D6456"R@?@C64DC5]=((T*9''^9@U
M?9,H*DEXHE<"GOZON=A *7GAOV;C#Y24=T)3\4F4%=_&9F,;96T[I62GR2:;
MWG?)*7U%_X=9]H[L(#_Q_H^4B*U$",9FOJ_-8>F\G4;92,46OOZM?3.Q-2B+
MV(F#XB&DQ$YL%),LGD-T(9%2PON;*"G?\K'?\3F^IYCLBD_&L3N243@V$>53
M9J-^]J-H3)A$F;@?32ECT)0JMF.EF#2+*@FW<A^EI"GM7C2EWXVFC!%HSKB3
M#$=+.DG3:$Z]D^>.1'W:/:BAP%1FC$*%8SPJE\]$[5N+T+3[ [05'8"SLQ).
M3ZM<Z=TIOI>D0Z=33%7MU59_]^C##0U=T2HLXKOME3+#K[D<FJC=]]/3<$85
M%1657S-*2E145/X#\T]*B<?%"S2G:&N'=E'G16MS.VZ4UF+[EN-XY;FOD)WV
M*AX=NPIC!\^GE&3CGIALW!<G5F_/IY#D83P%1/  !64"MQ.))B6:F#S$[</D
M$3*E?PZF]<NFE#@P2RR0*&?:TIO; V5$WXJJ20J%))T7[N9(L8I[EIQQRZXW
MN5LC+5VD1& A-N[+B3 CWV2FF)@I)6:?C"P*"102#;^4:$*RLF^JE!&QWLAJ
M29*<XE?TBABL[1M D#YT*TC'MS\)Z_LDXXG>27CR]PFR4O+D[V;CJ=_/PK-]
MYF!C2"+>BDC'1]%9^":6XA#MP$^1=NP(M\DF=R$FNX+,$M$_(H9K;0L6U0X+
MON=[V40IV12:P=L4$[[^'X(S->$(LA&'1E\^;U^;CI7W#;)X7^/[( LV!?%Y
M^/XWAZ9@9VPR#@]-Q+G1"2A^:!8J'W\4M0F3T9 \#HV4$4-*_/!^JI 50TI&
M44J$F-R%YO21.B.XWV D&M*%F(Q 7<IPU&:,1&W>.-2]D(:&;S>@^?0W:&NX
MB(Z.6@J(BT+BE3+2IM/N%6+BE:O ^\5:0WR7Q3Z/WB?EDQ(#0TR4E*BHJ/P/
M1TF)BHK*?V"Z#\4*&,IR"RG1UB9Q$E[R><7?HGE1QXN\^MIF7#A;AD__O ?+
M\]['W$>>P;AABW!?OSS<&Y<CA61,OSQ=2O(I)/EX@$P@$[EO$D5$$Y)<;1B7
ME)(<2DDVIO;/QO1^HI_$(=<E$=/_)L78Y'"M)+V/1#2XB\9V(26BOR0M6EL@
M4:S>+M8E$8LFVDS:U,"BO\029>DB)>*VE5+BB#0C3Y>2^8:4]" D6J4DG5*B
M#=N24A)$(0FBC 1I,K*.$B)83_$P>"+(S_H@;=^Z((WU?1(E4D;(4[V2\62O
M1,+CO>9@;>_9/&\6G@Z9@Q?#$_%F9)H4DZ]C[-@2HXM)F%4;OD4AV=DG4_:)
M_-17DY(?*"6;^'[$L*OO*%2;R.;@#$J)61.-((J(E!*[)BB&B$A9T1""(@FR
M8G,?BDEO,^4D'9M#DK$].A'[!R7@Q+US<?G!QU'VV#14)3R$^I0):$BEF*3J
M%9- A)!(*;F/TG%O *,DC>GWH(&B(H=V98R0J[\WI0U%4^( -"6+&;KN1,/:
M1U'W03[J][Z-QM(#:&TJ0X>[@Q+BD3+2:L#O<3L%PRF^QSXI$7+=R6^^4TJ)
M6W['O03ZUJOMDX_Q*"E145'Y'X^2$A45E?_ W*I'Y&8I$;-K:6+BEL->Q 6=
MP.WN1$=;&TJ**K!OQQF\]L(WL"1NQ,.C5^+N?KFXFT(R*CX'H_OGX7XRC@(R
MGDP8H,G(@_TU)O.8;'274$;(E/Z:D#Q*(9D9;Y=#M\1"B0D4DN0 M%X234Q\
M4B*';NF5$A^:D&A2HJW@;B#6*+&+OI*(#+EP8H'16R(:VT,S9!])5[09N);Z
M>D9$\WJ2G#UKE1B:U=<0C7D^GB!/WD2"G]Z4E=Z).DF2];R]KO<\K.X]!ZMZ
MSR*/8ZT0D^"Y>"4\&>_PM7_"]_I-K /?1]NQU63#MM L_$@)^4D(29!H3K=@
MFZB$<-]F"LBFX$R2@>_[:FRFM&P.RB)VXM#EQ.:KB @!,=#.$UCQO9"2/A9*
MB:B6I.#'J"3L&9B 8_?,Q86)LU R8SHJYSU"*9E(*1E/*=&K(UVD9(Q?2GH0
M$R$EC>E"2NZ2*[\;4M*<-!#-R0/1E#D,]8LGHOKE5%1_M0&U)[Y#\XT+:&]O
M1J?;%5 I\:*-W^$.?H==QO?8XY)B+?!+B5<' ;<U(5%2HJ*B\K\1)24J*BK_
M@?GOAV_YF]P]/@R!$7+2V=&.^MIZG#YV&5]_LAMKEWR QQY:A]'#"C"4(C""
M%\OW]*.44$#&#M2%A (RB4R64P"3^#P\0J908J;R7,&C_309F4:F4TC$HHEB
ML<1YE)#$:(H'28FV2:28Q&AB(@1%S,(E^DG29;4D2Z[>;I%H,B+Z1R218BK@
M=#GSECU"S+Z5AER23^:'IV$!$8LDRH42#<(%J=R7JJW2'IJ,I:%)OMFRQ/HB
MJX(I$7WG4A[F4D;F4D8TGB1/]9Z+I[LP#\_H/-TK 4_UTL1$5$S6!FE])ZN#
MYF%E[]E8WNMQ+/_]8UC9ZS&LI: \RY_U&E_W>S%9^"3.@2]C'/@VTH[OPVVR
M07V+E!$*"B5BF^P7H6!0(C;WR=1$(BA=1U0[A&#PL7T<% Z;E XI*WP.OXAH
M0[8TK-@DH)AL"A*2DX:MD<G8-2 11^Z:AW,39J-X^@Q4S)F"^N0'T9CR .5#
M&\;5F'P_MSJ4$HW1:$R[3TX/["-02M*%E(PD=_+8,#2G#)(TI@]%;>X85*R:
MAHJWEJ!RVP=HO'@4[0VU<#D[Y> L;1B7!^W\OLHJ"8W#XZ:4R*J?-A31S3.I
M)/Z>$KWW1$.7$B@I45%1^9^/DA(5%97_P/RS4B(/R NZYL9F%%\IPXXM1_"G
ME[Y$;N8?,'GT,MPU,!>#HZP8'I>-N_KG8C2%1%1))O;+QV0A(7%YF!J;AT<-
MXG+Q:+R 0A*?+:5$"@F9(:LDAI18I90D23&Q:0143 PI$8LF"C%)XP5[.LF(
ML6B]([J4B'5)A(@X(M(H(ZG((P7A*921%,I("A:&)U,\DN5VD8&)]W46A"?Q
M6!)%)9%RDBC7%5D:.@_+0^913.923.9B3=\Y%(LY6$?6DR?ZS*&4S)$R\HQ!
MKWE=\(M) M;)6;GF44SFRDK)ZM_/PNK?/8ZU9#UO/T/)>9%2]$=3!MZC='T4
M;<<740Y\$^' =V$4C!#*A3[4:@OE82O9TMN"'WI3-OID2#0Y,5,L*!=];,3.
MVS;M/J5$(GM'-+[SD87O^'S?"OCX[T2S?&0J=@Y(PL]W)>+L W-P;=ICE)*I
MJ$N>3 &9@*842DFR+B4^,1FC0RD1"RFFWJN1-DKC)C$QJB7#*#E#I:#49MV#
MBKP)J'C6BJJ/7T+CD1UHK[P.%X59=#S)CA&OJ)"X-2%Q\7OL"I0234C<@8WN
M$B4E*BHJ__M14J*BHO(?F%^2$HU;28G8YW*Z4%-5CY-'+^*S#W_$VL5O(WGF
M4[C_SOFX@U(QD!?)P_KE8.3 /"DEX\50K?A\/$()F1:3A^G1>9A!IO/VM%AM
MAJUI%!))0)5D9ARE)%9(B15S*1H) 6*2U$U*DGUHP[A28K.0*A90C#4C,T8?
MJJ4+2;8I#7GAE)$PBH@0D%!*!ED<EB1%8Q%%8U&83KC&0A,)-YC'8QJ+0^=2
M2N9B&85$DQ)*!*5D39 F)E)*R)-]A)3,N:64///_L7<7T%%=:]_ 8U"_;8%X
M< _!+01W@@0-<9>)&R1 D! G[NY&%*U3;]^ZT +%:[04C0,A^O^>O<^99)#V
MO??[OO9]U^(\K'_/F9DST]Y)[EKGQ][/WEI"HND\@L*F;H41/L+IV@@M>K^&
M!:+4+?CQ #V.U;-&RE '9(UP1?%H#U012@Z/\<6QD3YX91CA9(@G']%@_1]O
MZA!*M-TH,CIW[47):PHH>96%KN?P&.PJA*%#S"N]<<-Q^LSC])G'=>GQ8!>\
M-=H)'TQTP)=S[ DEUOAYHQFN66Q"@]U:--FO(I0L%U!BMT0!)@HH<5! B>-\
M!9C,4X#)' Z3%N?9!)-9=-U,-#@9XJ;+?-S<8XU;6?O1]/YQW/OE$CKNMO1.
MN>KN$:=LL1$2.4HH;,2$3]OBHR0"2L1??>%]D% BE512_;,EH40JJ:1ZLJIW
M=SDQCS2\*T[3ZGX4)=T]N-_6CM]_O8$/W_X:64F'X.D0CTTK]F'>U&V$$C],
MT_?%S$G^,"*0,)2L()2LU0_@(R1RD @H(9#PD1(?;& AC&R<0"@AD @H\224
M>'"46!(P6*S&N?-1$_DJ7&S%+083!W&4Q$$$B8 2-SB/DPF[MQ-(/#E('.%/
M&-D^E#!"V3'$#KN&V&+78!L$#[&A<X*&&':^:ZABK(00/%B"Q>RF["&([*6$
MZ%D02"P(%!8(IRBB)+HWPG0N>?@(BK85XC2M$$N)T:#GM:P0I4V0(:#$$582
M-"CJ=(TZ@42#GM>T1+RV+5+T')$WP@WEA)(Z^DZ/C/;#T1$^.#;4$\?TA!&-
MU]C4+1V&$S>\J<M&2V1\ZI4P\N'!0?(*BYXP^L&@P4/7L!P7<XQ>.T:?=90^
M\Z@VA<Z/$5[>&.6"]PR<\(6A(TXOM\6/&RWPA\460HD)H<28$$(HL5N&9EL&
M$X41$_O%0N0P<7C,B(G3/"'.1GP5KA:7.<**7 XST61',+&9A0;_C6B(\4?3
M\3*TGOT6;8TWT='5+JZT)8:AI(-%&#%A(R>]3>P*(!$&"WM$F"C^D5 BE512
M_;TEH40JJ:1ZLNH_0,G#,&'7=M/-'%L&^/+YWW"L]@-$[BF"^;H0K##: <,)
M 9C-LPUS)@5@/H%D">LE,1!0LIY-U^*C(T(V$$@V3/#%>@+)>@+)>HX2+XZ2
M+002UD]B3L@0X@YS?2$6;.=V^;XD?!E@H9=$B#N?NB5,WY)/W7*!QTAG>(]P
M@N]P1P0,=4#@$$+)8'OL'$PHT2.4Z!%**+OT""2#A;#S8,IN%EUK["%,"+'L
MS5X](?LH(?0XE"#"5\NB1- YF[H5I?L@2J+$7I,(,>QQ# $D@;"1H&Z!^$$6
M! \+Q#!X$$B2-&V0HD%1MT:B")-H?@T]UK9#]E!7E(SR0@VAY- 8RD@?'![F
MA<.#"0X<)FZ\!^0-WE?"SN6C'^Z$#0\<)Y#P\,>$C\'.0O1<'LA1>NT(O?\(
M ><PH>0P(><(F]XU4H9W)[C@,T-GG%IFC\L;K''5?"OJ;=>CT6X-P6,%@41$
M"3MRF"CB1 $E'"8B3ISZ<-+B-%?<SV2N@!.VJ:+-=+183$.SNS&:]KF@\6 Z
M&K]\#ZW7?D);6S.AX[ZP?'4/7U)+&"'Y"Y1  24]#Z%$VJ=$*JFD^KM+0HE4
M4DGU!-?#*%'85([_#?.CNUYWT0U=<^,=G#YY&:7YKV&[9QJ,YV_#_"G^F$DW
MQ7/T S'/( @+)V['DHELZI8_1PF;OL5Z2M:R&,CC1_'!.L*("4>) DC&,Y (
M*&&C)6:$D:T3W&%*,9O@ 8L)P@[N\KU)V%+ ;'\2Y['N<!GKSAO=W?B*6S)X
MCG*!UPAG^ QW@M]0)P0,<<3VP023P0PF=MA!*.'1M440P81E!V6G+D%%QP9[
MM&VP3\L&(02$$$V*EE5?M*VPGQ(JABWARZ9;1=*1C71$:\M'1(2^DF@1(1%Z
M=*V>T!3/X!*C;4$H,4?2(,I ,\*).>())HF:5DBF?V>:N@U2*4F#K DM5C@P
MT!*QA)0$+3MD#G9%T0A/'!SMAVI*#:&DEE!2-\1#@,E@=S[MZE5=%AG/<1YW
M'".,](:N.4;P.$H@>30N!!!7'*;/.$0H.:3M(1Q9;\D(-[P]089/9KO@NZ6.
MA!);0HDYH60CH60M(60E6FR7$R*6B3A9)HR<V,E'3A8+,)%'[#-IX5D@A,&$
M3>5R82,G1FBQGX4[UM-QSVPJ[C@O14N0)>IS(W'KG4-HN'02K8U_H+/S#H&C
M7?C=[I;#1(Z2GMY5MB242"655/\;2D*)5%))]027(DJZ\"A*Y#NW]]VQ=;1W
MXN;U1GSQR0_(2*J#NWT<%D[WP6Q]'\P8Y8^YXX*P>,).+)L0B!4&VRC^0@@H
M*R814%CDFR9.\L7J23Y8.U% "1LEV4P@$:9M$4CTA9@1/K:R$$1,#3QZ4<(V
M3;2G.(T75MQR&>T.V2@WN(V4P8-NE+TH/B/=X$OQH^=]*3X4MB>)UQA7>(ZE
MC'.%UWAZK$]X89G@QN--\=%W@_]X-VP;YX; L6[8,4:&G:-87"DNV#72&<$C
MG;![N"/V#G/ _B$.""?H1.G9$3YL>?,ZZQ.)93NS:UCV)D;+DD,E4L1)E(B2
M1$))LKH9D@DEB822!(82NCZ)WI],26((H<2I$TKX-"X!)>EZSL@;YH;2D5ZH
M&.6#2D))]0@O@HDG#@WUP)$A#"9NXO2KOO!I6(21H[I>PI%0PD=#!CL]%&?"
MC0L.$7[J]-Q1I^N!6AU/U!),ZEAOR7!WO$7?U<>S7'%RB1,NK;?#[V86N&VS
MB5"RCN!A3"!905F.9ALV:L(B3NGB49C*I3"E2]C+1,2)DP 3W@#/1DT<#'''
M9@;:S*?B+KW>ZK<1]4E!N'DX#[>__0#-URZA_7ZC.%HBCO9U=XE[[G0K+/LK
M;)*HL+A<;S^5A!*II)+JGRP))5)))=437@^C1-SIFN]'HH@2X6;M?MM]7/GE
M!MY[ZVO$AI?!SC02LR=Z8/H8;TP?N0WSQ^[$<OU@K!H?!&/];5AIP/8H\<?B
M*0$4.D[UQY)I?E@ZU1?+I_@23GRP9J(P=6NSOA=,QPNC)&9RD$P0LE6,F8$G
M!PF;OF5'CQWI&F>ZGFV8*"-\N ]SA<<0%W@/<87?$!FV#?? ]E%>V#[6!W[Z
MOO R\(5LDC<<IWK#=H8/; S]8#,W #;SM\%FX79*(&P7!<%^81 <*<X+@B";
M'P3W>4'P- J"MV$@O&=OA\^L /A.]X/_5!]LF^B%G02CO6/<$4[_#0>&RQ!+
M-_)Q.HZ(U[!#_ #"P\L$C)?,D?22!1(&6B*.X82-HK#^$H82'7,D:IIQE*0,
MVDH ,>,C)_$:PH@)NYXE5MYWHD5'+1O$:]LA1=<1F82&?())"1LQ&>6-*@)*
M+:5N.(.).P[3=W&8CW2P*5@L,CX-ZPCAX@BAY BAA$W%.JS'\.%$<13CQ%-'
M_WOJ""6UA)):NK9&QTN B8X'C@YSQQN$MX]FRO#-8F=<6&>'W[9:$DHV$TI,
M"!VK"20KT6)-&*$CCZTB3L0F>'G$:5W"GB:+A(BC)FQ*5XOC?+0Z&.&N[2S<
MMYR*>XYST>JU"O61[KA9$H=;'QU#TX_?H>WN371VW>OM#^%M[?+F=;X?"?I0
MHF!RUC<EH40JJ:3ZITM"B5122?6$U\.C)9T*Z0(4;L38JEM-#2TX>_HG'*O[
M"/MWYL-B?2AF$0ZFC_8EE&PGE.S",D+)2OT@K)RPC4_?6CK9'PNG"EDTU0]+
M""3+IOA@)0>)T$^R2=^;0,+V)5$(:W:?(!S-*9;TG)5\SY)Q;)3$$P[TO!,+
M/<^F;[D0"F3#9' ?[@:OD9[P'>\'W\D,$;L@FQL,NX7!V+HT&":K@F&\;@]6
M; [!"O-PK+".P@J[ UCI$ MCQSBL=HC#&H=XK'.,AXEC M8[)&"C?3PVV<1A
MBU4,3,VC8+8Y');K0F"[8C=<%N^$#\%E!Z$E9'H@0@EBX>.\$$Y B20T'-"T
M1=P@:R0.L$+B0"LD#+(B; C-[7%:K'?$@J,D28/!9"L2-024Q&F:(X82S4+7
M1+-1%MX +ZS@%:MM@P0=6X*)/;*&.*. -;V/]D+5:&_4L1!2ZH:Z<5#4Z0DY
M1" YS,)Z0P@6APD8APD:?&H6H:1.SXGPX2C&28PS14!)#4>)=R],C@[SX"CY
M\!&4;$&C[7JTV*XAE!@32AA,5M'Y*@$I/"OH]664I4+LQ-BS$$SL'X:)@)-6
MA[FX8S<;]VRFX8ZC(5K<EZ!QCPWJ,_:BX8URM)S]'&TMU]#>>9<O#2QLD]C%
MCWR9X![TPJ2[ZZ%?^:Z>7I@H_I%**JFD^CM+0HE44DDEU9_"I*OO"KI!:[O;
MANM_W,*7GYY!1>$;V.&3@2VK0S"+0#%]C!]FC K"O'&[L(10LIQ0LMQ@&Y;R
M41)_+)A&*)GFQU&R=(HO5A!(5A-(3-B^)!PDWC"C;-7WYB!A>Y3P& @H82"Q
MH9M\N[&4,9["LL!L?Q)ZS6ZB-^P(-G9T#5^)BUYWHFM=)OI!-G,'7!?L@_.J
M"%B91&+#EB@LMXB"D5TT9KC&8(IW B9O3\.4X"Q,V9>':?L+,#VL"#-XBC$C
MH@0S(THQ,[(4L^A\=F@QC/858-ZN'"STS\!2]V2L(LALM(R"]98(R$S"X6\<
MCNV+]V+'G)W801 +IO_.D!$R1 QV(DC8(T[#%O$#"1,,*8.$YO4D#0LD$3P8
M2I(T^E 2RS%BA@AMBHXYQ0)1.L+T+P83CA,M @X!)76P/7*&NZ)T#*%DK#<.
MC?5!W4@/CI):/LKAPF%1IR<CF+#>$-87XDGQXL<Z>JY6UP4UA) : HD0)S'.
M%%>*'"4^'":U]-ZCP_M0\K4B2JQ-T62S@;"QEC"R&BU6A!%K8R$V"CBQE<-$
MC-TR$29+%&"B@!.'A822^6BU-T2KW72T.L[BO29-VS>C*<87S8=RT'KR ]QK
M_!WW.^Z"=96P313OT^\S.[8SH/!-$NDWOEOH@W_0XL*&);W+8DL@D4HJJ?Z!
MDE BE5122<7KOT=)2_,=_/+3[_C@[2^1FW88?J[)V+AB+Z'$%S/&!&#FZ"#,
M';\+"PUV8?'$("R>M(V#9)$X;6OI%#\L9_TD$WVQAC!BPC9+U/?!EO%RE/AP
ME)A.\.Y#"=^KQ M6X[QA2S?;=J.]8#O:$]:C/6 ^UH.OT+5U,KUGFB],9VW#
M%J- ;%ZP$QN6[L9ZXQ"8;(S &HL8K'),Q")9,F9[I6"27PK&;$_%\. ,#-V?
M@Z%1A1@:6XJAB148EE*)X:G5&)9&2:_!L*PZ#,T^A*&YAS",CL,S:S$RK0JC
MZ=IQ!THP(30?DPDTLP+3L# @%:M\4K"1H++9*1ZF-M$PVQH&ZPW[X&*\&UX+
M [%MAB]VCI-AKYX](@@GL2];(^EE*Z0,M$*RNB7%0N@K43?GY_&:%KS?)$J'
MK>1E(:SBQ39B9$WT?.2$0M?$TN-$/5MD#G=&,7TOE82R.@)<+TJ&""BIX:,=
M,@Z0.AW6$^+)8<%&/&KHN6I"214AI(I (AQ9G"DNJ*;WU>AYT'5>J-;V1HVV
M?*2$3=^2$4I<\<T2)UPTL</OO2C92/!81Q!90RA9+>"$A8V<V(@XL97#1(S=
M<@$F]@HP<5BL$ 83MG2P$9H<9Z")+0_L9(AF[S5H#77%W?)DM'U^ O?K?R.4
MW"&( &UL9W?Z?6[C.&&C)N"C)7^%$H7U':222BJI_O:24"*55%))Q4M^!Z9X
MA];=]RJAI*&^&1?._8PWCG^$U-A*>-C'P63);LS6]\/,L=LP:VP0YDS8B7F3
M=F+^Y$#,G[*-3]EB,&%3N%9.],-J S^L8\L ZPL@V21'B3X#B0)*] 60;*&;
M:S.ZN;8:XPV;T003BM48]IPG-HWW@,E$3ZR=[H,U<[=CS;)@K#+9CV5F45A@
M&PM#UP3,\$[&E.UI, C.Q-A]V1@6F@N=\#RH1^5C8$PA!B248$!*!09D5&-
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ML[X2 DD"@22!0))(($DZ"*64*BBE54,IO9I@PC919)LJLEW?"]$_N0C/I99
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M,=X-(P,/S!Y+,!GM#:-QA)*) 9@SC4 R;Q=F&(=B\M8#&.N4A,%N D9>\$[
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M4')/[.+I0TDG'S'IZ$-)SZ,HZ9)0(I544OW#):%$*JFD>G*JY\'(&Z?_+91
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M)THEE53_0$DHD4HJJ9Z<^A.4*&[GURE&$26*,.GJ[.9])=]_=0F%6<?@(TO
MHCF>F#'%'08&7I@X;Q<,UD1@C$4<ACHF0EV6A!?<$]'//1YJG@E0]4J$FC?K
M(V$@$5'B):!$S2\=*OX94-Z6":5 0HD<)CL)'KL('<'BKN[[""0A>0),]N?R
MJ(026$(+H!I63"&0A!%&""4J$022R%(H19403(J@&E. %Y**H9M5@:GE1V%\
M_&TX?O@Y@K[^'@?.7$#RN4O(O' 9&><O42X@_=QYI/UP%JFGSR#[S%D4G[N
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M-@99"[<A8;0C$K2MD33($FGJ5H01 2?I&@X$$1>*&T^JAA.2"2()&N:(4[=
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MPZ+P9'04H60FI./""2/!D(T-H/A"-LZ'H$(8(9!("21<""0R@@B7R9Z0<_&
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M0=(W$O*^,Z#H%PY%_W H^\_@;A7]0PDFOT2)'P<3^3!?;AF7? 0]'D7/CPZ
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M9&@0-TA1.HQ>$V)&B6ID(%2CS%T2'P*))V03W"&=Z K))!=43B* L%@XHYQ
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MQY$\1N'&2\S*2%Q_F==6AA,EX3"\% ;#RSQ?'4Z0\/HZ F9=-+3K8IA8GD^
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M5T3 ^F(D$PT+46)ZB;!8.0DZHJ1S52QNK(G!];4.E*P/AV9=*+3KB0E&OX%
MV1#)1$/_:BPQPO=NG BC"$$B9_-D&+<P6WDMCL_'$R\),3 0)L:D<!B30V%*
M(2Q2B8SM@3#O\(<EG9#8Z0/K+B46 L62P6L9?K#N]8=U7P"L1(F5*+$>#(&%
M*)%SA,EDCHE1$G[6*3^8L[Q@)D;,V03'.8+CO NL.8Y<8')=8<WC,=\9%M'1
MO8@8*1D!2QE3P502(U6C(56/@51#C! F4NUHV.J8^A&P-PR#O9$@:;H/:&$(
M$\@P$2,F XF203"\/@SZ]R= ]_$*&+_)AT7_1]ZJ6F5@3VGE#E@=*)%NH439
M_E>286+K#A+[]T%B5T&BEEIJ_4REHD0MM=2Z#>M?1XE=(D0D*V/A=='EW2(W
MH=.9-/CBVZ]Q]=T/D7VQ#1N2+F#>PQD(GT&$Q&R&QZ0X>,Y(A-?L;?"<FT*8
MI&+<O!2XS-L&9^)DK"-C")31,DZ8AQ+DD9/1,DP2,7*)H[^):+RX. 5.#^_
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MF-/"8-E.9.P@-M*#(.TD/'8QNP-AS6#V!$+:2Y#L%R@)@.4@<XCX.!P \Y$
MF(XRQ_QA.L&<\H61(#&>\8#AK!N,YUQA.N\,4XXSS,2(.9?)(U3R"96"+I",
MA+ED.,RE3K"4#R=*1A(E8V"M=(%4Y0);M3-L-6-@JQT)>ZT3['6#@08BI'$0
MT$2(--^KH*3U+J5AHA@IN3H"QK?]8?C](]!_F@[C]6:835] $LT1?Q0E-GD$
M1>G@+F*5CS9Y)R[';ES?@XF*$K744NOG*Q4E:JFEUFU8_Q64*""Q2TKC.=CY
MA0]&6"0#M$8=/OKKYZAK?P\[]I?AD6<.8OSL9'C';(+GQ*WPFI8([UDI\)Z3
M"L\Y:7#CT65N*IR)%#E$RMCYVP@3XD3N I_PO2E=8L1D)'$R8G$2AB\66P:G
MP>D7.S'B5P<P>L,)N*9=@,?A4GB=JX5K42.&5[?@OKH6#"1([B8:[B50AO+Q
M<*)D)%$RBJ 8162,X5$>0:EKASOC092X$R5N1,@XD2;E7%SSXNM\^'Z_VE;X
M,CYU"FA<&L6ZE28$--00)H5XO.@$DK)W(.?@6KR9^C@^W;R \)@"\TNQMT9*
MQ)H2@D2_*A*&5>'0KU:B71.!3J*D8T,8.C:&X<9F'K>$H7-+N!R-'.)$9"L3
MQR1$0-<]8MH6HV<,241),G&R+1JFE!B84F.(DBB8MT<2)1&PI$? NI/9Q?/=
MX01)**Q[0V#=%^0 B3_,A_Q@.N(+4Z8/C$>9X]XPG/"&\12/!(F!(-&?=8?^
MG!OTY\?!D.,*XP4F3^G@+G=Q+W"%N9 HN3@:YN(1,DC,94RY&"D9S3@3)6Y$
MR3BBQ 7VFM',<*)D,%%"C#0,($J8IH% "V'2PFNM V G2L36P)8W/&%\=P8,
M?]H PY=Y,&K>A]EZ U8!9W2[Q;^'$DF. A(EMN]M$=P=)BI*U%)+K9^O5)2H
MI99:MV']R'J2'Z+$[D")^,)&D-@D8L1FX&4#GS3Q:(:5SWWYS0V\_?XG.)[=
MB%^M/HZ9B[8C:-(6^$[:"I^I"? 1B]]GI<)[]G9XS$[#.,:5<2%27.<R\PB5
M^00*82)/Z1+K3;K#9#%ALEB!B=.R;1CV2!J&/9.!$2\?ADM\-CSV%,$GJP9N
M!8T84=6*0;4MZ%??A/[,7?7-,E*&\-HP@F)8G1(G9D2=&$$A3H@2%Z)$Q)D(
M&4N,C&E4CN*Q:WT[W 1<:ID:GC/.O#:JH1TCFUHPMJD!OO45F%IY 4\79F)[
M5@J*]Z_&FRE/XM.-"_'=FAG0OCP1AI=C87PEFAB)@'%U*$RK@V%:Q:P.@7Y-
M&+3K1#^22-S8&(7K6Z)P8TLD.@B0CJW$R=90=,:%0B,2SR2$0)/()#F2' *M
M''Y.<CATVPB4E&CH4V)A2!T/0]H$&$6V,SO&P[23V<7L)I0R"):]!,N^<)@/
MA,!\,!"FPWXP'B%$,HF/8Y[0'R= 3C*GF"P^/L-D>T)WECG'\_-,CB<,%XB$
M/";?"Z8"IM #IHL$2I$S3"6C8"H= 5/92**$2"DG5BK&P5KA#EOE.-BKB)+J
MT4"-$U![/U!_%T%R)T'"M-RI8*25&&GM!XDHL5P>!O-;43#]]FF8_GH8QN]>
M@TG_-YAYGUK%E*RN^[QK*V 9(PI Y BXV+IBO0421]\2.2I*U%)+K9^Q5)2H
MI99:MV%U1\F/[ %\<]<MFZ/[=1=*]')@-T'^\S-?>*-3CX_^\A4NEEU%W+8<
M+']J+V)G)2!X6AQ\I\3#=UH2?&:DP&=F&CQG;H?[K.UPFRVR VYSF7G;,6X^
M<3)_F[+>9*%8"._8H6M1G ,G B9$R9)D#"5,ACR^ TXO[(/+QE/P2B]$P,E:
M>.8U8U1%&P95MZ!/71/Z,OV8NXF2^\2T+J)$Y'YB9# SA!E.E"@C*$0&43**
M"!G)C&A4CB*CZR\3+Y<QMO8*QM9<P9B:RWS/93CQN<&-;1C2U$R<U,*_K@0S
M*\YC1=XA[#V5@HO[UN*UE&?PX9;%^'S]3-Q8,Q'ZU?SR3Y!8"!++ZD FB(^#
M8%P3"AU1HMD0C8Z-L;BQ>3PZML00)%$R3#KC"!-BI),8Z4P(1F=BL-(P,3D0
MG=N8%!$^3B%04L*@28V -C4*VK18:+>/AV[[1.AV3%*2/EGNVJ[?/1F&C$DP
M["&8]A%,^R-A/!@*XZ$@&([XP9#I _U1+QDDNA/NT-U$":^=8;*]&;[FK"\,
MY_CZ\X1,#G/!#Z8\?YCR_6 N\%%@4D28%!,FI6.($A%GHL25*''KAA)G0*"D
M=CA0)U!RMX*2YC[$2&_8VNZ$U-X/5A[-[8-@NN(*TZ_GPOR'>)@_+X6Y\V.8
M33=@MDFPV)7N(C(I[%W; $N0NJ'$;G?DAXT4592HI99:_TVEHD0MM=2ZC>K'
M]_W]\?8D"EK$&A(9)3;'2 G3'24ZO0F?_^,ZFMK?Q\&C%7AQ[3',7I:*R%GQ
M\)^R!3Z3X^ S-0F^,U+A_8 "$\]9.^ Q.QT><YEYS'QB97X*<9(,UP6)A$D\
M8:+T-1E+E(R1%\$GPHD9LC@1]S^<@J%/[X+KVN/P3<U'Z/$Z^.:V8&SY)0RJ
M:D6OVB;T=L!D(%%R#W-OK1A%:<4]XDB0W"OCI W#&*>Z=CC5*QG6T)5+2NJO
M\#6OP:GV=4>N\O$5#"%6[N7K[FGBYS4U871C#8)K2["@[!Q>R3^"G:>VX]S^
M5]&P_9=X+V$QOM@X36Z$*!$D-D)$8@1,9)2L#8%A/2'Q:BPT&R="LVD2-)LG
M0+.%CPD335R$W(]$DQ#J&"$)AH88D9,2@,[4 '2D!3+$2AKQLCV<B4+GCAAF
M/#3I_*QT?BXQHMDU!9K=4Z'-8/9,@6X?H;)_//0'HJ _& ;]X6#H18^23%_H
MCGI#=\P+NN.>T)]@Y*E;1$@6$7+&'X;L !BS^?N?#8;I7(@<\WGF0C#,>417
MOK\,$W.A)V'B#E.)&V$RCB!Q<X#$#1)CJW0E2L8Z4#*"*!D*-(BU)/U@;Q$@
MZ4&0](+E4E\8V_O#<&D8#%>#87SO*5@^/@;KUZ_#JN^ Q6J&A7>E1;X[Q:H0
MY1]Y0;MC#8G-L5D#NL5N[[Y%\ ^7N:LH44LMM7Z>4E&BEEIJW4;U?XD2NX(2
MVX^@Q&BVXEJ'#K]^_V,4E%Y&XHY<//+<7DR<GX# R1OA-7XCO"?%P6_Z-O@^
MD J?6=OA/2L=7D2)UYR=\"1,/.=MEQ?"NQ,E8NM@N:?)0J4+O/-#!,HBL0 ^
M <,?2L 0/KY_21*&/IX.MU7'$)A2@.CC#0C.;<>X\BNXKZH-O6J:T%/ A.E7
MVXR!M2VXNT:).!>YRP&3^XF2(5VI;\/@FVG'_?67F"O,5;[N#=Q/E-Q/E-Q?
MRY]3>QGW\#4#&UKE-2R#&QK@5E>)V,H"+"W.PLL7#B+M5!JR#ZY#<_I3^%/B
M7%S;-!'6M6&PK0F%M"8$EC7\,K^67^H=NVWIB!(=4:+;-!FZS3P2);JMT=")
M-21$B98HD4.4: D2[3^A) @=VPF3'81)>@1#F.R,9F+1N6L\.G=/9":A,X,X
M(4@T>R=!NW\BM ?X<PY&0G>H"R4!C!]1X@/],6_HY?4D/C"(!>ZG_6',(D:R
M F$Z0WQD$R'9H3"?#8-%Y%PH+#G\_Y9+=.7YPU+@2Y1X$R5>1 EQ4NI!E'@0
M)>X.E+@2)<Y$R1B@1J!D%%#O!#3>!S2+*5M](+7=09#T@O'RG=!?&03=U7'0
MO345Q@_6P?+914C7/H#-:((D2?)=V84228"D"R5VJXH2M=12Z__I4E&BEEIJ
MW4;UXU.V_BLHD4=,^+@+)5;)!KW)@D\^^QJ77O\ AT_58,6&8YBQ* E!D];#
M(VJM#!/_:8GP?R %_D2)+T'B,WLGO&68["!,MC.IA,DVN,U/(DP29)B(+O N
M1(BSW'"1*.&U(0OB<-]#B1CZ""&S\AA"MQ5BTO%F1.1=@6?%ZQA<U8Y>U4WH
MX8!)WYIF]&<&5C=C0+5RWH\HZ5]'F#A&3\0HRGTB=4H$5@81*8/J+A$>5YBK
MN)LHN9LHN:?F*@;57&$N\_WM&,#7]2-,[JYOPO#:6OA6E6)262X6%9W&BWF'
MD'XZ&86'5N+='4OP5?QT6#9$05H7 6EM.,SK0@F28!@V$"6O*BC1RWU()L.P
M:0(,FV-AV!(%P]8(Z./#&:*!*-$G\O7)0= )F*00)D2)W"AQ>R!!0IBDAZ!C
M9R@Z=H6C8W<$$X6.C&@F%AU[QC,3T+EW(C3[)D"S?SQ1$@WMP0CH#H="=Z0+
M):*;NR\,QXB1XSXPGO!3NKB?)D9.!\&<%0Q+5@BL9\)@S0Z7(YUESH5!(DJD
M"X&PRBCQ(TI\B1(?HH0I]29*O!PH<25*QA(EHXF240I*ZICZD43)$*#E+MA:
M^\)*E!B)$MV5_M!<=8+F+?Y_?W<)C'_<#NN7S;!U? J8[7(K'<=F6X0)[TW>
MOTK^:RB15)2HI99:_PVEHD0MM=2Z3:IK(;OM!['?:MJ.6TQ1OI9)#I28'"@Q
MWD2),B=?]'VPPT*8?'--@]__\>^X6'D5R;OSL?S9W8B=O1F^L6O@';L.OI,V
MPT^&22K\9NV [RS"A$=O(L5KMMB=*P4><Y/A/B^1,$D@3.(9T0F>,!&=X!],
MP$A>&SH_#H-Y+G;B\EIQ%.&)!9ARM E1%R[#J^PJAE2VH;<#)2)]>'XGT[^J
M"?T<YW?6BA ICA&4>PB502*\=H\C=]<J:+F+,!E8=QD#:U_#P)K7<%?U%>8R
M[J[F]1JBI*8-_?FZN_FSAE35P+6\%(&E^9A4<AX/%9W"JMP]V']J"VKV/X/?
MIBW"-UNG0[-Q$DP;8IE(&#<0)J^&$"+$QL9(8B0&QLWC&1X)$N,67ML:#H,
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M*(.H5UDE^A:5XMZ"(HS-S4=8SEG,/W<4+V;O0G)6 HZ=6HN"XR^@X<AC>/O
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MA/&UR3"_OQ363]9!^NH ;#?*8-.^#;O^[["9.F&S2/*TOEO]1;J:']IAZ&J
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MTFD72%DBA,II#]@($ML)$9Z?<H.-*+&>'07+>8&2(=#GW _]>8+D_!"8SX^
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MI5;9?I79CFNM^N#U5GEX@Y5WW6*E/;=;:=\6*^W?:B,'[G% 9+L-C^QR8.2
M/^200P])TO,E?9_,CR7[KU7\NY&QA6VEW6]]\6E:S(HX ,(,2>5 +?7+[_+F
M[Q8I4J1(TYLB*(D4*5*D":116!'.AH30X]"2O</84JF]%] AVNYG3TII&7%@
MA3(\DI2A$3O@RJX#0W;W[KUVU0,[K.>..^W+UZZW-ZR]R/[?BK,=2.AWP&25
M<^H=$.A9:S,6N[(D.5P1X"%@DNR&Y4J/>]_C/N]QP(54KV[6I#C@TCWH/G/
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MOAWQYXF4S8$2.Y 6!TS<:\4!$ITUDHQ!4I+9DN&@)+,GH^ D+&':UEA0HF3
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M;;8#+G,6.E RO\].F#=@CSIKI3UJWBKW?K4=Y\KL^9P]LMK:%G)((B>W#R:
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MBA1INE&XIJ0.*"F^K)H!)G7^JLG!@]HF>$1%*5%LN5NMU$HUG1FIAD4[?^6
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M4_;^][_?WOG.=_KW/_G)3^SLL\_V/@3@H15;+1X&C#";<=UUU]EEEUWFP31
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M!GB4^DK^K[GFFIH.X+,L+[?2GE9T;'BB>SU00AW"#7&RCGPV",LK;44O<R0
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MW ]\X .^\#\[-("PB13!8# 'QH:!8\ 0>!A. ]1*U%>*'.'&\"$0*&_J![B
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MGBD%'XZ!^$AC$8Z#^HU^1#&A6*DO2DL&+ 2)S8(H78NBP*E#H7!_%"=UQ $
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M/,:XTE?P+,$EGD>_<U_T*,_"7BI"VZSSGM7OX<P_M@XP"A]K_2.\I8@Z;5'
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M/*4<8D";=K' "=>.55J AZ%'F=)6>$H; :!D!' P'CA4/#MOD6Z1\Q)^CY'
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M_]"1\  %72E0@G_%^% /ZHANA=?A%5+&M)TP.IRQ@%_H,_0C^H-Z9'<\/"9
M2;WO*,H+I9-P$& $F!##@G'&N/ _B@<&03FBW+0[$&A.BREUF S_P_B@1NZ+
M<.#THXQA+.4/*I*&XD1P$2X&44YPT;:??*:9$AB0.J,$J2\,!^.BO.2HR^%0
MNH]F$F!6+;Q'P6G_=YB)J"_3;S ,S@;78;AA;OH"9P@A5405PPG(X9X@9OHF
MG%Z6HQ[NE*-H&6W6K@L(!N. D"AJH[0YS02@.'!JN9;?4/B]=M% R:+H8&S
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M[W5.C@Y-0[YXCWSSG78;0RX5@) LPR/4%QEC3'$H,9RT4_GR>>.1):5O,5M
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MQP(E+$.OWVEJ5"5T,+(H?SR@I"A]2WU%.^A3G"2$'N7+/5'VS+Y@4!!\E">
M!86'H*)<BYR5(IX*@0G]P,P!!@9%@V*6XP(_,.8H,O@\;Z>>O-W#LJ $!UB@
M!&4IX(M#AD&#]YAM$M#2^3A:V%=DB,/=/&B/' P,)M$3^)H(CE(_<)AQ!E!B
MU$VY](WDOQEJ%90@"XPWLD3?4R\<;&0 )4]?$2@ +"*CS#2&SGW>-J-A/<*Q
MEH./T\DX,I[,.N"8(-_PEX")3LTFTHJ<9K<.54X\!@0]0QT!)!1T!R!%AHEQ
M1,;"+4B;T:U96=<Y%,@2#@3@#?ZAC] =@'3T$N..0] ** %<P0^ $G@4/:0
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M_1C>,YQQRX)"@1+XGKHC!P+IC .O_,\X8U_1]XPS]D8'$,H7#?5RGHZ6OZ
M$6./'" /^)S8#7@ &<%>X7LB'^'Q#D6@1&NQ=5BB,B/@?X($R((R00@<4+1;
M(7H;><%?(K"$OM Y5H](4"+C#)+#^<21UD),%"@*#490OJ,<NL.I%_= (2C_
M'&94)!TFQ, 1I<#!TPX$6NR3%4J4"PR TD(Q@=ZUR!*E+P.@!:LP-H)$Q *&
M:12EK4<H&9Z-XT,J&,^F[P!7,#?&FF=I*\W0,<H*3Y9H%XRK*7)-Q6M=#XXO
M#E6X&TXS?=\***&_>)9V!T&@ZH$2^A(!0N!1DBA>^(<H]C.?^4SO,,)3<E(Q
MF@!*E,3A. I2#(PG?8)R)JU*LR4X93AD<C(QJA+T+%C+ R4H0/I;H$11.G@,
M98E#B8$!#&GK5"TD'6^[J <R0F1=XZ]=V'@>BI39,O%QUK&82%!2Q*.0(H#A
MMHX81 P*,D!=2<=$\:*$=7A6O?K4DPL^@\\80Z*P]+?RP!D7^(S"LP$6*'F,
M?'A:+_=F_.%GE#_Z#=F"YZDW!HJT!%*3Y(S4ZZMF^UBIFTIS0[_A4./,*UJ*
MK,%OZ+M600EI%-P3_4=? -((!LA9A#\Q>%R;E[;3B 06Z#?X#H<'64;G2<=J
M#0FRCWR36D%;LEM:MD(:<^Y#WRC809NT88"<88TW>K&>/$PV94$),B!0$LX8
M*S4:NZN91&R*#H9LE6@;XPH(1'<0%*.OL!L\6UO8,SXXQP+<>: DZTSR.?*.
M3. /,.."K##N\!GO 5::)98CW&CFN]ZXP#>,N]:Z D@)>B#?DE?:I$7*VJ(]
M=.K#YZAM #ZN4SO@6^PVFYAH=IT +3P,P./Z>J=J%VT.$/8IXX+>(E.$<9$S
M3/_1!@4QX?%0/K/W#^L@4*) 1Q$HT?J(5G@?_D6.<*C1L\PF:0<Q^@N;"IC@
MV8QUWJ'11210 DC#]^ ^2@_3&DKTHM8*8O< B?BH%Z3;Y.9ESV3')^]S/1O?
M QE@G)GM8_QY+H$_Y)59:^1#!RIFQR(/E&@M#?<&E-#OZ'OJ# \#,NA3!7:0
M=W06_9L'2C:G9\L5 >Q6Z*B#$E$SSB\-9[I(@X.@X\AI5@%!T9[*S1QLV,A8
MRSB#(''H431,*Z,TE0*EO%0<'68C8,+L@80A*!%S*7(#(VM;1"U\)]I,))=!
MU_J"O/HU.^B:XF0:3GG#* 0,CJ;C<6[(%V0Z+YOK7(\4R1%PD^-%1 5EAJ,*
M8-%)UHTHCP\D5!@9^H\H*P8>9P8!5;1(9[TT B4H">J#TJ4_$&R4&,:#/'/
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M7>@N74@]-8NH,TL48("7L1/*1*C'__7:1;N1#^Z%?B!@1DJ*TIKA!^7-:W.
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MA#Q=D==_6>)WR E&2CGY&%^<*^1-&S+0KF;Z(@^4T!: ,WR*<T)@1.N/"(S
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M06,<"0G8Z!/V*BF!>)CJ!'R8;VT*  (,0!M%)3-9.*"AW=0DA-I]B\U?0TH
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M CR84Q\IX2.^^9N_^5D'.^_",XR$2A#Q!_[RRRZO5]?XN=]<NK;NXS/MT\_
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M_!-],!I2-K01$02]]FZU3QU]7V99/[%KSWWOI$1[@0/$C*R_\1N_\1G< JD
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MRZ;)6, W4B$#!Y@!UGR-J9;(55,U3,&DTV1LF@?;!M(Z\V"O'5NDSO_ZC[T
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MIX7\@C4G0+%]?UQX^ZAV-/\6B+'0%\#7AK8T1K2 $ %"H/@(I*3^,VQ/?F0
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M[F04@9M&D610Z;S@3M; (8=^M+V7OC>3$?;O_H I>;*O\41OGS5ELZV ]9<
M3A=:M&N$F%Z0)YMRWRV;ZOGC0OM+A$1A(^04F9-H8"?DR=[&-27OB93H-[\U
M(LUNQ N !"!%0O6=45:CZX#IZ*-G61[-*!\IG<8M+B!$?(]U8A(.[$72H<7W
M;W&B^Q8IF4]TOP5L';6=%2EI@X(CI*32"$-3D\4B]VHV C!MNVS@=-ZZ]1;Y
M[L4%LE0?_H><]2/==\$LL(0VZ]O 9/?C)R1 K>=@_^T2R6])S+8>CJY+W*[T
M\P@IF673-/5F4Y ' M%4N*9OZ<=Y2^!/F91LU;L1]Y&4[.V^]0^O-'VK<VHD
MMT]2\D)EI=!E[ 2^=KS"V@LRAN4I2+NJ"/;M.+-US][?>_[\/B-5!TY"'61<
MU$'F8MS=@\(*U!2?H8S3KT92 E3X/J.1Q6FO<9DI]Q8T!3"!:MX!ZA9"4E]2
M6-E/\ZH!1PY?'8S6  8 &F?)439UZ=*SW@,I 6Q6I&1VU &T<6V//M!^_>\O
M1XGX:DLC/%OK.(X2DKE][L5Q *1TBB,%TCA0 91>FWJB/8 IAW2)3$1*_.9S
M(R4KX.AO(%7VE"P%6,"D'6SR'T8CK"N9#U%</>M(?<:B#AV QO;(2!\)D *T
MJ4:""=\%7+00UFN?21+04=-$^1J;,P#PYGH#<K,\5Z3DR)2M;$S[$3E97(%.
MD@1(U&?T2;\!>/>0$E-27F+ZUGBZ-Q_&5_,5^J_18&UI47U@<&N+Y'O7\;6&
MA"\%^A%C&7Q^Q^B3-@//I@\&QBYMP?[H\IJD9 _ \W%DQN]*V+%-I(2^7T-*
MVAJ8? %=]BZNNE\+P^E?,6[>Y?*6]JU*NU>Q>7;.Q_.+GB_&\\EB(YV7).,?
MQGC+%[%_QQ[07QC!EOWB5$<(2-3N9>97?F O-OE<'0+ L$ [A1JIC93H1S:T
M.J=D2\[J^-*DA$\<20F,**9*-.I'_?52I.0EUY3P(?3C)"6O5"Z!.$Z#H^G
M0L; 2#@9V8,6B1NAL!9CZS3T6TO9CK;F%*01"@J/E C2#%8V40;$%IJ-V(S.
MKNE;%'LD)<!&4\ $?N\WI00P: 'K/26 QM$A=QP_X"U0>SXP;BI3VQ(#[?K\
MR#QG_0WL"AJ72,DU)RD?(25 FM&JHZ2D>PEN@ " H!\$+<Z%/G7B=XMB$<EY
M9[>YCD<"[U@X<<Y#,(H@MHF#MC1*0M_H-%FL#DP<RTN2DB-D*U)"#XSZO#0I
M&>LVC@;,Q$2]!#FC7DYTMC5P6V"/FQO(6F9OCP2&@KR (F (BD"HJ6QLG+V9
MKLDG\!MLQ+-=Y*F_Z"A@)GF!A'O-!\U;VX[]L=+Y2PF 1I::/PT@J*?15 D8
M?L*T0C8"2!@MOH64K Y/?-1"]_P<0F?D2[P =OA4/EH?-M53OP.F\]J2:_KM
M4LG.R9[? HST)_MFHWR/]]H![BT Q6N0DBU 7/'9BI2P3_I.UXZ2$FT1?XWR
M 7"2F&R\'3(C.>0A'M^RP^*1-O,Y_&W9>_HN)JJ#?C7:T4&'%M\#L^-HN%C-
M_OD(]3>:SY_JD_$(@:,GB!])JC1=WLB=:=+ZW>P),8GM\)E-'V.O8LJ1<TK<
MF^X@4'[S$J2$'T)*3,M&^HR*PFAB>]-TW1\I&0_*O53RQ?KD+;8$+H%YDI)7
M+I?8>UL#<S2""6=.F0'Y#BR44:3P90X>L;M&64X@W;T!*T"[[>!D#@!Z1@I$
MRH0!SCU_;-\6*6'LB$TG,S/4#G:34?W:UT\(O;4M?M>\5B 8T 52VPZ7DU./
M1FC&49(C?;@B)=J@3P1@(-EGJSG[6_4MD%TB)5LC)5MK2BJ13,&6+!BV^W&Z
M$1,C%9RGH,+QJ_LJ>%T#7&I7NX !PJ:8</QS-J^U19S<O WPZEF<$=D]FI3L
M$9(]4D('/+\-! !<F3]]_\BDP1XI47+J0"I2T-1+P82] 6!LVB@*W6GA^+T+
MCP/([ [@)&O/ $3X+QE<?P4S@51 I6<=<,:'D"=2;U,,?H:^(_SDV=:V\[2^
MO6STBJRT]H9<W(^/X*/X4\&/GQ#\])4$0".ZUI3H3SIU9"W$D<,3'T%*\K6
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MGT;6KW%F1GTVVD?3C5Z*E"2C:TG)D=VW5J1T;!?YLXW6[45V(M?^9^]LE!T
M==H),Z@/?<V69OE'0-D;NV.K?N\^[E?"23N:!>$U $LGQ"JQ@,V[]UPB5>*=
MNK,_]=8G9%/LID?\&?Q!9_F?T?Y=])3LZ"F=UH_T5'WA"IB$+Q$GV#5?(S;1
M4[:OG_AP=J\-8J2I7:8WDPM?5Y_E?SQS/!QTBY30M4>0$NV",<16,M5?K2-3
M9\_SW/1(7XQX#_XPFX0]:DOK.,>%[I&2""Y_WL@1>;\&*:%;;#120E8G*7F!
M<B03FW $/@HB8\X@Q_GX%(4Q<:3 G2 #I)H"!4PR6@I'@=V' 3,DCL%G0+^
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M3;9%[_5)Z\L:"04(Z:I,G=$AOY,LD57F:]V/KK4M.]\UGKW1@E%^QS0'4TD
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3 ));-<?<UP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245591104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 19, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OPTION CARE HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">05-0489664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 Lakeside Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300N,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bannockburn,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">940-2443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OPCH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,816,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001014739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334690272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 219,513<span></span>
</td>
<td class="nump">$ 343,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">573,650<span></span>
</td>
<td class="nump">377,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">241,948<span></span>
</td>
<td class="nump">274,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">94,603<span></span>
</td>
<td class="nump">98,744<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,129,714<span></span>
</td>
<td class="nump">1,094,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NONCURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">120,969<span></span>
</td>
<td class="nump">120,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">87,789<span></span>
</td>
<td class="nump">84,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists', window );">Intangible assets, net</a></td>
<td class="nump">19,317<span></span>
</td>
<td class="nump">20,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_FiniteLivedCustomerListsNet', window );">Referral sources, net</a></td>
<td class="nump">307,482<span></span>
</td>
<td class="nump">315,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,540,246<span></span>
</td>
<td class="nump">1,540,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">44,045<span></span>
</td>
<td class="nump">42,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">2,119,848<span></span>
</td>
<td class="nump">2,122,780<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">3,249,562<span></span>
</td>
<td class="nump">3,217,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">485,736<span></span>
</td>
<td class="nump">426,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">42,624<span></span>
</td>
<td class="nump">92,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">83,383<span></span>
</td>
<td class="nump">75,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">19,209<span></span>
</td>
<td class="nump">18,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">636,952<span></span>
</td>
<td class="nump">618,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NONCURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount, deferred financing costs and current portion</a></td>
<td class="nump">1,056,282<span></span>
</td>
<td class="nump">1,056,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">89,207<span></span>
</td>
<td class="nump">85,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">37,884<span></span>
</td>
<td class="nump">34,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">1,183,462<span></span>
</td>
<td class="nump">1,177,054<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,820,414<span></span>
</td>
<td class="nump">1,795,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March&#160;31, 2024 and December&#160;31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0000 par value: 250,000,000 shares authorized, 183,397,817 shares issued and 173,816,056 shares outstanding as of March&#160;31, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December&#160;31, 2023</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock; 9,581,761 and 8,330,022 shares outstanding, at cost, as of March&#160;31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="num">(295,396)<span></span>
</td>
<td class="num">(255,107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Paid-in capital</a></td>
<td class="nump">1,205,693<span></span>
</td>
<td class="nump">1,204,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">502,304<span></span>
</td>
<td class="nump">457,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">16,529<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,429,148<span></span>
</td>
<td class="nump">1,421,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 3,249,562<span></span>
</td>
<td class="nump">$ 3,217,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_FiniteLivedCustomerListsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Customer Lists, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_FiniteLivedCustomerListsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Net, Excluding Customer Lists</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178341398480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">183,397,817<span></span>
</td>
<td class="nump">182,905,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">173,816,056<span></span>
</td>
<td class="nump">174,575,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">9,581,761<span></span>
</td>
<td class="nump">8,330,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334848736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">NET REVENUE</a></td>
<td class="nump">$ 1,146,052<span></span>
</td>
<td class="nump">$ 1,015,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">907,552<span></span>
</td>
<td class="nump">786,843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">238,500<span></span>
</td>
<td class="nump">229,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING COSTS AND EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">154,742<span></span>
</td>
<td class="nump">147,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">14,728<span></span>
</td>
<td class="nump">14,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">169,470<span></span>
</td>
<td class="nump">162,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME</a></td>
<td class="nump">69,030<span></span>
</td>
<td class="nump">66,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(13,202)<span></span>
</td>
<td class="num">(13,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Equity in earnings of joint ventures</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Total other expense</a></td>
<td class="num">(12,075)<span></span>
</td>
<td class="num">(12,396)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME BEFORE INCOME TAXES</a></td>
<td class="nump">56,955<span></span>
</td>
<td class="nump">54,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE</a></td>
<td class="nump">12,164<span></span>
</td>
<td class="nump">15,021<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME</a></td>
<td class="nump">44,791<span></span>
</td>
<td class="nump">39,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in unrealized gain (loss) on cash flow hedges, net of income tax (expense) benefit of $(454) and $1,152, respectively</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="num">(3,443)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">OTHER COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="num">(3,443)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">NET COMPREHENSIVE INCOME</a></td>
<td class="nump">$ 46,342<span></span>
</td>
<td class="nump">$ 35,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS PER COMMON SHARE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">173,928<span></span>
</td>
<td class="nump">181,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">175,624<span></span>
</td>
<td class="nump">182,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenseDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178240571760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Income taxes on unrealized gains (losses) on cash flow hedges</a></td>
<td class="num">$ (454)<span></span>
</td>
<td class="nump">$ 1,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245729872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 44,791<span></span>
</td>
<td class="nump">$ 39,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash (used in) provided by operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization expense</a></td>
<td class="nump">15,305<span></span>
</td>
<td class="nump">15,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease costs</a></td>
<td class="nump">7,663<span></span>
</td>
<td class="nump">5,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes - net</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">8,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of joint ventures</a></td>
<td class="num">(1,125)<span></span>
</td>
<td class="num">(1,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based incentive compensation expense</a></td>
<td class="nump">9,605<span></span>
</td>
<td class="nump">5,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Capital distribution from equity method investments</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other adjustments</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable, net</a></td>
<td class="num">(195,992)<span></span>
</td>
<td class="num">(17,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">32,056<span></span>
</td>
<td class="num">(25,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,878<span></span>
</td>
<td class="nump">9,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">59,223<span></span>
</td>
<td class="nump">70,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(49,884)<span></span>
</td>
<td class="num">(28,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,811<span></span>
</td>
<td class="nump">14,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liabilities</a></td>
<td class="num">(6,651)<span></span>
</td>
<td class="num">(5,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Other noncurrent assets and liabilities</a></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(5,313)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(68,784)<span></span>
</td>
<td class="nump">89,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(5,820)<span></span>
</td>
<td class="num">(5,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,820)<span></span>
</td>
<td class="num">(5,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding', window );">Exercise of stock options, vesting of restricted stock, and related tax withholdings</a></td>
<td class="num">(8,182)<span></span>
</td>
<td class="num">(1,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt principal</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="num">(40,050)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(49,732)<span></span>
</td>
<td class="num">(80,402)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(124,336)<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of the period</a></td>
<td class="nump">343,849<span></span>
</td>
<td class="nump">294,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - END OF PERIOD</a></td>
<td class="nump">219,513<span></span>
</td>
<td class="nump">297,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">12,173<span></span>
</td>
<td class="nump">11,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Cash paid for operating leases</a></td>
<td class="nump">$ 7,085<span></span>
</td>
<td class="nump">$ 6,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised, Restricted Stock Vested And Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334952576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,386,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (2,403)<span></span>
</td>
<td class="nump">$ 1,176,906<span></span>
</td>
<td class="nump">$ 190,423<span></span>
</td>
<td class="nump">$ 21,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings', window );">Exercise of stock options, vesting of restricted stock, and related tax withholdings</a></td>
<td class="num">(1,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based incentive compensation</a></td>
<td class="nump">5,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase of company stock</a></td>
<td class="num">(75,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">39,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(3,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2023</a></td>
<td class="nump">1,350,219<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(78,138)<span></span>
</td>
<td class="nump">1,180,992<span></span>
</td>
<td class="nump">229,631<span></span>
</td>
<td class="nump">17,716<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2023</a></td>
<td class="nump">1,421,672<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(255,107)<span></span>
</td>
<td class="nump">1,204,270<span></span>
</td>
<td class="nump">457,513<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings', window );">Exercise of stock options, vesting of restricted stock, and related tax withholdings</a></td>
<td class="num">(8,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based incentive compensation</a></td>
<td class="nump">9,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects', window );">Purchase of company stock, and related tax effects</a></td>
<td class="num">(40,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">44,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1,429,148<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (295,396)<span></span>
</td>
<td class="nump">$ 1,205,693<span></span>
</td>
<td class="nump">$ 502,304<span></span>
</td>
<td class="nump">$ 16,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Value, Including Related Tax Effects</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245498496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 93 full service pharmacies and 84 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#8217; homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company&#8217;s stock is listed on the Nasdaq Global Select Market as of March&#160;31, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company&#8217;s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company&#8217;s share of earnings from equity-method investments is included in the line entitled &#8220;Equity in earnings of joint ventures&#8221; in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company&#8217;s equity-method investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334438912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March&#160;31, 2024, cash equivalents consisted of money market funds.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $49.1&#160;million and $52.0&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March&#160;31, 2024 and December&#160;31, 2023, the balance of the investments was $21.3 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company&#8217;s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company&#8217;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#8217;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company&#8217;s proportionate share of earnings was $1.1 million and $1.4 million for the three months ended March&#160;31, 2024 and 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $0.8 million and $2.5 million, respectively. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#8217;s largest payer was approximately 14% for the three months ended March&#160;31, 2024 and 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, approximately 12% of the Company&#8217;s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 14%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12%, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company&#8217;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company&#8217;s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, approximately 66% and 72%, respectively, of the Company&#8217;s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239371664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text">REVENUE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the&#160;three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239338784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company recorded tax expense of $12.2&#160;million and $15.0&#160;million, respectively, which represents an effective tax rate of 21.4% and 27.7%, respectively. The variance in the Company&#8217;s effective tax rate of 21.4% for the three months ended March&#160;31, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the three months ended March&#160;31, 2024, the Company released $2.2&#160;million of state valuation allowance. The variance in the Company&#8217;s effective tax rate of 27.7% for the three months ended March&#160;31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to difference between federal and state tax rates, as well as various non-deductible expenses.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance of $4.2&#160;million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax expense of $12.2&#160;million and $15.0&#160;million for the three months ended March&#160;31, 2024 and March&#160;31, 2023, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.</span></div>The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (&#8220;Code&#8221;) Section 382 limitations. This may limit the Company&#8217;s ability to utilize its federal net operating losses<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239393408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March&#160;31, 2024 and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178240566624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company incurred operating lease expenses of $7.9 million and $7.0 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March&#160;31, 2024, the weighted-average remaining lease term was 7.0 years and the weighted-average discount rate was 6.36%.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March&#160;31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company incurred operating lease expenses of $7.9 million and $7.0 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March&#160;31, 2024, the weighted-average remaining lease term was 7.0 years and the weighted-average discount rate was 6.36%.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March&#160;31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245118736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,969&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245392592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the carrying amount of goodwill for the three months ended March&#160;31, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,423)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $8.6 million and $8.5 million for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178338426368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">INDEBTEDNESS</a></td>
<td class="text">INDEBTEDNESS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March&#160;31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,086,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,636)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the First Lien Term Loan was 8.19% and 8.21% as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 8.20% and 7.28% for the three months ended March&#160;31, 2024 and 2023, respectively. The interest rate on the Senior Notes was 4.375% as of March&#160;31, 2024 and December&#160;31, 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,086,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company&#8217;s debt obligations as of March&#160;31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of March&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,044,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (&#8220;First Lien Credit Agreement Amendment&#8221;). The First Lien Credit Agreement Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $400.0&#160;million (the &#8220;Revolver Facility&#8221;), pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. As of March&#160;31, 2024, the Company had $5.3 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $394.7 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239339568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE INSTRUMENTS</a></td>
<td class="text">DERIVATIVE INSTRUMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company&#8217;s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company&#8217;s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company&#8217;s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300&#160;million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan&#8217;s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company&#8217;s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive income (loss). The following table presents the pre-tax gain (loss) from derivative instruments recognized in other comprehensive income (loss) in the Company&#8217;s unaudited condensed consolidated statements of comprehensive income (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,595)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company&#8217;s unaudited condensed consolidated statements of comprehensive income related to the Company&#8217;s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245904608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASURMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at March&#160;31, 2024 and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239326512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company&#8217;s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239403104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED INCENTIVE COMPENSATION</a></td>
<td class="text">STOCK-BASED INCENTIVE COMPENSATION<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), approved at the annual meeting by the BioScrip, Inc. (&#8220;BioScrip&#8221;) stockholders on May 3, 2018 and amended and restated on May 19, 2021, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors, resulting in a total of 9,101,734 shares of common stock authorized for issuance. The 2018 Plan is administered by the Company&#8217;s Compensation Committee, a standing committee of the Company&#8217;s Board of Directors. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March&#160;31, 2024 and 2023. During the three months ended March&#160;31, 2024 and 2023, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $9.6 million and $6.0 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239341152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the three months ended March&#160;31, 2024 and 2023, warrant holders did not elect to exercise any warrants to purchase shares of common stock. As of March 31, 2024 and December&#160;31, 2023, the remaining warrant holders are entitled to purchase 51,838 shares of common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; During the three months ended March&#160;31, 2024 and 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of March 31, 2024 and December&#160;31, 2023, the remaining warrant holders are entitled to purchase 13,365 and 13,888 shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company purchased 1,251,739 and 2,475,166 shares of common stock for an average share price of $31.96 and $30.30, totaling $40.0 million and $75.0 million, respectively. All repurchased shares became treasury stock. As of March&#160;31, 2024, the Company is authorized to repurchase up to a remaining $210.0 million of common stock of the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245616096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED-PARTY TRANSACTIONS</a></td>
<td class="text">RELATED-PARTY TRANSACTIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.5 million and $1.3 million for the three months ended March&#160;31, 2024 and 2023, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $0.8 million and $2.5 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due from its joint ventures of $1.0 million as of March&#160;31, 2024. The Company had amounts due to its joint ventures of $0.5 million and due from its joint ventures of $0.1 million as of December&#160;31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245350224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 44,791<span></span>
</td>
<td class="nump">$ 39,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178335477296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334690608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company&#8217;s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March&#160;31, 2024, cash equivalents consisted of money market funds.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March&#160;31, 2024 and December&#160;31, 2023, the balance of the investments was $21.3 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company&#8217;s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company&#8217;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#8217;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company&#8217;s proportionate share of earnings was $1.1 million and $1.4 million for the three months ended March&#160;31, 2024 and 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $0.8 million and $2.5 million, respectively. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock', window );">Concentrations of Business Risk</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#8217;s largest payer was approximately 14% for the three months ended March&#160;31, 2024 and 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, approximately 12% of the Company&#8217;s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 14%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12%, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company&#8217;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company&#8217;s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, approximately 66% and 72%, respectively, of the Company&#8217;s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#8217;s financial condition or operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at March&#160;31, 2024 and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Business Risk, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239364944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue Earned by Category of Payer</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the&#160;three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,015,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178338426368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239342720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities, Operating</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178240428944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,419&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,969&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239326512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,423)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239355456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March&#160;31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,086,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,636)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,282&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Long-term Debt Maturities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,086,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Values of Debt Obligations</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company&#8217;s debt obligations as of March&#160;31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of March&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,044,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239429168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Amount and Location of Derivatives in the Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company&#8217;s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)</a></td>
<td class="text">The following table presents the pre-tax gain (loss) from derivative instruments recognized in other comprehensive income (loss) in the Company&#8217;s unaudited condensed consolidated statements of comprehensive income (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,595)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company&#8217;s unaudited condensed consolidated statements of comprehensive income related to the Company&#8217;s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334434480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>suite </div>
<div>pharmacy </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_NumberOfServiceLocations', window );">Number of service locations | pharmacy</a></td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_NumberOfInfusionSites', window );">Number of infusion sites | suite</a></td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bios_LegacyHealthSystemsMember', window );">Legacy Health Systems</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_NumberOfInfusionSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Infusion Sites</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_NumberOfInfusionSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_NumberOfServiceLocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Service Locations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_NumberOfServiceLocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bios_LegacyHealthSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bios_LegacyHealthSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239135552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Rebate receivable</a></td>
<td class="nump">$ 49,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in equity-method investees</a></td>
<td class="nump">21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Proportionate share of earnings in equity-method investees</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions received from the investees</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions received from the investees</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Company's Largest Payer | Largest Payer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration &#8203;risk</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration &#8203;risk</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bios_AccountsReceivableBenchmarkMember', window );">Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration &#8203;risk</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember', window );">Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration &#8203;risk</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_LargestPayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_LargestPayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bios_GovernmentHealthcareProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bios_GovernmentHealthcareProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bios_AccountsReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bios_AccountsReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=bios_FourVendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=bios_FourVendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178335329008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 1,146,052<span></span>
</td>
<td class="nump">$ 1,015,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=bios_CommercialCustomerMember', window );">Commercial payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">988,043<span></span>
</td>
<td class="nump">873,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=bios_GovernmentCustomerMember', window );">Government payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">138,310<span></span>
</td>
<td class="nump">122,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=bios_PatientCustomerMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 19,699<span></span>
</td>
<td class="nump">$ 19,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_CommercialCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_CommercialCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_GovernmentCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_GovernmentCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bios_PatientCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bios_PatientCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245891584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 12,164<span></span>
</td>
<td class="nump">$ 15,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">21.40%<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Release of valuation allowance</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245800800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">880,815<span></span>
</td>
<td class="nump">871,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_RestrictedStockAwardMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">279,144<span></span>
</td>
<td class="nump">342,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_PerformanceStockUnitMember', window );">Performance stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">149,561<span></span>
</td>
<td class="nump">90,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_RestrictedStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_RestrictedStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bios_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178355752224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 44,791<span></span>
</td>
<td class="nump">$ 39,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">173,928<span></span>
</td>
<td class="nump">181,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1,696<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">175,624<span></span>
</td>
<td class="nump">182,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share, basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share, diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334973568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, operating leases</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, operating leases</a></td>
<td class="nump">6.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in operating lease right-of-use asset and lease liabilities</a></td>
<td class="nump">$ 11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245862032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 19,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">25,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">22,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">18,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">12,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">42,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">140,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(31,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 108,416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178335146688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 245,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(124,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123,871)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">120,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation expense</a></td>
<td class="nump">6,696<span></span>
</td>
<td class="nump">$ 6,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Depreciation expense in cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation expense</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Depreciation expense in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation expense</a></td>
<td class="nump">6,120<span></span>
</td>
<td class="nump">$ 6,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_InfusionPumpsMember', window );">Infusion pumps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">36,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_EquipmentFurnitureAndOtherMember', window );">Equipment, furniture and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">100,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software, purchased and internally developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">50,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Assets under development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 33,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_InfusionPumpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_InfusionPumpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_EquipmentFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bios_EquipmentFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178335033728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">$ 554,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 554,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(227,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(219,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">326,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember', window );">Referral sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">514,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(206,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(199,084)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks/names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">39,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">(20,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,698)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total gross intangible assets</a></td>
<td class="nump">985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Total accumulated amortization</a></td>
<td class="num">$ (381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (341)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178335285392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,086,500<span></span>
</td>
<td class="nump">$ 1,088,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(6,636)<span></span>
</td>
<td class="num">(6,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(17,582)<span></span>
</td>
<td class="num">(18,376)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Balance</a></td>
<td class="nump">1,062,282<span></span>
</td>
<td class="nump">1,062,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">1,056,282<span></span>
</td>
<td class="nump">1,056,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">586,500<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="num">(6,636)<span></span>
</td>
<td class="num">(6,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(9,209)<span></span>
</td>
<td class="num">(9,678)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Balance</a></td>
<td class="nump">570,655<span></span>
</td>
<td class="nump">571,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(8,373)<span></span>
</td>
<td class="num">(8,698)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Balance</a></td>
<td class="nump">491,627<span></span>
</td>
<td class="nump">491,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Revolver Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_SecondLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_SecondLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178239663040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS - Additional Information (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 07, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member', window );">Credit Agreements Amendment | Revolver Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Undrawn letters of credit issued and outstanding</a></td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bios_FirstLienCreditAgreementSecondAmendmentMember', window );">Second Lien Credit Agreement | Revolver Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Available borrowing capacity</a></td>
<td class="nump">$ 394,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember', window );">First Lien Term Loan | Credit Agreements Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate on term loans at end of period</a></td>
<td class="nump">8.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate paid on term loans during period</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">7.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember', window );">Second Lien Term Loan | Credit Agreements Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate on term loans at end of period</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate paid on term loans during period</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_CreditAgreementsEnteredInto2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_FirstLienCreditAgreementSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_FirstLienCreditAgreementSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_SeniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LienCategoryAxis=us-gaap_JuniorLienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245742400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Long Term Debt Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 1,086,500<span></span>
</td>
<td class="nump">$ 1,088,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178339512176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">$ 1,062,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Markets for Identical Item (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">1,044,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">491,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">570,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Markets for Identical Item (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">456,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">588,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total debt instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178238164032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS - Additional Information (Details) - Interest rate cap designated as cash flow hedge - First Lien Term Loan - Designated as Hedging Instrument - Senior Notes<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative, term of contract</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bios_FirstLienTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334784672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total derivative assets</a></td>
<td class="nump">$ 21,934<span></span>
</td>
<td class="nump">$ 19,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest rate cap designated as cash flow hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total derivative assets</a></td>
<td class="nump">10,421<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other noncurrent assets | Interest rate cap designated as cash flow hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total derivative assets</a></td>
<td class="nump">$ 11,513<span></span>
</td>
<td class="nump">$ 10,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178245637216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - Interest rate cap designated as cash flow hedge - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Interest rate cap designated as cash flow hedge</a></td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="num">$ (4,595)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Interest rate cap designated as cash flow hedge</a></td>
<td class="nump">$ 2,980<span></span>
</td>
<td class="nump">$ 2,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480627/815-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178334829824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED INCENTIVE COMPENSATION (Details) - 2018 Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 03, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,101,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bios_HCIIncentiveUnitsMember', window );">HC I Incentive Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bios_A2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bios_A2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bios_HCIIncentiveUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bios_HCIIncentiveUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178341975072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares, acquired (in shares)</a></td>
<td class="nump">1,251,739<span></span>
</td>
<td class="nump">2,475,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share (in dollars per share)</a></td>
<td class="nump">$ 31.96<span></span>
</td>
<td class="nump">$ 30.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized to be repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2017 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">51,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2015 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">13,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bios_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bios_A2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bios_A2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bios_A2015WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bios_A2015WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140178335143808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED-PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Management fee income</a></td>
<td class="nump">$ 1,146,052<span></span>
</td>
<td class="nump">$ 1,015,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions received from the investees</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Management fee income</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions received from the investees</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from joint ventures</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Due to joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(YY:'QJO;[1<Y.>N$ZFUC//+N>"!4.8#>#^54F]OS \41_?=_P!02P,$%
M  @ +H"76-G$TPNX!P  ER   !@   !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6RM6FUOVS@2_BN$MUCL DXMDGI-$P.NG=T&ETURL7N'^\C(="Q4%KT4G33W
MZV\HO\@2*3HYY$MC2</1,T-RGF>H7KP(^:-<<J[0SU5>E)>]I5+K\\&@3)=\
MQ<K/8LT+>+(0<L447,JG0;F6G,VK0:M\0#PO'*Q85O2&%]6]>SF\$!N59P6_
MEZC<K%9,OG[EN7BY[.'>_L9#]K14^L9@>+%F3WS*U??UO82KP<'+/%OQHLQ$
M@21?7/9&^'Q,$SV@LOA7QE_*H]](A_(HQ ]]<3V_['D:$<]YJK0+!G^>^9CG
MN?8$./[>.>T=WJD''O_>>_^C"AZ">60E'XO\W]E<+2][<0_-^8)M<O4@7K[Q
M74"!]I>*O*S^12\[6Z^'TDVIQ&HW&!"LLF+[E_W<)>)H /8[!I#= /+6 70W
M@%:!;I%584V88L,+*5Z0U-;@3?^H<E.-AFBR0D_C5$EXFL$X-1S?W4ZN;J=7
M$P2_IG<WUY/1#"Z^CFY&M^,K-/UV=36;HC/T?3I!OWWZ'7U"68%F2[$I63$O
M+P8*,&A/@W3WOJ_;]Y&.]_W%Y&=$<1\1C_B6X6/W\ E/#\-I<_@ (C^$3P[A
MD\H?[0K_^\/#U>T,C:93B//<%L_6@6]WH'?9>;EF*;_LP38JN7SFO>&OO^#0
M^V*+[H.<-6*EAUBIR_MPS,HE@EE#J?[!_]YDSRSGA;+.XM956+G2I>!Y2' 2
M8,CY\W$\IAGU:>PG![,&4O^ U'<B':6IV  PJ!,I!Y2/.>^C@BL;T*VGX A!
M$-$P\%I 33,:16$0VX$&!Z"!$^AU\0P)%#+CUB0&QDN)CQ,_;F&SF$6^Y_EV
M;.$!6^C$=B_YFF5SQ']"R2]Y64V]4$LNH:Y(";@1*TMNG_[0@)3XH=>>?8M5
M'/D=N*,#[LB)>R84R]\ ,3)>CC%)(NRW0%KLO,0G06"'&1]@QL[*<7MW^X;B
M$7]D\?@@9XUPDT.XR8G5!,I!JM=J%>G:L08N5YV[,C&33KPD3%IS8S4+J6>?
M&NS5I.8YT=X!5J:RX@GE'#@>24WF9V)QMH&+:DE9F<LSX,11%+=!V\Q\''34
M/'S$Q/A$,5&L>,J@V.U6?6=V=XX:>4LHCMI 33-0=PGI %IS)G;2U/"!+[B4
ML$E+L9$I=^ D9M7U(C\F;: 6.QS0K@J(:\;#;LK[4XCY2Y;G5G#43&+@@RH)
MV^A.&S;AU32'W3QW5U7C0A2GJQTV"<SW/3]H8[68$=K%Q[CF.>PFNFU1?AM2
M"YUAG,0&[5D-"8GBKNU?,Q]V4]_L;C:ZV95E*T23N"CQDR T%J;-$$<>[2 /
M7),<CMXD/&^N1U^O;ZYGUU=V L%.LGPO@WR4MV;0-65B)T75NF[-7K6HLP8<
MFRLXUI*N/346.Q(>*]0FR)KHL)OI *3<<%#)8J6%$]MVFYKU5NM<O'*.'GG!
M%UG'ZC<I#6"1MBBQF"4D\#KD**F)C[B);P_>(?KRC#UF>:8Z-"NQL!NE<5OZ
M6<RBP,,=6Y?4)$C<)#C>H5P+625>+)!HD?D^@%<K?!LU@O1HP[>8Q5!Z.N ?
MM9-N:K3 ST7Q=*:X7*$Y?[32)#'I+_2\=@=SRJJ)N*9(XJ;(IMP^M3A,*@QI
MF 3MNFFSPS'U.GB(U(Q)_+>J[E.5DSBY]]V-^P=Y:\9=\R]Q\^]-8Q%5@DNO
MK7E65A6UKT^N0)/!SE]D!2M2O5M24:IM 4B;J]*:+9.,L0>$:&BU#L/CCKL9
M8\W:Q,W:;=%^V.>'<-\2A\G8,>S_MC2VF05^W"$X24WKQ-V\3O;3D!7 'QPI
M]K-C)YEM*8WBN,T3-C,?XNG 63,Q<3.QH3Q/;7R3;8V^R&+3A;,F8^(F8T-W
MGL)IZ2BA\/B&LK,:1I$7="P!6E,P=5/P%O()G-2D3^ ?SS=.+VR&41+0L$/G
MT)II*7:6TNGL;OR/;W<WDZN'Z:^_Q"!KOZ"K?WZ_GOW'6DZID[??6TX_RELS
M]IJFJ9NF[^5^GY9*I#^^H$_>9^!2#,)4HF>6;_@7A$D_\+P^W$;EDDFMI39J
M*63V7SZ'BB3V=\5&E="XSW7A8J4N4W\QF2ZW:/<GW549GO"4KQZY;#RBUF2;
M7-^6 TZ39EJ.#HA/G!"+U0I$2R,G7IV3<P0252>D*RFPT_HTB?HQCO:/L[+4
M>E2'CR,*3\(^L,6[<@=3$9-^X@7]($BL?OU^$,%3&G7[?4?N+>U^NW5UVS2S
M7VL;ZCX-F$F@O8U\W><_Z0<Q[D<AKJ*,^Y1"X@FQQ-A'3%5TW_^_5F ?@;\U
MKSZHY5953<UCA3,"52AI=V56PR# 1P3<S$ZM@*A; =VS;'Z6%2AEZPP*K!6E
M19H06&V)\=7":NB3J&L'U1J&NC7, U<,;D$#QF0!,V,O_J;X"& :/*/VFW8^
M+/2N%I?6*H6Z50ITB9O5)F>*'YI#:'8E7^K/L\]\)UZLT"VGZ6% VE+ 9N8G
M7>T5K64+=<N6+;=6^V,I\CF7Y9ZY])&TO2.DIBS!/DFP<1YE-\1AU'%@2FL5
M0T^HF.H\ZJAA0:/;">HF8&L8B?FIS7IF936TG5D-CKX:ZT_V4#2>LJ($];V
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M#*$GI$('P/TIYVHUT5U'V67Z?P!02P,$%     @ +H"76)#8/HH:!@  ]!<
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M8B$ SY=1Q/<+\8+BH+_W'U!+ P04    "  N@)=8[V7,N)X"  #_!0  &
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M?SM-R:%1F@3:7PFA]X$YH/'\X#=02P,$%     @ +H"76*L!I\#5!P  8B
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MV;;4#V+_%=M\>H8O%:6R7]@WL?' @72KM*A:,"FH"M[\V6M;AQ- XK\!"%M
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MC=+VR*)NG]B,8=UPPK9&C5MY0L ,,"@)EY(HK?-+C4O,ES$L41(ZX7VSBEJ
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M@6/T--H+HK0B9,\JJ LI GH9Z%#^;-<K]F3CX1Q]1AYPL9PT312\LW9-V*3
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MU4#9#;A>26F&@14POO[6_P%02P,$%     @ +H"76-G6R=1_ P  1P@  !D
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M<R]S:&5E=#$Y+GAM;*566V_;-A3^*X0*],FP'2=I@]0QD%O;/"0-FFQ[&/9
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MM2D_'(4*=3;\H9>T1WDXGZ!O#5(&29DXX*=RQ+F;RZ%G"9B /C!-T6CD.$.
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M917H?".E:03KH/WD&?\/4$L#!!0    ( "Z EUC"_OJM! 0  %(*   9
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M%41-+EQ26 VZ10JG/"'Q1KM'[\?C2WXY/'I*!$M(^S5GZ:Z)N1,R9_%*(),
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M7]AULKX#::.TJ#IE8E 5O/VSQ\X/;U$(.X70\FX/LBROF&;SJ10[D$::T,S
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M=P+8-H %WFVBP/**.SZ;&+T!X[T)S0NAU!!-Y(3R35DX0Z>"XMSL]OI\<;V
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M!3XIT'F6,?4ZP%1N>Y5&97_PS)<K8P_J_>Z:+7&"YNOZ2=&N7J+,>89"<RE
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M1VE0 PEZ/@GO$:MMK]EJUB#L-+PX:-%;#<_? 5Z4D+1JM+RH'=3L=1QX03N
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M5M%\6VA--NL.QS76_7O*>O2DS=MJV](^)F[_+PFN^Q%L[D<\IFIGME#29*%
MA(9HKB*) R5NI<LP4SOYQL.&X,\AC .E]7FV6B7WNJL.&=<R/V49?[AMH\\<
MTKZ?H54TWQ9:<SKJO@B[MD6-K?8W5M%\6VA--NO^!ALK_OU$76(U!38<;HFZ
MU>I@>Z\VQ[5OWMV-8R-53"_SXS>!\OVX.!>IGE9'?-/\8&OK^8E[Y!4'=35,
M<6YXKKKHF J4P$)!JHQ4D<6+H[CB1K)5?CAUPZ2JZ//+"$@(7!NH]PO&Y,.-
M'J Z$)W\"U!+ P04    "  N@)=8[2$!]D@#  !S#0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6RU5UUOFS 4_2L6JZ9.V@J&?$"7(+5IME5:JZA=
MNX=I#VZX(:A@9[:3-/]^MB$TI)2M*GT)V-QSN.?Z$%\/UHS?BSF 1 ]92L70
MFDNY.+9M,9U#1L016P!53V:,9T2J(8]ML>! (@/*4MMUG)Z=D81:X<#,37@X
M8$N9)A0F'(EEEA&^.864K8<6MK835TD\EWK"#@<+$L,UR)O%A*N17;)$2094
M)(PB#K.A=8*/1]C3 !-QF\!:[-PC+>6.L7L].(^&EJ,S@A2F4E,0=5G!"-)4
M,ZD\_A2D5OE.#=R]W[)_,>*5F#LB8,32GTDDYT/+MU $,[),Y15;?X-"4%?S
M35DJS"]:%[&.A:9+(5E6@%4&64+S*WDH"K$#4#SU +< N/N SC, KP"8RMEY
M9D;6&9$D''"V1EQ'*S9]8VICT$I-0O4R7DNNGB8*)\.K\>WX\F:,/J%+Y9DK
M6 %= AH33B%"=QLT(A)BQC>(S="$;("CPS.0)$G%!X6YN3Y#AP<?T %**/HQ
M9TM!:"0&ME29:7Y[6F1QFF?A/I.%ARX8E7.!QC2"J(JWE:)2EKN5=>HV$EX0
M?H0\_!&YCMNIR6?T_W"O(1VOK+)G^+QG^,X20>*80TR,=U4MMY7^]5V%HG,)
MF?A=5[><MU//J[_Q8[$@4QA:ZB,6P%=@A>_?X9[SN4YT2V25$G3*$G2:V$-M
M+YZ+KM.9@WL&K/]Z5B'&G9[3=0?V:E="39R#NW['+^,JV77+[+J-V8U8E@&?
M)B1%"^WR6@\W4KQT+5HBJZCME6I[;V3'7ILE:(FL4H)^68+^:^R8@[L[-@M\
MW^EX>VY\&N;WO0#C>C/Z96Y^8VY?V0HX57NE;#!C(\5+5Z(ELHK:H%0;O)$9
M@S9+T!)9I038>=R%G=?8L4#O&@U[OH>=/3_6Q;ENWP_J#8EWN@3<F-]$+8[R
M8_W6W@A]Z3JTQ585ZCX*==_(C05Q6V5HB:U:AL=^!3?V O_TH_=T&PYZ0;!O
MQ[HP_&2OMG?:5[4+QZ:K%VC*EE3F+5\Y6YX<3DR_O#=_JD\4IBU^I,F/(ZJA
MBQ,J4 HS1>D<]=4GPO,./Q](MC!-\AV3JN4VMW-U*@*N ]3S&6-R.] O*,]9
MX5]02P,$%     @ +H"76$\X");N @  S@D  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&ULM5;;;M- $/V5E:E0D2"^Y5H22VT:1"4*5=,6),3#UA['
MIO9NV%TGX>^972<F25VK1>'%WLO,F7/V-C-<<O$@$P!%5GG&Y,A*E)J?V+8,
M$\BI;/$Y,)R)N<BIPJZ8V7(N@$;&*<]LSW&Z=DY39@5#,W8E@B$O5)8RN!)$
M%GE.Q>\SR/AR9+G69N ZG25*#]C!<$YG, 5U.[\2V+,KE"C-@<F4,R(@'EFG
M[LEXH.V-P5T*2[G5)EK)/></NG,1C2Q'$X(,0J41*/X6,(8LTT!(X]<:TZI"
M:L?M]@;]@]&.6NZIA#'/OJ:12D96WR(1Q+3(U#5??H2UGH[&"WDFS9<L2]LV
M&H>%5#Q?.R.#/&7EGZ[6Z[#E@#CU#M[:P=MW:#_AX*\=?".T9&9DG5-%@Z'@
M2R*T-:+IAED;XXUJ4J9W<:H$SJ;HIX*+S^,OEQ-R<_IM,B7'YZ!HFLDWY!VY
MG9Z3XZ,WY(BDC-PDO)"417)H*PRJ7>UP'>"L#. ]$< GEYRI1)()BR#:];>1
M;,78VS ^\QH!+ZEH$=]]2SS':]?P&3_?W6^@XU<+Z!L\_ZD%9"'/@=S0%9FL
M*.X0-<?S^R>T(Q<*<OFC;M%*T'8]J+ZZ)W).0QA9>#<EB 58P>M7;M=Y7Z?X
M0& [^MN5_G83^D:_0OVPPK=%0IW<$J-K,/3#L@A<S^WB]BVV==18=1S/K:QV
M"'8J@IU&@I,X!O-6&(Z"JEJ")8;K;,5V6IZ[S[#>K->KI]BM*'8;*4X5LB(_
M"Y'**#7/6QW%1HR7'ID#@>W([55R>__CRO0.J?] 8#OZ^Y7^?N-V7V,2P\Q#
M>$P6-"M*]33#A$I96'LZ^X\NAH=I>N]L-@;]1TF#2M*@4=+=\W0,'NEH/];1
M&.FE.NRMU)B#F)F*09*0%TR5.:<:K8J24Y.+]\;/L%@I:XN_,&6E@QEEEC))
M,H@1TFGU\)$09?50=A2?FP1\SQ6F<]-,L. "H0UP/N9<;3HZ0%7"!7\ 4$L#
M!!0    ( "Z EU@&FJ2M, ,  / ,   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;,U776O;,!3]*\*#T<)6?^:K2P)IFJV%M82$;0]C#ZI]DXC:DB?)
M2??O)\F.&Z>.6<&#OB26K'MTSM&QN1[N&'\4&P")GI*8BI&UD3*]M&T1;B#!
MXH*E0-6=%>,)EFK(U[9(.>#(%"6Q[3E.UTXPH=9X:.;F?#QDF8P)A3E'(DL2
MS/]<0<QV(\NU]A,+LMY(/6&/ARE>PQ+DMW3.U<@N42*2 !6$4<1A-;(F[N74
M-05FQ7<".W%PC;24!\8>]> V&EF.9@0QA%)#8/6WA2G$L492/'X7H%:YIRX\
MO-ZC?S;BE9@'+&#*XA\DDIN1U;=0!"N<Q7+!=C=0".IHO)#%PORB7;'6L5"8
M"<F2HE@Q2 C-__%38<1!@<*I+_"* N^X(#A1X!<%OA&:,S.RKK'$XR%G.\3U
M:H6F+XPWIEJI(50?XU)R=9>H.CF>31;WM_=?EF@^6Z#ES60Q0Q_1A$H2D3C3
M#J,EA!DGDH! LZ<PSB*(T(JS!$U9DF82F]-@*S3#G!*Z%F@.'"TWF ,ZNP:)
M22S.%:;0,V)H2T5:;VV'!<&KG*!W@J"/[AB5&[4Y53M7ZVTEME3L[15?>8V
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M::9H"$7$,TID0\X;X5Y[;"V!592[SG/OX+R)I!<T6O*L+;2J:0<-E_M?TU[
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M[6?2$.IK?RDOI/E%V\;6<U!:2<7+!@P1E)35__A7DX@. /S8 4$#" X!O2.
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MXV/@7A_XN /NN'87?=#\1'2O0?<&T9<QR/:\$<#Z GC= (;1#3"XQ(D!)DV
MR7  *G#2QS[IO&!&AN=VWS&]=5X[9,6EM]J@^@21[65+,HX2V$BE<3F6V\2J
MMEY-!,W+SKBB0O;9<AC++R%@JD!>WU J7B>JV3;?5L$_4$L#!!0    ( "Z
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MAW>GT^'=!0QO)M/Q[?7%S70"G^",98Q'")/22U<B8F79Q0P&*-,E,]57<#A
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MV^ S**C;]ZO2.)PINFIWNF1#L#>39%*HE*DF39NL0Z.!8!G847PVA[LNRA!
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MB".8 _" (5%DWX-[[Z-P_9X*-_\A'/T!4$L#!!0    ( "Z EUB7BKL<P
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M*&8&#1>[4I#:Q,24XUI6SK,)(8)%(=NCO"1!M6\*2B8FIAS7LG)^8,ZYWBD
M%0VI-R04O!$D-#O=PY3C65;.6P)_'D,F)B8?S[)\<(&;Z=+#Y.-9ED]/X&?$
M%RM]-!UYF'H\VPN:/N3/P\C$1!^?6%;/3YAA#6NO7*CM/JIS$Q-3C_<+=\<
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MK$,468<HL@[_4]9W8U9__9>VN:>5+NIC/FM_A4\_ 5!+ 0(4 Q0    ( "Z
MEU@'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ +H"76 #CU5#N    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ +H"76)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  N@)=8T])&I/,%  #&'P  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ +H"76-G$TPNX!P
MER   !@              ("!-@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( "Z EUA4FG5W-P,  '$*   8              " @206
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  N@)=8D-@^
MBAH&  #T%P  &               @(&1&0  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ +H"76.]ES+B> @  _P4  !@
M ("!X1\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "Z
MEUBK :? U0<  &(@   8              " @;4B  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  N@)=8]2:<4#<&  !6)P  &
M        @(' *@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ +H"76,_L/X8#!@  E@X  !@              ("!+3$  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "Z EUBIQ51U\P<  !(5   8
M              " @68W  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  N@)=8/E1Y"[("  #?!0  &0              @(&//P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "Z EUB*7,^?K 0
M %0,   9              " @7A"  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ +H"76%<^!F20!   \ P  !D              ("!
M6T<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  N@)=8
MSLW!(S,$  !4#@  &0              @($B3   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( "Z EUB8IX1K-00   D*   9
M      " @8Q0  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ +H"76-G6R=1_ P  1P@  !D              ("!^%0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  N@)=8+A+$K3(&   @$
M&0              @(&N6   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( "Z EUCA"O*<]P4  &00   9              " @1=?  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ +H"76&581>=G
M!0  I X  !D              ("!164  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  N@)=8;)403-8$  "^"@  &0
M@('C:@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "Z
MEUB'DJ!$[ ,  /X(   9              " @?!O  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ +H"76,+^^JT$!   4@H  !D
M         ("!$W0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  N@)=8+T&AI!L$   T"@  &0              @(%.>   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "Z EUAL"Q9#0@(  )H%
M   9              " @:!\  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ +H"76";:+PY$ @  B@8  !D              ("!&7\
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  N@)=80O"/
MG3L,   I)0  &0              @(&4@0  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( "Z EU@O#,00S (   P&   9
M  " @0:.  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M+H"76/9!;0G" P  4@H  !D              ("!"9$  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  N@)=8-@+N>L$"  #.!0  &0
M            @($"E0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( "Z EUB>BMFC:@,  %T'   9              " @?J7  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ +H"76*J8P1Y$ P
M>0<  !D              ("!FYL  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  N@)=8^7CB#7D$  #0"P  &0              @($6
MGP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "Z EU@%
MA6(J 00  -X*   9              " @<:C  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ +H"76 _*W*W? @  Q <  !D
M     ("!_J<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Z EU@$R0HJE@,  +T,   9              "
M@8ZZ  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ +H"7
M6$G._PSG @  @ @  !D              ("!6[X  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  N@)=8PH=?L;<"  ##!P  &0
M        @(%YP0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( "Z EU@?7QN17@4  "HC   9              " @6?$  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ +H"76)X$?)5T!   YA<
M !D              ("!_,D  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  N@)=8RQ1D;5@$  !^%0  &0              @(&GS@
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "Z EU@L(C8@
MI00  !0<   9              " @3;3  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ +H"76'U(X!RQ @  9PD  !D
M ("!$M@  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  N
M@)=8A8PCRD8$  #(&0  &0              @('ZV@  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "Z EUALU.I"H@(  ,X%   9
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M970U,2YX;6Q02P$"% ,4    "  N@)=85,<@9VX#  !.#@  &0
M    @($+\0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M "Z EUBNN+AX1 ,  "X4   -              "  ;#T  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ +H"76)>*NQS     $P(   L              ( !
M'_@  %]R96QS+RYR96QS4$L! A0#%     @ +H"76..0<G#*!   C2(   \
M             ( !"/D  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "Z
MEUB*,79?SP$  #,?   :              "  ?_]  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "Z EU@RX8'AQP$  !(?   3
M          "  08  0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     \ #P
*6Q   /X! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>228</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/EARNINGSPERSHARE</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INDEBTEDNESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESS</Role>
      <ShortName>INDEBTEDNESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - DERIVATIVE INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS</Role>
      <ShortName>DERIVATIVE INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - FAIR VALUE MEASURMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS</Role>
      <ShortName>FAIR VALUE MEASURMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - RELATED-PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/REVENUE</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/EARNINGSPERSHARETables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/EARNINGSPERSHARE</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/LEASES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - INDEBTEDNESS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSTables</Role>
      <ShortName>INDEBTEDNESS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/INDEBTEDNESS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables</Role>
      <ShortName>DERIVATIVE INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails</Role>
      <ShortName>NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails</Role>
      <ShortName>REVENUE - Net Revenue Earned by Category of Payer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/INCOMETAXES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails</Role>
      <ShortName>EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASESAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - INDEBTEDNESS - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails</Role>
      <ShortName>INDEBTEDNESS - Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - INDEBTEDNESS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails</Role>
      <ShortName>INDEBTEDNESS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - INDEBTEDNESS - Long Term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails</Role>
      <ShortName>INDEBTEDNESS - Long Term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails</Role>
      <ShortName>INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails</Role>
      <ShortName>STOCK-BASED INCENTIVE COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="bios-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED-PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="bios-20240331.htm">bios-20240331.htm</File>
    <File>bios-20240331.xsd</File>
    <File>bios-20240331_cal.xml</File>
    <File>bios-20240331_def.xml</File>
    <File>bios-20240331_lab.xml</File>
    <File>bios-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bios-20240331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="468">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bios-20240331.htm": {
   "nsprefix": "bios",
   "nsuri": "http://www.bioscrip.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "bios-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "bios-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bios-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bios-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bios-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bios-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 216,
   "keyCustom": 12,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 20,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 134,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 484,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 468,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.bioscrip.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "longName": "0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical",
     "longName": "0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "longName": "0000008 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS",
     "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bioscrip.com/role/REVENUE",
     "longName": "0000010 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bioscrip.com/role/INCOMETAXES",
     "longName": "0000011 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bioscrip.com/role/EARNINGSPERSHARE",
     "longName": "0000012 - Disclosure - EARNINGS PER SHARE",
     "shortName": "EARNINGS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bioscrip.com/role/LEASES",
     "longName": "0000013 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT",
     "longName": "0000014 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS",
     "longName": "0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bioscrip.com/role/INDEBTEDNESS",
     "longName": "0000016 - Disclosure - INDEBTEDNESS",
     "shortName": "INDEBTEDNESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS",
     "longName": "0000017 - Disclosure - DERIVATIVE INSTRUMENTS",
     "shortName": "DERIVATIVE INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS",
     "longName": "0000018 - Disclosure - FAIR VALUE MEASURMENTS",
     "shortName": "FAIR VALUE MEASURMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION",
     "longName": "0000020 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY",
     "longName": "0000021 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "0000022 - Disclosure - RELATED-PARTY TRANSACTIONS",
     "shortName": "RELATED-PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.bioscrip.com/role/REVENUETables",
     "longName": "9954472 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.bioscrip.com/role/EARNINGSPERSHARETables",
     "longName": "9954473 - Disclosure - EARNINGS PER SHARE (Tables)",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bioscrip.com/role/LEASESTables",
     "longName": "9954474 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables",
     "longName": "9954476 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSTables",
     "longName": "9954477 - Disclosure - INDEBTEDNESS (Tables)",
     "shortName": "INDEBTEDNESS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables",
     "longName": "9954478 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)",
     "shortName": "DERIVATIVE INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails",
     "longName": "9954479 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)",
     "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "bios:NumberOfServiceLocations",
      "unitRef": "pharmacy",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "bios:NumberOfServiceLocations",
      "unitRef": "pharmacy",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "longName": "9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails",
     "longName": "9954481 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)",
     "shortName": "REVENUE - Net Revenue Earned by Category of Payer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bioscrip.com/role/INCOMETAXESDetails",
     "longName": "9954482 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9954483 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-59",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-59",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails",
     "longName": "9954484 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)",
     "shortName": "EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails",
     "longName": "9954485 - Disclosure - LEASES - Additional Information (Details)",
     "shortName": "LEASES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9954486 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)",
     "shortName": "LEASES - Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails",
     "longName": "9954487 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails",
     "longName": "9954488 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
     "longName": "9954489 - Disclosure - INDEBTEDNESS - Debt (Details)",
     "shortName": "INDEBTEDNESS - Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
     "longName": "9954490 - Disclosure - INDEBTEDNESS - Additional Information (Details)",
     "shortName": "INDEBTEDNESS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails",
     "longName": "9954491 - Disclosure - INDEBTEDNESS - Long Term Debt Maturities (Details)",
     "shortName": "INDEBTEDNESS - Long Term Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails",
     "longName": "9954492 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)",
     "shortName": "INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
     "longName": "9954493 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)",
     "shortName": "DERIVATIVE INSTRUMENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-112",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-112",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
     "longName": "9954494 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)",
     "shortName": "DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails",
     "longName": "9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)",
     "shortName": "DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
     "longName": "9954496 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)",
     "shortName": "STOCK-BASED INCENTIVE COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
     "longName": "9954497 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "longName": "9954498 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED-PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bios-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "bios_A2015WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "A2015WarrantsMember",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Warrants",
        "label": "2015 Warrants [Member]",
        "documentation": "2015 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bios_A2017WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "A2017WarrantsMember",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Warrants",
        "label": "2017 Warrants [Member]",
        "documentation": "2017 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bios_A2018PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "A2018PlanMember",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Plan",
        "label": "2018 Plan [Member]",
        "documentation": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r605"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to joint ventures",
        "label": "Accounts Payable, Other",
        "documentation": "Amount of obligations incurred and payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "bios_AccountsReceivableBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "AccountsReceivableBenchmarkMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Benchmark",
        "label": "Accounts Receivable, Benchmark [Member]",
        "documentation": "Accounts Receivable, Benchmark"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237"
     ]
    },
    "bios_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r152",
      "r467"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r98",
      "r160",
      "r464",
      "r485",
      "r486"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r27",
      "r398",
      "r401",
      "r430",
      "r481",
      "r482",
      "r700",
      "r701",
      "r702",
      "r710",
      "r711",
      "r712"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r494",
      "r710",
      "r711",
      "r712",
      "r754",
      "r767"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based incentive compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r331"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash (used in) provided by operations:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r672"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r675"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r641",
      "r651",
      "r668",
      "r676",
      "r680",
      "r688"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r367"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred financing costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r419",
      "r590",
      "r591",
      "r705"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense for intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r42"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets under development",
        "label": "Asset under Construction [Member]",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r156",
      "r188",
      "r217",
      "r227",
      "r231",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r388",
      "r390",
      "r411",
      "r460",
      "r526",
      "r605",
      "r617",
      "r722",
      "r723",
      "r759"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r162",
      "r188",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r388",
      "r390",
      "r411",
      "r605",
      "r722",
      "r723",
      "r759"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncurrent assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r388",
      "r390",
      "r411",
      "r722",
      "r723",
      "r759"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NONCURRENT ASSETS:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r67"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r112",
      "r113"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r150",
      "r579"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents - beginning of the period",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r109",
      "r184"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r109"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants exercised (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercised",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants exercised (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Exercised",
        "documentation": "Class of Warrant or Right, Number of Securities Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "bios_CommercialCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "CommercialCustomerMember",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial payers",
        "label": "Commercial Customer [Member]",
        "documentation": "Commercial Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r252",
      "r253",
      "r576",
      "r719"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r710",
      "r711",
      "r754",
      "r764",
      "r767"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r513"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r92",
      "r513",
      "r532",
      "r767",
      "r768"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock; $0.0000 par value: 250,000,000 shares authorized, 183,397,817 shares issued and 173,816,056 shares outstanding as of March\u00a031, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December\u00a031, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r463",
      "r605"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET COMPREHENSIVE INCOME",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r171",
      "r173",
      "r178",
      "r456",
      "r472"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r73",
      "r74",
      "r235",
      "r575"
     ]
    },
    "bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "ConcentrationRiskBusinessRiskPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Business Risk",
        "label": "Concentration Risk, Business Risk, Policy [Policy Text Block]",
        "documentation": "Concentration Risk, Business Risk, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r73",
      "r74",
      "r235",
      "r487",
      "r575"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r73",
      "r74",
      "r235",
      "r575",
      "r696"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration \u200brisk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r73",
      "r74",
      "r235"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r37",
      "r38",
      "r73",
      "r129",
      "r575"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r73",
      "r74",
      "r235",
      "r575"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r582"
     ]
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebate receivable",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r320",
      "r574"
     ]
    },
    "us-gaap_CorporateJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateJointVentureMember",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint Venture",
        "label": "Corporate Joint Venture [Member]",
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COST OF REVENUE",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r440"
     ]
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsProductLineMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service, Product and Service Benchmark",
        "label": "Cost of Goods and Service, Product and Service Benchmark [Member]",
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense in cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "bios_CreditAgreementsEnteredInto2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "CreditAgreementsEnteredInto2019Member",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Credit Agreements Amendment",
        "label": "Credit Agreements, Entered Into 2019 [Member]",
        "documentation": "Credit Agreements, Entered Into 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's Largest Payer",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r235"
     ]
    },
    "us-gaap_CustomerListsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerListsMember",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Referral sources",
        "label": "Customer Lists [Member]",
        "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INDEBTEDNESS",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r186",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r279",
      "r286",
      "r287",
      "r289"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r88",
      "r89",
      "r131",
      "r132",
      "r190",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r420",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r706"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Amount",
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r132",
      "r290"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r79",
      "r264",
      "r420",
      "r588",
      "r589"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective rate on term loans at end of period",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r77",
      "r292",
      "r420"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r420",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r706"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r190",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r420",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r706"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r46",
      "r47",
      "r76",
      "r77",
      "r79",
      "r83",
      "r122",
      "r123",
      "r190",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r420",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r706"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r724"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Issuance Costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r724"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes - net",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r126",
      "r143",
      "r382",
      "r383",
      "r708"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r461"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r43"
     ]
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAmortizationAndAccretionNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Amortization and Accretion, Net",
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r221"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total derivative assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r410",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r519",
      "r520",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r581",
      "r609",
      "r765"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r505",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r565",
      "r566",
      "r568",
      "r570",
      "r607",
      "r609"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r68",
      "r69",
      "r503",
      "r505",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r565",
      "r566",
      "r568",
      "r570",
      "r581",
      "r607",
      "r609"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DERIVATIVE INSTRUMENTS",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r395",
      "r403"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount of derivative",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r753"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r59",
      "r60",
      "r61",
      "r62",
      "r65",
      "r68",
      "r70",
      "r71",
      "r72",
      "r403"
     ]
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, term of contract",
        "label": "Derivative, Term of Contract",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Revenue Earned by Category of Payer",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED INCENTIVE COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r333",
      "r361",
      "r362",
      "r363",
      "r602"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS PER COMMON SHARE:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, basic (in dollars per share)",
        "verboseLabel": "Earnings per common share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r205",
      "r207",
      "r209",
      "r210",
      "r211",
      "r215",
      "r406",
      "r407",
      "r457",
      "r473",
      "r583"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per common share, basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, diluted (in dollars per share)",
        "verboseLabel": "Earnings per common share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r207",
      "r209",
      "r210",
      "r211",
      "r215",
      "r406",
      "r407",
      "r457",
      "r473",
      "r583"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per common share, diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r212",
      "r213",
      "r214"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "bios_EquipmentFurnitureAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "EquipmentFurnitureAndOtherMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, furniture and other",
        "label": "Equipment, Furniture, And Other [Member]",
        "documentation": "Equipment, Furniture, And Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r146",
      "r174",
      "r175",
      "r176",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r203",
      "r216",
      "r243",
      "r244",
      "r307",
      "r364",
      "r365",
      "r366",
      "r378",
      "r379",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r405",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r430",
      "r481",
      "r482",
      "r483",
      "r494",
      "r557"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241"
     ]
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital distribution from equity method investments",
        "verboseLabel": "Distributions received from the investees",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r6",
      "r100",
      "r469"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in equity-method investees",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r238",
      "r698",
      "r715"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r75",
      "r240"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r672"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634",
      "r644",
      "r669"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r409",
      "r437",
      "r438",
      "r439",
      "r588",
      "r589",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Markets for Identical Item (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r322",
      "r327",
      "r409",
      "r437",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r322",
      "r327",
      "r409",
      "r438",
      "r588",
      "r589",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r409",
      "r439",
      "r588",
      "r589",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r437",
      "r438",
      "r439",
      "r588",
      "r589",
      "r599",
      "r600",
      "r601"
     ]
    },
    "bios_FiniteLivedCustomerListsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "FiniteLivedCustomerListsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Referral sources, net",
        "label": "Finite Lived Customer Lists, Net",
        "documentation": "Finite Lived Customer Lists, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Total accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r248"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r441",
      "r442"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gross intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r442"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r441"
     ]
    },
    "bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "FiniteLivedIntangibleAssetsNetExcludingCustomerLists",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists",
        "documentation": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists"
       }
      }
     },
     "auth_ref": []
    },
    "bios_FirstLienCreditAgreementSecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "FirstLienCreditAgreementSecondAmendmentMember",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Lien Credit Agreement",
        "label": "First Lien Credit Agreement, Second Amendment [Member]",
        "documentation": "First Lien Credit Agreement, Second Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "bios_FirstLienTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "FirstLienTermLoanMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Lien Term Loan",
        "verboseLabel": "First Lien Term Loan",
        "label": "First Lien Term Loan [Member]",
        "documentation": "First Lien Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r676"
     ]
    },
    "bios_FourVendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "FourVendorsMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Vendors",
        "label": "Four Vendors [Member]",
        "documentation": "Four Vendors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r245",
      "r455",
      "r586",
      "r605",
      "r717",
      "r718"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentContractsConcentrationRiskMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Governmental Healthcare Programs",
        "label": "Government Contracts Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "bios_GovernmentCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "GovernmentCustomerMember",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government payers",
        "label": "Government Customer [Member]",
        "documentation": "Government Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bios_GovernmentHealthcareProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "GovernmentHealthcareProgramsMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Healthcare Programs",
        "label": "Government Healthcare Programs [Member]",
        "documentation": "Government Healthcare Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "GROSS PROFIT",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r188",
      "r217",
      "r226",
      "r230",
      "r232",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r411",
      "r585",
      "r722"
     ]
    },
    "bios_HCIIncentiveUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "HCIIncentiveUnitsMember",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HC I Incentive Units",
        "label": "HC I Incentive Units [Member]",
        "documentation": "HC I Incentive Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r394"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r99",
      "r135",
      "r217",
      "r226",
      "r230",
      "r232",
      "r458",
      "r470",
      "r585"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equity in earnings of joint ventures",
        "terseLabel": "Proportionate share of earnings in equity-method investees",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r100",
      "r134",
      "r222",
      "r238",
      "r469"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r541"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r541"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r368",
      "r373",
      "r374",
      "r377",
      "r380",
      "r384",
      "r385",
      "r386",
      "r490"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Line Items]",
        "label": "Income Tax Examination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationTable",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Table]",
        "label": "Income Tax Examination [Table]",
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAX EXPENSE",
        "verboseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r144",
      "r202",
      "r203",
      "r223",
      "r371",
      "r381",
      "r474"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other noncurrent assets and liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r641",
      "r651",
      "r668",
      "r676",
      "r680",
      "r688"
     ]
    },
    "bios_InfusionPumpsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "InfusionPumpsMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infusion pumps",
        "label": "Infusion Pumps [Member]",
        "documentation": "Infusion Pumps [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r692"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r692"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r692"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense, net",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r137",
      "r177",
      "r220",
      "r418",
      "r542",
      "r615",
      "r766"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r182",
      "r183"
     ]
    },
    "us-gaap_InterestRateCapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateCapMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails",
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap designated as cash flow hedge",
        "label": "Interest Rate Cap [Member]",
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r580",
      "r605"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in earnings of joint ventures",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106"
     ]
    },
    "us-gaap_JuniorLienMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "JuniorLienMember",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Lien Term Loan",
        "label": "Junior Lien [Member]",
        "documentation": "Legal right, after the claims of senior lien holders are satisfied, for a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes second mortgage loans."
       }
      }
     },
     "auth_ref": []
    },
    "bios_LargestPayerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "LargestPayerMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Largest Payer",
        "label": "Largest Payer [Member]",
        "documentation": "Largest Payer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bios_LegacyHealthSystemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "LegacyHealthSystemsMember",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legacy Health Systems",
        "label": "Legacy Health Systems [Member]",
        "documentation": "Legacy Health Systems [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities, Operating",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undrawn letters of credit issued and outstanding",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r188",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r389",
      "r390",
      "r391",
      "r411",
      "r512",
      "r584",
      "r617",
      "r722",
      "r759",
      "r760"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r133",
      "r466",
      "r605",
      "r707",
      "r716",
      "r755"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r149",
      "r188",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r389",
      "r390",
      "r391",
      "r411",
      "r605",
      "r722",
      "r759",
      "r760"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncurrent liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r85",
      "r86",
      "r87",
      "r90",
      "r188",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r389",
      "r390",
      "r391",
      "r411",
      "r722",
      "r759",
      "r760"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NONCURRENT LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LienCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LienCategoryAxis",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lien Category [Axis]",
        "label": "Lien Category [Axis]",
        "documentation": "Information by category of lien, for example, but not limited to, senior or junior."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LienCategoryDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LienCategoryDomain",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lien Category [Domain]",
        "label": "Lien Category [Domain]",
        "documentation": "Legal claim on the property of another party to secure the payment of a debt or the satisfaction of an obligation by category, for example, but not limited to, senior or junior."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available borrowing capacity",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Balance",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r132",
      "r276",
      "r291",
      "r588",
      "r589",
      "r761"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "negatedLabel": "Less: current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total debt instruments",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r281"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r281"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r281"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r281"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "bios_LongTermDebtMaturityAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "LongTermDebtMaturityAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Four",
        "documentation": "Long-Term Debt, Maturity, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net of discount, deferred financing costs and current portion",
        "verboseLabel": "Total long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate paid on term loans during period",
        "label": "Long-Term Debt, Weighted Average Interest Rate, over Time",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r45"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r594",
      "r725",
      "r762",
      "r763"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r594",
      "r725",
      "r762",
      "r763"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME",
        "terseLabel": "Net income",
        "verboseLabel": "Net income",
        "netLabel": "Net income",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r111",
      "r136",
      "r147",
      "r169",
      "r172",
      "r176",
      "r188",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r208",
      "r217",
      "r226",
      "r230",
      "r232",
      "r242",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r407",
      "r411",
      "r471",
      "r534",
      "r555",
      "r556",
      "r585",
      "r615",
      "r722"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r668",
      "r676"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "bios_NumberOfInfusionSites": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "NumberOfInfusionSites",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of infusion sites",
        "label": "Number Of Infusion Sites",
        "documentation": "Number Of Infusion Sites"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "bios_NumberOfServiceLocations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "NumberOfServiceLocations",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of service locations",
        "label": "Number Of Service Locations",
        "documentation": "Number Of Service Locations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense in operating expenses",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING COSTS AND EXPENSES:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OPERATING INCOME",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r226",
      "r230",
      "r232",
      "r585"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating leases",
        "label": "Operating Lease, Payments, Use",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease costs",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate, operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r604"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term, operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r604"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized gain (loss) on cash flow hedges, net of income tax (expense) benefit of $(454) and $1,152, respectively",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes on unrealized gains (losses) on cash flow hedges",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap designated as cash flow hedge",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r392",
      "r393",
      "r396"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap designated as cash flow hedge",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r166",
      "r168"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OTHER COMPREHENSIVE INCOME (LOSS)",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r127",
      "r170",
      "r173"
     ]
    },
    "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherExpenseDisclosureNonoperatingAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSE):",
        "label": "Other Expense, Nonoperating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other amortizable intangible assets",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from joint ventures",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r521"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r649",
      "r674"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r677"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r677"
     ]
    },
    "bios_PatientCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "PatientCustomerMember",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patients",
        "label": "Patient Customer [Member]",
        "documentation": "Patient Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of company stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "bios_PerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "PerformanceStockUnitMember",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock unit awards",
        "label": "Performance Stock Unit [Member]",
        "documentation": "Performance Stock Unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614",
      "r764",
      "r767"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r294"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r513"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r513",
      "r532",
      "r767",
      "r768"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March\u00a031, 2024 and December\u00a031, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r462",
      "r605"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financing activities",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r703"
     ]
    },
    "bios_ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings",
        "label": "Proceeds From (Payments For) Stock Options Exercised, Restricted Stock Vested And Tax Withholding",
        "documentation": "Proceeds From (Payments For) Stock Options Exercised, Restricted Stock Vested And Tax Withholding"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r440",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r578",
      "r592",
      "r606",
      "r697",
      "r720",
      "r721",
      "r725",
      "r762"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r440",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r578",
      "r592",
      "r606",
      "r697",
      "r720",
      "r721",
      "r725",
      "r762"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r139",
      "r141",
      "r142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r151",
      "r468"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r459",
      "r468",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634",
      "r644",
      "r669"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r434",
      "r435",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r531",
      "r533",
      "r564"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r541"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r434",
      "r435",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r531",
      "r533",
      "r564",
      "r758"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED-PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r491",
      "r492",
      "r493",
      "r539",
      "r540",
      "r541",
      "r561",
      "r563"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of debt principal",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r645",
      "r670"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r671"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r643",
      "r653",
      "r678"
     ]
    },
    "bios_RestrictedStockAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "RestrictedStockAwardMember",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards",
        "label": "Restricted Stock Award [Member]",
        "documentation": "Restricted Stock Award [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r124",
      "r465",
      "r484",
      "r486",
      "r489",
      "r514",
      "r605"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r203",
      "r243",
      "r244",
      "r364",
      "r365",
      "r366",
      "r378",
      "r379",
      "r397",
      "r399",
      "r400",
      "r402",
      "r405",
      "r481",
      "r483",
      "r494",
      "r767"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET REVENUE",
        "verboseLabel": "Net revenue",
        "netLabel": "Management fee income",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r225",
      "r228",
      "r229",
      "r233",
      "r234",
      "r235",
      "r318",
      "r319",
      "r440"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r695"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/REVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r321"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolver Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease right-of-use asset and lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r604"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r387"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Estimated Fair Values of Debt Obligations",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r68",
      "r394"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount and Location of Derivatives in the Balance Sheet",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Maturities",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r537",
      "r538",
      "r541"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "bios_SecondLienTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "SecondLienTermLoanMember",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Second Lien Term Loan [Member]",
        "documentation": "Second Lien Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SeniorLienMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorLienMember",
     "presentation": [
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Lien Term Loan",
        "label": "Senior Lien [Member]",
        "documentation": "Legal right, before the claims of other creditors, of a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes first mortgage loans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSDebtDetails",
      "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based incentive compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r185"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software, purchased and internally developed",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r24",
      "r146",
      "r174",
      "r175",
      "r176",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r203",
      "r216",
      "r243",
      "r244",
      "r307",
      "r364",
      "r365",
      "r366",
      "r378",
      "r379",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r405",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r430",
      "r481",
      "r482",
      "r483",
      "r494",
      "r557"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r216",
      "r440",
      "r488",
      "r495",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r535",
      "r536",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r610"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r216",
      "r440",
      "r488",
      "r495",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r535",
      "r536",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r610"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r648",
      "r673"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings",
        "label": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings",
        "documentation": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option awards",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized to be repurchased (in shares)",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of company stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r91",
      "r92",
      "r124",
      "r494",
      "r557",
      "r572",
      "r616"
     ]
    },
    "bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioscrip.com/20240331",
     "localname": "StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of company stock, and related tax effects",
        "label": "Stock Repurchased During Period, Value, Including Related Tax Effects",
        "documentation": "Stock Repurchased During Period, Value, Including Related Tax Effects"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Equity, beginning balance",
        "periodEndLabel": "Equity, ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r96",
      "r114",
      "r515",
      "r532",
      "r558",
      "r559",
      "r605",
      "r617",
      "r707",
      "r716",
      "r755",
      "r767"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r187",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r404",
      "r560",
      "r562",
      "r573"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Supply Vendors",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks/names",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bioscrip.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock acquired, average cost per share (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, at cost (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock; 9,581,761 and 8,330,022 shares outstanding, at cost, as of March\u00a031, 2024 and December\u00a031, 2023, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r48",
      "r49"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares, acquired (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r92",
      "r124"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r48",
      "r124"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioscrip.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Release of valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Weighted average number of common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r211"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails",
      "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r211"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001014739-24-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001014739-24-000022-xbrl.zip
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MM^1!5$SBA]?,,WG2\:BPBU4OK7^E)4K7O*95W.KD[ZY4QXE_>*>44=Q3@AO
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M8!.:!!)Y&1.+/89-%A]A.7C+\>Q)& 6OE/1&IA7XH AX_LBQI @8S691$AS
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M4?B>3IF"-FR*N5$0-2]+LIIR*/'=*>BR#C?<FXY]Y7B298Z=R'3%>89=N]K
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M^X\)ZV%.O:8! <Q;#MCIWG2WP^OX%RT7^6&"CE3'^RB- __)04NI_RKYTU9
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M>ZIPO- ?+:=>4SB@O\MJ=/U QC'"64>A?B2- \>SG+'IBES07?VH,ZAV!K<
MT\SL@,V+4XNNBBS0DZ:;#=[2/>E&4Q1NZ.:RM.K[26 -3:95XU%5TWMEBK-0
MC?>-18$B FP1P[<SN/%'(]^CND=F[E +=4.1E90JZ4++/6E2VC((E2,I84V
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MTDVG?=ML=]FO;N>N==O RU];[4;[IM6XD[H]N/"]V>YU5Q>Y)5<:A:T@\_G
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MO/;Q\:,-OCV1$[Q<%$#)(RG8T$52\,4G!<\73,(SD,[@]4A.:CUKGG#LOL7
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ML/<,IYUMJ4%#GV4&!/*OPRKAX(S1?@BQ/3!5E4[5#)@"'<$]"5D5;=94(>Y
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MX^6IQZ24(^)(E]EF=I>ES/QC?=YZDEBZXF41X=@W_*L;=(4$W@T&[C:%=F=
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MYGFZ#50)/6/^:&WK4Y&B33AW!<%IAGC:*W "EYBA&Q6"=^H7'YM:0ZUWM@;
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MAXL,#A6I\Z(8_CW'Z;>0R&BWBVICA!NW+=Y4QH*[+K^R5V8KVA0%WM%$!H1
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MR.*>:J [QBQ$-"W@8O:3C<9P.]A:^D@?1#3"47ELA/&DT(%-G"\*A>!!.7M
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M@M C9\L/QV/7"R)GBR0%]C\@:\KE KH#ZP63R*7JAWC[%(H,/&H<>L!@BFZ
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M4J&CA[!+X7F B_/R^5]4540[4LK'C])*Z-#@_>FU)6JB;=\YX0Y A1U42W8
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MT-^,HNFP/L(- 1*-F6'UK01.^/GV)K:0/2 2)RSU?8GZ7%%'*]1XJ?E:Z+.
MXR8@5BFWQAV-0H<PTQ>&58 _P$Z+ *51PQ(L.5#B9FBQ/LP9.\;C[O2 O7$(
MW=<4OWV)'3/Q&QTTZ&.@QMBSJ#N"BVC:[AM-&<\%8*X^^4$>&^B>F>JI8Z9X
M*@V&[8=C;$_H1U'\&-R9 O (KIW1V6!?TTL>%[OZYC2$OR,:I64-9@VA60*!
M&W=8HO5GL>;)[F^Z;'K)].>FB ,3VVS<>VF-8=.)2-+&8/$LBJ_2;Y(S*\(Q
M1B3D6)L3XG)"M"<F>HN64Z_#FM'".5,G=;SUI9BY6' ^\200XT437R=2G$"6
MBF9^W 3$MIC$,:@UL:&?EPI(313;^H$:(W#G;U#SC5&Z_%,N?V<W+G];NOQG
MYO(?GH.S-?3C]=,+WU;N[G(KW@*,_^'EC]LGY>[^R\/3M^N7NX?[C9W2>K5\
M3JE6%J?T*UBH-O?=&%J-Q7+>UM+U!R'KTA%\P8U=^$34L\@FJHX3JJH\.H,;
M/7;M4+2:JAR+$;+G *8U^(')L1.J3!@Y<XQ4HL$QB*M&CL:FYZ%)0(V+)G\>
M>))1;.T?FP?,ZO42ZJ;K2CET$P:$L148GNX62BWM_,R01X'%.38W_WE7KJ1+
M?*IK<7+2BAY%ZM@ZU>PW%5*>:C[WB.W:[U0EX@1%M#E,TUJT.YP+05>4ZZ2S
M+PZ9:XK0$?T'Z6C;<8,HJQ!<F1^.^^;@+$,Z(B;7Z(VE+C 9C(,'KZQ13!X\
M/]9M?]HK,E\Q13+VC]:@#HSN-W>ZLS'12A6]X^/3\G#,-4AJ'3"+P'U;W!FA
M3+EDG\'3FY#;ZS%KU,,V2A3=(3)GD=6.>J.KZ=;2/-*7P6TE/=&?H88(;\9,
MX6-$SJ"X3Y1"C/%':M?(?L[T-S0YB7LL>$-9CP.@V.8;>YCVN8G 'RDH:3!K
M3#G!45L^$@\#:(%=NL&"IU:0V+?Q:6J@Z; 4\#OU7\05 1<G[L$=DF[!(5)X
MU[!U:^0K(QSPV.9CBQ=T[#H4.8U_U:=;3>(SF8_-QQE,@\7#I> P/#U.+X&U
MPWXE(E*9E0R-],,.ILP94!X-#4!D).%>'F OR[YKA+YH5$\-(>EMO4DZ,,DS
M@7AF$7.&F,83]P5/!XS]B0^:3K0KQXPZ[*Y.?E%*+20QOHKRSZ%%7?_B-XEL
M(C\)%<['!WW*J@;28"*VSQ7(1.6M1J,%=5Q*F/$H+XNO=$PN?Q&]J/^M0:98
MR#!M*)471>W$..&%,O9]U[#T* Z/1HYG7F$$>8)KAET[HX0B4):B^R8FL/-Q
M3#6!S!H,?&.;?$/3DZU,*! 1&,70[4(-HBY1(;C-@%K64;C4Z)2 MY>-6LIB
M#T;*PIS+GU?)_.[Y\$9A@7]WT%+D5RB_>VXX5E.)9"9<;TREW%LBY9ZOC&GY
M7CBF+!P<:#Q*G SN. ,A7Q@T=AT'YTT;;M2(=S[!7W24Y(O-^_!21)U7 0=)
M/TT\9L',KD"\A9XKF(R8ETLRZI-807&JFJ$1&0TII4WWIPR#Y91-4HQ@XR:"
M&4$JD<YP02GAH0\>OV!P<E&\>UWSN54^\[E6$NOYN^.Q 6@+AJ=.S[K-$Q)O
M02R!W9\YWT<I:-]Y<K$( Y3@2/H.]SQ/>129T=E3*ZE5,GO(]<G5/9.?O(,$
M<A<!3Q]?28WY0WZD$">)PR\#3Q]1S^:QJ+/0!P,\B@R8\DNS.I-?/IL5/WVL
MA_L+9>#SA\(;<"-+CG-!15A<M5 V:UDMP?D.;&3O^;%&3]L4M+FBW23:KV>=
M3"8+XL]1F%3R?^M.B'M5<FH$F]1@F'6>>(+MV>KU2J-:*V+[LD+V5).#6G=0
MW9/K/I?=S>9Q.=+7QLW82M'*YX6:/-^'HQZW79^'5#0360/G2I9K& MXK6#&
M88SA4;=,:E1.U#E3DJSB%$SBH9 H6K]A#RQK>Z)<.XX;DI?X:.N\MN61VS^+
M<5M/FXS7:&_^I"H5Y3.:$)[R)]8XI4CZ@G[S-WVB_(L%RB>6(G&2Y;:<G)L"
M.6[4_*YHL"2SYN!5;"!&5N Z_17WA6RW'HG+@7G7;K;43G=#T+NU>:V([8RV
M6,6BB4ON1D=KSKW0G%O7*IT-FVT5FF^E)CJU%96:Z+0U4:W65+M:7:U5FT7C
MWC. E?W">MZ,L1A_5>MN82V>;?>J1K>A=AH;(D06 ./QM%>G7JMH<FV*N392
M<HJ\.C6MJL(+5*U^I!4Z@^8<O/HKV8JGJ\&.&;4I'[_2\6GMPV8V90'\'KDZ
M<G7DZLC5V>5.7)!V*RN.LP[?0ZV$3*"IM::FMNMYFU7E(D6QVPR<5\@OW]P+
MS;MUK=+=KH5&,?E6ZJ+36U.IBTY;%VT=UMCS\<-\/Y)UZR&ZY:N':):D'N*!
MP*+ODCSNXE<Y7)ONF(-??7--*@:,VWR\,&]D.3$J&,>9J_::5YK(LJ(:?I&\
MSJ?^XNE4VG7M>5B=-)KJ0UZ>=/U[++OBA1"82N8*2*_IL@4J5/B;]?.]XSKW
MX0C>9% 9'4SA"?%CC"OM0G'T$8R;&>9[)!]23P/:$-&9^<76!Q<*9Q:0W9_!
M^[[UDYDP)]MG%R30_:MF#;%)UG[-O>ML_B;MXJ/.;_C;;U-O_#C[655&Q"X(
MI.9M2(47;^0$ZPZMM@41<KVH?O$Q$(R_F@R*/B468UNG>GFXXBK]?2#$0D_$
M(A?>EP3>F@+>ZNX$>*M1.P3P%DS2N +">;H1O!?P+1_*A,8U-0'V<VCUK.##
ML<>W=XBN-9<M;;7]._0#JS\YIIW4*@LDU"WGH_RVP6%)G:U_+O5W2C2!Q9KY
M^'5SW6ZETZSG+9O3M$IW1]52G6:ETU[^J-.IEA(<(0I!LGW&LM=H?&:^X5GC
M*<]FG;**Q!7.Z-V9<XWA*4>*9@'/KG/4OOO)DFK9J7FP<L9'-@^V')\P#]A/
MK:I=<?\6$3)^L@C%N3(,1H2I1S7L#W2%<H-5[AQ/0\7^F!4%_(@KZBM!CLXS
M559'%^-"D;O,E,L8'?J=<HF@YR;U3\ :[G>5#&-C#9$ID5#4MM-RDNWWP?:U
M;=C^B?D!>+=!S/.(=",Y/N;XNN3XXG%\?1N.?V0>!880-TNR? ;+KY-D*%G^
MP"S?2+-\%+#^N3LE'X,!G1W'U[6U;'W)\0?D>'=L#&%L=4W[B3'Q:AW^JO[\
MB[-[PK?BM&I1VY9QZ/G8.@Y!E;0.=]._5YXK-Q5$]<*[^7=:O5GE77CX@<C4
MC5-7UJNUZ&3H6?=ZNL/\JX>?-IM0=R."O:O63E]>3LD-J!9<7I:/;U9>:NO+
MRWP;(RDO^RHWD_)23'FI[7!_4;83E6ZU)46E)K>6PHK*#K<6*2H[\-.URMW]
M\[ZDY0@S^M]/3U_!747(< -AP8P0<V?RG#V59::X=L\W?YS:VKWH/UW''4U@
MIPR80[U'GXTA&^DGOY@WUU_/8#%O=-O 1KGX]U?+^=%#>.A37]K/MU_.8&D_
M8Y=IZ[Q6]NOUIS-8V:]ZC]G^^:SJX]/M&:SJH\=\6,2STL5[.Y8ZUKI^H?1T
M]'1NJ OSHSY@\TNW<?%/H[E9\4]A6KX^W_U^?_WR_>GV>=J-*T59R6/*>:66
M?+PM%6\J%3FO2=>4VY^\A5_DP6K=>D,5-PZH=18\"HM0S-">4-<@:C9/+;.P
M8[=HJ8-=OGB_>XOZ:PUUNX^=KGB_2_#L^06BE53H8,\A?* >!D/7PU8\14YR
MW; Y1*M;J=7R=1%8]*A:I])L;] 3H+6.ACI@7>1J":PFK7 ?'K'?LG)S_72K
M_'%[_?7E#U6YN[^IK-YF-I_V'C3S:L%-S7F/6VB\HLLBDGN=XF<]8.^5Z[%G
MV7RVM?H,NE02+EN:^!KIW;5ATH_)XMFT^,W_3?EF@?)E-D+/CRW/51;^;Y\<
M?U0JS%!@1_-<Q?TSNS@:()U*(X-61Z+*HF VUL(FIT%_4G<,,,AYP[_+1P^;
M_XWA^NP[/^.&>QUON-%O[Q;%JN<-P#.N!ZQ7%]<#_M9SS0G\9QB,[(__'U!+
M P04    "  N@)=8X=1[JB,-  "^@0  $0   &)I;W,M,C R-# S,S$N>'-D
M[5U;<^(X%G[O7Z%EJW9[JM9-(/=LIZ<<,(EK";"8I*>?NH0MP-7&9B0Y'>;7
M[Y&,@\$&V83LLN/T0QK;.M^Y?$>R='S[_.OSU$-/A#(W\*\KM4]'%41\.W!<
M?WQ=>1BTM(O*KU\^?/C\%TW[[:;?1LW #J?$YZA!">;$03]=/D%\0M#7@/YP
MGS#J>9B/ CK5M"]2K!',YM0=3SBJ']5/XF;Q47IUC/&1;0]'6OWXY%0[.:LY
MVL5P1+33X],:MNUC@FMG_QA?G9^=.)=G];HV/+-M[:1V>:'ALZ&CG5\XQQ<7
M)V=V[<R6H,_LBMD3,L4(7//9U3.[KDPXGUU5JS]__OST\_A30,?5^M%1K?K;
M?=N232N+MI[K_UAI_3RD7MS^N"H.#S$C<?.A&ZR"BQTV=6>?[&!:%>X>'1_7
MXM8"R]V"[OJ,8]]^07<XU?A\1E@M6PB.5\5QH>A(.ZII]5I*5"U9UXZ.-6$D
MYIRZPY"3%I#7)",<>ORZ$OJ_A]AS1RYQ(#,\(KA?:9 XS#$=$][!4\)FV"8Y
M(O/E T*",'<Z"RA'?DITA-E0FLPH%V+'%121VPYLS&7.BI8,FDKO4NVKQ.-,
M;&EBZ],S<RK5_%I#IHTQGA72G)2)M"_V%+$@D:FUR\O+ZK-(O6P+,G-)MM?$
M3ZU6!WH+J-V4E/EUPY86R^W#AF6W*V9#+/=*&S+[V:9<4$G*;?9:,UXZ;6$S
M%I*%S)! C-B?QL%3U2%NGNZPWES\*-(!5D"([131&3<7/S)T8M\/N)07>Q;[
M9C/7'P71#M@E4N<JSI\^&<5#>.H$D=%)Y7]7F-HT\!0]NCJCP8Q0[A*6/+E(
M@ DEH^N*&#>U>+S\/J/D$U@2-TDI6.T$XC!H( S&;.EO>^E0#"'RX+K"@ >/
M1"$Z9/\=,BKJ/XBXOONG\-[#PZ+>@PCQ_N\=M[%7U'$0L4-OEZP7X@,XCESG
MNM((8&[<PV,P3^Q_Z)N;9S52[U(@1HUQEXGXY4C^JR%M.9W6D)1$0O1S=5U@
M#2IDQ.GZ7^3O]?Z]$%XTV2*X%J'<<JL=*E-LL3..Y+;X=CM-HV,93?AA==MF
M4Q\8S1N]K7<:AG5G& ,K=^#52$I&ZD"#!:$D,24Q)DJ"H@4JBF#?V4K$N(<I
MN#<AW 6#]T?=*JR2Q^-=>$0?5[3\4B)>'SKZ0],<2 +23%@#^'MO= 96M]7H
MWO?ZQAVT,1\-LP.;1EZ67Z=$R?G)&N<OZC:QO]2(NBVTHA-%2M\S(!\Y.W7Z
M/6I4YL;I_G/C?;3(PYQNW;7:W:^Y3^*[0"O9/WLE^Z )257O'&<080VZC7_=
M==M-HV\9_WXP!]_V3W:&#B7KYZ]C/:GR;W^]J-?._XDBU27*@HX^>.@;W5:W
M9_3U@0G1TCM-& HMB)+<[K9:9@?F4*;>7H8O+_\[HBN9OQ#K*I?97L!"2F C
M4B187:I"H LEE8G#+^H2R5 BNJV'^WN]_PWZFWG;,5MF0X?8-!K=A\[ [-SV
MH*<T3",WO3G1E'1>KM.Y ):]= F-EM@H!B\1=WWCT>@\Y)Z,Q\U5T:\=K4=_
M(5FBT$83OH'^6_[<3XHH0UQ;#_%BABG%2Q1G0^]WH/=:,$9;=WH_=RZGY)01
MKZ]'/(9 @($D2(GBWC9T*W]J+UHK8WR\'N-(L$1Q[?7%=&/P#68:8N;8$].)
MO%'.E%7&_&0]YC&,G.V\ )6(@]MNM_G5;+?!_^[@SNB;, ?IW)HW(AFM M5E
M)8Z2F]-U;F)(R8T$14M4%,&6B"D3,OT&UF$=PRIPFDW(*!DX2Y]GE^(EBC0L
M:<U'6/.(8IHUZ#\46K1E"RMC?[X>^R4.2@"5B(66;O8?]?8#K#)UZZ%?B(1,
M624'J76Q@$$2!R6 2L0!3+/OS8'T&@;A1E>N'HU.D57N-@@E(ZFE;0)-GA96
M\$I$C*R^W<!\L0EK(8@&#!.B"&]T+%FKR5V"4,"H"*JG5K\249.0Z 43)4'+
MQM).I=\="KKUU#(Y"?+W\A5G^T9;U*U[.LSO!WT=TJ\A*YOY2T ;Y)5,I);/
M"RA-8J$D6(GXR%?O[ 6>:[N$[;>*^H*ZA;O+R].3D_-T+\I=344?8S5ENMJY
MJ'<.\-#+S]JJD)*4C XEY=''"*%,\5ZOYA4+_ 9I)0.I:E6Z(EA&,J*:73$*
M5F24@4^5K"+Q,@8[J^97+/1;$)1$I.I3V;7#,A*C*OX5(RDGFI*P5#DK3T&Q
MC/0ERWS%J,J05-*2JG0E0<H8_LR*83$>MD$H"4F5O;)+CV6D9K<[<)J$8]?+
M3=[KE"CI3=707G6W#_JX4%RF-,BWQM0=1RK$GNF+Y[NET05S80^:5 EQD:[9
MY5_A:FBI&R64ES(M%HO0#N%]\D3\D!B8^L09SAN8DW% Y\&HA^>$%LR!HK!*
MPE,EC7CU#&,!X6BA!45JT'".8D4H&"&IJI3T)NY1*LA@AJ22I%2)(WF34RGC
MOUZJT'WN.JX7<O>)6,0.J2N>CS2>;2]TB#.BP;013&=AY&XP$NGL^F/6(]2:
M8$H*<OA&VI5YD*?0 J-PPAJT- ?%]B!A$$I8)+IR;!,"HY"TZCVO()SB#2=.
MZ)%@=(.9:V/?:8K($B>.5SM@[)794TB',D=2-:','(EU"NJE5@1JT4+O,AD^
M"M6_E#(3HE+:/N9M.9"4K*8*3(M*W_N<*T79/>:+$2\8M0EFI.WBH>O)/3LQ
MEP=026"JX/1"X!)>=$:I "4TO#.Y+?#?:WOG\GOMG<VWK\T7[(G;()1LI:J*
MFZKS)>1&55!O8$KG,!?0IT$(3OJ.;MOA5)A-'-A'N?O'8E9KBL-C=^@1G3'"
MBXZU;V^(,D]2Q<Y<%P4T%)N&(MOD5"IA'4J:)T:%I8$HLK"4F9<L[3?)D!=>
M1V>+*UE.U3Q7KC' ,0![)V09T?RGV,T [Z3L@Y1]+$9RXZDHNTR5BM<H>U^8
M9)+8#OSQ@(AW@ [Y<K+X"A:W RIIS'B <H5& 8\$?M0'$_/;LC-I,.Y.Q0F^
MA5WZB+U0+"I$D+I#SQU+0U_#:Q%X)<L9%>05EE^4(:$-1>K$7$62GM!82M8S
M+Z'O8S0N#JQD.E4CWG#%_GV 5A%\@SWQ$EYK0@B/7YHJ>B!UG["HK1?MW*]3
MHB0^5?C=2/Q")Y)*4:PUZNTO>M_S((Y8CT(@GF^QZXMJN.B*<9!,GW$J7T&Y
MEUPHI$B9#ZF2\<9\ +T:*$9"<USRAWQ8JD<)_:7,"\6S4$5OY,B'IF0X5854
M/V!57O96'IC:A;!, "5'J=ICUH-7I61ETR-4A>^(V0ZC9"A5]=O\0-:?G:?/
MU=6WN4?;*V]\%^][7WS)0K(H"/FNUX]JIU\QI1A.$/=D.B2T@O 0SAG8YM<5
M.'60BGQ-_74ELZGO>IZX?S1N*C_V<36#\T_@#.3;IIV02A,JB(6 Z_)0;-W2
M()Q=5Z+F+B?3"HI>3KW\^L>5$TSAM&;"08&T?)%]V@G;%M5;UB<V@?,>F'-#
M?'LRQ?2'PB6UX$$X:/P>NC/Y"9*00G9 LNN^T^430K?[IY8["/<:P71*J.UB
MKQ$R'DQ5;FUN?Q#N]&A@$^*P%@VF/3R7<Z]60"T>V#^Z,[D6-YZ%_="M^P0<
M=&U8OLO#C[!)'"!I@)^_NGPR"3SQ2:)D($;88R^1> M516(8'1M&JQ(X0(8N
MSQG9:,\T\&%<IO,<8865;B@^U]0+IS/%4)79]"!R0X;>9"PDCJS4K)&225R*
M([8Q'_8%?Z@Y  ,VV.,8SS/B,\+BT:P14O%2XL35^HT1*H"@#D+TM1^>BH%-
MB?-V09 L]LDLI/8$ X'-D )K/6F79-WTQ>V"L*]/Y&5,H-<8C8C-%8FS*^:A
M9LNM^+2$+_;=$>SQB8TI@1%S3/%4,8#DD3R(\41,RBYZ$$SUW&VEV4$8;Q$[
M\)VV2WQQE:(=J+S8W/X@W,FXG#/71YS0;P335A#2C;TOA^2A#D9MPA@A73 $
MPNN/5^[,F@^"&]+#KI,S"CM '6I86BYE/']F;VQ^$(G=""!B/H_T]%WVXP9F
M5SZP)7[+EV/,H[\#\LQO/#B3;.1X%ZBWC &/U10ZG>1;IFQN?Q"LON1<0_8$
M?4R);!&-LCK\=,1FSL3-!_)VCA<[99[G+WFDFAX$>7<-TY0]R7TB#["T5SBR
ML?E!.-,2)2\8ZI^($_>4MLLXZQ"^<2#9*K/[6>%-YZ,PG987:\550S'?%DQL
MYVV;Q$%0UQ;?OF5</DZXW96LE@?A0L/#C'5'BV[>I7WQT>9.*"SLCI+/A"W6
MRYO/;86!]NY_M(>)A\!8#M?7R@/Z3TR=[2QNDS@(-MMDC.UYM&JSY@P$%$/C
M%H&#<"@QT*W?'@UC7?1D(,R65P;!/*-F ;!#'4XA]+DG8QL:'P3%RS&"/KDV
MB6_KV$SC9H$"5!4@Q?4Y&1-:P)6X FL!F-J/M=;_:R?$TO(19JX!58P=&0T/
M(J'6)N/, ->I[/(!S&@O%5=7\@G_=QV5US.CKV!_^? ?4$L#!!0    ( "Z
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M V Y):M@0'V?&*C ^GHP&(]A,CX>#N(=%2E* ,8$R0[MEBS6RGJO2%06<@X
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M_ORA5P8:S>:-;F$UFR>JANW=,>LJ6?!WO0%NGJ/>QU(2>?^UL\OTE'0Y!$N
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M>.["8\L@:E7*^03-ALHXU]+2"RI?0\3=*#_*5*;M1Q)Y$+C_\4"\<)YDRU,
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M93PYLTMB.K['NB#*! YM>++:A^HJGP=FQRR".D)OD")Y%MAL-NP2T!K9!"_
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M'0G!.B*<!*Z5U=PL5]BQZI-W@A/M9=[ _9S$14[@YG88+WTI1!Q<#/WUO *
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M.?3A!$.?XGEC]3XLQWE$,F"C/!/509H'J6_>).9/62'+E<K+1A2_?';;J-\
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M3%H!GO_X/T3K/VZL\?SQ!Z#<3[__,_D9[XC<_V*GBC+Z/P!02P,$%     @
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M/:JG5V51+<_^^UG>F7CUD+/S]0LO*\Z[!Q0'>R1-0Q@Q)X&(.*$XJD0^C+S
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MTZR)D(?8Y8Y/$(S<1"AK2#!,?$1@%/(@=%SJ.JY6CX_NXA,KZ%U>X15@'8*
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M]1T5][VBCK]P[+"UW4C'4ER/?N;L7MR7%C+05)]6=KDQN]15/_)]G"8N]+W
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M+U[EZ,6(HSCPQ.X:(RYV5S<D$&,WA1S[81")VYA'-9W2N\5GT$Y)2GN0_1L
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MVVP/XT9>B^XZLWDJ#C#?]4X<^K7A!++\\3%K\L@7:W$HKX<(\[7L'7^@ U^
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M%C,LNUGA4ES._XYEY7MU5=QD]P]5VP[=IR2B<8J;!K;(2QDDB"$8Q"XF!*.
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M[4O/FY.8EF'.UU;%X$G+Y,-2\$*/*ZVM4QVY36.<ZVQEE">2(1PF*:(1BU%
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M*(<[L]4:%OOQ?'[U4[!Z1.\'M1,\+LM"5+!>_'UKC+U7S^?>AK:W)0[8G/L
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MQ/+RQV.=1@"<K];U_LAJJ$NC[ZYNO1OU_\L?RB5X%%Z3!7'6O+5.-(;#4"Z
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M?+Y^_^7*N_SV[>KA&\RB -$U,RSC80:S+VL^ZD9"6TZ:IF#5^)..[7!P9'&
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MGQ/F^R*+A=V9X)C6V*ET"K-"%DSOWTT,]3:O1/FC3@UMN/'>U?QX(; 94Q^
MP-/ >;#8^O\7+0 77@O " ,M#41T[>.?H/0V7GVWR)U^?,\KEK=*Z]AR&WA>
M*S@.$R$903*.*<(TB%%."4%Q&H8RR'P9!$;=4OK)C*S;>RT8VHX+NMYP>S/2
M_B/PT-^!F>%ET=E( "^&-L*V!$=0XGZ97%W\G"8R[25/KZ!'%SK]3\,4-B^6
MU>Q>5*NR8*NV!5M=Y=U^^Q+L2]\/<^3S1&W),2?Z9)TCQGP<9S2-<&B4@CI
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MM B[M9T=3]BY&H:J5I>-4(P#'DF.:)RJ(V9,I3KPI+YR+%*9^21+DA!#? H
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M"PK4E8*+:NU'U:3&<*#V97#N/;7+OY'KM"]<M]]T\)RMCC5)'LV=WP/]V;;
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MR>:^:LQ+_]OHN6H[N6N>O6C3)KG[G;D5/_WPI_5OQ(>$ _[A3_\'4$L#!!0
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M?FN]NH/?=C)OX-A&H_\HD^.-M[0T[E84Q2"UH!@?24W0^1 L!N5DJ)WO>$+
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M!-<I9.]PZ]7V;E>DK=_G@LTAM!.5-@#5IP_,;B;A_0;S+Z5V\^Y%^&Q@E+8
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M6^< _SH;E)<UU&5!HC.^],/ PQJ$)3DE04%E(65GV=%[*AIY=U\QW;.9@!N
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M7J.HDJTJXR&7 ,=PGU,,G.C%';2T@CAO#5&,IT!S<"'4OD183LFVUN?IIS[
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M2)<K02!E'T1(>!:MA%TDY!%N\:L'S&Y+8[_8[18YDQ[4V#-<7^-C;W*)/M-
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M5?D#0;9LQ_,_)P-T<*W@SA'E$N[("(8X0&=;8_1O0_)4Q-KOYM8DL=\@N3F
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M9(_>D^VBY@IXLN.6'Q0&8JTUX,K!:&\%2R^>L+AQ<PPMA$9E+Y/J>4_V34N
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M"A.W@QCA,Y::XJ9" AV]9,\#-]PP8T/N@_-^DI8/EHN3LC-@[Y&6GYJ[^75
MC+@8EP%-9#I+M 883PGP/J0?42-5<4.9!"T?4Y<F96>X2A?4[YCA_4F(@S_.
M!GOA>-0A""2U8B6.1L//.("88<H$\P&V*Z8_^JGR?2PRT6<$S59@NP[VK_,6
M>Q)] 0"93%7BS$1_-3!@A0W&6*^YR-^8:V#W0/$.J)1=^=D:,(V8S#M;+">W
MJ7W/)SV9_ZZG=W[1A*2!<S.=W*P^E2NUU^53V1-]O><Y;MJ/:L.8T1P(CG&D
MDT/ 6&T IUA9IP06/O>5WK=KH2*4\0;9L+Z;"ZT#.LX(:$V-D,)2!G/[4N^E
MA4H7W-NT4.FBZ@KVMYW7$(+"EFA+ 28A!AE<B!CQ1OLJ/-,,6<N8'"/Q6__3
M=YW ;7.EIXNF*V3+NNQ3> F=(@A$W\ZD SP*M-0,*.>],<8[A<<(U=[%E9Y.
M"+>[TM-%W160YO5=$RR8A=YP0#U*E9Y* QFB]15.1 -LG*0^=^78^[C2TPG9
MHU=ZNJBY IX\^H,?[A]_^\O$SZ-0W^^_^)]^NEI04@@MC<. ,Y3>DHQ[M;$D
M &^""]Y:;[/GA=I)5OXP)^=V-0(:-7'L5Z^3&[A*:+V>W^:&'>40*<R!Y^EM
M9*M]:M\J ).2*VL)YCIW#Y=. I:U86,P9!\)L\-5$Q<_SW[<+1<KC:''1A.<
M,NLH0!*F4_MT$IJN1AB)':0!<9D]8#L@3B4\RT^"?70;B$BEY,*;J[Y!A*"Q
M!1[KN"T@C8'RF*;'WZE3@5!!WX)<N(8.(&7)U0>12LE%UE.!TB+HL ,X+HHX
M@9!J+'4T]YXYZ:3T.GL[D /BE"UC*$NN/HA40*X='<"L%@)Y@0%C6L?E 3U0
M@C(0($/,<&\]=9DYU;.7WILVF!GBW@_4<G4\>=:[R5@<N(EA+TQO:5(49R0M
M<X!Q1#RQWD#]W_:)T4X8M^VEUT7AI8_^]SV-B:B#4J1KFI2GDIJXH#3$#'@+
MC7!0V8"VCG_^$D^,=H*NS1.C7?18M$/>L4LI-CK\0@<,L*6I],]%XXH1!$P(
MZ5F B/EQ7QWX4N^KDODVGG[ZKF#W>5[H\NA\77.R6CA1,=1&Q1#"@/%*1(_.
MDN D#EJ.6;/V*$A-UJ8GQ >*TOKIN]ZW<3Z>77[^_>3J\^]GG[]^N[K\[=>S
MKU?9'\GI_I$LE1\#YY:MYF,^^:E3>X8G7BY.9NX7[VY215'JW/!PW^QU@8 /
M* 3+,/ R;HQ4(@Z4-0:X&#=Q1@-QV0^K!H@[?#O<?'K]@' TZ-)Q"YA&)LX^
M67DK'> ,<BUBO(ID?F?ZA0BE;=G;,.?U-MD?APJVQUUJNYPL_OUP)!Z$<SH]
M^QOG$1U%;8%D!@&&/:-<D2!M[@Z@A^2IA6 ]@-Y+FH%:KXI!I\ULM9Z>G9,C
M:33F1@"%T[T<',,6HR1-?>N,Q\(0)O(GA/;+4PN#AJ*^ETX#(:B 3L^[XYSJ
M'YMW: PQB!H,=*"I&#UU'F 0 D*BV@@E%F9O&;I3D%H(-!3G)K?2*V#.CBP:
MIP$SB>,,9,IT*!X#&6<M4(P0QQ1%BN<^XZCO;9><V]8@#5?'D6?Y->UX6/7V
MMU[%>?" TJFQ!=C3&.S&F7@R[BM %>>B.V'<-A?=1>&UYJ(QHU(8[0"T,O5M
MB+;1>*@ #S9EW01%8<N[^4ODHCM!UR87W46/%1B1=4CYT2\F-[,'.-(R,7&#
MI"HHP$SJCB2=!,9Q"C#C*.Z7R!F2.Q&]6Y+2!Z#Y-IP,FJZ2+^N%1 A4VOM5
M%W^6VO8Q8 27(!"! K?:2Y>[4?4^6<J:FAPX'Z5.#Z570)[-!+P[6:SG]&24
M-V=YF!(B8M@H&(NNOQ$.*(T9D!XRA;56\=_LSLM1L6JC5!_\7WDS><&H@%\[
M[\(()XFGE()@T_,VV'L@L4N]J(B@D&$<LM?Q]+Y7-N*!:KZ-;+"6*V3*Y@4V
MZYP.,(K-G4^]0050,E612ZU%--<$V]SW<=_-G;)."+>[4]9%W160YO5E)^X%
M5"FS&9R(SCY5"!BD''">(0>)AISFCK3?QYVR3L@>O5/61<T5\.3)V'YY+$,P
M,4K&G$B@XGX*J(Y[ME(^AH78,L(Y<4ZP[&[-*S%*MPT:X]2IGXZKHDGD^JHP
MX;$#N@N:4PZX3]U+"(I>G1,!.$<]4AQ+CO)W>-DM2^FLS4"0]Y)F@,:K8DY*
M/IV'S0G*M8 .41?-(P]4 ,IM-)0BQIR<*(;C3*)1'J]LY*4LM9P4Y&;. (W7
MVMU[9[G4!SW5,^N_??=^^24Q,GXDM<S9Z&%(6Z!A'QRO1*S?G"LH%V/!:\Y2
M5S-'2&0A-$ ;$1VOX%C\%5M'_L+E8EJJZ&XZ#0(A-"YL'?T(Q"C W#NO!!(N
M^^.^?YERL2[,.58NU@6'"G;1?8E:J+SW-$05I!,AN++H,>R%P1F#"8UQ2&Y/
M?<#1QYN5B'4"M^711P=-5\F7S1U*SU$(CL2@U$4?0+&HFO0"F_71'<#>:N9R
M9XW>U]%'%YS;'GUT47H%Y&F3;=>::>J$!9HJE2RP!R8H S#2*(;"#+OLG3_>
M[]%')_Q[''UT :,"?NUR75>+CQF%#8$(D*!3+2;F0 6G8GQK#0PH4"MS/_ZZ
M3Y9:0L+A&UH6;5?*FO7ZXE!2YV.T; )%J3M$C):%E(!3:[!CR$>'\0UX4\.V
ME@?M%A3JH?H*2'0Q]S_TQ)W]^<//%CX%'N?+[WZ^?A#M9+'PRTTBWRLC((E&
MFUG'X\RD HI%RXH\590H&W^:.TYM+UU]).O#A^9-P*F =JMY?&UF=L=4A,(<
M<:\ H2ZZG20&M))1"+QB!$,7IV9RG_D?$*?LOC<2L7*IOP(F';S+PA62CJ@
MH( .4!;C%L4@!<)%]2 CO5/Y'P$>>&_LS>HAA_A0V;1>%8-V7&:Q-&AGF$NO
M340EV51$A:$%4!O%@V<V:G$T!KVK>V.=4.]R;ZP+!!70:<\5)LF5BG$M@"$]
M7&Q%M-9.*Z")D,[R:&M%[C33>[LWU@GG=O?&.BB] N;L.O=T& =C:.KOG)I(
M.BR ,L8"2Z&23(3T#G(EI2=O5O^89^/JI^.J:/+@MUU'*TNDMAY R%G*TZ84
MK=; 0.LM10RR[ T4MV6HQ:ST!'4O27IH^%T5"L0(<ZG__$<TOU^:Q2*U5-EQ
M&IF[6*#31\<K&.@_]PJ*!C!*-M![0!S%@'JA@"0"@F@"132"6./M[G-_I:(!
M3Y"C"M.4N]. RA" HCK^D2HEL Z>FORO$_U%B@:Z,.=8T4 7'*K:.7?$+X('
M'?<& E0J+J/64Z YDB"Z$Q[":.EA]EN3[Z?'3">@N^0*NFB]*@;M"&"@LT8P
M;8%AP0-*I8L. K% !(L%AY8Q-UZ9^+O*%71"O4NNH L$%=!I=]B*TS4]&5U7
M%".=. D2@%0^74J/@2LE4%.<.P'^WG(%G7!NE2OHHO0JF!.=6_\MPK'J$?_B
M9!,IZ)E5 3 L J"&&Z"#LS'^0<H33.*/<WM'!\2IJW!@R$:62^?UTF>]NC#T
MW K-XQ32;4&A(= HS@C+0)3AF,KLG8P/"E36$&6#O1V=>F!0!:$>C.KZK'IS
M!9V@P @14>I5K)$:=Z6G#+6TEB-CM'MZRCGS3O9"D"H)U ?H/5M9?ZU70)U=
MV;L K3?8Q'4%=700I?7 :,V UA!:A#2!>+Q; =W2WF]V7ILG!NNGXPIH\E#Z
MTMS&[W^/9%\%%FE=I>3=J5Y\_S1M_DCY#[_)Z'WPH9G[2V^G>K&8A,G:;,_<
ME?[SVFME+$5QK4F8)B\%B(O% L\5]R2N.LAS5P9DG4 MOGE/.NVJ1RF"[7LD
M]O:T'Y219FX59@H*#""1++DC&FC%)? 4QG\HIQ*'TJS>*WTM@4(A2N=!M=;3
MIV]7YZ?_Y\/)M[./G[^>GGU-1S&GY[]>G'W]=G+U^?SK@".FEB-G.4?J,XM<
MAT6/F?QT@?DV^7NK"5SZ:;H+<=HLEHMOWR/5C5YX=Z'O'\X$-EE_Q$-PV/CH
M6P:2FDU)((-6  G#/*3::96]CF"0Q(/[O=COWMU-X[=7W_B0OO%<BM7_79S<
M+;\W\\G_\^ZWB-'\V[*Q_S[_D7Y^,=6SQ8?[LS_]W$X6_F(^L?Y2SVXVSIB@
M5!)MTU,D'%!./)#>26 Y=HH%8IW+;6G'G5%AA^+MV/VJ8TT]1*G &3GY0\_=
M4]LHBP.*B@4!QOV&,DW2!HA ("C&J!H&A7+?/WHA0%E2UL2,)A=,%7!LMS9/
MYO.DF]7"_G#_]'?6BWTUXZ=ISUS2[K->P,$10SQ)'<ZT23WB77339'3=J&.4
M"Z\XR5T0,<8\RC)^ *VVK6IIC$NWZO[E]'-T^..DHN?_VVSR>+V"::R,BUL5
M]T''54]C<"JH :G#K&<HQ'"#''-Y#WV@L,DL#GN3&8,*[.5&'0]E]EX:A)D
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MY8-VDBUL9JLSQ!3E$Q%C-(8H\%Q*0&&<D4J1'T9($LL4A=OO)PYWU@X)5)9
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MX,\%8'VHMH14^SNIDWQ^/[P97MSV!!ZWI4<Q [FILER.(YW-0)''>^L8D+@
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MVL#*-M*8,*"@)_GJ@.80>R_...Q*) ZJG6=3S/RLTUJ,EA[N%C9-"O>MA?J
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MM'!!5=1Q;2M'JC4&,FBT/G2K99RI#U@&;LDR3BDD1"UHZ3MKGM0LFPF FG2
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M_XB PN[VD1OB-SLF%Q\M+[_QA([D@I?KR?[[<1JNX,<LCZ.W_P]02P,$%
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M# 0"?0!H%%R/)*R$1&L$?"#)0OV)2E AF))9I_5B-D<Q(^VBE7;D5"]:RMW
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M@YN.G\/JJJE3B"C"6&N.Z4K] #6VNQR0GYTI?.@.,U"8SJ(&70Q!9;P<+N]
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M;?/W)NT5I\"L1FT_CK-P ?],BR2^^G]02P,$%     @ +H"76(/WZU0_%@
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M:@VH7Q]U)\ET1)@K23+B:.3A7VK]P>WE@='7#H]#>*)&2AIEDXWA8"P];7!
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MUB4+5IRS6DK>E Q\K>0L*Z4KMG0;?'.EGGZ!/ZTC[4*T;98JKX0U& +/(MM
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MI_FG @UU&8RXZ::_7%@$IY.\/ ":0 (9.OTZ!\W(X2N!WP2@.=.=CP[JL0\
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MS7CSN&LQ-!ZP*&?E7LM,;L?A:YGIV9>9\EBU04IDNT\6Y<Z^NO@$CI[6N34
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MUWIMACC4FR%Z=1F!A6?NNH>YSYS?/O\D7V<8>^H@1MHZ)8UY??4I%N7TQ&(
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MSJ;M%W?VM@3ZA8H4NQ[J1_4MDKQ@(8$+-&E3UL,Z[# B9FJNZ^5T7L#O$G.
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M@X-F^W[Y!42UXZ.:*LJ-%>@FAN>OZ)WV'N:=OK)W[[\R=_[_'U!+ P04
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M8-J6KV\#4WR^)P>]X=] [7<'/^&LD\K:W7\(T_^8$,AFI9A03&TQ 3;^3+M
M)Y"B*LS#Y=6*B-;)S%(A S*:C+**;M(0'7=JD!)T<:;0*IR%7#UV6FEI-1N@
M8]X+]%KQ3+7C7!3VD@N)*Y"/<02%< H*@Z:H@W1:%Y(Y$V8%)58Y#2-BAEQ/
M[/@U)A8$K6$\J<>DL2>/O/&#D'=O4M@ X/WIY-XX!'9G6C&\I#.59-Z4#M#D
M@H@Q)ZU:QA^(U'*L"^T7G.MN6I9W0X!*0$$$\A71M8(JT//7QJ!I;:= H0NY
M.4V-54&!4%I-J$+*+0!&]-"44<XB*!LCX+ ;]!0,^9P@)[;3.S WG,FB#I3
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M:G_[D-LN0V^]*&Z>\=KZ3;@N_P]02P,$%     @ +H"76+"W56H+!P  'Q\
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MA+#'2=B 4CF-7,)I::9\ 0/=A-*@(,\[@6HF@YE3#,O$:+[JA@"89X*7W:_
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M94IKM[B+@0U&V\LA<N2,KOWM0VZ[_+SU2KAYQ@OJ-^%B_$]02P,$%     @
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MYS]02P$"% ,4    "  N@)=8%&LQ%B+*  #0G@L $0              @ $
M    8FEO<RTR,#(T,#,S,2YH=&U02P$"% ,4    "  N@)=8X=1[JB,-  "^
M@0  $0              @ %1R@  8FEO<RTR,#(T,#,S,2YX<V102P$"% ,4
M    "  N@)=8'4TRY04<  "C! $ %0              @ &CUP  8FEO<RTR
M,#(T,#,S,5]C86PN>&UL4$L! A0#%     @ +H"76&#0"]Q$-P  ?E0" !4
M             ( !V_,  &)I;W,M,C R-# S,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( "Z EUATGV;Z%Q\  !X\   4              "  5(K 0!B:6]S+3(P
M,C0P,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( "Z EU@]:#&VC,L  -Z_!P 5
M          "  9M* 0!B:6]S+3(P,C0P,S,Q7VQA8BYX;6Q02P$"% ,4
M"  N@)=8U1=M3CET  !X.@4 %0              @ %:%@( 8FEO<RTR,#(T
M,#,S,5]P<F4N>&UL4$L! A0#%     @ +H"76 +$1'= &@  <*0  !X
M         ( !QHH" &5X,3 Q+6]P=&EO;F-A<F5X97AE8W5T:79E+FAT;5!+
M 0(4 Q0    ( "Z EU@=BQ\A<!<  %&,   >              "  4*E @!E
M>#$P,BUO<'1I;VYC87)E>&5X96-U=&EV92YH=&U02P$"% ,4    "  N@)=8
M@_?K5#\6  !QD@  '@              @ 'NO ( 97@Q,#,M;W!T:6]N8V%R
M97AE>&5C=71I=F4N:'1M4$L! A0#%     @ +H"76$);#U'(#@  ^E\  !X
M             ( !:=," &5X,3 T+6]P=&EO;F-A<F5X9&ER96-T;W)X+FAT
M;5!+ 0(4 Q0    ( "Z EU@=+WR1& <  #4?   ;              "  6WB
M @!O<&-H+65X,S$Q>#(P,C0P,S,Q,3!X<2YH=&U02P$"% ,4    "  N@)=8
ML+=5:@L'   ?'P  &P              @ &^Z0( ;W!C:"UE>#,Q,G@R,#(T
M,#,S,3$P>'$N:'1M4$L! A0#%     @ +H"76,.3[EG: P  ?@X  !L
M         ( ! O$" &]P8V@M97@S,C%X,C R-# S,S$Q,'AQ+FAT;5!+ 0(4
M Q0    ( "Z EUB_8,:(U@,  'X.   ;              "  17U @!O<&-H
M+65X,S(R>#(P,C0P,S,Q,3!X<2YH=&U02P4&      \ #P @!   )/D"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>bios-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bios="http://www.bioscrip.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bios-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bios:LegacyHealthSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:LargestPayerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:LargestPayerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bios:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bios:GovernmentHealthcareProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bios:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">bios:FourVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">bios:FourVendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:CommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:GovernmentCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bios:PatientCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:RestrictedStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bios:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:InfusionPumpsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bios:EquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:SecondLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:SeniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LienCategoryAxis">us-gaap:JuniorLienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienCreditAgreementSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-07</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:CreditAgreementsEnteredInto2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienCreditAgreementSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bios:FirstLienTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-03</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bios:HCIIncentiveUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bios:A2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2017WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bios:A2015WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-06</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014739</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pharmacy">
        <measure>bios:pharmacy</measure>
    </unit>
    <unit id="suite">
        <measure>bios:suite</measure>
    </unit>
    <unit id="segment">
        <measure>bios:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001014739</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-11993</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">OPTION CARE HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">05-0489664</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3000 Lakeside Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 300N,</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Bannockburn,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">60015</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">940-2443</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">OPCH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">173816267</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">219513000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">343849000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">573650000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">377658000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">241948000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">274004000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">94603000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">98744000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">1129714000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">1094255000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">120969000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">120630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">87789000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">84159000</us-gaap:OperatingLeaseRightOfUseAsset>
    <bios:FiniteLivedIntangibleAssetsNetExcludingCustomerLists contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">19317000</bios:FiniteLivedIntangibleAssetsNetExcludingCustomerLists>
    <bios:FiniteLivedIntangibleAssetsNetExcludingCustomerLists contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">20092000</bios:FiniteLivedIntangibleAssetsNetExcludingCustomerLists>
    <bios:FiniteLivedCustomerListsNet contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">307482000</bios:FiniteLivedCustomerListsNet>
    <bios:FiniteLivedCustomerListsNet contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">315304000</bios:FiniteLivedCustomerListsNet>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">1540246000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">1540246000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">44045000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">42349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">2119848000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">2122780000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">3249562000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">3217035000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">485736000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">426513000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">42624000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">92508000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bios:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">83383000</bios:AccruedExpensesAndOtherCurrentLiabilities>
    <bios:AccruedExpensesAndOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">75010000</bios:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">19209000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">18278000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">6000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">6000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">636952000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">618309000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">1056282000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">1056650000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">89207000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">85484000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">37884000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">34920000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">89000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">1183462000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">1177054000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">1820414000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">1795363000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-83" unitRef="shares">12500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-84" unitRef="shares">12500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-86" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-89"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-90"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-91" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-92" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-93" unitRef="shares">183397817</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-94" unitRef="shares">173816056</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-95" unitRef="shares">182905559</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-96" unitRef="shares">174575537</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-97" unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-99" unitRef="shares">9581761</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-100" unitRef="shares">8330022</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-3" id="f-101" unitRef="usd">295396000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">255107000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-103" unitRef="usd">1205693000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">1204270000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-105" unitRef="usd">502304000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-106" unitRef="usd">457513000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-107" unitRef="usd">16529000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">14978000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-109" unitRef="usd">1429148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">1421672000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-111" unitRef="usd">3249562000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">3217035000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">1146052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">1015848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">907552000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">786843000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">238500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">229005000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">154742000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">147866000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">14728000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">14514000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">169470000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-124" unitRef="usd">162380000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">69030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">66625000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">13202000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">13834000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">1125000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">1437000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-12075000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">-12396000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">56955000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-136" unitRef="usd">54229000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">12164000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">15021000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">44791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-140" unitRef="usd">39208000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">454000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax contextRef="c-5" decimals="-3" id="f-142" unitRef="usd">-1152000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">1551000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-5" decimals="-3" id="f-144" unitRef="usd">-3443000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">1551000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-3443000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">46342000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-148" unitRef="usd">35765000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-153" unitRef="shares">173928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-154" unitRef="shares">181262000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-155" unitRef="shares">175624000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-156" unitRef="shares">182735000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">44791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-158" unitRef="usd">39208000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">15305000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-5" decimals="-3" id="f-160" unitRef="usd">15225000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">7663000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-5" decimals="-3" id="f-162" unitRef="usd">5540000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">2964000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-164" unitRef="usd">8626000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">1132000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-5" decimals="-3" id="f-166" unitRef="usd">1083000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">1125000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-168" unitRef="usd">1437000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">9605000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-170" unitRef="usd">5988000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">750000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-5" decimals="-3" id="f-172" unitRef="usd">2500000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">108000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-5" decimals="-3" id="f-174" unitRef="usd">198000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">195992000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-5" decimals="-3" id="f-176" unitRef="usd">17812000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-32056000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">25362000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">-4878000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-180" unitRef="usd">-9977000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">59223000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-5" decimals="-3" id="f-182" unitRef="usd">70127000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">-49884000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">-28356000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">6811000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">14831000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">6651000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-188" unitRef="usd">5271000</us-gaap:OperatingLeasePayments>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">418000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">5313000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-68784000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">89752000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">5820000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">5760000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-5820000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">-5760000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <bios:ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-8182000</bios:ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding>
    <bios:ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">-1902000</bios:ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding>
    <us-gaap:RepaymentsOfDebt contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">1500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">1500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">40050000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">75000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">-2000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">-49732000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">-80402000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-124336000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">3590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-209" unitRef="usd">343849000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-210" unitRef="usd">294186000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-211" unitRef="usd">219513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-212" unitRef="usd">297776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">12173000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">11161000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">7085000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">6527000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-220" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-221" unitRef="usd">-2403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-222" unitRef="usd">1176906000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-223" unitRef="usd">190423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-224" unitRef="usd">21159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-225" unitRef="usd">1386103000</us-gaap:StockholdersEquity>
    <bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings contextRef="c-14" decimals="-3" id="f-226" unitRef="usd">1902000</bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings>
    <bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings contextRef="c-5" decimals="-3" id="f-227" unitRef="usd">1902000</bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-228" unitRef="usd">5988000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-229" unitRef="usd">5988000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-15" decimals="-3" id="f-230" unitRef="usd">75735000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-5" decimals="-3" id="f-231" unitRef="usd">75735000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-232" unitRef="usd">39208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-233" unitRef="usd">39208000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-234" unitRef="usd">-3443000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-235" unitRef="usd">-3443000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-236" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-237" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-238" unitRef="usd">-78138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-239" unitRef="usd">1180992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-240" unitRef="usd">229631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-241" unitRef="usd">17716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">1350219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-243" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-244" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-245" unitRef="usd">-255107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-246" unitRef="usd">1204270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-247" unitRef="usd">457513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-248" unitRef="usd">14978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-249" unitRef="usd">1421672000</us-gaap:StockholdersEquity>
    <bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings contextRef="c-30" decimals="-3" id="f-250" unitRef="usd">8182000</bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings>
    <bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">8182000</bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-252" unitRef="usd">9605000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">9605000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <bios:StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects contextRef="c-31" decimals="-3" id="f-254" unitRef="usd">40289000</bios:StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects>
    <bios:StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">40289000</bios:StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-256" unitRef="usd">44791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">44791000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-33" decimals="-3" id="f-258" unitRef="usd">1551000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">1551000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-260" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-261" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-262" unitRef="usd">-295396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-263" unitRef="usd">1205693000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-264" unitRef="usd">502304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-265" unitRef="usd">16529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-266" unitRef="usd">1429148000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-267">NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Corporate Organization and Business &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 93 full service pharmacies and 84 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients&#x2019; homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company&#x2019;s stock is listed on the Nasdaq Global Select Market as of March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company&#x2019;s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company&#x2019;s share of earnings from equity-method investments is included in the line entitled &#x201c;Equity in earnings of joint ventures&#x201d; in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the Company&#x2019;s equity-method investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <bios:NumberOfServiceLocations
      contextRef="c-3"
      decimals="INF"
      id="f-268"
      unitRef="pharmacy">93</bios:NumberOfServiceLocations>
    <bios:NumberOfInfusionSites contextRef="c-3" decimals="INF" id="f-269" unitRef="suite">84</bios:NumberOfInfusionSites>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-270"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-271">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company&#x2019;s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-272">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-40" decimals="2" id="f-273" unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-274">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March&#160;31, 2024, cash equivalents consisted of money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $49.1&#160;million and $52.0&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Method Investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March&#160;31, 2024 and December&#160;31, 2023, the balance of the investments was $21.3 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company&#x2019;s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company&#x2019;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#x2019;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company&#x2019;s proportionate share of earnings was $1.1 million and $1.4 million for the three months ended March&#160;31, 2024 and 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $0.8 million and $2.5 million, respectively. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for discussion of related-party transactions with these investees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#x2019;s largest payer was approximately 14% for the three months ended March&#160;31, 2024 and 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, approximately 12% of the Company&#x2019;s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 14%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12%, respectively,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Company&#x2019;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company&#x2019;s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, approximately 66% and 72%, respectively, of the Company&#x2019;s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#x2019;s financial condition or operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-275">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March&#160;31, 2024, cash equivalents consisted of money market funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss contextRef="c-3" decimals="-5" id="f-276" unitRef="usd">49100000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss contextRef="c-4" decimals="-5" id="f-277" unitRef="usd">52000000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-278">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Method Investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March&#160;31, 2024 and December&#160;31, 2023, the balance of the investments was $21.3 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company&#x2019;s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company&#x2019;s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company&#x2019;s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company&#x2019;s proportionate share of earnings was $1.1 million and $1.4 million for the three months ended March&#160;31, 2024 and 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $0.8 million and $2.5 million, respectively. See Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for discussion of related-party transactions with these investees.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestments contextRef="c-3" decimals="-5" id="f-279" unitRef="usd">21300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-5" id="f-280" unitRef="usd">20900000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-281" unitRef="usd">1100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-5" id="f-282" unitRef="usd">1400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-41" decimals="-5" id="f-283" unitRef="usd">800000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-42" decimals="-5" id="f-284" unitRef="usd">2500000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <bios:ConcentrationRiskBusinessRiskPolicyPolicyTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company&#x2019;s largest payer was approximately 14% for the three months ended March&#160;31, 2024 and 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, approximately 12% of the Company&#x2019;s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 14%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12%, respectively,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Company&#x2019;s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company&#x2019;s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, approximately 66% and 72%, respectively, of the Company&#x2019;s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company&#x2019;s financial condition or operating results.&lt;/span&gt;&lt;/div&gt;</bios:ConcentrationRiskBusinessRiskPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-43" decimals="2" id="f-286" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-44" decimals="2" id="f-287" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-45" decimals="2" id="f-288" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-46" decimals="2" id="f-289" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-47" decimals="2" id="f-290" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-48" decimals="2" id="f-291" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-49" decimals="2" id="f-292" unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-50" decimals="2" id="f-293" unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-294">REVENUE&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the net revenue earned by category of payer for the&#160;three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial payers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;873,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,015,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-295">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the net revenue earned by category of payer for the&#160;three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial payers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;873,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government payers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,015,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-51" decimals="-3" id="f-296" unitRef="usd">988043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-52" decimals="-3" id="f-297" unitRef="usd">873911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-53" decimals="-3" id="f-298" unitRef="usd">138310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-3" id="f-299" unitRef="usd">122789000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-55" decimals="-3" id="f-300" unitRef="usd">19699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-56" decimals="-3" id="f-301" unitRef="usd">19148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">1146052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-303" unitRef="usd">1015848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-304">INCOME TAXES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company recorded tax expense of $12.2&#160;million and $15.0&#160;million, respectively, which represents an effective tax rate of 21.4% and 27.7%, respectively. The variance in the Company&#x2019;s effective tax rate of 21.4% for the three months ended March&#160;31, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the three months ended March&#160;31, 2024, the Company released $2.2&#160;million of state valuation allowance. The variance in the Company&#x2019;s effective tax rate of 27.7% for the three months ended March&#160;31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to difference between federal and state tax rates, as well as various non-deductible expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a valuation allowance of $4.2&#160;million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s tax expense of $12.2&#160;million and $15.0&#160;million for the three months ended March&#160;31, 2024 and March&#160;31, 2023, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.&lt;/span&gt;&lt;/div&gt;The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (&#x201c;Code&#x201d;) Section 382 limitations. This may limit the Company&#x2019;s ability to utilize its federal net operating losses</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-305" unitRef="usd">12200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-306" unitRef="usd">15000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-307" unitRef="number">0.214</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-308" unitRef="number">0.277</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-309" unitRef="number">0.214</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-57" decimals="-5" id="f-310" unitRef="usd">-2200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-311" unitRef="number">0.277</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-58" decimals="-5" id="f-312" unitRef="usd">4200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-313" unitRef="usd">12200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-314" unitRef="usd">15000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-315">EARNINGS PER SHARE&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March&#160;31, 2024 and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;871,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s basic earnings per share and shares outstanding (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Earnings per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s diluted earnings per share and shares outstanding (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Earnings per common share: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-316">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock option awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;871,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance stock unit awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-317" unitRef="shares">880815</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-318" unitRef="shares">871491</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-319" unitRef="shares">279144</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-320" unitRef="shares">342894</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="0" id="f-321" unitRef="shares">149561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="0" id="f-322" unitRef="shares">90159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-323">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s basic earnings per share and shares outstanding (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Earnings per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s diluted earnings per share and shares outstanding (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Earnings per common share: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">44791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">39208000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-326" unitRef="shares">173928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-327" unitRef="shares">181262000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-328"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-329"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">44791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-331" unitRef="usd">39208000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-332" unitRef="shares">173928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-333" unitRef="shares">181262000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-334" unitRef="shares">1696000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-5" decimals="-3" id="f-335" unitRef="shares">1473000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-336" unitRef="shares">175624000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-337" unitRef="shares">182735000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-338"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-339"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-341">LEASES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company incurred operating lease expenses of $7.9 million and $7.0 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March&#160;31, 2024, the weighted-average remaining lease term was 7.0 years and the weighted-average discount rate was 6.36%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; re&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March&#160;31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-340">LEASES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company incurred operating lease expenses of $7.9 million and $7.0 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March&#160;31, 2024, the weighted-average remaining lease term was 7.0 years and the weighted-average discount rate was 6.36%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; re&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of March&#160;31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-342" unitRef="usd">7900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-5" decimals="-5" id="f-343" unitRef="usd">7000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-344">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="4" id="f-345" unitRef="number">0.0636</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases mature as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-347" unitRef="usd">19522000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-348" unitRef="usd">25120000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-349" unitRef="usd">22276000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-350" unitRef="usd">18617000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-351" unitRef="usd">12198000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bios:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-3" decimals="-3" id="f-352" unitRef="usd">42303000</bios:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-353" unitRef="usd">140036000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-354" unitRef="usd">31620000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-355" unitRef="usd">108416000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-356" unitRef="usd">11300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-357">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment was as follows as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Infusion pumps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equipment, furniture and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software, purchased and internally developed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets under development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(124,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(123,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment was as follows as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Infusion pumps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equipment, furniture and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer software, purchased and internally developed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets under development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(124,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(123,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation expense in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-65" decimals="-3" id="f-359" unitRef="usd">36484000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-66" decimals="-3" id="f-360" unitRef="usd">36943000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-67" decimals="-3" id="f-361" unitRef="usd">24685000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-68" decimals="-3" id="f-362" unitRef="usd">23593000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-69" decimals="-3" id="f-363" unitRef="usd">100109000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-70" decimals="-3" id="f-364" unitRef="usd">99725000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-365" unitRef="usd">50982000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-72" decimals="-3" id="f-366" unitRef="usd">50572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-367" unitRef="usd">33159000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-368" unitRef="usd">33668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-369" unitRef="usd">245419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-370" unitRef="usd">244501000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-371" unitRef="usd">124450000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-372" unitRef="usd">123871000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-373" unitRef="usd">120969000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-374" unitRef="usd">120630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-75" decimals="-3" id="f-375" unitRef="usd">576000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-76" decimals="-3" id="f-376" unitRef="usd">711000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-77" decimals="-3" id="f-377" unitRef="usd">6120000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-78" decimals="-3" id="f-378" unitRef="usd">6012000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">6696000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-380" unitRef="usd">6723000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-381">GOODWILL AND OTHER INTANGIBLE ASSETS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no change in the carrying amount of goodwill for the three months ended March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and accumulated amortization of intangible assets consist of the following as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(199,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(227,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(219,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for intangible assets was $8.6 million and $8.5 million for the three months ended March&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and accumulated amortization of intangible assets consist of the following as of March&#160;31, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Referral sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(199,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks/names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(227,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(219,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-79" decimals="-3" id="f-383" unitRef="usd">514388000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-80" decimals="-3" id="f-384" unitRef="usd">514388000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-81" decimals="-3" id="f-385" unitRef="usd">39136000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-82" decimals="-3" id="f-386" unitRef="usd">39136000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-83" decimals="-3" id="f-387" unitRef="usd">985000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-84" decimals="-3" id="f-388" unitRef="usd">995000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-3" id="f-389" unitRef="usd">554509000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-390" unitRef="usd">554519000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-79" decimals="-3" id="f-391" unitRef="usd">206906000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-80" decimals="-3" id="f-392" unitRef="usd">199084000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-81" decimals="-3" id="f-393" unitRef="usd">20423000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-82" decimals="-3" id="f-394" unitRef="usd">19698000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-83" decimals="-3" id="f-395" unitRef="usd">381000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-84" decimals="-3" id="f-396" unitRef="usd">341000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">227710000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-398" unitRef="usd">219123000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-399" unitRef="usd">326799000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-400" unitRef="usd">335396000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-401" unitRef="usd">8600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-5" id="f-402" unitRef="usd">8500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-403">INDEBTEDNESS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revolver Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,086,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,062,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,056,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revolver Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,088,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,062,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,056,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate on the First Lien Term Loan was 8.19% and 8.21% as of March&#160;31, 2024 and December&#160;31, 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 8.20% and 7.28% for the three months ended March&#160;31, 2024 and 2023, respectively. The interest rate on the Senior Notes was 4.375% as of March&#160;31, 2024 and December&#160;31, 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt matures as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,086,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated fair values of the Company&#x2019;s debt obligations as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Markets for Identical Item (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;456,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,062,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,044,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (&#x201c;First Lien Credit Agreement Amendment&#x201d;). The First Lien Credit Agreement Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $400.0&#160;million (the &#x201c;Revolver Facility&#x201d;), pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. As of March&#160;31, 2024, the Company had $5.3 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $394.7 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revolver Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,086,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,062,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,056,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revolver Facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,088,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,062,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,056,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-85" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-85" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-85" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-85" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-86" decimals="-3" id="f-409" unitRef="usd">586500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-86" decimals="-3" id="f-410" unitRef="usd">6636000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-86" decimals="-3" id="f-411" unitRef="usd">9209000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-86" decimals="-3" id="f-412" unitRef="usd">570655000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-87" decimals="-3" id="f-413" unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-87" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-87" decimals="-3" id="f-415" unitRef="usd">8373000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-87" decimals="-3" id="f-416" unitRef="usd">491627000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-417" unitRef="usd">1086500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-3" decimals="-3" id="f-418" unitRef="usd">6636000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-3" decimals="-3" id="f-419" unitRef="usd">17582000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-420" unitRef="usd">1062282000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-421" unitRef="usd">6000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-422" unitRef="usd">1056282000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-88" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-88" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-88" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-88" decimals="-3" id="f-426" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-89" decimals="-3" id="f-427" unitRef="usd">588000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-89" decimals="-3" id="f-428" unitRef="usd">6974000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-89" decimals="-3" id="f-429" unitRef="usd">9678000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-89" decimals="-3" id="f-430" unitRef="usd">571348000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-90" decimals="-3" id="f-431" unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-90" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-90" decimals="-3" id="f-433" unitRef="usd">8698000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-90" decimals="-3" id="f-434" unitRef="usd">491302000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-435" unitRef="usd">1088000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-4" decimals="-3" id="f-436" unitRef="usd">6974000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-4" decimals="-3" id="f-437" unitRef="usd">18376000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-438" unitRef="usd">1062650000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-439" unitRef="usd">6000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-440" unitRef="usd">1056650000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-91" decimals="4" id="f-441" unitRef="number">0.0819</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-92" decimals="4" id="f-442" unitRef="number">0.0821</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime contextRef="c-93" decimals="4" id="f-443" unitRef="number">0.0820</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime contextRef="c-94" decimals="4" id="f-444" unitRef="number">0.0728</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-95" decimals="5" id="f-445" unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-96" decimals="5" id="f-446" unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime contextRef="c-97" decimals="5" id="f-447" unitRef="number">0.04375</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime contextRef="c-98" decimals="5" id="f-448" unitRef="number">0.04375</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-449">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt matures as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,086,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-450" unitRef="usd">4500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-3" decimals="-3" id="f-451" unitRef="usd">6000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-3" decimals="-3" id="f-452" unitRef="usd">6000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-3" decimals="-3" id="f-453" unitRef="usd">6000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-3" decimals="-3" id="f-454" unitRef="usd">564000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <bios:LongTermDebtMaturityAfterYearFour contextRef="c-3" decimals="-3" id="f-455" unitRef="usd">500000000</bios:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-3" decimals="-3" id="f-456" unitRef="usd">1086500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated fair values of the Company&#x2019;s debt obligations as of March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value as of March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Markets for Identical Item (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;First Lien Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;456,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,062,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,044,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue contextRef="c-86" decimals="-3" id="f-458" unitRef="usd">570655000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-99" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-100" decimals="-3" id="f-460" unitRef="usd">588729000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-101" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-102" decimals="-3" id="f-462" unitRef="usd">491627000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-103" decimals="-3" id="f-463" unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-104" decimals="-3" id="f-464" unitRef="usd">456250000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-105" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-3" decimals="-3" id="f-466" unitRef="usd">1062282000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-106" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-107" decimals="-3" id="f-468" unitRef="usd">1044979000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-108" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-109" decimals="INF" id="f-470" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-110" decimals="-5" id="f-471" unitRef="usd">5300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-111" decimals="-5" id="f-472" unitRef="usd">394700000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-473">DERIVATIVE INSTRUMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company&#x2019;s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company&#x2019;s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company&#x2019;s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300&#160;million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan&#x2019;s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and location of the Company&#x2019;s derivative instruments in the condensed consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value - Derivatives in Asset Position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain (loss) associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive income (loss). The following table presents the pre-tax gain (loss) from derivative instruments recognized in other comprehensive income (loss) in the Company&#x2019;s unaudited condensed consolidated statements of comprehensive income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amount and location of pre-tax income recognized in the Company&#x2019;s unaudited condensed consolidated statements of comprehensive income related to the Company&#x2019;s derivative instruments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-112" decimals="INF" id="f-474" unitRef="usd">300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract contextRef="c-113" id="f-475">P5Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-476">&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and location of the Company&#x2019;s derivative instruments in the condensed consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value - Derivatives in Asset Position&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets contextRef="c-114" decimals="-3" id="f-477" unitRef="usd">10421000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-115" decimals="-3" id="f-478" unitRef="usd">9746000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-116" decimals="-3" id="f-479" unitRef="usd">11513000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-117" decimals="-3" id="f-480" unitRef="usd">10183000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-3" decimals="-3" id="f-481" unitRef="usd">21934000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-4" decimals="-3" id="f-482" unitRef="usd">19929000</us-gaap:DerivativeAssets>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-483">The following table presents the pre-tax gain (loss) from derivative instruments recognized in other comprehensive income (loss) in the Company&#x2019;s unaudited condensed consolidated statements of comprehensive income (in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amount and location of pre-tax income recognized in the Company&#x2019;s unaudited condensed consolidated statements of comprehensive income related to the Company&#x2019;s derivative instruments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate cap designated as cash flow hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-118" decimals="-3" id="f-484" unitRef="usd">2005000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-119" decimals="-3" id="f-485" unitRef="usd">-4595000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-120" decimals="-3" id="f-486" unitRef="usd">2980000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-121" decimals="-3" id="f-487" unitRef="usd">2352000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-489">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Inputs to the fair value measurement are unobservable inputs or valuation techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Lien Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the First Lien Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Cap: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the fair value of the interest rate cap.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Money Market Funds:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other material assets or liabilities measured at fair value at March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-488">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Inputs to the fair value measurement are unobservable inputs or valuation techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Lien Term Loan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the First Lien Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the carrying amount and fair value of the Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Cap: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of the fair value of the interest rate cap.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Money Market Funds:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other material assets or liabilities measured at fair value at March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-490">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company&#x2019;s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company&#x2019;s condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-491">STOCK-BASED INCENTIVE COMPENSATION&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Under the Company&#x2019;s 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), approved at the annual meeting by the BioScrip, Inc. (&#x201c;BioScrip&#x201d;) stockholders on May 3, 2018 and amended and restated on May 19, 2021, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors, resulting in a total of 9,101,734 shares of common stock authorized for issuance. The 2018 Plan is administered by the Company&#x2019;s Compensation Committee, a standing committee of the Company&#x2019;s Board of Directors. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March&#160;31, 2024 and 2023. During the three months ended March&#160;31, 2024 and 2023, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $9.6 million and $6.0 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-122"
      decimals="INF"
      id="f-492"
      unitRef="shares">9101734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-5" id="f-493" unitRef="usd">9600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-5" id="f-494" unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-495">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2017 Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; During the three months ended March&#160;31, 2024 and 2023, warrant holders did not elect to exercise any warrants to purchase shares of common stock. As of March 31, 2024 and December&#160;31, 2023, the remaining warrant holders are entitled to purchase 51,838 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2015 Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; During the three months ended March&#160;31, 2024 and 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of March 31, 2024 and December&#160;31, 2023, the remaining warrant holders are entitled to purchase 13,365 and 13,888 shares of common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company purchased 1,251,739 and 2,475,166 shares of common stock for an average share price of $31.96 and $30.30, totaling $40.0 million and $75.0 million, respectively. All repurchased shares became treasury stock. As of March&#160;31, 2024, the Company is authorized to repurchase up to a remaining $210.0 million of common stock of the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-125"
      decimals="INF"
      id="f-496"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-126"
      decimals="INF"
      id="f-497"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-127"
      decimals="INF"
      id="f-498"
      unitRef="shares">51838</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-126"
      decimals="INF"
      id="f-499"
      unitRef="shares">51838</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bios:ClassOfWarrantOrRightNumberOfSecuritiesExercised contextRef="c-128" decimals="0" id="f-500" unitRef="shares">0</bios:ClassOfWarrantOrRightNumberOfSecuritiesExercised>
    <bios:ClassOfWarrantOrRightNumberOfSecuritiesExercised contextRef="c-129" decimals="0" id="f-501" unitRef="shares">0</bios:ClassOfWarrantOrRightNumberOfSecuritiesExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-130"
      decimals="INF"
      id="f-502"
      unitRef="shares">13365</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-131"
      decimals="INF"
      id="f-503"
      unitRef="shares">13888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c-132"
      decimals="-5"
      id="f-504"
      unitRef="shares">500000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="INF" id="f-505" unitRef="shares">1251739</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-5" decimals="INF" id="f-506" unitRef="shares">2475166</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-1"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">31.96</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-5"
      decimals="2"
      id="f-508"
      unitRef="usdPerShare">30.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-5" id="f-509" unitRef="usd">40000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-5" decimals="-5" id="f-510" unitRef="usd">75000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-3" decimals="-5" id="f-511" unitRef="usd">210000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-512">RELATED-PARTY TRANSACTIONS&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transactions with Equity-Method Investees &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.5 million and $1.3 million for the three months ended March&#160;31, 2024 and 2023, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March&#160;31, 2024 and 2023, the Company received distributions from the investees of $0.8 million and $2.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had amounts due from its joint ventures of $1.0 million as of March&#160;31, 2024. The Company had amounts due to its joint ventures of $0.5 million and due from its joint ventures of $0.1 million as of December&#160;31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-41" decimals="-5" id="f-513" unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-42" decimals="-5" id="f-514" unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-41" decimals="-5" id="f-515" unitRef="usd">800000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-42" decimals="-5" id="f-516" unitRef="usd">2500000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:OtherReceivables contextRef="c-133" decimals="-5" id="f-517" unitRef="usd">1000000</us-gaap:OtherReceivables>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c-134" decimals="-5" id="f-518" unitRef="usd">500000</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:OtherReceivables contextRef="c-134" decimals="-5" id="f-519" unitRef="usd">100000</us-gaap:OtherReceivables>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-520">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-521">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-522">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-523">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
